

8434143



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

November 21, 2023

**THIS IS TO CERTIFY THAT ANNEXED IS A TRUE COPY FROM THE
RECORDS OF THIS OFFICE OF THE FILE WRAPPER AND CONTENTS
OF:**

APPLICATION NUMBER: 13/647,081

FILING DATE: *October 08, 2012*

PATENT NUMBER: 8916752

ISSUE DATE: *December 23, 2014*



Certified by

Kathi

Performing the Functions and Duties of the
Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

SCORE Placeholder Sheet for IFW Content

Application Number: 13647081

Document Date: 10/08/2012

The presence of this form in the IFW record indicates that the following document type was received in electronic format on the date identified above. This content is stored in the SCORE database.

- **Sequence Listing**

Since this was an electronic submission, there is no physical artifact folder, no artifact folder is recorded in PALM, and no paper documents or physical media exist. The TIFF images in the IFW record were created from the original documents that are stored in SCORE.

To access the documents in the SCORE database, refer to instructions developed by SIRA.

At the time of document entry (noted above):

- Examiners may access SCORE content via the eDAN interface.
- Other USPTO employees can bookmark the current SCORE URL (<http://es/ScoreAccessWeb/>).
- External customers may access SCORE content via the Public and Private PAIR interfaces.

Form Revision Date: February 8, 2006




FIG. 1

```

AAD-12 1 10 20 30 40 50 60 70 80
tfdA 1 ----MOTTLCITPTGATIGAVIGVHAT-LDAGFAALHAAVLOHALITFPQCHLSNDQOITFAARRFG-----
AAD-2 1 -----MSVVANPLHPLFAACVEDIDREALSTEVETIERLMDKSVLFRGQPLSQDQOIAFAARFEGPLEG-
AAD-1 1 -----MTIATIRQLQTHFGVSGIDLRKPLPFGGEARVESAMDKYAVVFDQOITDEQOAFALNFGQREDA
tauD 1 MHAALSPLSQRFERIAVQPLTGVIGAEITGVNDIREPLDSTWNEILDAFTYQMTYFPGQAITNECHIAFSRFRG-----
1 -----MSERLSITPLGPYIGAOISGADITRPLSDNQFEQLYHVALRHQVFLRDQAITPQOORALAQRRFG-----

AAD-12 90 100 110 120 130 140 150 160
tfdA 64 ----AIERIGGGDIVAISNVKADGTVRQHSPAEWDDMMKVIVGNMAWHADSTYMPVMAQGAVFSAFVVPVAVGGRTCEADM
67 -GFTKVNQRFPSRFKYAEALADISNVSLDGKVAQDAREVYGNFANOLWHSDSSFOQPAARAYSMLSAVVPPSCGDTFQDM
AAD-2 69 RGGTVTKEDYRLQ-SGLNDVSNLKGDKPLAKDSRTHLFNLGCLWHSDSSFRIPAKFTSLISARVNPICGNTFEDM
AAD-1 75 ----PVDPVPELLKSIIEGYPEVQMIIRREANESGR-----VIGDDWHDDSTFLDAPPAAVVMRAIDVPEHGGDTGFLSM
tauD 65 ----ELHIHEVYPHAEVDEIIVLDTNDNPP-----DNDNWHDDVTFTETPPAGAILAAKELPSTGGDTLWTSG
***** * * * *
170 180 190 200 210 220 230 240

AAD-12 141 RAAVDALDEATRALVHORSAEESLVTSOS-----KLGHVQOAGSAYIGYGMDDTTATPLPLVKVHPETGRPSLIGR-HAH
tfdA 147 RAAVDALPRDLQSELEGLEAEHVALHSRF-----LLGDTYSEAOARNAMPVNWPIVTRTHAGSGRKEFIGA-HAS
AAD-2 148 RAAVDALDDETKAETEDLVCEHSLMTSRG-----SLGFTETDEEKQMFPEVLQRLVTRTHPHRRKSLYLSS-HAG
AAD-1 144 YTAETLSPTMQATIEGLNVVHSATRYGSLYQAOQNRRFNTSVKVMVDYDAGDRETVHPLVTHPSGRKGLVNVQVYCO
tauD 132 IAAVEALSVFPRLQLSLRAEHDFRKSFPP---EYKYRKTETEEHQRWREAVAKNPBLLHPVVRTHPSGKQALFVNEGFTT
***** * * * *

AAD-12 250 260 270 280 290 300 310
tfdA 216 AIPGMDAESERFTEGLVDWAQOAPRVHAHQAAAGDVVWMDNRCILLHRAEPWDFKLPVWVHHSRLAQRPETEGAALV-
217 HVEGLPVVAEGRMLLAELEHATQREFVTRHRNVVGDVWMDNRCVILHRRRYDTSARRELRATITLDDAVV-----
AAD-2 218 KIAGSVPEGRLLLRDLNEHATQPEFVYVHKKLHDVWMDNRCQTMHRRYRXYDQSQPRDERRATVAGTEPTVQOQAAE
AAD-1 224 RIEGMDAESKPLLOFLYEHAHTRFDTCRVRKKDQVLVWMDNRCQTMHRAVPDYAGKFRYLRITVCGVRRPAR-----
tauD 209 RIVDYSEKESALLSELFAHTKPEFQVRWRKQPNQDIALWMDNRCQTMANADYLFQRRIRERATITIGDKPFYRAG---
* * * * *

```

FIG. 2




FIG. 3

NOVEL HERBICIDE RESISTANCE GENESCross-Reference To Related Application

[0001] This application is a continuation of U.S. Patent Application Serial No. 12/091,896, filed November 3, 2008, which claims the benefit of PCT International Application Serial No. PCT/US2006/042133, filed October 27, 2006, which claims the benefit of U.S. Provisional Application Serial No. 60/731,044, filed October 28, 2005, the disclosures each of which are expressly incorporated herein by reference.

Background of the Invention

[0002] Weeds can quickly deplete soil of valuable nutrients needed by crops and other desirable plants. There are many different types of herbicides presently used for the control of weeds. One extremely popular herbicide is glyphosate.

[0003] Crops, such as corn, soybeans, canola, cotton, sugar beets, wheat, turf, and rice, have been developed that are resistant to glyphosate. Thus, fields with actively growing glyphosate resistant soybeans, for example, can be sprayed to control weeds without significantly damaging the soybean plants.

[0004] With the introduction of genetically engineered, glyphosate tolerant crops (GTCs) in the mid-1990's, growers were enabled with a simple, convenient, flexible, and inexpensive tool for controlling a wide spectrum of broadleaf and grass weeds unparalleled in agriculture. Consequently, producers were quick to adopt GTCs and in many instances abandon many of the accepted best agronomic practices such as crop rotation, herbicide mode of action rotation, tank mixing, incorporation of mechanical with chemical and cultural weed control. Currently glyphosate tolerant soybean, cotton, corn, and canola are commercially available in the United States and elsewhere in the Western Hemisphere. Alfalfa was the first perennial GTC introduced, furthering the opportunity for repeated use of glyphosate on the same crop and fields repeatedly over a period of years. More GTCs (*e.g.*, wheat, rice, sugar beets, turf, *etc.*) are poised for introduction pending global market acceptance. Many other glyphosate resistant species are in experimental to development stages (*e.g.*, sugar cane, sunflower, beets, peas, carrot, cucumber, lettuce, onion, strawberry, tomato, and tobacco; forestry species like poplar and sweetgum; and horticultural species like marigold, petunia, and

BDDDB01 9494151v1

begonias; see “isb.vt.edu/cfdocs/fieldtests1.cfm, 2005” website). Additionally, the cost of glyphosate has dropped dramatically in recent years to the point that few conventional weed control programs can effectively compete on price and performance with glyphosate GTC systems.

[0005] Glyphosate has been used successfully in burndown and other non-crop areas for total vegetation control for more than 15 years. In many instances, as with GTCs, glyphosate has been used 1-3 times per year for 3, 5, 10, up to 15 years in a row. These circumstances have led to an over-reliance on glyphosate and GTC technology and have placed a heavy selection pressure on native weed species for plants that are naturally more tolerant to glyphosate or which have developed a mechanism to resist glyphosate’s herbicidal activity.

[0006] Extensive use of glyphosate-only weed control programs is resulting in the selection of glyphosate-resistant weeds, and is selecting for the propagation of weed species that are inherently more tolerant to glyphosate than most target species (*i.e.*, weed shifts). (Powles and Preston, 2006; Ng *et al.*, 2003; Simarmata *et al.*, 2003; Lorraine-Colwill *et al.*, 2003; Sfiligoj, 2004; Miller *et al.*, 2003; Heap, 2005; Murphy *et al.*, 2002; Martin *et al.*, 2002.) Although glyphosate has been widely used globally for more than 15 years, only a handful of weeds have been reported to have developed resistance to glyphosate (Heap, 2005); however, most of these have been identified in the past five years. Resistant weeds include both grass and broadleaf species—*Lolium rigidum*, *Lolium multiflorum*, *Eleusine indica*, *Sorghum halepense*, *Ambrosia artemisiifolia*, *Conyza canadensis*, *Conyza bonariensis*, *Plantago lanceolata*, *Amaranthus palmerii*, and *Amaranthus rudis*. Additionally, weeds that had previously not been an agronomic problem prior to the wide use of GTCs are now becoming more prevalent and difficult to control in the context of GTCs, which comprise >80% of U.S. cotton and soybean acres and >20% of U.S. corn acres (Gianessi, 2005). These weed shifts are occurring predominantly with (but not exclusively) difficult-to-control broadleaf weeds. Some examples include *Ipomoea*, *Amaranthus*, *Chenopodium*, *Taraxacum*, and *Commelina* species.

[0007] In areas where growers are faced with glyphosate resistant weeds or a shift to more difficult-to-control weed species, growers can compensate for glyphosate’s weaknesses by tank mixing or alternating with other herbicides that will control the missed weeds. One popular and efficacious tankmix partner for controlling broadleaf escapes in many instances has been 2,4-dichlorophenoxyacetic acid (2,4-D). 2,4-D has been used agronomically and in

BDDDB01 9494151v1

non-crop situations for broad spectrum, broadleaf weed control for more than 60 years. Individual cases of more tolerant species have been reported, but 2,4-D remains one of the most widely used herbicides globally. A limitation to further use of 2,4-D is that its selectivity in dicot crops like soybean or cotton is very poor, and hence 2,4-D is not typically used on (and generally not near) sensitive dicot crops. Additionally, 2,4-D's use in grass crops is somewhat limited by the nature of crop injury that can occur. 2,4-D in combination with glyphosate has been used to provide a more robust burndown treatment prior to planting no-till soybeans and cotton; however, due to these dicot species' sensitivity to 2,4-D, these burndown treatments must occur at least 14-30 days prior to planting (Agrilience, 2005).

[0008] 2,4-D is in the phenoxy acid class of herbicides, as is MCPA. 2,4-D has been used in many monocot crops (such as corn, wheat, and rice) for the selective control of broadleaf weeds without severely damaging the desired crop plants. 2,4-D is a synthetic auxin derivative that acts to deregulate normal cell-hormone homeostasis and impede balanced, controlled growth; however, the exact mode of action is still not known. Triclopyr and fluroxypyr are pyridyloxyacetic acid herbicides whose mode of action is as a synthetic auxin, also.

[0009] These herbicides have different levels of selectivity on certain plants (*e.g.*, dicots are more sensitive than grasses). Differential metabolism by different plants is one explanation for varying levels of selectivity. In general, plants metabolize 2,4-D slowly, so varying plant response to 2,4-D may be more likely explained by different activity at the target site(s) (WSSA, 2002). Plant metabolism of 2,4-D typically occurs via a two-phase mechanism, typically hydroxylation followed by conjugation with amino acids or glucose (WSSA, 2002).

[0010] Over time, microbial populations have developed an alternative and efficient pathway for degradation of this particular xenobiotic, which results in the complete mineralization of 2,4-D. Successive applications of the herbicide select for microbes that can utilize the herbicide as a carbon source for growth, giving them a competitive advantage in the soil. For this reason, 2,4-D currently formulated has a relatively short soil half-life, and no significant carryover effects to subsequent crops are encountered. This adds to the herbicidal utility of 2,4-D.

[0011] One organism that has been extensively researched for its ability to degrade 2,4-D is *Ralstonia eutropha* (Streber *et al.*, 1987). The gene that codes for the first enzymatic step in the mineralization pathway is *tfdA*. See U.S. Patent No. 6,153,401 and GENBANK Acc. No.

BDDDB01 9494151v1

M16730. *TfdA* catalyzes the conversion of 2,4-D acid to dichlorophenol (DCP) via an α -ketoglutarate-dependent dioxygenase reaction (Smejkal *et al.*, 2001). DCP has little herbicidal activity compared to 2,4-D. *TfdA* has been used in transgenic plants to impart 2,4-D resistance in dicot plants (*e.g.*, cotton and tobacco) normally sensitive to 2,4-D (Streber *et al.* (1989), Lyon *et al.* (1989), Lyon (1993), and U.S. Patent No. 5,608,147).

[0012] A large number of *tfdA*-type genes that encode proteins capable of degrading 2,4-D have been identified from the environment and deposited into the Genbank database. Many homologues are similar to *tfdA* (>85% amino acid identity) and have similar enzymatic properties to *tfdA*. However, there are a number of homologues that have a significantly lower identity to *tfdA* (25-50%), yet have the characteristic residues associated with α -ketoglutarate dioxygenase Fe^{+2} dioxygenases. It is therefore not obvious what the substrate specificities of these divergent dioxygenases are.

[0013] One unique example with low homology to *tfdA* (31% amino acid identity) is *sdpA* from *Delftia acidovorans* (Kohler *et al.*, 1999, Westendorf *et al.*, 2002, Westendorf *et al.*, 2003). This enzyme has been shown to catalyze the first step in (S)-dichlorprop (and other (S)-phenoxypropionic acids) as well as 2,4-D (a phenoxyacetic acid) mineralization (Westendorf *et al.*, 2003). Transformation of this gene into plants, has not heretofore been reported.

[0014] Development of new herbicide-tolerant crop (HTC) technologies has been limited in success due largely to the efficacy, low cost, and convenience of GTCs. Consequently, a very high rate of adoption for GTCs has occurred among producers. This created little incentive for developing new HTC technologies.

[0015] Aryloxyalkanoate chemical substructures are a common entity of many commercialized herbicides including the phenoxyacetate auxins (such as 2,4-D and dichlorprop), pyridyloxyacetate auxins (such as fluroxypyr and triclopyr), aryloxyphenoxypropionates (AOPP) acetyl-coenzyme A carboxylase (ACCase) inhibitors (such as haloxyfop, quizalofop, and diclofop), and 5-substituted phenoxyacetate protoporphyrinogen oxidase IX inhibitors (such as pyraflufen and flumiclorac). However, these classes of herbicides are all quite distinct, and no evidence exists in the current literature for common degradation pathways among these chemical classes. A multifunctional enzyme for the degradation of herbicides covering multiple modes of action

has recently been described (PCT US/2005/014737; filed May 2, 2005). Another unique multifunctional enzyme and potential uses are described hereafter.

Brief Summary of the Invention

[0016] The subject invention provides novel plants that are not only resistant to 2,4-D, but also to pyridyloxyacetate herbicides. Heretofore, there was no expectation or suggestion that a plant with both of these advantageous properties could be produced by the introduction of a single gene. The subject invention also includes plants that produce one or more enzymes of the subject invention “stacked” together with one or more other herbicide resistance genes, including, but not limited to, glyphosate-, ALS- (imidazolinone, sulfonylurea), aryloxyalkanoate-, HPPD-, PPO-, and glufosinate-resistance genes, so as to provide herbicide-tolerant plants compatible with broader and more robust weed control and herbicide resistance management options. The present invention further includes methods and compositions utilizing homologues of the genes and proteins exemplified herein.

[0017] In some embodiments, the invention provides monocot and dicot plants tolerant to 2,4-D, MCPA, triclopyr, fluroxypyr, and one or more commercially available herbicides (*e.g.*, glyphosate, glufosinate, paraquat, ALS-inhibitors (*e.g.*, sulfonylureas, imidazolinones, triazolopyrimidine sulfonanilides, *et al.*), HPPD inhibitors (*e.g.*, mesotrione, isoxaflutole, *et al.*), dicamba, bromoxynil, aryloxyphenoxypropionates, and others). Vectors comprising nucleic acid sequences responsible for such herbicide tolerance are also disclosed, as are methods of using such tolerant plants and combinations of herbicides for weed control and prevention of weed population shifts. The subject invention enables novel combinations of herbicides to be used in new ways. Furthermore, the subject invention provides novel methods of preventing the development of, and controlling, strains of weeds that are resistant to one or more herbicides such as glyphosate. The subject invention enables novel uses of novel combinations of herbicides and crops, including preplant application to an area to be planted immediately prior to planting with seed for plants that would otherwise be sensitive to that herbicide (such as 2,4-D).

[0018] The subject invention relates in part to the identification of an enzyme that is not only able to degrade 2,4-D, but also surprisingly possesses novel properties, which distinguish the enzyme of the subject invention from previously known tfdA proteins, for example. More specifically, the subject invention relates to the use of an enzyme that is capable of degrading

BDDDB01 9494151v1

both 2,4-D and pyridyloxyacetate herbicides. No α -ketoglutarate-dependent dioxygenase enzyme has previously been reported to have the ability to degrade herbicides of both the phenoxyacetate and pyridyloxyacetates auxin herbicides. The preferred enzyme and gene for use according to the subject invention are referred to herein as *AAD-12* (AryloxyAlkanoate Dioxygenase). This highly novel discovery is the basis of significant herbicide-tolerant crop (HTC) trait and selectable marker opportunities. Plants of the subject invention can be resistant throughout their entire life cycle.

[0019] There was no prior motivation to produce plants comprising an *AAD-12* gene (preferably an *AAD-12* polynucleotide that has a sequence optimized for expression in one or more types of plants, as exemplified herein), and there was no expectation that such plants could effectively produce an AAD-12 enzyme to render the plants resistant a phenoxyacetic acid herbicide (such as 2,4-D) and/or one or more pyridyloxyacetates herbicides such as triclopyr and fluroxypyr. Thus, the subject invention provides many advantages that were not heretofore thought to be possible in the art.

[0020] This invention also relates in part to the identification and use of genes encoding aryloxyalkanoate dioxygenase enzymes that are capable of degrading phenoxyacetate auxin and/or pyridyloxyacetates auxin herbicides. Methods of screening proteins for these activities are within the scope of the subject invention. Thus, the subject invention includes degradation of 2,4-dichlorophenoxyacetic acid and other aryloxyalkanoate auxin herbicides by a recombinantly expressed AAD-12 enzyme. The subject invention also includes methods of controlling weeds wherein said methods comprise applying one or more pyridyloxyacetate or phenoxyacetate auxin herbicides to plants comprising an *AAD-12* gene. The subject invention also provides methods of using an *AAD-12* gene as a selectable marker for identifying plant cells and whole plants transformed with *AAD-12*, optionally including one, two, or more exogenous genes simultaneously inserted into target plant cells. Methods of the subject invention include selecting transformed cells that are resistant to appropriate levels of an herbicide. The subject invention further includes methods of preparing a polypeptide, having the biological activity of aryloxyalkanoate dioxygenase, by culturing plants and/or cells of the subject invention.

Brief Description of the Figures

- [0021] **Figure 1** illustrates the general chemical reaction that is catalyzed by AAD-12 enzymes of the subject invention.
- [0022] **Figure 2** is an amino acid sequence alignment of an exemplified AAD-12 protein, TfdA, AAD-2, AAD-1, and TauD.
- [0023] **Figure 3** illustrates activity of AAD-12 (v2) on 2,4-D and enantiomers of dichlorprop.

Brief Description of the Sequences


- [0024] **SEQ ID NO:1** is the nucleotide sequence of *AAD-12* from *Delftia acidovorans*.
- [0025] **SEQ ID NO:2** is the translated protein sequence encoded by SEQ ID NO:1.
- [0026] **SEQ ID NO:3** is the plant optimized nucleotide sequence of *AAD-12 (v1)*.
- [0027] **SEQ ID NO:4** is the translated protein sequence encoded by SEQ ID NO:3.
- [0028] **SEQ ID NO:5** is the E.coli optimized nucleotide sequence of *AAD-12 (v2)*.
- [0029] **SEQ ID NO:6** is the sequence of the M13 forward primer.
- [0030] **SEQ ID NO:7** is the sequence of the M13 reverse primer.
- [0031] **SEQ ID NO:8** is the sequence of the forward *AAD-12 (v1)* PTU primer.
- [0032] **SEQ ID NO:9** is the sequence of the reverse *AAD-12 (v1)* PTU primer.
- [0033] **SEQ ID NO:10** is the sequence of the forward *AAD-12 (v1)* coding PCR primer.
- [0034] **SEQ ID NO:11** is the sequence of the reverse *AAD-12 (v1)* coding PCR primer.
- [0035] **SEQ ID NO:12** shows the sequence of the “sdpacodF” *AAD-12 (v1)* primer.
- [0036] **SEQ ID NO:13** shows the sequence of the “sdpacodR” *AAD-12 (v1)* primer.
- [0037] **SEQ ID NO:14** shows the sequence of the “NcoI of Brady” primer.
- [0038] **SEQ ID NO:15** shows the sequence of the “SacI of Brady” primer.
- [0039] **SEQ ID NO:16** shows the sequence of forward primer brjap 5' (speI).
- [0040] **SEQ ID NO:17** shows the sequence of reverse primer brjap 3' (xhoI).

Detailed Description of the Invention

- [0041] The subject development of a 2,4-D resistance gene and subsequent resistant crops provides excellent options for controlling broadleaf, glyphosate-resistant (or highly tolerant and shifted) weed species for in-crop applications. 2,4-D is a broad-spectrum, relatively inexpensive, and robust broadleaf herbicide that would provide excellent utility for growers if greater crop tolerance could be provided in dicot and monocot crops alike. 2,4-D-tolerant

BDDDB01 9494151v1

transgenic dicot crops would also have greater flexibility in the timing and rate of application. An additional utility of the subject herbicide tolerance trait for 2,4-D is its utility to prevent damage to normally sensitive crops from 2,4-D drift, volatilization, inversion (or other off-site movement phenomenon), misapplication, vandalism, and the like. An additional benefit of the *AAD-12* gene is that unlike all *tfdA* homologues characterized to date, AAD-12 is able to degrade the pyridyloxyacetates auxins (*e.g.*, triclopyr, fluroxypyr) in addition to achiral phenoxy auxins (*e.g.*, 2,4-D, MCPA, 4-chlorophenoxyacetic acid). *See Table 1.* A general illustration of the chemical reactions catalyzed by the subject AAD-12 enzyme is shown in **Figure 1**. (Addition of O₂ is stereospecific; breakdown of intermediate to phenol and glyoxylate is spontaneous.) It should be understood that the chemical structures in Figure 1 illustrate the molecular backbones and that various R groups and the like (such as those shown in Table 1) are included but are not necessarily specifically illustrated in Figure 1. Multiple mixes of different phenoxy auxin combinations have been used globally to address specific weed spectra and environmental conditions in various regions. Use of the *AAD-12* gene in plants affords protection to a much wider spectrum of auxin herbicides, thereby increasing the flexibility and spectra of weeds that can be controlled. The subject invention can also be used to protect from drift or other off-site synthetic auxin herbicide injury for the full breadth of commercially available phenoxy auxins. **Table 1** defines commercially available pyridyloxy and phenoxy auxins and provides relevant chemical structures.

Table 1. Commercially available phenoxyacetate and pyridyloxyacetate auxins. Reference to phenoxy auxin and pyridyloxy auxin herbicides is generally made to the active acid but some are commercially formulated as any of a variety of corresponding ester formulations and these are likewise considered as substrates for AAD-12 enzyme <i>in planta</i> as general plant esterases convert these esters to the active acids <i>in planta</i> . Likewise reference can also be for the corresponding organic or inorganic salt of the corresponding acid. Possible use rate ranges can be as stand-alone treatments or in combination with other herbicides in both crop and non-crop uses.				
Chemical name	CAS no	Possible use rate ranges (g ae/ha)	Preferred use rate ranges (g ae/ha)	Structure
2,4-D	94-75-7	25 – 4000	280 - 1120	

BDDB01 9494151v1

Table 1. Commercially available phenoxyacetate and pyridyloxyacetate auxins. Reference to phenoxy auxin and pyridyloxy auxin herbicides is generally made to the active acid but some are commercially formulated as any of a variety of corresponding ester formulations and these are likewise considered as substrates for AAD-12 enzyme *in planta* as general plant esterases convert these esters to the active acids *in planta*. Likewise reference can also be for the corresponding organic or inorganic salt of the corresponding acid. Possible use rate ranges can be as stand-alone treatments or in combination with other herbicides in both crop and non-crop uses.

Chemical name	CAS no	Possible use rate ranges (g ae/ha)	Preferred use rate ranges (g ae/ha)	Structure
2,4,5-T	93-76-5	25 – 4000	25 – 4000	
4-CPA	122-88-3	25 – 4000	25 – 4000	
3,4-DA	588-22-7	25 – 4000	25 – 4000	
MCPA	94-74-6	25 – 4000	125 - 1550	
Triclopyr	55335-06-3	50 – 2000	70 – 840	
Fluroxypyr	69377-81-7	25 – 2000	35 – 560	

[0042]

A single gene (*AAD-12*) has now been identified which, when genetically engineered for expression in plants, has the properties to allow the use of phenoxy auxin herbicides in

BDDb01 9494151v1

plants where inherent tolerance never existed or was not sufficiently high to allow use of these herbicides. Additionally, *AAD-12* can provide protection *in planta* to pyridyloxyacetate herbicides where natural tolerance also was not sufficient to allow selectivity, expanding the potential utility of these herbicides. Plants containing *AAD-12* alone now may be treated sequentially or tank mixed with one, two, or a combination of several phenoxy auxin herbicides. The rate for each phenoxy auxin herbicide may range from 25 to 4000 g ae/ha, and more typically from 100 to 2000 g ae/ha for the control of a broad spectrum of dicot weeds. Likewise, one, two, or a mixture of several pyridyloxyacetate auxin compounds may be applied to plants expressing *AAD-12* with reduced risk of injury from said herbicides. The rate for each pyridyloxyacetate herbicide may range from 25 to 2000 g ae/ha, and more typically from 35-840 g ae/ha for the control of additional dicot weeds.

[0043] Glyphosate is used extensively because it controls a very wide spectrum of broadleaf and grass weed species. However, repeated use of glyphosate in GTCs and in non-crop applications has, and will continue to, select for weed shifts to naturally more tolerant species or glyphosate-resistant biotypes. Tankmix herbicide partners used at efficacious rates that offer control of the same species but having different modes of action is prescribed by most herbicide resistance management strategies as a method to delay the appearance of resistant weeds. Stacking *AAD-12* with a glyphosate tolerance trait (and/or with other herbicide-tolerance traits) could provide a mechanism to allow for the control of glyphosate resistant dicot weed species in GTCs by enabling the use of glyphosate, phenoxy auxin(s) (e.g., 2,4-D) and pyridyloxyacetates auxin herbicides (e.g., triclopyr)—selectively in the same crop. Applications of these herbicides could be simultaneously in a tank mixture comprising two or more herbicides of different modes of action; individual applications of single herbicide composition in sequential applications as pre-plant, preemergence, or postemergence and split timing of applications ranging from approximately 2 hours to approximately 3 months; or, alternatively, any combination of any number of herbicides representing each chemical class can be applied at any timing within about 7 months of planting the crop up to harvest of the crop (or the preharvest interval for the individual herbicide, whichever is shortest).

[0044] It is important to have flexibility in controlling a broad spectrum of grass and broadleaf weeds in terms of timing of application, rate of individual herbicides, and the ability to control difficult or resistant weeds. Glyphosate applications in a crop with a glyphosate resistance gene/*AAD-12* stack could range from about 250-2500 g ae/ha; phenoxy

auxin herbicide(s) (one or more) could be applied from about 25-4000 g ae/ha; and pyridyloxyacetates auxin herbicide(s) (one or more) could be applied from 25-2000 g ae/ha. The optimal combination(s) and timing of these application(s) will depend on the particular situation, species, and environment, and will be best determined by a person skilled in the art of weed control and having the benefit of the subject disclosure.

[0045] Plantlets are typically resistant throughout the entire growing cycle. Transformed plants will typically be resistant to new herbicide application at any time the gene is expressed. Tolerance is shown herein to 2,4-D across the life cycle using the constitutive promoters tested thus far (primarily CsVMV and AtUbi 10). One would typically expect this, but it is an improvement upon other non-metabolic activities where tolerance can be significantly impacted by the reduced expression of a site of action mechanism of resistance, for example. One example is Roundup Ready cotton, where the plants were tolerant if sprayed early, but if sprayed too late the glyphosate concentrated in the meristems (because it is not metabolized and is translocated); viral promoters Monsanto used are not well expressed in the flowers. The subject invention provides an improvement in these regards.

[0046] Herbicide formulations (*e.g.*, ester, acid, or salt formulation; or soluble concentrate, emulsifiable concentrate, or soluble liquid) and tankmix additives (*e.g.*, adjuvants, surfactants, drift retardants, or compatibility agents) can significantly affect weed control from a given herbicide or combination of one or more herbicides. Any combination of these with any of the aforementioned herbicide chemistries is within the scope of this invention.

[0047] One skilled in the art would also see the benefit of combining two or more modes of action for increasing the spectrum of weeds controlled and/or for the control of naturally more tolerant or resistant weed species. This could also extend to chemistries for which herbicide tolerance was enabled in crops through human involvement (either transgenically or non-transgenically) beyond GTCs. Indeed, traits encoding glyphosate resistance (*e.g.*, resistant plant or bacterial *EPSPS*, glyphosate oxidoreductase (*GOX*), *GAT*), glufosinate resistance (*e.g.*, *Pat*, *bar*), acetolactate synthase (ALS)-inhibiting herbicide resistance (*e.g.*, imidazolinone, sulfonylurea, triazolopyrimidine sulfonanilide, pyrimidinylthiobenzoates, and other chemistries = *AHAS*, *Csr1*, *SurA*, *et al.*), bromoxynil resistance (*e.g.*, *Bxn*), resistance to inhibitors of HPPD (4-hydroxyphenyl-pyruvate-dioxygenase) enzyme, resistance to inhibitors of phytoene desaturase (PDS), resistance to photosystem II inhibiting herbicides (*e.g.*, *psbA*), resistance to photosystem I inhibiting herbicides, resistance to protoporphyrinogen oxidase

IX (PPO)-inhibiting herbicides (*e.g.*, *PPO-I*), resistance to phenylurea herbicides (*e.g.*, *CYP76B1*), dicamba-degrading enzymes (*see, e.g.*, US 20030135879), and others could be stacked alone or in multiple combinations to provide the ability to effectively control or prevent weed shifts and/or resistance to any herbicide of the aforementioned classes. *In vivo* modified EPSPS can be used in some preferred embodiments, as well as Class I, Class II, and Class III glyphosate resistance genes.

[0048] Regarding additional herbicides, some additional preferred ALS inhibitors include but are not limited to the sulfonylureas (such as chlorsulfuron, halosulfuron, nicosulfuron, sulfometuron, sulfosulfuron, trifloxysulfuron), imidazoloninones (such as imazamox, imazethapyr, imazaquin), triazolopyrimidine sulfonanilides (such as cloransulam-methyl, diclosulam, florasulam, flumetsulam, metosulam, and penoxsulam), pyrimidinylthiobenzoates (such as bispyribac and pyriithiobac), and flucarbazone. Some preferred HPPD inhibitors include but are not limited to mesotrione, isoxaflutole, and sulcotrione. Some preferred PPO inhibitors include but are not limited to flumiclorac, flumioxazin, flufenpyr, pyraflufen, fluthiacet, butafenacil, carfentrazone, sulfentrazone, and the diphenylethers (such as acifluorfen, fomesafen, lactofen, and oxyfluorfen).

[0049] Additionally, *AAD-12* alone or stacked with one or more additional HTC traits can be stacked with one or more additional input (*e.g.*, insect resistance, fungal resistance, or stress tolerance, *et al.*) or output (*e.g.*, increased yield, improved oil profile, improved fiber quality, *et al.*) traits. Thus, the subject invention can be used to provide a complete agronomic package of improved crop quality with the ability to flexibly and cost effectively control any number of agronomic pests.

[0050] The subject invention relates in part to the identification of an enzyme that is not only able to degrade 2,4-D, but also surprisingly possesses novel properties, which distinguish the enzyme of the subject invention from previously known *tfdA* proteins, for example. Even though this enzyme has very low homology to *tfdA*, the genes of the subject invention can still be generally classified in the same overall family of α -ketoglutarate-dependent dioxygenases. This family of proteins is characterized by three conserved histidine residues in a “HX(D/E)X₂₃₋₂₆(T/S)X₁₁₄₋₁₈₃HX₁₀₋₁₃R” motif which comprises the active site. The histidines coordinate Fe⁺² ion in the active site that is essential for catalytic activity (Hogan *et al.*, 2000). The preliminary *in vitro* expression experiments discussed herein were tailored to help select for novel attributes. These experiments also indicate the AAD-12 enzyme is

BDDDB01 9494151v1

unique from another disparate enzyme of the same class, disclosed in a previously filed patent application (PCT US/2005/014737; filed May 2, 2005). The AAD-1 enzyme of that application shares only about 25% sequence identity with the subject AAD-12 protein.

[0051] More specifically, the subject invention relates in part to the use of an enzyme that is not only capable of degrading 2,4-D, but also pyridyloxyacetate herbicides. No α -ketoglutarate-dependent dioxygenase enzyme has previously been reported to have the ability to degrade herbicides of different chemical classes and modes of action. Preferred enzymes and genes for use according to the subject invention are referred to herein as AAD-12 (AryloxyAlkanoate Dioxygenase) genes and proteins.

[0052] This invention also relates in part to the identification and use of genes encoding aryloxyalkanoate dioxygenase enzymes that are capable of degrading phenoxy auxin and pyridyloxyacetate herbicides. Thus, the subject invention relates in part to the degradation of 2,4-dichlorophenoxyacetic acid, other phenoxyacetic acids, and pyridyloxyacetic acid herbicides by a recombinantly expressed AAD-12 enzyme.

[0053] The subject proteins tested positive for 2,4-D conversion to 2,4-dichlorophenol ("DCP"; herbicidally inactive) in analytical assays. Partially purified proteins of the subject invention can rapidly convert 2,4-D to DCP *in vitro*. An additional advantage that AAD-12 transformed plants provide is that parent herbicide(s) are metabolized to inactive forms, thereby reducing the potential for harvesting herbicidal residues in grain or stover.

[0054] The subject invention also includes methods of controlling weeds wherein said methods comprise applying a pyridyloxyacetate and/or a phenoxy auxin herbicide to plants comprising an AAD-12 gene.

[0055] In light of these discoveries, novel plants that comprise a polynucleotide encoding this type of enzyme are now provided. Heretofore, there was no motivation to produce such plants, and there was no expectation that such plants could effectively produce this enzyme to render the plants resistant to not only phenoxy acid herbicides (such as 2,4-D) but also pyridyloxyacetate herbicides. Thus, the subject invention provides many advantages that were not heretofore thought to be possible in the art.

[0056] Publicly available strains (deposited in culture collections like ATCC or DSMZ) can be acquired and screened, using techniques disclosed herein, for novel genes. Sequences disclosed herein can be used to amplify and clone the homologous genes into a recombinant expression system for further screening and testing according to the subject invention.

BDDDB01 9494151v1

[0057] As discussed above in the Background section, one organism that has been extensively researched for its ability to degrade 2,4-D is *Ralstonia eutropha* (Streber *et al.*, 1987). The gene that codes for the first enzyme in the degradation pathway is *tfdA*. See U.S. Patent No. 6,153,401 and GENBANK Acc. No. M16730. *TfdA* catalyzes the conversion of 2,4-D acid to herbicidally inactive DCP via an α -ketoglutarate-dependent dioxygenase reaction (Smejkal *et al.*, 2001). *TfdA* has been used in transgenic plants to impart 2,4-D resistance in dicot plants (*e.g.*, cotton and tobacco) normally sensitive to 2,4-D (Streber *et al.*, 1989; Lyon *et al.*, 1989; Lyon *et al.*, 1993). A large number of *tfdA*-type genes that encode proteins capable of degrading 2,4-D have been identified from the environment and deposited into the Genbank database. Many homologues are quite similar to *tfdA* (>85% amino acid identity) and have similar enzymatic properties to *tfdA*. However, a small collection of α -ketoglutarate-dependent dioxygenase homologues are presently identified that have a low level of homology to *tfdA*.

[0058] The subject invention relates in part to surprising discoveries of new uses for and functions of a distantly related enzyme, *sdpA*, from *Delftia acidivorans* (Westendorf *et al.*, 2002, 2003) with low homology to *tfdA* (31% amino acid identity). This α -ketoglutarate-dependent dioxygenase enzyme purified in its native form had previously been shown to degrade 2,4-D and S-dichlorprop (Westendorf *et al.*, 2002 and 2003). However, no α -ketoglutarate-dependent dioxygenase enzyme has previously been reported to have the ability to degrade herbicides of pyridyloxyacetate chemical class. *SdpA* has never been expressed in plants, nor was there any motivation to do so in part because development of new HTC technologies has been limited due largely to the efficacy, low cost, and convenience of GTCs (Devine, 2005).

[0059] In light of the novel activity, proteins and genes of the subject invention are referred to herein as AAD-12 proteins and genes. AAD-12 was presently confirmed to degrade a variety of phenoxyacetate auxin herbicides *in vitro*. However, this enzyme, as reported for the first time herein, was surprisingly found to also be capable of degrading additional substrates of the class of aryloxyalkanoate molecules. Substrates of significant agronomic importance include the pyridyloxyacetate auxin herbicides. This highly novel discovery is the basis of significant Herbicide Tolerant Crop (HTC) and selectable marker trait opportunities. This enzyme is unique in its ability to deliver herbicide degradative activity to a range of broad spectrum broadleaf herbicides (phenoxyacetate and pyridyloxyacetate auxins).

BDDDB01 9494151v1

[0060] Thus, the subject invention relates in part to the degradation of 2,4-dichlorophenoxyacetic acid, other phenoxyacetic auxin herbicides, and pyridyloxyacetate herbicides by a recombinantly expressed aryloxyalkanoate dioxygenase enzyme (AAD-12). This invention also relates in part to identification and uses of genes encoding an aryloxyalkanoate dioxygenase degrading enzyme (AAD-12) capable of degrading phenoxy and/or pyridyloxy auxin herbicides.

[0061] The subject enzyme enables transgenic expression resulting in tolerance to combinations of herbicides that would control nearly all broadleaf weeds. *AAD-12* can serve as an excellent herbicide tolerant crop (HTC) trait to stack with other HTC traits [*e.g.*, glyphosate resistance, glufosinate resistance, ALS-inhibitor (*e.g.*, imidazolinone, sulfonylurea, triazolopyrimidine sulfonanilide) resistance, bromoxynil resistance, HPPD-inhibitor resistance, PPO-inhibitor resistance, *et al.*], and insect resistance traits (*CryIF*, *CryIAb*, *Cry 34/45*, other Bt. Proteins, or insecticidal proteins of a non-*Bacillus* origin, *et al.*) for example. Additionally, *AAD-12* can serve as a selectable marker to aid in selection of primary transformants of plants genetically engineered with a second gene or group of genes.

[0062] In addition, the subject microbial gene has been redesigned such that the protein is encoded by codons having a bias toward both monocot and dicot plant usage (hemicot). *Arabidopsis*, corn, tobacco, cotton, soybean, canola, and rice have been transformed with *AAD-12*-containing constructs and have demonstrated high levels of resistance to both the phenoxy and pyridyloxy auxin herbicides. Thus, the subject invention also relates to “plant optimized” genes that encode proteins of the subject invention.

[0063] Oxyalkanoate groups are useful for introducing a stable acid functionality into herbicides. The acidic group can impart phloem mobility by “acid trapping,” a desirable attribute for herbicide action and therefore could be incorporated into new herbicides for mobility purposes. Aspects of the subject invention also provide a mechanism of creating HTCs. There exist many potential commercial and experimental herbicides that can serve as substrates for AAD-12. Thus, the use of the subject genes can also result in herbicide tolerance to those other herbicides as well.

[0064] HTC traits of the subject invention can be used in novel combinations with other HTC traits (including but not limited to glyphosate tolerance). These combinations of traits give rise to novel methods of controlling weed (and like) species, due to the newly acquired resistance or inherent tolerance to herbicides (*e.g.*, glyphosate). Thus, in addition to the HTC

traits, novel methods for controlling weeds using herbicides, for which herbicide tolerance was created by said enzyme in transgenic crops, are within the scope of the invention.

[0065] This invention can be applied in the context of commercializing a 2,4-D resistance trait stacked with current glyphosate resistance traits in soybeans, for example. Thus, this invention provides a tool to combat broadleaf weed species shifts and/or selection of herbicide resistant broadleaf weeds, which culminates from extremely high reliance by growers on glyphosate for weed control with various crops.

[0066] The transgenic expression of the subject *AAD-12* genes is exemplified in, for example, *Arabidopsis*, tobacco, soybean, cotton, rice, corn and canola. Soybeans are a preferred crop for transformation according to the subject invention. However, this invention can be utilized in multiple other monocot (such as pasture grasses or turf grass) and dicot crops like alfalfa, clover, tree species, *et al.* Likewise, 2,4-D (or other AAD-12-substrates) can be more positively utilized in grass crops where tolerance is moderate, and increased tolerance via this trait would provide growers the opportunity to use these herbicides at more efficacious rates and over a wider application timing without the risk of crop injury.

[0067] Still further, the subject invention provides a single gene that can provide resistance to herbicides that control broadleaf weed. This gene may be utilized in multiple crops to enable the use of a broad spectrum herbicide combination. The subject invention can also control weeds resistant to current chemicals, and aids in the control of shifting weed spectra resulting from current agronomic practices. The subject AAD-12 can also be used in efforts to effectively detoxify additional herbicide substrates to non-herbicidal forms. Thus, the subject invention provides for the development of additional HTC traits and/or selectable marker technology.

[0068] Separate from, or in addition to, using the subject genes to produce HTCs, the subject genes can also be used as selectable markers for successfully selecting transformants in cell cultures, greenhouses, and in the field. There is high inherent value for the subject genes simply as a selectable marker for biotechnology projects. The promiscuity of AAD-12 for other aryloxyalkanoate auxinic herbicides provides many opportunities to utilize this gene for HTC and/or selectable marker purposes.

[0069] Proteins (and source isolates) of the subject invention. The present invention provides functional proteins. By “functional activity” (or “active”) it is meant herein that the proteins/enzymes for use according to the subject invention have the ability to degrade or

diminish the activity of a herbicide (alone or in combination with other proteins). Plants producing proteins of the subject invention will preferably produce “an effective amount” of the protein so that when the plant is treated with a herbicide, the level of protein expression is sufficient to render the plant completely or partially resistant or tolerant to the herbicide (at a typical rate, unless otherwise specified; typical application rates can be found in the well-known *Herbicide Handbook* (Weed Science Society of America, Eighth Edition, 2002), for example). The herbicide can be applied at rates that would normally kill the target plant, at normal field use rates and concentrations. (Because of the subject invention, the level and/or concentration can optionally be higher than those that were previously used.) Preferably, plant cells and plants of the subject invention are protected against growth inhibition or injury caused by herbicide treatment. Transformed plants and plant cells of the subject invention are preferably rendered resistant or tolerant to an herbicide, as discussed herein, meaning that the transformed plant and plant cells can grow in the presence of effective amounts of one or more herbicides as discussed herein. Preferred proteins of the subject invention have catalytic activity to metabolize one or more aryloxyalkanoate compounds.

[0070]

One cannot easily discuss the term “resistance” and not use the verb “tolerate” or the adjective “tolerant.” The industry has spent innumerable hours debating Herbicide Tolerant Crops (HTC) versus Herbicide Resistant Crops (HRC). HTC is a preferred term in the industry. However, the official Weed Science Society of America definition of resistance is “the inherited ability of a plant to survive and reproduce following exposure to a dose of herbicide normally lethal to the wild type. In a plant, resistance may be naturally occurring or induced by such techniques as genetic engineering or selection of variants produced by tissue culture or mutagenesis.” As used herein unless otherwise indicated, herbicide “resistance” is heritable and allows a plant to grow and reproduce in the presence of a typical herbicidally effective treatment by a herbicide for a given plant, as suggested by the current edition of *The Herbicide Handbook* as of the filing of the subject disclosure. As is recognized by those skilled in the art, a plant may still be considered “resistant” even though some degree of plant injury from herbicidal exposure is apparent. As used herein, the term “tolerance” is broader than the term “resistance,” and includes “resistance” as defined herein, as well an improved capacity of a particular plant to withstand the various degrees of herbicidally induced injury that typically result in wild-type plants of the same genotype at the same herbicidal dose.

BDDDB01 9494151v1

[0071] Transfer of the functional activity to plant or bacterial systems can involve a nucleic acid sequence, encoding the amino acid sequence for a protein of the subject invention, integrated into a protein expression vector appropriate to the host in which the vector will reside. One way to obtain a nucleic acid sequence encoding a protein with functional activity is to isolate the native genetic material from the bacterial species which produce the protein of interest, using information deduced from the protein's amino acid sequence, as disclosed herein. The native sequences can be optimized for expression in plants, for example, as discussed in more detail below. An optimized polynucleotide can also be designed based on the protein sequence.

[0072] The subject invention provides classes of proteins having novel activities as identified herein. One way to characterize these classes of proteins and the polynucleotides that encode them is by defining a polynucleotide by its ability to hybridize, under a range of specified conditions, with an exemplified nucleotide sequence (the complement thereof and/or a probe or probes derived from either strand) and/or by their ability to be amplified by PCR using primers derived from the exemplified sequences.

[0073] There are a number of methods for obtaining proteins for use according to the subject invention. For example, antibodies to the proteins disclosed herein can be used to identify and isolate other proteins from a mixture of proteins. Specifically, antibodies may be raised to the portions of the proteins that are most conserved or most distinct, as compared to other related proteins. These antibodies can then be used to specifically identify equivalent proteins with the characteristic activity by immunoprecipitation, enzyme linked immunosorbent assay (ELISA), or immuno-blotting. Antibodies to the proteins disclosed herein, or to equivalent proteins, or to fragments of these proteins, can be readily prepared using standard procedures. Such antibodies are an aspect of the subject invention. Antibodies of the subject invention include monoclonal and polyclonal antibodies, preferably produced in response to an exemplified or suggested protein.

[0074] One skilled in the art would readily recognize that proteins (and genes) of the subject invention can be obtained from a variety of sources. Since entire herbicide degradation operons are known to be encoded on transposable elements such as plasmids, as well as genomically integrated, proteins of the subject invention can be obtained from a wide variety of microorganisms, for example, including recombinant and/or wild-type bacteria.

BDDDB01 9494151v1

[0075] Mutants of bacterial isolates can be made by procedures that are well known in the art. For example, asporogenous mutants can be obtained through ethylmethane sulfonate (EMS) mutagenesis of an isolate. The mutant strains can also be made using ultraviolet light and nitrosoguanidine by procedures well known in the art.

[0076] A protein “from” or “obtainable from” any of the subject isolates referred to or suggested herein means that the protein (or a similar protein) can be obtained from the isolate or some other source, such as another bacterial strain or a plant. “Derived from” also has this connotation, and includes proteins obtainable from a given type of bacterium that are modified for expression in a plant, for example. One skilled in the art will readily recognize that, given the disclosure of a bacterial gene and protein, a plant can be engineered to produce the protein. Antibody preparations, nucleic acid probes (DNA, RNA, or PNA, for example), and the like can be prepared using the polynucleotide and/or amino acid sequences disclosed herein and used to screen and recover other related genes from other (natural) sources.

[0077] Standard molecular biology techniques may be used to clone and sequence the proteins and genes described herein. Additional information may be found in Sambrook *et al.*, 1989, which is incorporated herein by reference.

[0078] Polynucleotides and probes. The subject invention further provides nucleic acid sequences that encode proteins for use according to the subject invention. The subject invention further provides methods of identifying and characterizing genes that encode proteins having the desired herbicidal activity. In one embodiment, the subject invention provides unique nucleotide sequences that are useful as hybridization probes and/or primers for PCR techniques. The primers produce characteristic gene fragments that can be used in the identification, characterization, and/or isolation of specific genes of interest. The nucleotide sequences of the subject invention encode proteins that are distinct from previously described proteins.

[0079] The polynucleotides of the subject invention can be used to form complete “genes” to encode proteins or peptides in a desired host cell. For example, as the skilled artisan would readily recognize, the subject polynucleotides can be appropriately placed under the control of a promoter in a host of interest, as is readily known in the art. The level of gene expression and temporal/tissue specific expression can greatly impact the utility of the invention. Generally, greater levels of protein expression of a degradative gene will result in faster and more complete degradation of a substrate (in this case a target herbicide).

BDDDB01 9494151v1

Promoters will be desired to express the target gene at high levels unless the high expression has a consequential negative impact on the health of the plant. Typically, one would wish to have the *AAD-12* gene constitutively expressed in all tissues for complete protection of the plant at all growth stages. However, one could alternatively use a vegetatively expressed resistance gene; this would allow use of the target herbicide in-crop for weed control and would subsequently control sexual reproduction of the target crop by application during the flowering stage. In addition, desired levels and times of expression can also depend on the type of plant and the level of tolerance desired. Some preferred embodiments use strong constitutive promoters combined with transcription enhancers and the like to increase expression levels and to enhance tolerance to desired levels. Some such applications are discussed in more detail below, before the Examples section.

[0080] As the skilled artisan knows, DNA typically exists in a double-stranded form. In this arrangement, one strand is complementary to the other strand and vice versa. As DNA is replicated in a plant (for example), additional complementary strands of DNA are produced. The “coding strand” is often used in the art to refer to the strand that binds with the anti-sense strand. The mRNA is transcribed from the “anti-sense” strand of DNA. The “sense” or “coding” strand has a series of codons (a codon is three nucleotides that can be read as a three-residue unit to specify a particular amino acid) that can be read as an open reading frame (ORF) to form a protein or peptide of interest. In order to produce a protein *in vivo*, a strand of DNA is typically transcribed into a complementary strand of mRNA which is used as the template for the protein. Thus, the subject invention includes the use of the exemplified polynucleotides shown in the attached sequence listing and/or equivalents including the complementary strands. RNA and PNA (peptide nucleic acids) that are functionally equivalent to the exemplified DNA molecules are included in the subject invention.

[0081] In one embodiment of the subject invention, bacterial isolates can be cultivated under conditions resulting in high multiplication of the microbe. After treating the microbe to provide single-stranded genomic nucleic acid, the DNA can be contacted with the primers of the invention and subjected to PCR amplification. Characteristic fragments of genes of interest will be amplified by the procedure, thus identifying the presence of the gene(s) of interest.

[0082] Further aspects of the subject invention include genes and isolates identified using the methods and nucleotide sequences disclosed herein. The genes thus identified can encode herbicidal resistance proteins of the subject invention.

[0083] Proteins and genes for use according to the subject invention can be identified and obtained by using oligonucleotide probes, for example. These probes are detectable nucleotide sequences that can be detectable by virtue of an appropriate label or may be made inherently fluorescent as described in International Application No. WO 93/16094. The probes (and the polynucleotides of the subject invention) may be DNA, RNA, or PNA. In addition to adenine (A), cytosine (C), guanine (G), thymine (T), and uracil (U; for RNA molecules), synthetic probes (and polynucleotides) of the subject invention can also have inosine (a neutral base capable of pairing with all four bases; sometimes used in place of a mixture of all four bases in synthetic probes) and/or other synthetic (non-natural) bases. Thus, where a synthetic, degenerate oligonucleotide is referred to herein, and "N" or "n" is used generically, "N" or "n" can be G, A, T, C, or inosine. Ambiguity codes as used herein are in accordance with standard IUPAC naming conventions as of the filing of the subject application (for example, R means A or G, Y means C or T, *etc.*).

[0084] As is well known in the art, if a probe molecule hybridizes with a nucleic acid sample, it can be reasonably assumed that the probe and sample have substantial homology/similarity/identity. Preferably, hybridization of the polynucleotide is first conducted followed by washes under conditions of low, moderate, or high stringency by techniques well-known in the art, as described in, for example, Keller, G.H., M.M. Manak (1987) *DNA Probes*, Stockton Press, New York, NY, pp. 169-170. For example, as stated therein, low stringency conditions can be achieved by first washing with 2x SSC (Standard Saline Citrate)/0.1% SDS (Sodium Dodecyl Sulfate) for 15 minutes at room temperature. Two washes are typically performed. Higher stringency can then be achieved by lowering the salt concentration and/or by raising the temperature. For example, the wash described above can be followed by two washings with 0.1x SSC/0.1% SDS for 15 minutes each at room temperature followed by subsequent washes with 0.1x SSC/0.1% SDS for 30 minutes each at 55° C. These temperatures can be used with other hybridization and wash protocols set forth herein and as would be known to one skilled in the art (SSPE can be used as the salt instead of SSC, for example). The 2x SSC/0.1% SDS can be prepared by adding 50 ml of 20x SSC and 5 ml of 10% SDS to 445 ml of water. 20x SSC can be prepared by combining NaCl

BDDDB01 9494151v1

(175.3 g/0.150 M), sodium citrate (88.2 g/0.015 M), and water, adjusting pH to 7.0 with 10 N NaOH, then adjusting the volume to 1 liter. 10% SDS can be prepared by dissolving 10 g of SDS in 50 ml of autoclaved water, then diluting to 100 ml.

[0085] Detection of the probe provides a means for determining in a known manner whether hybridization has been maintained. Such a probe analysis provides a rapid method for identifying genes of the subject invention. The nucleotide segments used as probes according to the invention can be synthesized using a DNA synthesizer and standard procedures. These nucleotide sequences can also be used as PCR primers to amplify genes of the subject invention.

[0086] Hybridization characteristics of a molecule can be used to define polynucleotides of the subject invention. Thus the subject invention includes polynucleotides (and/or their complements, preferably their full complements) that hybridize with a polynucleotide exemplified herein. That is, one way to define a gene (and the protein it encodes), for example, is by its ability to hybridize (under any of the conditions specifically disclosed herein) with a known or specifically exemplified gene.

[0087] As used herein, "stringent" conditions for hybridization refers to conditions which achieve the same, or about the same, degree of specificity of hybridization as the conditions employed by the current applicants. Specifically, hybridization of immobilized DNA on Southern blots with ³²P-labeled gene-specific probes can be performed by standard methods (see, e.g., Maniatis *et al.* 1982). In general, hybridization and subsequent washes can be carried out under conditions that allow for detection of target sequences. For double-stranded DNA gene probes, hybridization can be carried out overnight at 20-25° C below the melting temperature (T_m) of the DNA hybrid in 6x SSPE, 5x Denhardt's solution, 0.1% SDS, 0.1 mg/ml denatured DNA. The melting temperature is described by the following formula (Beltz *et al.* 1983):

$$T_m = 81.5^\circ \text{ C} + 16.6 \text{ Log}[\text{Na}^+] + 0.41(\% \text{G+C}) - 0.61(\% \text{formamide}) - 600/\text{length of duplex in base pairs.}$$

[0088] Washes can typically be carried out as follows:

- (1) Twice at room temperature for 15 minutes in 1x SSPE, 0.1% SDS (low stringency wash).
- (2) Once at T_m-20° C for 15 minutes in 0.2x SSPE, 0.1% SDS (moderate stringency wash).

[0089] For oligonucleotide probes, hybridization can be carried out overnight at 10-20° C below the melting temperature (T_m) of the hybrid in 6x SSPE, 5x Denhardt's solution, 0.1% SDS, 0.1 mg/ml denatured DNA. T_m for oligonucleotide probes can be determined by the following formula:

$$T_m (^{\circ}\text{C}) = 2(\text{number T/A base pairs}) + 4(\text{number G/C base pairs})$$

(Suggs *et al.*, 1981).

[0090] Washes can typically be out as follows:

- (1) Twice at room temperature for 15 minutes 1x SSPE, 0.1% SDS (low stringency wash).
- (2) Once at the hybridization temperature for 15 minutes in 1x SSPE, 0.1% SDS (moderate stringency wash).

[0091] In general, salt and/or temperature can be altered to change stringency. With a labeled DNA fragment >70 or so bases in length, the following conditions can be used:

Low: 1 or 2x SSPE, room temperature

Low: 1 or 2x SSPE, 42° C

Moderate: 0.2x or 1x SSPE, 65° C

High: 0.1x SSPE, 65° C.

[0092] Duplex formation and stability depend on substantial complementarity between the two strands of a hybrid, and, as noted above, a certain degree of mismatch can be tolerated. Therefore, the probe sequences of the subject invention include mutations (both single and multiple), deletions, insertions of the described sequences, and combinations thereof, wherein said mutations, insertions and deletions permit formation of stable hybrids with the target polynucleotide of interest. Mutations, insertions, and deletions can be produced in a given polynucleotide sequence in many ways, and these methods are known to an ordinarily skilled artisan. Other methods may become known in the future.

[0093] PCR technology. Polymerase Chain Reaction (PCR) is a repetitive, enzymatic, primed synthesis of a nucleic acid sequence. This procedure is well known and commonly used by those skilled in this art (*see* Mullis, U.S. Patent Nos. 4,683,195, 4,683,202, and 4,800,159; Saiki *et al.*, 1985). PCR is based on the enzymatic amplification of a DNA fragment of interest that is flanked by two oligonucleotide primers that hybridize to opposite strands of the target sequence. The primers are preferably oriented with the 3' ends pointing towards each other. Repeated cycles of heat denaturation of the template, annealing of the primers to

their complementary sequences, and extension of the annealed primers with a DNA polymerase result in the amplification of the segment defined by the 5' ends of the PCR primers. The extension product of each primer can serve as a template for the other primer, so each cycle essentially doubles the amount of DNA fragment produced in the previous cycle. This results in the exponential accumulation of the specific target fragment, up to several million-fold in a few hours. By using a thermostable DNA polymerase such as *Taq* polymerase, isolated from the thermophilic bacterium *Thermus aquaticus*, the amplification process can be completely automated. Other enzymes which can be used are known to those skilled in the art.

[0094] Exemplified DNA sequences, or segments thereof, can be used as primers for PCR amplification. In performing PCR amplification, a certain degree of mismatch can be tolerated between primer and template. Therefore, mutations, deletions, and insertions (especially additions of nucleotides to the 5' end) of the exemplified primers fall within the scope of the subject invention. Mutations, insertions, and deletions can be produced in a given primer by methods known to an ordinarily skilled artisan.

[0095] Modification of genes and proteins. The subject genes and proteins can be fused to other genes and proteins to produce chimeric or fusion proteins. The genes and proteins useful according to the subject invention include not only the specifically exemplified full-length sequences, but also portions, segments and/or fragments (including contiguous fragments and internal and/or terminal deletions compared to the full-length molecules) of these sequences, variants, mutants, chimerics, and fusions thereof. Proteins of the subject invention can have substituted amino acids so long as they retain desired functional activity. "Variant" genes have nucleotide sequences that encode the same proteins or equivalent proteins having activity equivalent or similar to an exemplified protein.

[0096] The top two results of BLAST searches with the native aad-12 nucleotide sequence show a reasonable level of homology (about 85%) over 120 basepairs of sequence. Hybridization under certain conditions could be expected to include these two sequences. See GENBANK Acc. Nos. DQ406818.1 (89329742; *Rhodoferrax*) and AJ6288601.1 (44903451; *Sphingomonas*). *Rhodoferrax* is very similar to *Delftia* but *Sphingomonas* is an entirely different Class phylogenetically.

[0097] The terms "variant proteins" and "equivalent proteins" refer to proteins having the same or essentially the same biological/functional activity against the target substrates and

BDDDB01 9494151v1

equivalent sequences as the exemplified proteins. As used herein, reference to an “equivalent” sequence refers to sequences having amino acid substitutions, deletions, additions, or insertions that improve or do not adversely affect activity to a significant extent. Fragments retaining activity are also included in this definition. Fragments and other equivalents that retain the same or similar function or activity as a corresponding fragment of an exemplified protein are within the scope of the subject invention. Changes, such as amino acid substitutions or additions, can be made for a variety of purposes, such as increasing (or decreasing) protease stability of the protein (without materially/substantially decreasing the functional activity of the protein), removing or adding a restriction site, and the like. Variations of genes may be readily constructed using standard techniques for making point mutations, for example.

[0098] In addition, U.S. Patent No. 5,605,793, for example, describes methods for generating additional molecular diversity by using DNA reassembly after random or focused fragmentation. This can be referred to as gene “shuffling,” which typically involves mixing fragments (of a desired size) of two or more different DNA molecules, followed by repeated rounds of renaturation. This can improve the activity of a protein encoded by a starting gene. The result is a chimeric protein having improved activity, altered substrate specificity, increased enzyme stability, altered stereospecificity, or other characteristics.

[0099] “Shuffling” can be designed and targeted after obtaining and examining the atomic 3D (three dimensional) coordinates and crystal structure of a protein of interest. Thus, “focused shuffling” can be directed to certain segments of a protein that are ideal for modification, such as surface-exposed segments, and preferably not internal segments that are involved with protein folding and essential 3D structural integrity.

[00100] Specific changes to the “active site” of the enzyme can be made to affect the inherent functionality with respect to activity or stereospecificity (see alignment **Figure 2**). Muller *et. al.* (2006). The known tauD crystal structure was used as a model dioxygenase to determine active site residues while bound to its inherent substrate taurine. Elkins *et al.* (2002) “X-ray crystal structure of *Escherichia coli* taurine/alpha-ketoglutarate dioxygenase complexed to ferrous iron and substrates,” *Biochemistry* 41(16):5185-5192. Regarding sequence optimization and designability of enzyme active sites, see Chakrabarti *et al.*, PNAS, (Aug. 23, 2005), 102(34):12035-12040.

[00101] Variant genes can be used to produce variant proteins; recombinant hosts can be used to produce the variant proteins. Using these “gene shuffling” techniques, equivalent genes and proteins can be constructed that comprise any 5, 10, or 20 contiguous residues (amino acid or nucleotide) of any sequence exemplified herein. As one skilled in the art knows, the gene shuffling techniques, for example, can be adjusted to obtain equivalents having, for example, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, or 293 contiguous residues (amino acid or nucleotide), corresponding to a segment (of the same size) in any of the exemplified or suggested sequences (or the complements (full complements) thereof). Similarly sized segments, especially those for conserved regions, can also be used as probes and/or primers.

[00102] Fragments of full-length genes can be made using commercially available exonucleases or endonucleases according to standard procedures. For example, enzymes such as *Bal31* or site-directed mutagenesis can be used to systematically cut off nucleotides from the ends of these genes. Also, genes that encode active fragments may be obtained using a variety of restriction enzymes. Proteases may be used to directly obtain active fragments of these proteins.

[00103] It is within the scope of the invention as disclosed herein that proteins can be truncated and still retain functional activity. By “truncated protein” it is meant that a portion

BDDDB01 9494151v1

of a protein may be cleaved off while the remaining truncated protein retains and exhibits the desired activity after cleavage. Cleavage can be achieved by various proteases. Furthermore, effectively cleaved proteins can be produced using molecular biology techniques wherein the DNA bases encoding said protein are removed either through digestion with restriction endonucleases or other techniques available to the skilled artisan. After truncation, said proteins can be expressed in heterologous systems such as *E. coli*, baculoviruses, plant-based viral systems, yeast, and the like and then placed in insect assays as disclosed herein to determine activity. It is well-known in the art that truncated proteins can be successfully produced so that they retain functional activity while having less than the entire, full-length sequence. For example, *B.t.* proteins can be used in a truncated (core protein) form (*see, e.g., Höfte et al. (1989), and Adang et al. (1985)*). As used herein, the term “protein” can include functionally active truncations.

[00104] In some cases, especially for expression in plants, it can be advantageous to use truncated genes that express truncated proteins. Preferred truncated genes will typically encode 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% of the full-length protein.

[00105] Certain proteins of the subject invention have been specifically exemplified herein. As these proteins are merely exemplary of the proteins of the subject invention, it should be readily apparent that the subject invention comprises variant or equivalent proteins (and nucleotide sequences coding for equivalents thereof) having the same or similar activity of the exemplified proteins. Equivalent proteins will have amino acid similarity (and/or homology) with an exemplified protein. The amino acid identity will typically be at least 60%, preferably at least 75%, more preferably at least 80%, even more preferably at least 90%, and can be at least 95%. Preferred proteins of the subject invention can also be defined in terms of more particular identity and/or similarity ranges. For example, the identity and/or similarity can be 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% as compared to a sequence exemplified or suggested herein. Any number listed above can be used to define the upper and lower limits.

[00106] Unless otherwise specified, as used herein, percent sequence identity and/or similarity of two nucleic acids is determined using the algorithm of Karlin and Altschul, 1990, modified

BDDDB01 9494151v1

as in Karlin and Altschul 1993. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul *et al.*, 1990. BLAST nucleotide searches are performed with the NBLAST program, score = 100, wordlength = 12. Gapped BLAST can be used as described in Altschul *et al.*, 1997. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (NBLAST and XBLAST) are used. *See* NCBI/NIH website. To obtain gapped alignments for comparison purposes, the AlignX function of Vector NTI Suite 8 (InforMax, Inc., North Bethesda, MD, U.S.A.), was used employing the default parameters. These were: a Gap opening penalty of 15, a Gap extension penalty of 6.66, and a Gap separation penalty range of 8.

[00107] Various properties and three-dimensional features of the protein can also be changed without adversely affecting the activity/functionality of the protein. Conservative amino acid substitutions can be tolerated/made to not adversely affect the activity and/or three-dimensional configuration of the molecule. Amino acids can be placed in the following classes: non-polar, uncharged polar, basic, and acidic. Conservative substitutions whereby an amino acid of one class is replaced with another amino acid of the same type fall within the scope of the subject invention so long as the substitution is not adverse to the biological activity of the compound. **Table 2** provides a listing of examples of amino acids belonging to each class.

Table 2	
Class of Amino Acid	Examples of Amino Acids
Nonpolar	Ala, Val, Leu, Ile, Pro, Met, Phe, Trp
Uncharged Polar	Gly, Ser, Thr, Cys, Tyr, Asn, Gln
Acidic	Asp, Glu
Basic	Lys, Arg, His

[00108] In some instances, non-conservative substitutions can also be made. However, preferred substitutions do not significantly detract from the functional/biological activity of the protein.

[00109] As used herein, reference to “isolated” polynucleotides and/or “purified” proteins refers to these molecules when they are not associated with the other molecules with which they would be found in nature. Thus, reference to “isolated” and/or “purified” signifies the involvement of the “hand of man” as described herein. For example, a bacterial “gene” of the

subject invention put into a plant for expression is an “isolated polynucleotide.” Likewise, a protein derived from a bacterial protein and produced by a plant is an “isolated protein.”

[00110] Because of the degeneracy/redundancy of the genetic code, a variety of different DNA sequences can encode the amino acid sequences disclosed herein. It is well within the skill of a person trained in the art to create alternative DNA sequences that encode the same, or essentially the same, proteins. These variant DNA sequences are within the scope of the subject invention. This is also discussed in more detail below in the section entitled “Optimization of sequence for expression in plants.”

[00111] Optimization of sequence for expression in plants. To obtain high expression of heterologous genes in plants it is generally preferred to reengineer the genes so that they are more efficiently expressed in (the cytoplasm of) plant cells. Maize is one such plant where it may be preferred to re-design the heterologous gene(s) prior to transformation to increase the expression level thereof in said plant. Therefore, an additional step in the design of genes encoding a bacterial protein is reengineering of a heterologous gene for optimal expression, using codon bias more closely aligned with the target plant sequence, whether a dicot or monocot species. Sequences can also be optimized for expression in any of the more particular types of plants discussed elsewhere herein.

[00112] Transgenic hosts. The protein-encoding genes of the subject invention can be introduced into a wide variety of microbial or plant hosts. The subject invention includes transgenic plant cells and transgenic plants. Preferred plants (and plant cells) are corn, *Arabidopsis*, tobacco, soybeans, cotton, canola, rice, wheat, turf, legume forages (e.g., alfalfa and clover), pasture grasses, and the like. Other types of transgenic plants can also be made according to the subject invention, such as fruits, vegetables, ornamental plants, and trees. More generally, dicots and/or monocots can be used in various aspects of the subject invention.

[00113] In preferred embodiments, expression of the gene results, directly or indirectly, in the intracellular production (and maintenance) of the protein(s) of interest. Plants can be rendered herbicide-resistant in this manner. Such hosts can be referred to as transgenic, recombinant, transformed, and/or transfected hosts and/or cells. In some aspects of this invention (when cloning and preparing the gene of interest, for example), microbial (preferably bacterial) cells can be produced and used according to standard techniques, with the benefit of the subject disclosure.

BDDDB01 9494151v1

[00114] Plant cells transfected with a polynucleotide of the subject invention can be regenerated into whole plants. The subject invention includes cell cultures including tissue cell cultures, liquid cultures, and plated cultures. Seeds produced by and/or used to generate plants of the subject invention are also included within the scope of the subject invention. Other plant tissues and parts are also included in the subject invention. The subject invention likewise includes methods of producing plants or cells comprising a polynucleotide of the subject invention. One preferred method of producing such plants is by planting a seed of the subject invention.

[00115] Although plants can be preferred, the subject invention also includes production of highly active recombinant AAD-12 in a *Pseudomonas fluorescens* (Pf) host strain, for example. The subject invention includes preferred growth temperatures for maintaining soluble active AAD-12 in this host; a fermentation condition where AAD-12 is produced as more than 40% total cell protein, or at least 10 g/L; a purification process results high recovery of active recombinant AAD-12 from a Pf host; a purification scheme which yields at least 10 g active AAD-12 per kg of cells; a purification scheme which can yield 20 g active AAD-12 per kg of cells; a formulation process that can store and restore AAD-12 activity in solution; and a lyophilization process that can retain AAD-12 activity for long-term storage and shelf life.

[00116] Insertion of genes to form transgenic hosts. One aspect of the subject invention is the transformation/transfection of plants, plant cells, and other host cells with polynucleotides of the subject invention that express proteins of the subject invention. Plants transformed in this manner can be rendered resistant to a variety of herbicides with different modes of action.

[00117] A wide variety of methods are available for introducing a gene encoding a desired protein into the target host under conditions that allow for stable maintenance and expression of the gene. These methods are well known to those skilled in the art and are described, for example, in U.S. Patent No. 5,135,867.

[00118] Vectors comprising an *AAD-12* polynucleotide are included in the scope of the subject invention. For example, a large number of cloning vectors comprising a replication system in *E. coli* and a marker that permits selection of the transformed cells are available for preparation for the insertion of foreign genes into higher plants. The vectors comprise, for example, pBR322, pUC series, M13mp series, pACYC184, *etc.* Accordingly, the sequence encoding the protein can be inserted into the vector at a suitable restriction site. The resulting

plasmid is used for transformation into *E. coli*. The *E. coli* cells are cultivated in a suitable nutrient medium, then harvested and lysed. The plasmid is recovered by purification away from genomic DNA. Sequence analysis, restriction analysis, electrophoresis, and other biochemical-molecular biological methods are generally carried out as methods of analysis. After each manipulation, the DNA sequence used can be restriction digested and joined to the next DNA sequence. Each plasmid sequence can be cloned in the same or other plasmids. Depending on the method of inserting desired genes into the plant, other DNA sequences may be necessary. If, for example, the Ti or Ri plasmid is used for the transformation of the plant cell, then at least the right border, but often the right and the left border of the Ti or Ri plasmid T-DNA, has to be joined as the flanking region of the genes to be inserted. The use of T-DNA for the transformation of plant cells has been intensively researched and described in EP 120 516; Hoekema (1985); Fraley *et al.* (1986); and An *et al.* (1985).

[00119] A large number of techniques are available for inserting DNA into a plant host cell. Those techniques include transformation with T-DNA using *Agrobacterium tumefaciens* or *Agrobacterium rhizogenes* as transformation agent, fusion, injection, biolistics (microparticle bombardment), silicon carbide whiskers, aerosol beaming, PEG, or electroporation as well as other possible methods. If *Agrobacteria* are used for the transformation, the DNA to be inserted has to be cloned into special plasmids, namely either into an intermediate vector or into a binary vector. The intermediate vectors can be integrated into the Ti or Ri plasmid by homologous recombination owing to sequences that are homologous to sequences in the T-DNA. The Ti or Ri plasmid also comprises the vir region necessary for the transfer of the T-DNA. Intermediate vectors cannot replicate themselves in *Agrobacteria*. The intermediate vector can be transferred into *Agrobacterium tumefaciens* by means of a helper plasmid (conjugation). Binary vectors can replicate themselves both in *E. coli* and in *Agrobacteria*. They comprise a selection marker gene and a linker or polylinker which are framed by the right and left T-DNA border regions. They can be transformed directly into *Agrobacteria* (Holsters, 1978). The *Agrobacterium* used as host cell is to comprise a plasmid carrying a vir region. The vir region is necessary for the transfer of the T-DNA into the plant cell. Additional T-DNA may be contained. The bacterium so transformed is used for the transformation of plant cells. Plant explants can be cultivated advantageously with *Agrobacterium tumefaciens* or *Agrobacterium rhizogenes* for the transfer of the DNA into the plant cell. Whole plants can then be regenerated from the infected plant material (for

BDDDB01 9494151v1

example, pieces of leaf, segments of stalk, roots, but also protoplasts or suspension-cultivated cells) in a suitable medium, which may contain antibiotics or biocides for selection. The plants so obtained can then be tested for the presence of the inserted DNA. No special demands are made of the plasmids in the case of injection and electroporation. It is possible to use ordinary plasmids, such as, for example, pUC derivatives.

[00120] The transformed cells grow inside the plants in the usual manner. They can form germ cells and transmit the transformed trait(s) to progeny plants. Such plants can be grown in the normal manner and crossed with plants that have the same transformed hereditary factors or other hereditary factors. The resulting hybrid individuals have the corresponding phenotypic properties.

[00121] In some preferred embodiments of the invention, genes encoding the bacterial protein are expressed from transcriptional units inserted into the plant genome. Preferably, said transcriptional units are recombinant vectors capable of stable integration into the plant genome and enable selection of transformed plant lines expressing mRNA encoding the proteins.

[00122] Once the inserted DNA has been integrated in the genome, it is relatively stable there (and does not come out again). It normally contains a selection marker that confers on the transformed plant cells resistance to a biocide or an antibiotic, such as kanamycin, G418, bleomycin, hygromycin, or chloramphenicol, *inter alia*. Plant selectable markers also typically can provide resistance to various herbicides such as glufosinate (*e.g.*, *PAT/bar*), glyphosate (*EPSPS*), ALS-inhibitors (*e.g.*, imidazolinone, sulfonylurea, triazolopyrimidine sulfonamide, *et al.*), bromoxynil, HPPD-inhibitor resistance, PPO-inhibitors, ACC-ase inhibitors, and many others. The individually employed marker should accordingly permit the selection of transformed cells rather than cells that do not contain the inserted DNA. The gene(s) of interest are preferably expressed either by constitutive or inducible promoters in the plant cell. Once expressed, the mRNA is translated into proteins, thereby incorporating amino acids of interest into protein. The genes encoding a protein expressed in the plant cells can be under the control of a constitutive promoter, a tissue-specific promoter, or an inducible promoter.

[00123] Several techniques exist for introducing foreign recombinant vectors into plant cells, and for obtaining plants that stably maintain and express the introduced gene. Such techniques include the introduction of genetic material coated onto microparticles directly

BDDBO1 9494151v1

into cells (U.S. Patent Nos. 4,945,050 to Cornell and 5,141,131 to DowElanco, now Dow AgroSciences, LLC). In addition, plants may be transformed using *Agrobacterium* technology, *see* U.S. Patent Nos. 5,177,010 to University of Toledo; 5,104,310 to Texas A&M; European Patent Application 0131624B1; European Patent Applications 120516, 159418B1 and 176,112 to Schilperoot; U.S. Patent Nos. 5,149,645, 5,469,976, 5,464,763 and 4,940,838 and 4,693,976 to Schilperoot; European Patent Applications 116718, 290799, 320500, all to Max Planck; European Patent Applications 604662 and 627752, and U.S. Patent No. 5,591,616, to Japan Tobacco; European Patent Applications 0267159 and 0292435, and U.S. Patent No. 5,231,019, all to Ciba Geigy, now Syngenta; U.S. Patent Nos. 5,463,174 and 4,762,785, both to Calgene; and U.S. Patent Nos. 5,004,863 and 5,159,135, both to Agracetus. Other transformation technology includes whiskers technology. *See* U.S. Patent Nos. 5,302,523 and 5,464,765, both to Zeneca, now Syngenta. Other direct DNA delivery transformation technology includes aerosol beam technology. *See* U.S. Patent No. 6,809,232. Electroporation technology has also been used to transform plants. *See* WO 87/06614 to Boyce Thompson Institute; U.S. Patent Nos. 5,472,869 and 5,384,253, both to Dekalb; and WO 92/09696 and WO 93/21335, both to Plant Genetic Systems. Furthermore, viral vectors can also be used to produce transgenic plants expressing the protein of interest. For example, monocotyledonous plants can be transformed with a viral vector using the methods described in U.S. Patent No. 5,569,597 to Mycogen Plant Science and Ciba-Geigy (now Syngenta), as well as U.S. Patent Nos. 5,589,367 and 5,316,931, both to Biosource, now Large Scale Biology.

[00124] As mentioned previously, the manner in which the DNA construct is introduced into the plant host is not critical to this invention. Any method that provides for efficient transformation may be employed. For example, various methods for plant cell transformation are described herein and include the use of Ti or Ri-plasmids and the like to perform *Agrobacterium* mediated transformation. In many instances, it will be desirable to have the construct used for transformation bordered on one or both sides by T-DNA borders, more specifically the right border. This is particularly useful when the construct uses *Agrobacterium tumefaciens* or *Agrobacterium rhizogenes* as a mode for transformation, although T-DNA borders may find use with other modes of transformation. Where *Agrobacterium* is used for plant cell transformation, a vector may be used which may be introduced into the host for homologous recombination with T-DNA or the Ti or Ri plasmid

BDDDB01 9494151v1

present in the host. Introduction of the vector may be performed via electroporation, tri-parental mating and other techniques for transforming gram-negative bacteria which are known to those skilled in the art. The manner of vector transformation into the *Agrobacterium* host is not critical to this invention. The Ti or Ri plasmid containing the T-DNA for recombination may be capable or incapable of causing gall formation, and is not critical to said invention so long as the vir genes are present in said host.

[00125] In some cases where *Agrobacterium* is used for transformation, the expression construct being within the T-DNA borders will be inserted into a broad spectrum vector such as pRK2 or derivatives thereof as described in Ditta *et al.* (1980) and EPO 0 120 515. Included within the expression construct and the T-DNA will be one or more markers as described herein which allow for selection of transformed *Agrobacterium* and transformed plant cells. The particular marker employed is not essential to this invention, with the preferred marker depending on the host and construction used.

[00126] For transformation of plant cells using *Agrobacterium*, explants may be combined and incubated with the transformed *Agrobacterium* for sufficient time to allow transformation thereof. After transformation, the *Agrobacteria* are killed by selection with the appropriate antibiotic and plant cells are cultured with the appropriate selective medium. Once calli are formed, shoot formation can be encouraged by employing the appropriate plant hormones according to methods well known in the art of plant tissue culturing and plant regeneration. However, a callus intermediate stage is not always necessary. After shoot formation, said plant cells can be transferred to medium which encourages root formation thereby completing plant regeneration. The plants may then be grown to seed and said seed can be used to establish future generations. Regardless of transformation technique, the gene encoding a bacterial protein is preferably incorporated into a gene transfer vector adapted to express said gene in a plant cell by including in the vector a plant promoter regulatory element, as well as 3' non-translated transcriptional termination regions such as Nos and the like.

[00127] In addition to numerous technologies for transforming plants, the type of tissue that is contacted with the foreign genes may vary as well. Such tissue would include but would not be limited to embryogenic tissue, callus tissue types I, II, and III, hypocotyl, meristem, root tissue, tissues for expression in phloem, and the like. Almost all plant tissues may be transformed during dedifferentiation using appropriate techniques described herein.

[00128] As mentioned above, a variety of selectable markers can be used, if desired. Preference for a particular marker is at the discretion of the artisan, but any of the following selectable markers may be used along with any other gene not listed herein which could function as a selectable marker. Such selectable markers include but are not limited to aminoglycoside phosphotransferase gene of transposon Tn5 (Aph II) which encodes resistance to the antibiotics kanamycin, neomycin and G41; hygromycin resistance; methotrexate resistance, as well as those genes which encode for resistance or tolerance to glyphosate; phosphinothricin (bialaphos or glufosinate); ALS-inhibiting herbicides (imidazolinones, sulfonyleureas and triazolopyrimidine herbicides), ACC-ase inhibitors (e.g., aryloxypropionates or cyclohexanediones), and others such as bromoxynil, and HPPD-inhibitors (e.g., mesotrione) and the like.

[00129] In addition to a selectable marker, it may be desirable to use a reporter gene. In some instances a reporter gene may be used with or without a selectable marker. Reporter genes are genes that are typically not present in the recipient organism or tissue and typically encode for proteins resulting in some phenotypic change or enzymatic property. Examples of such genes are provided in Weising *et al.*, 1988. Preferred reporter genes include the beta-glucuronidase (GUS) of the *uidA* locus of *E. coli*, the chloramphenicol acetyl transferase gene from Tn9 of *E. coli*, the green fluorescent protein from the bioluminescent jellyfish *Aequorea victoria*, and the luciferase genes from firefly *Photinus pyralis*. An assay for detecting reporter gene expression may then be performed at a suitable time after said gene has been introduced into recipient cells. A preferred such assay entails the use of the gene encoding beta-glucuronidase (GUS) of the *uidA* locus of *E. coli* as described by Jefferson *et al.*, (1987) to identify transformed cells.

[00130] In addition to plant promoter regulatory elements, promoter regulatory elements from a variety of sources can be used efficiently in plant cells to express foreign genes. For example, promoter regulatory elements of bacterial origin, such as the octopine synthase promoter, the nopaline synthase promoter, the mannopine synthase promoter; promoters of viral origin, such as the cauliflower mosaic virus (35S and 19S), 35T (which is a re-engineered 35S promoter, *see* U.S. Patent No. 6,166,302, especially Example 7E) and the like may be used. Plant promoter regulatory elements include but are not limited to ribulose-1,6-bisphosphate (RUBP) carboxylase small subunit (ssu), beta-conglycinin promoter, beta-phaseolin promoter, ADH promoter, heat-shock promoters, and tissue specific promoters.

BDDDB01 9494151v1

Other elements such as matrix attachment regions, scaffold attachment regions, introns, enhancers, polyadenylation sequences and the like may be present and thus may improve the transcription efficiency or DNA integration. Such elements may or may not be necessary for DNA function, although they can provide better expression or functioning of the DNA by affecting transcription, mRNA stability, and the like. Such elements may be included in the DNA as desired to obtain optimal performance of the transformed DNA in the plant. Typical elements include but are not limited to Adh-intron 1, Adh-intron 6, the alfalfa mosaic virus coat protein leader sequence, osmotin UTR sequences, the maize streak virus coat protein leader sequence, as well as others available to a skilled artisan. Constitutive promoter regulatory elements may also be used thereby directing continuous gene expression in all cells types and at all times (*e.g.*, actin, ubiquitin, CaMV 35S, and the like). Tissue specific promoter regulatory elements are responsible for gene expression in specific cell or tissue types, such as the leaves or seeds (*e.g.*, zein, oleosin, napin, ACP, globulin and the like) and these may also be used.

[00131] Promoter regulatory elements may also be active (or inactive) during a certain stage of the plant's development as well as active in plant tissues and organs. Examples of such include but are not limited to pollen-specific, embryo-specific, corn-silk-specific, cotton-fiber-specific, root-specific, seed-endosperm-specific, or vegetative phase-specific promoter regulatory elements and the like. Under certain circumstances it may be desirable to use an inducible promoter regulatory element, which is responsible for expression of genes in response to a specific signal, such as: physical stimulus (heat shock genes), light (RUBP carboxylase), hormone (Em), metabolites, chemical (tetracycline responsive), and stress. Other desirable transcription and translation elements that function in plants may be used. Numerous plant-specific gene transfer vectors are known in the art.

[00132] Plant RNA viral based systems can also be used to express bacterial protein. In so doing, the gene encoding a protein can be inserted into the coat promoter region of a suitable plant virus which will infect the host plant of interest. The protein can then be expressed thus providing protection of the plant from herbicide damage. Plant RNA viral based systems are described in U.S. Patent No. 5,500,360 to Mycogen Plant Sciences, Inc. and U.S. Patent Nos. 5,316,931 and 5,589,367 to Biosource, now Large Scale Biology.

[00133] Means of further increasing tolerance or resistance levels. It is shown herein that plants of the subject invention can be imparted with novel herbicide resistance traits without

observable adverse effects on phenotype including yield. Such plants are within the scope of the subject invention. Plants exemplified and suggested herein can withstand 2X, 3X, 4X, and 5X typical application levels, for example, of at least one subject herbicide. Improvements in these tolerance levels are within the scope of this invention. For example, various techniques are known in the art, and can foreseeably be optimized and further developed, for increasing expression of a given gene.

[00134] One such method includes increasing the copy number of the subject AAD-12 genes (in expression cassettes and the like). Transformation events can also be selected for those having multiple copies of the genes.

[00135] Strong promoters and enhancers can be used to “supercharge” expression. Examples of such promoters include the preferred 35T promoter which uses 35S enhancers. 35S, maize ubiquitin, Arabidopsis ubiquitin, A.t. actin, and CSMV promoters are included for such uses. Other strong viral promoters are also preferred. Enhancers include 4 OCS and the 35S double enhancer. Matrix attachment regions (MARs) can also be used to increase transformation efficiencies and transgene expression, for example.

[00136] Shuffling (directed evolution) and transcription factors can also be used for embodiments according to the subject invention.

[00137] Variant proteins can also be designed that differ at the sequence level but that retain the same or similar overall essential three-dimensional structure, surface charge distribution, and the like. See *e.g.* U.S. Patent No. 7,058,515; Larson et al., *Protein Sci.* 2002 11: 2804-2813, “Thoroughly sampling sequence space: Large-scale protein design of structural ensembles.”; Crameri *et al.*, *Nature Biotechnology* 15, 436 - 438 (1997), “Molecular evolution of an arsenate detoxification pathway by DNA shuffling.”; Stemmer, W.P.C.1994. DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution. *Proc. Natl. Acad. Sci. USA* 91: 10747–10751; Stemmer, W.P.C.1994. Rapid evolution of a protein in vitro by DNA shuffling. *Nature* 370: 389–391; Stemmer, W.P.C.1995. Searching sequence space. *Bio/Technology* 13: 549–553; Crameri, A., Cwirla, S. and Stemmer, W.P.C.1996. Construction and evolution of antibody-phage libraries by DNA shuffling. *Nature Medicine* 2: 100–103; and Crameri, A., Whitehorn, E.A., Tate, E. and Stemmer, W.P.C. 1996. Improved green fluorescent protein by molecular evolution using DNA shuffling. *Nature Biotechnology* 14: 315–319.

BDDDB01 9494151v1

[00138] The activity of recombinant polynucleotides inserted into plant cells can be dependent upon the influence of endogenous plant DNA adjacent the insert. Thus, another option is taking advantage of events that are known to be excellent locations in a plant genome for insertions. *See e.g.* WO 2005/103266 A1, relating to cry1F and cry1Ac cotton events; the subject AAD-12 gene can be substituted in those genomic loci in place of the cry1F and/or cry1Ac inserts. Thus, targeted homologous recombination, for example, can be used according to the subject invention. This type of technology is the subject of, for example, WO 03/080809 A2 and the corresponding published U.S. application (USPA 20030232410), relating to the use of zinc fingers for targeted recombination. The use of recombinases (cre-lox and flp-frt for example) is also known in the art.

[00139] AAD-12 detoxification is believed to occur in the cytoplasm. Thus, means for further stabilizing this protein and mRNAs (including blocking mRNA degradation) are included in aspects of the subject invention, and art-known techniques can be applied accordingly. The subject proteins can be designed to resist degradation by proteases and the like (protease cleavage sites can be effectively removed by re-engineering the amino acid sequence of the protein). Such embodiments include the use of 5' and 3' stem loop structures like UTRs from osmotin, and per5 (AU-rich untranslated 5' sequences). 5' caps like 7-methyl or 2'-O-methyl groups, e.g., 7-methylguanylic acid residue, can also be used. *See, e.g.:* Proc. Natl. Acad. Sci. USA Vol. 74, No. 7, pp. 2734-2738 (July 1977) *Importance of 5'-terminal blocking structure to stabilize mRNA in eukaryotic protein synthesis*. Protein complexes or ligand blocking groups can also be used.

[00140] Computational design of 5' or 3' UTR most suitable for AAD-12 (synthetic hairpins) can also be conducted within the scope of the subject invention. Computer modeling in general, as well as gene shuffling and directed evolution, are discussed elsewhere herein. More specifically regarding computer modeling and UTRs, computer modeling techniques for use in predicting/evaluating 5' and 3' UTR derivatives of the present invention include, but are not limited to: MFold version 3.1 available from Genetics Corporation Group, Madison, WI (see Zucker et al., Algorithms and Thermodynamics for RNA Secondary Structure Prediction: A Practical Guide. In *RNA Biochemistry and Biotechnology*, 11-43, J. Barciszewski & B.F.C. Clark, eds., NATO ASI Series, Kluwer Academic Publishers, Dordrecht, NL, (1999); Zucker et al., *Expanded Sequence Dependence of Thermodynamic Parameters Improves Prediction of RNA Secondary Structure*. *J. Mol. Biol.* 288, 911-940

BDDB01 9494151v1

(1999); Zucker *et al.*, RNA Secondary Structure Prediction. In *Current Protocols in Nucleic Acid Chemistry* S. Beaucage, D.E. Bergstrom, G.D. Glick, and R.A. Jones eds., John Wiley & Sons, New York, 11.2.1-11.2.10, (2000)), COVE (RNA structure analysis using covariance models (stochastic context free grammar methods)) v.2.4.2 (Eddy & Durbin, Nucl. Acids Res. 1994, 22: 2079-2088) which is freely distributed as source code and which can be downloaded by accessing the website genetics.wustl.edu/eddy/software/, and FOLDALIGN, also freely distributed and available for downloading at the website bioinf.au.dk.FOLDALIGN/ (see *Finding the most significant common sequence and structure motifs in a set of RNA sequences.* J. Gorodkin, L. J. Heyer and G. D. Stormo. Nucleic Acids Research, Vol. 25, no. 18 pp 3724-3732, 1997; *Finding Common Sequence and Structure Motifs in a set of RNA Sequences.* J. Gorodkin, L. J. Heyer, and G. D. Stormo. ISMB 5;120-123, 1997).

[00141] Embodiments of the subject invention can be used in conjunction with naturally evolved or chemically induced mutants (mutants can be selected by screening techniques, then transformed with AAD-12 and possibly other genes). Plants of the subject invention can be combined with ALS resistance and/or evolved glyphosate resistance. Aminopyralid resistance, for example, can also be combined or “stacked” with an AAD-12 gene.

[00142] Traditional breeding techniques can also be combined with the subject invention to powerfully combine, introgress, and improve desired traits.

[00143] Further improvements also include use with appropriate safeners to further protect plants and/or to add cross resistance to more herbicides. (Safeners typically act to increase plants immune system by activating/expressing cP450. Safeners are chemical agents that reduce the phytotoxicity of herbicides to crop plants by a physiological or molecular mechanism, without compromising weed control efficacy.)

[00144] Herbicide safeners include benoxacor, cloquintocet, cyometrinil, dichlormid, dicyclonon, dietholate, fenchlorazole, fenclorim, flurazole, fluxofenim, furilazole, isoxadifen, mefenpyr, mephenate, naphthalic anhydride, and oxabetrinil. Plant activators (a new class of compounds that protect plants by activating their defense mechanisms) can also be used in embodiments of the subject invention. These include acibenzolar and probenazole.

[00145] Commercialized safeners can be used for the protection of large-seeded grass crops, such as corn, grain sorghum, and wet-sown rice, against preplant-incorporated or preemergence-applied herbicides of the thiocarbamate and chloroacetanilide families. Safeners also have been developed to protect winter cereal crops such as wheat against

BDDBO1 9494151v1

postemergence applications of aryloxyphenoxypropionate and sulfonylurea herbicides. The use of safeners for the protection of corn and rice against sulfonylurea, imidazolinone, cyclohexanedione, isoxazole, and triketone herbicides is also well-established. A safener-induced enhancement of herbicide detoxification in safened plants is widely accepted as the major mechanism involved in safener action. Safeners induce cofactors such as glutathione and herbicide-detoxifying enzymes such as glutathione *S*-transferases, cytochrome P450 monooxygenases, and glucosyl transferases. Hatzios KK, Burgos N (2004) "Metabolism-based herbicide resistance: regulation by safeners," *Weed Science*: Vol. 52, No. 3 pp. 454–467.

[00146] Use of a cytochrome p450 monooxygenase gene stacked with AAD-12 is one preferred embodiment. There are P450s involved in herbicide metabolism; cP450 can be of mammalian or plant origin, for example. In higher plants, cytochrome P450 monooxygenase (P450) is known to conduct secondary metabolism. It also plays an important role in the oxidative metabolism of xenobiotics in cooperation with NADPH-cytochrome P450 oxidoreductase (reductase). Resistance to some herbicides has been reported as a result of the metabolism by P450 as well as glutathione *S*-transferase. A number of microsomal P450 species involved in xenobiotic metabolism in mammals have been characterized by molecular cloning. Some of them were reported to metabolize several herbicides efficiently. Thus, transgenic plants with plant or mammalian P450 can show resistance to several herbicides.

[00147] One preferred embodiment of the foregoing is the use cP450 for resistance to acetochlor (acetochlor-based products include Surpass®, Keystone®, Keystone LA, FulTime® and TopNotch® herbicides) and/or trifluralin (such as Treflan®). Such resistance in soybeans and/or corn is included in some preferred embodiments. For additional guidance regarding such embodiments, *see e.g.* Inui *et al.*, "A selectable marker using cytochrome P450 monooxygenases for Arabidopsis transformation," *Plant Biotechnology* 22, 281–286 (2005) (relating to a selection system for transformation of *Arabidopsis thaliana* via *Agrobacterium tumefaciens* that uses human cytochrome P450 monooxygenases that metabolize herbicides; herbicide tolerant seedlings were transformed and selected with the herbicides acetochlor, amiprofos-methyl, chlorpropham, chlorsulfuron, norflurazon, and pendimethalin); Siminszky *et al.*, "Expression of a soybean cytochrome P450 monooxygenase cDNA in yeast and tobacco enhances the metabolism of phenylurea herbicides," *PNAS* Vol. 96, Issue 4, 1750-1755, February 16, 1999; Sheldon *et al.*, *Weed*

BDDB01 9494151v1

Science: Vol. 48, No. 3, pp. 291–295, “A cytochrome P450 monooxygenase cDNA (CYP71A10) confers resistance to linuron in transgenic *Nicotiana tabacum*”; and “Phytoremediation of the herbicides atrazine and metolachlor by transgenic rice plants expressing human CYP1A1, CYP2B6, and CYP2C19,” *J Agric Food Chem*. 2006 Apr 19;54(8):2985-91 (relating to testing a human cytochrome p450 monooxygenase in rice where the rice plants reportedly showed high tolerance to chloroacetamides (acetochlor, alachlor, metolachlor, pretilachlor, and thenylchlor), oxyacetamides (mefenacet), pyridazinones (norflurazon), 2,6-dinitroanilines (trifluralin and pendimethalin), phosphamides (amiprofos-methyl, thiocarbamates (pyributicarb), and ureas (chlortoluron)).

[00148] There is also the possibility of altering or using different 2,4-D chemistries to make the subject AAD-12 genes more efficient. Such possible changes include creating better substrates and better leaving groups (higher electronegativity).

[00149] Auxin transport inhibitors (e.g. diflufenzopyr) can also be used to increase herbicide activity with 2,4-D.

[00150] Unless specifically indicated or implied, the terms “a”, “an”, and “the” signify “at least one” as used herein.

[00151] All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety to the extent they are not inconsistent with the explicit teachings of this specification.

[00152] Following are examples that illustrate procedures for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

Example 1 – Method for Identifying Genes That Impart Resistance to 2,4-D *In Planta*

[00153] As a way to identify genes which possess herbicide degrading activities *in planta*, it is possible to mine current public databases such as NCBI (National Center for Biotechnology Information). To begin the process, it is necessary to have a functional gene sequence already identified that encodes a protein with the desired characteristics (*i.e.*, α -ketoglutarate dioxygenase activity). This protein sequence is then used as the input for the BLAST (Basic

BDDDB01 9494151v1

Local Alignment Search Tool) (Altschul *et al.*, 1997) algorithm to compare against available NCBI protein sequences deposited. Using default settings, this search returns upwards of 100 homologous protein sequences at varying levels. These range from highly identical (85-98%) to very low identity (23-32%) at the amino acid level. Traditionally only sequences with high homology would be expected to retain similar properties to the input sequence. In this case, only sequences with $\leq 50\%$ homology were chosen. As exemplified herein, cloning and recombinantly expressing homologues with as little as 31% amino acid conservation (relative to *tfdA* from *Ralstonia eutropha*) can be used to impart commercial levels of resistance not only to the intended herbicide, but also to substrates never previously tested with these enzymes.

[00154] A single gene (*sdpA*) was identified from the NCBI database (see the ncbi.nlm.nih.gov website; accession #AF516752) as a homologue with only 31% amino acid identity to *tfdA*. Percent identity was determined by first translating both the *sdpA* and *tfdA* DNA sequences deposited in the database to proteins, then using ClustalW in the VectorNTI software package to perform the multiple sequence alignment.

Example 2 – Optimization of Sequence for Expression in Plants and Bacteria

[00155] 2.1 – Background.

[00156] To obtain higher levels of expression of heterologous genes in plants, it may be preferred to reengineer the protein encoding sequence of the genes so that they are more efficiently expressed in plant cells. Maize is one such plant where it may be preferred to re-design the heterologous protein coding region prior to transformation to increase the expression level of the gene and the level of encoded protein in the plant. Therefore, an additional step in the design of genes encoding a bacterial protein is reengineering of a heterologous gene for optimal expression.

[00157] One reason for the reengineering of a bacterial protein for expression in maize is due to the non-optimal G+C content of the native gene. For example, the very low G+C content of many native bacterial gene(s) (and consequent skewing towards high A+T content) results in the generation of sequences mimicking or duplicating plant gene control sequences that are known to be highly A+T rich. The presence of some A+T-rich sequences within the DNA of gene(s) introduced into plants (*e.g.*, TATA box regions normally found in gene promoters) may result in aberrant transcription of the gene(s). On the other hand, the presence of other

BDDDB01 9494151v1

regulatory sequences residing in the transcribed mRNA (*e.g.*, polyadenylation signal sequences (AAUAAA), or sequences complementary to small nuclear RNAs involved in pre-mRNA splicing) may lead to RNA instability. Therefore, one goal in the design of genes encoding a bacterial protein for maize expression, more preferably referred to as plant optimized gene(s), is to generate a DNA sequence having a higher G+C content, and preferably one close to that of maize genes coding for metabolic enzymes. Another goal in the design of the plant optimized gene(s) encoding a bacterial protein is to generate a DNA sequence in which the sequence modifications do not hinder translation.

[00158] **Table 3** illustrates how high the G+C content is in maize. For the data in **Table 3**, coding regions of the genes were extracted from GenBank (Release 71) entries, and base compositions were calculated using the MacVector™ program (Accelrys, San Diego, California). Intron sequences were ignored in the calculations.

Table 3: Compilation of G + C contents of protein coding regions of maize genes		
Protein Class ^a	Range % G + C	Mean % G + C ^b
Metabolic Enzymes (76)	44.4-75.3	59.0 (±.8.0)
Structural Proteins (18)	48.6-70.5	63.6 (±.6.7)
Regulatory Proteins (5)	57.2-68.8	62.0 (±.4.9)
Uncharacterized Proteins (9)	41.5-70.3	64.3 (±.7.2)
All Proteins (108)	44.4-75.3	60.8 (±.5.2) ^c

^a Number of genes in class given in parentheses.

^b Standard deviations given in parentheses.

^c Combined groups mean ignored in mean calculation

[00159] Due to the plasticity afforded by the redundancy/degeneracy of the genetic code (*i.e.*, some amino acids are specified by more than one codon), evolution of the genomes in different organisms or classes of organisms has resulted in differential usage of redundant codons. This “codon bias” is reflected in the mean base composition of protein coding regions. For example, organisms with relatively low G+C contents utilize codons having A or T in the third position of redundant codons, whereas those having higher G+C contents utilize codons having G or C in the third position. It is thought that the presence of “minor” codons within an mRNA may reduce the absolute translation rate of that mRNA, especially when the relative abundance of the charged tRNA corresponding to the minor codon is low. An extension of this is that the diminution of translation rate by individual minor codons would be at least additive for multiple minor codons. Therefore, mRNAs having high relative contents of minor codons would have correspondingly low translation rates. This rate would be reflected by subsequent low levels of the encoded protein.

[00160] In engineering genes encoding a bacterial protein for maize (or other plant, such as cotton or soybean) expression, the codon bias of the plant has been determined. The codon bias for maize is the statistical codon distribution that the plant uses for coding its proteins and the preferred codon usage is shown in **Table 4**. After determining the bias, the percent frequency of the codons in the gene(s) of interest is determined. The primary codons preferred by the plant should be determined, as well as the second, third, and fourth choices of preferred codons when multiple choices exist. A new DNA sequence can then be designed which encodes the amino sequence of the bacterial protein, but the new DNA sequence differs from the native bacterial DNA sequence (encoding the protein) by the substitution of the plant (first preferred, second preferred, third preferred, or fourth preferred) codons to specify the amino acid at each position within the protein amino acid sequence. The new

BDDB01 9494151v1

sequence is then analyzed for restriction enzyme sites that might have been created by the modification. The identified sites are further modified by replacing the codons with first, second, third, or fourth choice preferred codons. Other sites in the sequence which could affect transcription or translation of the gene of interest are the exon:intron junctions (5' or 3'), poly A addition signals, or RNA polymerase termination signals. The sequence is further analyzed and modified to reduce the frequency of TA or GC doublets. In addition to the doublets, G or C sequence blocks that have more than about four residues that are the same can affect transcription of the sequence. Therefore, these blocks are also modified by replacing the codons of first or second choice, *etc.* with the next preferred codon of choice.

Table 4. Preferred amino acid codons for proteins expressed in maize

Amino Acid	Codon*
Alanine	GCC/GCG
Cysteine	TGC/TGT
Aspartic Acid	GAC/GAT
Glutamic Acid	GAG/GAA
Phenylalanine	TTC/TTT
Glycine	GGC/GGG
Histidine	CAC/CAT
Isoleucine	ATC/ATT
Lysine	AAG/AAA
Leucine	CTG/CTC
Methionine	ATG
Asparagine	AAC/AAT
Proline	CCG/CCA
Glutamine	CAG/CAA
Arginine	AGG/CGC
Serine	AGC/TCC
Threonine	ACC/ACG
Valine	GTG/GTC
Tryptophan	TGG
Tryrosine	TAC/TAT
Stop	TGA/TAG

[00161]

It is preferred that the plant optimized gene(s) encoding a bacterial protein contain about 63% of first choice codons, between about 22% to about 37% second choice codons, and between about 15% to about 0% third or fourth choice codons, wherein the total percentage is 100%. Most preferred the plant optimized gene(s) contains about 63% of first choice codons, at least about 22% second choice codons, about 7.5% third choice codons, and

BDDDB01 9494151v1

about 7.5% fourth choice codons, wherein the total percentage is 100%. The method described above enables one skilled in the art to modify gene(s) that are foreign to a particular plant so that the genes are optimally expressed in plants. The method is further illustrated in PCT application WO 97/13402.

[00162] Thus, in order to design plant optimized genes encoding a bacterial protein, a DNA sequence is designed to encode the amino acid sequence of said protein utilizing a redundant genetic code established from a codon bias table compiled from the gene sequences for the particular plant or plants. The resulting DNA sequence has a higher degree of codon diversity, a desirable base composition, can contain strategically placed restriction enzyme recognition sites, and lacks sequences that might interfere with transcription of the gene, or translation of the product mRNA. Thus, synthetic genes that are functionally equivalent to the proteins/genes of the subject invention can be used to transform hosts, including plants. Additional guidance regarding the production of synthetic genes can be found in, for example, U.S. Patent No. 5,380,831.

[00163] 2.2 – AAD-12 Plant rebuild analysis.

[00164] Extensive analysis of the 876 base pairs (bp) of the DNA sequence of the native *AAD-12* coding region (SEQ ID NO:1) revealed the presence of several sequence motifs that are thought to be detrimental to optimal plant expression, as well as a non-optimal codon composition. The protein encoded by SEQ ID NO:1 (*AAD-12*) is presented as SEQ ID NO:2. To improve production of the recombinant protein in monocots as well as dicots, a “plant-optimized” DNA sequence *AAD-12 (v1)* (SEQ ID NO:3) was developed that encodes a protein (SEQ ID NO:4) which is the same as the native SEQ ID NO:2 except for the addition of an alanine residue at the second position (underlined in SEQ ID NO:4). The additional alanine codon (GCT; underlined in SEQ ID NO:3) encodes part of an *NcoI* restriction enzyme recognition site (CCATGG) spanning the ATG translational start codon. Thus, it serves the dual purpose of facilitating subsequent cloning operations while improving the sequence context surrounding the ATG start codon to optimize translation initiation. The proteins encoded by the native and plant-optimized (v1) coding regions are 99.3% identical, differing only at amino acid number 2. In contrast, the native and plant-optimized (v1) DNA sequences of the coding regions are only 79.7% identical. **Table 5** shows the differences in codon compositions of the native (Columns A and D) and plant-optimized sequences

(Columns B and E), and allows comparison to a theoretical plant-optimized sequence (Columns C and F).

Table 5. Codon composition comparisons of coding regions of Native *AAD-12*, Plant-Optimized version (v1) and a Theoretical Plant-Optimized version.

		A	B	C			D	E	F
Amino Acid	Codon	Native #	Plant Opt v1 #	Theor. Plant Opt. #	Amino Acid	Codon	Native #	Plant Opt v1 #	Theor. Plant Opt. #
ALA (A)	GCA	1	10	11	LEU (L)	CTA	0	0	0
	GCC	35	16	15		CTC	1	8	8
	GCG	7	0	0		CTG	23	0	0
	GCT	0	18	17		CTT	0	8	8
ARG (R)	AGA	0	4	5		TTA	0	0	0
	AGG	0	4	6		TTG	0	8	8
	CGA	0	0	0	LYS (K)	AAA	1	1	2
	CGC	15	6	4		AAG	5	5	4
	CGG	3	0	0	MET (M)	ATG	10	10	10
ASN (N)	CGT	0	4	3		TTC	7	5	5
	AAC	3	2	2	PHE (F)	TTT	1	3	3
	AAT	1	2	2		CCA	0	5	6
ASP (D)	GAC	15	9	9	PRO (P)	CCC	9	4	4
	GAT	2	8	8		CCG	5	0	0
CYS (C)	TGC	3	2	2		CCT	0	5	5
	TGT	0	1	1		AGC	5	4	3
END	TAA	1	0	1	SER (S)	AGT	0	0	0
	TAG	0	0			TCA	0	3	3
	TGA	0	1			TCC	2	3	3
GLN (Q)	CAA	1	8	7		TCG	6	0	0
	CAG	13	6	7		TCT	0	3	3
GLU (E)	GAA	3	4	4	THR (T)	ACA	1	4	5
	GAG	8	7	7		ACC	11	7	7
GLY (G)	GGA	0	8	7		ACG	5	0	0
	GGC	24	7	7		ACT	1	7	6
	GGG	1	3	4	TRP (W)	TGG	8	8	8
	GGT	0	7	7		TAC	4	3	3
HIS (H)	CAC	8	9	9	TYR (Y)	TAT	1	2	2
	CAT	8	7	7	VAL (V)	GTA	0	0	0
ILE (I)	ATA	0	2	2		GTC	6	8	7
	ATC	10	4	5		GTG	18	8	9
	ATT	1	5	4		GTT	0	8	8
	Totals	163	164	163		Totals	130	130	130

[00165]

It is clear from examination of Table 5 that the native and plant-optimized coding regions, while encoding nearly identical proteins, are substantially different from one another. The Plant-Optimized version (v1) closely mimics the codon composition of a theoretical plant-optimized coding region encoding the AAD-12 protein.

BDDBO1 9494151v1

[00166] 2.3 Rebuild for *E. coli* Expression

[00167] Specially engineered strains of *Escherichia coli* and associated vector systems are often used to produce relatively large amounts of proteins for biochemical and analytical studies. It is sometimes found that a native gene encoding the desired protein is not well suited for high level expression in *E. coli*, even though the source organism for the gene may be another bacterial genus. In such cases it is possible and desirable to reengineer the protein coding region of the gene to render it more suitable for expression in *E. coli*. *E. coli* Class II genes are defined as those that are highly and continuously expressed during the exponential growth phase of *E. coli* cells. (Henaut, A. and Danchin, A. (1996) in *Escherichia coli and Salmonella typhimurium cellular and molecular biology*, vol. 2, pp. 2047–2066. Neidhardt, F., Curtiss III, R., Ingraham, J., Lin, E., Low, B., Magasanik, B., Reznikoff, W., Riley, M., Schaechter, M. and Umberger, H. (eds.) American Society for Microbiology, Washington, DC). Through examination of the codon compositions of the coding regions of *E. coli* Class II genes, one can devise an average codon composition for these *E. coli*-Class II gene coding regions. It is thought that a protein coding region having an average codon composition mimicking that of the Class II genes will be favored for expression during the exponential growth phase of *E. coli*. Using these guidelines, a new DNA sequence that encodes the AAD-12 protein (SEQ ID NO:4); including the additional alanine at the second position, as mentioned above), was designed according to the average codon composition of *E. coli* Class II gene coding regions. The initial sequence, whose design was based only on codon composition, was further engineered to include certain restriction enzyme recognition sequences suitable for cloning into *E. coli* expression vectors. Detrimental sequence features such as highly stable stemloop structures were avoided, as were intragenic sequences homologous to the 3' end of the 16S ribosomal RNA (*i.e.* Shine Dalgarno sequences) The *E. coli*-optimized sequence (v2) is disclosed as SEQ ID NO:5 and encodes the protein disclosed in SEQ ID NO:4.

[00168] The native and *E. coli*-optimized (v2) DNA sequences are 84.0% identical, while the plant-optimized (v1) and *E. coli*-optimized (v2) DNA sequences are 76.0% identical. Table 6 presents the codon compositions of the native *AAD-12* coding region (Columns A and D), an *AAD-12* coding region optimized for expression in *E. coli* (v2; Columns B and E) and the codon composition of a theoretical coding region for the AAD-12 protein having an optimal codon composition of *E. coli* Class II genes (Columns C and F).

BDDDB01 9494151v1

Table 6. Codon composition comparisons of coding regions of Native *AAD-12*, *E. coli*-Optimized version (v2) and a Theoretical *E. coli* Class II-Optimized version.

		A	B	C			D	E	F
Amino Acid	Codon	Native #	<i>E. coli</i> Opt v2 #	Theor. Class II #	Amino Acid	Codon	Native #	<i>E. coli</i> Opt v2 #	Theor. Class II #
ALA (A)	GCA	1	13	13	LEU (L)	CTA	0	0	0
	GCC	35	0	0		CTC	1	2	0
	GCG	7	18	17		CTG	23	20	24
	GCT	0	13	14		CTT	0	1	0
ARG (R)	AGA	0	0	0		TTA	0	1	0
	AGG	0	0	0	LYS (K)	TTG	0	0	0
	CGA	0	0	0		AAA	1	4	5
	CGC	15	6	6	AAG	AAG	5	2	1
	CGG	3	0	0		ATG	10	10	10
CGT	CGT	0	12	12	PHE (F)	TTC	7	6	6
	AAC	3	4	4		TTT	1	2	2
ASN (N)	AAT	1	0	0	PRO (P)	CCA	0	3	2
	GAC	15	10	9		CCC	9	0	0
ASP (D)	GAT	2	7	8		CCG	5	11	12
	TGC	3	2	2		CCT	0	0	0
CYS (C)	TGT	0	1	1	SER (S)	AGC	5	4	4
	TAA	1	1	1		AGT	0	0	0
END	TAG	0	0	0		TCA	0	0	0
	TGA	0	0	0		TCC	2	5	4
GLN (Q)	CAA	1	3	3		TCG	6	0	0
	CAG	13	11	11		TCT	0	4	5
GLU (E)	GAA	3	8	8	THR (T)	ACA	1	0	0
	GAG	8	3	3		ACC	11	12	12
GLY (G)	GGA	0	0	0		ACG	5	0	0
	GGC	24	12	11		ACT	1	6	6
	GGG	1	0	0	TRP (W)	TGG	8	8	8
	GGT	0	13	14		TAC	4	3	3
HIS (H)	CAC	8	11	11	TYR (Y)	TAT	1	2	2
	CAT	8	5	5	VAL (V)	GTA	0	6	6
ILE (I)	ATA	0	0	0		GTC	6	0	0
	ATC	10	7	7		GTG	18	8	7
	ATT	1	4	4		GTT	0	10	11
	Totals	163	164	164		Totals	130	130	130

[00169]

It is clear from examination of Table 6 that the native and *E. coli*-optimized coding regions, while encoding nearly identical proteins, are substantially different from one another. The *E. coli*-Optimized version (v2) closely mimics the codon composition of a theoretical *E. coli*-optimized coding region encoding the AAD-12 protein.

[00170]

2.4 – Design of a soybean-codon-biased DNA sequence encoding a soybean EPSPS having mutations that confer glyphosate tolerance. This example teaches the design of a new DNA sequence that encodes a mutated soybean 5-enolpyruvoylshikimate 3-phosphate

BDDBO1 9494151v1

synthase (EPSPS), but is optimized for expression in soybean cells. The amino acid sequence of a triply-mutated soybean EPSPS is disclosed as SEQ ID NO:5 of WO 2004/009761. The mutated amino acids in the so-disclosed sequence are at residue 183 (threonine of native protein replaced with isoleucine), residue 186 (arginine in native protein replaced with lysine), and residue 187 (proline in native protein replaced with serine). Thus, one can deduce the amino acid sequence of the native soybean EPSPS protein by replacing the substituted amino acids of SEQ ID NO:5 of WO 2004/009761 with the native amino acids at the appropriate positions. Such native protein sequence is disclosed as SEQ ID NO:20 of PCT/US2005/014737 (filed May 2, 2005). A doubly mutated soybean EPSPS protein sequence, containing a mutation at residue 183 (threonine of native protein replaced with isoleucine), and at residue 187 (proline in native protein replaced with serine) is disclosed as SEQ ID NO:21 of PCT/US2005/014737.

[00171] A codon usage table for soybean (*Glycine max*) protein coding sequences, calculated from 362,096 codons (approximately 870 coding sequences), was obtained from the “kazusa.or.jp/codon” World Wide Web site. Those data were reformatted as displayed in Table 7. Columns D and H of Table 7 present the distributions (in % of usage for all codons for that amino acid) of synonymous codons for each amino acid, as found in the protein coding regions of soybean genes. It is evident that some synonymous codons for some amino acids (an amino acid may be specified by 1, 2, 3, 4, or 6 codons) are present relatively rarely in soybean protein coding regions (for example, compare usage of GCG and GCT codons to specify alanine). A biased soybean codon usage table was calculated from the data in Table 7. Codons found in soybean genes less than about 10% of total occurrences for the particular amino acid were ignored. To balance the distribution of the remaining codon choices for an amino acid, a weighted average representation for each codon was calculated, using the formula:

$$\text{Weighted \% of C1} = 1/(\%C1 + \%C2 + \%C3 + \text{etc.}) \times \%C1 \times 100$$

where C1 is the codon in question, C2, C3, etc. represent the remaining synonymous codons, and the % values for the relevant codons are taken from columns D and H of Table 7 (ignoring the rare codon values in bold font). The Weighted % value for each codon is given in Columns C and G of Table 7. TGA was arbitrarily chosen as the translation terminator. The biased codon usage frequencies were then entered into a specialized genetic code table

for use by the OptGene™ gene design program (Ocimum Biosolutions LLC, Indianapolis, Indiana).

Table 7. Synonymous codon representation in soybean protein coding sequences, and calculation of a biased codon representation set for soybean-optimized synthetic gene design.

A	B	C	D	E	F	G	H
Amino Acid	Codon	Weighted %	Soybean %	Amino Acid	Codon	Weighted %	Soybean %
ALA (A)	GCA	33.1	30.3	LEU (L)	CTA	DNU	9.1
	GCC	24.5	22.5		CTC	22.4	18.1
	GCG	DNU*	8.5		CTG	16.3	13.2
	GCT	42.3	38.7		CTT	31.5	25.5
ARG (R)	AGA	36.0	30.9		TTA	DNU	9.8
	AGG	32.2	27.6		TTG	29.9	24.2
	CGA	DNU	8.2	LYS (K)	AAA	42.5	42.5
	CGC	14.8	12.7		AAG	57.5	57.5
	CGG	DNU	6.0	MET (M)	ATG	100.0	100
	CGT	16.9	14.5	PHE (F)	TTC	49.2	49.2
ASN (N)	AAC	50.0	50.0		TTT	50.8	50.8
	AAT	50.0	50.0	PRO (P)	CCA	39.8	36.5
ASP (D)	GAC	38.1	38.1		CCC	20.9	19.2
	GAT	61.9	61.9		CCG	DNU	8.3
CYS (C)	TGC	50.0	50.0		CCT	39.3	36.0
	TGT	50.0	50.0	SER (S)	AGC	16.0	15.1
END	TAA	DNU	40.7		AGT	18.2	17.1
	TAG	DNU	22.7		TCA	21.9	20.6
	TGA	100.0	36.6		TCC	18.0	16.9
					TCG	DNU	6.1
GLN (Q)	CAA	55.5	55.5		TCT	25.8	24.2
	CAG	44.5	44.5	THR (T)	ACA	32.4	29.7
GLU (E)	GAA	50.5	50.5		ACC	30.2	27.7
	GAG	49.5	49.5		ACG	DNU	8.3
GLY (G)	GGA	31.9	31.9		ACT	37.4	34.3
	GGC	19.3	19.3	TRP (W)	TGG	100.0	100
	GGG	18.4	18.4		TAC	48.2	48.2
	GGT	30.4	30.4	TYR (Y)	TAT	51.8	51.8
HIS (H)	CAC	44.8	44.8	VAL (V)	GTA	11.5	11.5
	CAT	55.2	55.2		GTC	17.8	17.8
ILE (I)	ATA	23.4	23.4		GTG	32.0	32.0
	ATC	29.9	29.9		GTT	38.7	38.7
	ATT	46.7	46.7				

*DNU = Do Not Use

[00172] To derive a soybean-optimized DNA sequence encoding the doubly mutated EPSPS protein, the protein sequence of SEQ ID NO:21 from PCT/US2005/014737 was reverse-translated by the OptGene™ program using the soybean-biased genetic code derived above. The initial DNA sequence thus derived was then modified by compensating codon changes (while retaining overall weighted average representation for the codons) to reduce the numbers of CG and TA doublets between adjacent codons, increase the numbers of CT and TG doublets between adjacent codons, remove highly stable intrastrand secondary structures, remove or add restriction enzyme recognition sites, and to remove other sequences that might be detrimental to expression or cloning manipulations of the engineered gene. Further refinements of the sequence were made to eliminate potential plant intron splice sites, long runs of A/T or C/G residues, and other motifs that might interfere with RNA stability, transcription, or translation of the coding region in plant cells. Other changes were made to eliminate long internal Open Reading Frames (frames other than +1). These changes were all made within the constraints of retaining the soybean-biased codon composition as described above, and while preserving the amino acid sequence disclosed as SEQ ID NO:21 of PCT/US2005/014737.

[00173] The soybean-biased DNA sequence that encodes the EPSPS protein of SEQ ID NO:21 is disclosed as bases 1-1575 of SEQ ID NO:22 of PCT/US2005/014737. Synthesis of a DNA fragment comprising SEQ ID NO:22 of PCT/US2005/014737 was performed by a commercial supplier (PicoScript, Houston TX).

Example 3-Cloning of expression and transformation vectors

[00174] 3.1 Construction of E.coli, pET expression vector.

[00175] Using the restriction enzymes corresponding to the sites added with the additional cloning linkers (Xba 1, Xho 1) *AAD-12* (v2) was cut out of the picoscript vector, and ligated into a pET280 streptomycin/spectinomycin resistant vector. Ligated products were then transformed into TOP10F' *E. coli*, and plated on to Luria Broth + 50 µg/ml Streptomycin & Spectinomycin (LB S/S) agar plates.

[00176] To differentiate between *AAD-12* (v2) : pET280 and pCR2.1 : pET280 ligations, approximately 20 isolated colonies were picked into 6 ml of LB-S/S, and grown at 37° C for 4 hours with agitation. Each culture was then spotted onto LB + Kanamycin 50 µg/ml plates, which were incubated at 37° C overnight. Colonies that grew on the LB-K were assumed to

BDDDB01 9494151v1

have the pCR2.1 vector ligated in, and were discarded. Plasmids were isolated from the remaining cultures as before, and checked for correctness with digestion by XbaI / XhoI. The final expression construct was given the designation pDAB3222.

[00177] 3.2- Construction of *Pseudomonas* expression vector

[00178] The *AAD-12* (v2) open reading frame was initially cloned into the modified pET expression vector (Novagen), “pET280 S/S”, as an XbaI – XhoI fragment. The resulting plasmid pDAB725 was confirmed with restriction enzyme digestion and sequencing reactions. The *AAD-12* (v2) open reading frame from pDAB725 was transferred into the *Pseudomonas* expression vector, pMYC1803, as an XbaI – XhoI fragment. Positive colonies were confirmed via restriction enzyme digestion. The completed construct pDAB739 was transformed into the MB217 and MB324 *Pseudomonas* expression strains.

[00179] 3.3 – Completion of binary vectors.

[00180] The plant optimized gene *AAD-12* (v1) was received from Picoscript (the gene rebuild design was completed (see above) and out-sourced to Picoscript for construction) and sequence verified (SEQ ID NO:3) internally, to confirm that no alterations of the expected sequence were present. The sequencing reactions were carried out with M13 Forward (SEQ ID NO:6) and M13 Reverse (SEQ ID NO:7) primers using the Beckman Coulter “Dye Terminator Cycle Sequencing with Quick Start Kit” reagents as before. Sequence data was analyzed and results indicated that no anomalies were present in the plant optimized *AAD-12* (v1) DNA sequence. The *AAD-12* (v1) gene was cloned into pDAB726 as an Nco I – Sac I fragment. The resulting construct was designated pDAB723, containing: [AtUbi10 promoter: Nt OSM 5’UTR: *AAD-12* (v1): Nt OSM3’UTR: ORF1 polyA 3’UTR] (verified with a PvuII and a Not I restriction digests). A Not I-Not I fragment containing the described cassette was then cloned into the Not I site of the binary vector pDAB3038. The resulting binary vector, pDAB724, containing the following cassette [AtUbi10 promoter: Nt OSM5’UTR: *AAD-12* (v1): Nt OSM 3’UTR: ORF1 polyA 3’UTR: CsVMV promoter: *PAT*: ORF25/26 3’UTR] was restriction digested (with Bam HI, Nco I, Not I, SacI, and Xmn I) for verification of the correct orientation. The verified completed construct (pDAB724) was used for transformation into *Agrobacterium* (see section 7.2).

[00181] 3.4 - Cloning of additional transformation constructs.

[00182] All other constructs created for transformation into appropriate plant species were built using similar procedures as previously described herein, and other standard molecular

cloning methods (Maniatis *et al.*, 1982). **Table 8** lists all the transformation constructs used with appropriate promoters and features defined, as well as the crop transformed.

Table 8. Binary constructs used in transformation of various plant species.													
pDAB #	pDAS #	Species * Transformed into	Gene of interest (GOI)	Promoter	Feature 1	Feature 2	GOI 2	Promoter	Bacterial Selection gene	Bacterial Selection gene 2	Plant Selection gene	Promoter	Trxn Method
724	-	A, Ct, S	AAD12 v1	AtUbi10	NtOsm	-	-	-	Erythromycin	-	pat	CsVMV	Agro binary
3274	-	A	AAD12 v1	AtUbi10	NtOsm	RB7 Mar v2	-	-	Spectinomycin	-	-	-	Agro binary
3278	1580	T	AAD12 v1	CsVMV	NtOsm	RB7 Mar v2	-	-	Spectinomycin	-	pat	AtUbi10	Agro binary
3285	-	A	AAD12 v1	CsVMV	NtOsm	RB7 Mar v2	-	-	Spectinomycin	-	pat	AtUbi10	Agro binary
3759	-	A, Ca, S	AAD12 v1	CsVMV	NtOsm	RB7 Mar v2	EPSPS	AtUbi10	Spectinomycin	-	pat	AtUbi10	Agro binary
4101	1863	Cn, R	AAD12 v1	ZmUbi1	-	RB7 Mar v2	-	-	Ampicillin	-	AHAS v3	OsAct1	Whiskers / Gun
4464	-	S	AAD12 v1	CsVMV	-	RB7 Mar v2	-	-	Spectinomycin	-	pat	CsVMV	Agro binary
4468	-	S	AAD12 v1	AtUbi10	-	RB7 Mar v2	-	-	Spectinomycin	-	pat	CsVMV	Agro binary
4472	-	S	AAD12 v1	AtUbi3	-	RB7 Mar v2	-	-	Spectinomycin	-	pat	CsVMV	Agro binary
4476	-	S	AAD12 v1	ZmUbi1	-	RB7 Mar v2	-	-	Spectinomycin	-	pat	CsVMV	Agro binary
4480	-	S	AAD12 v1	AtAct2	-	RB7 Mar v2	-	-	Spectinomycin	-	pat	CsVMV	Agro binary
*A = Arabidopsis T = Tobacco S = Soybean Ct = Cotton R = Rice Cn = Corn Ca = Canola													
CsVMV = Cassava Vein Mosaic Virus Promoter AtUbi10 = Arabidopsis thaliana Ubiquitin 10 Promoter Atubi3= Arabidopsis thaliana Ubiquitin 3 Promoter AtAct2= Arabidopsis thaliana Actin 2 Promoter RB7 Mar v2 = Nicotiana tabacum matrix associated region (MAR) Nt Osm = Nicotiana tabacum Osmotin 5' Untranslated Region and the Nicotiana tabacum Osmotin 3' Untranslated Region													
ZmUbi1 = Zea mays Ubiquitin 1 Promoter HptII = hygromycin phosphotransferase													

BDD801 9494151v1

Example 4 - Recombinant AAD-12 (v2) Expression and Purification in *Pseudomonas fluorescens*

[00183] 4.1- *Pseudomonas fluorescens* fermentation

[00184] For shake flask experiment, 200 µl of *Pseudomonas fluorescens* strain MB324 glycerol stock carried AAD-12 (v2) construct pDAB739 (sec 3.2) was used to inoculate 50 ml fresh LB media supplemented with 30 µg/ml tetracycline/HCl. The culture (in a 250 ml baffled Erlenmeyer flask) was incubated on a shaker (New Brunswick Scientific Model Innova 44) at 300 rpm and 30 °C for 16 hrs. 20 ml of seed culture was transferred into 1 L *Pseudomonas fluorescens* culture media (Yeast extract, 5 g/L; K₂HPO₄, 5 g/L; (NH₄)₂PO₄, 7.5 g/L; (NH₄)₂SO₄; MgSO₄·7H₂O, 1 g/L; KCl, 0.5 g/L; CaCl₂·2H₂O, 0.5 g/L; NaCitrate-2H₂O, 15 g/L; Glycerol, 95 g/L; Trace element solution, 10 ml/L; Trace element solution: FeCl₃·6H₂O, 5.4 g/L; MnCl₂·4H₂O, 1 g/L; ZnSO₄·7H₂O, 1.45 g/L; CuSO₄·5H₂O, 0.25 g/L; H₃BO₃, 0.1 g/L; (NH₄)₆MO₇O₂₄, 0.1 g/L; concentrated HCl, 13 ml/L) supplemented with 20 µg/ml tetracycline/HCl and 250 µl of Pluronic L61(anti-foam) in a 2.8 L baffled Erlenmeyer flask. The cultures were incubated at 30 °C and 300 rpm for 24 hrs. Isopropyl β-D-1-thiogalacto-pyranoside (IPTG) was added to 1 mM final in the cultures and continued to incubate for approximately 48 hrs at 25 °C. Cells were harvested by centrifugation at 7 krpm at 4 °C for 15 min, and cell paste was stored at -80 °C or immediately processed for purification.

[00185] For tank experiments, 1 ml each of the glycerol stock was inoculated a 1 L baffled flask containing 200 ml of LB media supplemented with 30 µg/ml tetracycline/HCl at 300 rpm and 32 °C for 16-24 hrs. The combined culture from three flasks (600 ml) was then aseptically transferred to a 20 L fermentor (B. Braun Bioreactor Systems) containing 10 L of Dow proprietary defined medium (through Teknova, Hollister, CA) designed to support high cell density growth. Growth temperature was maintained at 32 °C and the pH was controlled at the desired set-point through the addition of aqueous ammonia. Dissolved oxygen was maintained at a positive level in the liquid culture by regulating the sparged air flow and the agitation rates. The fed-batch fermentation process was carried out for approximately 24 hrs till cell density reached 170-200 OD₅₇₅. IPTG was added to 1 mM to induce the recombinant protein expression and the temperature was reduced and maintained to 25 °C using circulation of cold-water supply. The induction phase of the fermentation was allowed to continue for another 24 hrs. Samples (30 ml) were collected for various analyses to determine cell density

BDDDB01 9494151v1

and protein expression level at 6, 12, and 18 hrs post-induction time points. At the end of a fermentation run, cells were harvested by centrifugation at 10 krpm for 30 min. The cell pellets were frozen at -80 °C for further processing.

[00186] 4.2- Purification of AAD-12 (v2) for Biochemical Characterization and Antibody Production

[00187] Approximately 100-200 g of frozen (or fresh) *Pseudomonas* cells were thawed and resuspended in 1-2 L of extraction buffer containing 20 mM Tris-HCl, pH 8.5, and 25 ml of Protease inhibitor cocktail (Sigma cat# P8465). The cells were disrupted using Microfluidizer (model M110L or 110Y) (Microfluidics, Newton, MA) on ice with one pass at 11,000-12,000 psi. The lysate was centrifuged at 24,000 rpm for 20 min. The supernatant was transferred and dialyzed against 10 volumes of 20 mM Tris-HCl, pH 8.5 overnight at 4 °C, or diafiltrated with this buffer and filtered through a 0.45 µm membrane before applying to the column separations. All subsequent protein separations were performed using Pharmacia AKTA Explorer 100 and operated at 4 °C. Prior to loading, a Q Sepharose Fast Flow column (Pharmacia XK 50/00, 500 ml bed size) was equilibrated with 20 mM Tris-HCl, pH 8.5 buffer. The sample was applied to the column at 15 ml/min and then washed with this buffer until the eluate OD₂₈₀ returned to baseline. Proteins were eluted with 2 L of linear gradient from 0 to 0.3 M NaCl at a flow rate of 15 ml/min, while 45 ml fractions were collected. Fractions containing AAD-12 activity as determined by the colorimetric enzyme assay and also corresponding to the predicted molecular weight of AAD-12 protein (about 32 kDa band on SDS-PAGE) were pooled. Solid ammonium sulfate to final 0.5 M was added to the sample, and then applied to a Phenyl HP column (Pharmacia XK 50/20, 250 ml bed size) equilibrated in 0.5 M ammonium sulfate in 20 mM Tris-HCl, pH 8.0. This column was washed with the binding buffer at 10 ml/min until the OD₂₈₀ of the eluate returned to baseline, proteins were eluted within 2 column volumes at 10 ml/min by a linear gradient from 0.5 M to 0 Ammonium sulfate in 20 mM Tris-HCl, pH 8.0, and 12.5 ml fractions were collected. The main peak fractions containing AAD-12 were pooled, and if necessary, concentrated using a MWCO 10 kDa cut-off membrane centrifugal filter device (Millipore). In some cases the sample was further applied to a Superdex 75 gel filtration column (Pharmacia XK 16/60, 110 ml bed size) with PBS buffer at a flow rate of 1 ml/min. Peak fractions containing pure AAD-12 were pooled and stored at -80 °C. In most cases, AAD-12 protein purity is approaching or above 99% after sequential ion-exchange column and

BDDDB01 9494151v1

hydrophobic interaction column two-step separation. A typical yield for purified AAD-12 is 12-18 mg/g of wet cells. Bulk protein sample was formulated in 20 mM Tris-HCl, pH 8.0, 0.1 M NaCl, 2 mM DTT, and 1% Trehalose by diafiltration, and lyophilized on the Virtis Freezemobile Model 25EL (Virtis, Cardiner, NY) for long-term storage.

[00188] Protein concentration was initially measured by Bradford assay using Bio-Rad Protein assay kit (cat# 500-0006) with bovine serum albumin as standard. When needed, more accurate protein concentration was determined by using total amino acid hydrolysis. The sample was analyzed in Agilent 1100 HPLC system (Agilent Technologies, Santa Clara, CA) with amino acid calibration standards (cat# PN5061-3330) purchased from Agilent.

[00189] AAD-12 activity was determined through out the processes to ensure no loss of the enzyme activity by each treatment and manipulation, as described in the Example 5 below. Protein purity was monitored by using SDS-PAGE and analytical size exclusion chromatography. Purified protein sample was further verified and confirmed by N-terminal amino acid sequencing, and shown consisting of expected AQTTLQITPT residues at its N-terminus. Short and long-term protein stability was tested by enzymatic activity and by native-PAGE and SDS-PAGE gel analysis under both non-reducing and reducing conditions. And it was noticed that AAD-12 is prone to oligomerization via disulfide bond formation, therefore typically 2 mM DTT was used for protein storage. Phosphate-buffer saline (PBS) and Tris-buffer saline (TBS) were tested for protein lyophilization, with and without the presence of 1% trehalose. Additionally, the endotoxin and DNA contaminant context from purified sample were measured respectively, and the integrity of the AAD-12 protein was also assessed by isoelectric focusing (IEF) analysis.

[00190] Ten milligrams of purified AAD-12 (v2) was delivered to Zymed Laboratories, Inc. (South San Francisco, CA) for rabbit polyclonal antibody production. The rabbit received 5 injections in the period of 5 weeks with each injection containing 0.5 mg of the purified protein suspended in 1 ml of complete Freund's Adjuvant. Sera were tested in both ELISA and Western blotting experiments to confirm specificity and affinity before affinity purification, and horseradish peroxidase (HRP) conjugation (Zymed Lab Inc).

Example 5 – *In vitro* assays of AAD-12 activity

[00191] 5.1 – Assay via colorimetric phenol detection.

BDDb01 9494151v1

[00192] Enzyme activity was measured by colorimetric detection of the product phenol using a protocol modified from that of Fukumori and Hausinger (1993) (*J. Biol. Chem.* 268: 24311-24317) to enable deployment in a 96-well microplate format. The colorimetric assay has been described for use in measuring the activity of dioxygenases cleaving 2,4-D and dichlorprop to release the product 2,4-dichlorophenol. The color yield from several phenols was compared to that of 2,4-dichlorophenol using the detection method previously described to ascertain which phenol products could be readily detected. Phenols and phenol analogs were tested at a final concentration of 100 μM in 0.15 ml 20 mM MOPS pH 6.75 containing 200 μM $\text{NH}_4(\text{FeSO}_4)_2$, 200 μM sodium ascorbate. Pyridinols derived from fluroxypyr and triclopyr produced no significant color. The color yield of 2,4-dichlorophenol was linear and proportional to the concentration of phenol in the assay up to ~ 500 μM . A calibration curve performed under standard assay conditions (160 μl final assay volume) indicated that an absorbance at 510 nm of 0.1 was obtained from 17.2 μM phenol.

[00193] Enzyme assays were performed in a total volume of 0.16 ml 20 mM MOPS pH 6.75 containing 200 μM NH_4FeSO_4 , 200 μM sodium ascorbate, 1 mM α -ketoglutarate, the appropriate substrate (added from a 100 mM stock made up in DMSO), and enzyme. Assays were initiated by addition of the aryloxyalkanoate substrate, enzyme or α -ketoglutarate at time zero. After 5 minutes of incubation at 25° C, the reaction was terminated by addition of 30 μl of a 1:1:1 mix of 50 mM Na EDTA; pH 10 buffer (3.09 g boric acid + 3.73 g KCl + 44 ml 1 N KOH) and 0.2 % 4-aminoantipyrine. Then 10 μl 0.8 % potassium ferricyanide was added and after 5 or 10 min, the absorbance at 510 nm was recorded in a spectrophotometric microplate reader. Blanks contained all reagents except for enzyme to account for the occasional slight contamination of some of the substrates by small amounts of phenols.

[00194] 5.2 – Assay via detection of chloropyridinol

[00195] AAD-12 action on potential substrates such as the herbicide triclopyr containing a substituted pyridine (rather than benzene rings) will release a pyridinol on cleavage of the aryloxyalkanoate bond. Pyridinols were not detected using the aminoantipyrine/ferricyanide phenol detection described in the preceding section. However, it was found that product chloropyridinols absorb strongly in the near UV with λ_{max} of 325 nm at pH 7 (extinction coefficient $\sim 8,400 \text{ M}^{-1}.\text{cm}^{-1}$). This was used to create a continuous microplate-based spectrophotometric assay. Assays were performed in a total volume of 0.2 ml 20 mM MOPS pH 6.75 containing 200 μM NH_4FeSO_4 , 200 μM sodium ascorbate, 1 mM α -ketoglutarate,

BDDDB01 9494151v1

the appropriate substrate (added from a 100 mM stock made up in DMSO), and enzyme. Assays were initiated by addition of the aryloxyalkanoate substrate, enzyme or α -ketoglutarate at time zero and the increase in absorbance followed for 10 minutes at 325 nm in a microplate reader. The first 2 minutes of the reaction was used to determine initial rates. A calibration curve performed under standard assay conditions (200 μ l final assay volume) indicated that an absorbance at 510 nm of 0.1 was obtained from 11.9 μ M chloropyridinol.

[00196] 5.3 – Colorimetric assay using 2-(2-chloro,4-nitrophenoxy)propionate

[00197] A convenient assay of AAD-12 was devised using 2-(2-chloro,4-nitrophenoxy)propionate (CNPP) as substrate. Cleavage of CNPP by AAD-12 releases 2-chloro,4-nitrophenol. This phenol has a bright yellow absorbance at 410 nm at pH 7 enabling the reaction to be followed continuously or by endpoint analysis. The presence of AAD-12 activity can be monitored visually without the need for addition of further reagents. Microplate-based spectrophotometric assays were performed in a total volume of 0.2 ml 20 mM MOPS pH 6.75 containing 200 μ M NH_4FeSO_4 , 200 μ M sodium ascorbate, 1 mM α -ketoglutarate, the appropriate amount of CNPP (added from a 10 mM stock made up in DMSO), and enzyme. Assays were initiated by addition of CNPP, enzyme, or α -ketoglutarate at time zero and the increase in absorbance followed for 10 min at 410 nm in a microplate reader. The first 2 min of the reaction was used to determine initial rates. A calibration curve performed under standard assay conditions (200 μ l final assay volume) indicated that an absorbance at 410 nm of 0.1 was obtained from 25.1 μ M 2-chloro, 4-nitrophenol. Using this assay, the kinetic constants for CNPP as a substrate were determined to be $K_m = 31 \pm 5.5 \mu\text{M}$ and $k_{\text{cat}} = 16.2 \pm 0.79 \text{ min}^{-1}$.

Example 6 – *In vitro* activity of AAD-12 on various substrates

[00198] 6.1 – AAD-12 (v2) activity on (R,S)- dichlorprop, (R)-dichlorprop, (S)-dichlorprop and 2,4-D

[00199] Using the phenol detection assay described in Example 5.1, four phenoxyalkanoates were assayed in a reaction mix containing 4.4 μ g purified AAD-12 (v2). (R,S)-dichlorprop (R,S-DP) was tested at 1 mM and (R)-dichlorprop, (S)-dichlorprop and 2,4-D were tested at 0.5 mM. The results are shown in **Figure 3**, which illustrates activity of AAD-12 (v2) on 2,4-D and enantiomers of dichlorprop. 4.4 μ g AAD-12 (v2) was incubated with 0.5 mM substrate (1 mM for (R,S)-dichlorprop) and the reaction initiated by addition of α -






ketoglutarate. After 5 minutes, the reaction was quenched, and the absorbance at 510 nm determined after addition of colorimetric detection reagents. The background value without enzyme was subtracted.

[00200] AAD-12 (v2) has excellent activity on (R,S)-dichlorprop and (S)-dichlorprop and has minimal activity on (R)-dichlorprop. This indicates that AAD-12 (v2) has a clear (S)-enantiomeric preference. The activity of AAD-12 (v2) on 2,4-D was equivalent to that on (S)-dichlorprop indicating that the enzyme can process oxypropionate and oxyacetates effectively.

[00201] 6.2 – AAD-12 (v2) activity on pyridyloxyalkanoates

[00202] Using the pyridinol assay described in Example 5.2, five pyridyloxyalkanoates were assayed at 1 mM in a reaction mix containing 6.8 µg purified AAD-12 (v2). The rates of each reaction were monitored and are presented in Table 9. All five pyridyloxyalkanoates were cleaved to release pyridinols by AAD-12 (v2). The rates for the oxypropionate substrates 116844 and 91767 were somewhat faster than those for the corresponding acetates (triclopyr and 93833 respectively) indicating a preference of AAD-12 (v2) for oxypropionate over oxyacetate side chains. These data show that AAD-12 (v2) is able to effectively degrade pyridyloxyalkanoate herbicides such as triclopyr.

Table 9. Rates of pyridyloxyalkanoate cleavage by AAD-12 (v2). 6.8µg AAD-12 (v2) was incubated with 1 mM substrate, the reaction initiated by addition of α -ketoglutarate and the subsequent increase in absorbance monitored at 325 nm. The background rate of 1.4 mAU/min without α -ketoglutarate was subtracted from the rates with substrate.

STRUCTURE	ID	Rate (mAU/min)	Rate relative to triclopyr
	triclopyr	97	1
	66357	225	2.3
	91767	190	0.8
	116844	257	1.4
	93833	118	0.5

[00203] 6.3 – Kinetic constants of AAD-12 (v2) for 2,4-D, (R,S)-DCP and triclopyr

[00204] The K_m and k_{cat} values of purified AAD-12 (v2) for the herbicides 2,4-D, (R,S)-dichlorprop and triclopyr were determined using the appropriate assay method. Substrate inhibition occurred at high concentrations (>1 mM) of 2,4-D and (R,S)-DCP so concentrations below this were used to fit the data to the Michaelis-Menten equation using

BDDb01 9494151v1

Grafit 4.0 (Erithacus Software, UK). No substrate inhibition was noted for triclopyr up to 2 mM. The kinetic constants are summarized in Table 10. From these data, the rate of AAD-12 (v2) cleavage of triclopyr is ~5% that of 2,4-D, under maximal velocity conditions.

Table 10. Kinetic constants of AAD-12 (v2) for three herbicide substrates				
Substrate	K_m , μM ($\pm\text{SE}$)	k_{cat} , min^{-1} ($\pm\text{SE}$)	Assay method	Substrate inhibition at 2 mM
2,4-D	102 (± 18.4)	54.1 (± 3.1)	Phenol detection	55%
(R,S)-dichlorprop	122 (± 2.7)*	63.4 (± 0.5)	Phenol detection	55%
Triclopyr	241 (± 30)	2.6 (± 0.1)	$\Delta\text{A}_{325\text{ nm}}$	0%

* Because of the (S)-enantiomeric preference of AAD-12, the K_m value was calculated assuming 50% of the racemic mixture was available as a substrate

Example 7 – Transformation into *Arabidopsis* and Selection

[00205] 7.1 – *Arabidopsis thaliana* growth conditions.

[00206] Wildtype *Arabidopsis* seed was suspended in a 0.1% Agarose (Sigma Chemical Co., St. Louis, MO) solution. The suspended seed was stored at 4° C for 2 days to complete dormancy requirements and ensure synchronous seed germination (stratification).

[00207] Sunshine Mix LP5 (Sun Gro Horticulture, Bellevue, WA) was covered with fine vermiculite and sub-irrigated with Hoagland's solution until wet. The soil mix was allowed to drain for 24 hours. Stratified seed was sown onto the vermiculite and covered with humidity domes (KORD Products, Bramalea, Ontario, Canada) for 7 days.

[00208] Seeds were germinated and plants were grown in a Conviron (models CMP4030 and CMP3244, Controlled Environments Limited, Winnipeg, Manitoba, Canada) under long day conditions (16 hours light/8 hours dark) at a light intensity of 120-150 $\mu\text{mol}/\text{m}^2\text{sec}$ under constant temperature (22° C) and humidity (40-50%). Plants were initially watered with Hoagland's solution and subsequently with deionized water to keep the soil moist but not wet.

[00209] 7.2 – *Agrobacterium* transformation.

[00210] An LB + agar plate with erythromycin (Sigma Chemical Co., St. Louis, MO) (200mg/L) or spectinomycin (100 mg/L) containing a streaked DH5 α colony was used to provide a colony to inoculate 4 ml mini prep cultures (liquid LB + erythromycin). The cultures were incubated overnight at 37° C with constant agitation. Qiagen (Valencia, CA)

Spin Mini Preps, performed per manufacturer's instructions, were used to purify the plasmid DNA.

[00211] Electro-competent *Agrobacterium tumefaciens* (strains Z707s, EHA101s, and LBA4404s) cells were prepared using a protocol from Weigel and Glazebrook (2002). The competent *Agrobacterium* cells were transformed using an electroporation method adapted from Weigel and Glazebrook (2002). 50 µl of competent agro cells were thawed on ice and 10-25 ng of the desired plasmid was added to the cells. The DNA and cell mix was added to pre-chilled electroporation cuvettes (2 mm). An Eppendorf Electroporator 2510 was used for the transformation with the following conditions, Voltage: 2.4kV, Pulse length: 5msec.

[00212] After electroporation, 1 ml of YEP broth (per liter: 10 g yeast extract, 10 g Bacto-peptone, 5 g NaCl) was added to the cuvette, and the cell-YEP suspension was transferred to a 15 ml culture tube. The cells were incubated at 28° C in a water bath with constant agitation for 4 hours. After incubation, the culture was plated on YEP + agar with erythromycin (200 mg/L) or spectinomycin (100 mg/L) and streptomycin (Sigma Chemical Co., St. Louis, MO) (250 mg/L). The plates were incubated for 2-4 days at 28° C.

[00213] Colonies were selected and streaked onto fresh YEP + agar with erythromycin (200 mg/L) or spectinomycin (100 mg/L) and streptomycin (250 mg/L) plates and incubated at 28°C for 1-3 days. Colonies were selected for PCR analysis to verify the presence of the gene insert by using vector specific primers. Qiagen Spin Mini Preps, performed per manufacturer's instructions, were used to purify the plasmid DNA from selected *Agrobacterium* colonies with the following exception: 4 ml aliquots of a 15 ml overnight mini prep culture (liquid YEP + erythromycin (200 mg/L) or spectinomycin (100 mg/L)) and streptomycin (250 mg/L)) were used for the DNA purification. An alternative to using Qiagen Spin Mini Prep DNA was lysing the transformed *Agrobacterium* cells, suspended in 10 µl of water, at 100° C for 5 minutes. Plasmid DNA from the binary vector used in the *Agrobacterium* transformation was included as a control. The PCR reaction was completed using Taq DNA polymerase from Takara Mirus Bio Inc. (Madison, Wisconsin) per manufacturer's instructions at 0.5x concentrations. PCR reactions were carried out in a MJ Research Peltier Thermal Cycler programmed with the following conditions; 1) 94° C for 3 minutes, 2) 94° C for 45 seconds, 3) 55° C for 30 seconds, 4) 72° C for 1 minute, for 29 cycles then 1 cycle of 72° C for 10 minutes. The reaction was maintained at 4° C after cycling. The amplification was analyzed by 1% agarose gel electrophoresis and visualized by

BDDDB01 9494151v1

ethidium bromide staining. A colony was selected whose PCR product was identical to the plasmid control.

[00214] 7.3 – *Arabidopsis* transformation.

[00215] *Arabidopsis* was transformed using the floral dip method. The selected colony was used to inoculate one or more 15-30 ml pre-cultures of YEP broth containing erythromycin (200 mg/L) or spectinomycin (100 mg/L) and streptomycin (250 mg/L). The culture(s) was incubated overnight at 28° C with constant agitation at 220 rpm. Each pre-culture was used to inoculate two 500 ml cultures of YEP broth containing erythromycin (200 mg/L) or spectinomycin (100 mg/L) and streptomycin (250 mg/L) and the cultures were incubated overnight at 28° C with constant agitation. The cells were then pelleted at approx. 8700x g for 10 minutes at room temperature, and the resulting supernatant discarded. The cell pellet was gently resuspended in 500 ml infiltration media containing: 1/2x Murashige and Skoog salts/Gamborg's B5 vitamins, 10% (w/v) sucrose, 0.044µM benzylamino purine (10 µl/liter of 1 mg/ml stock in DMSO) and 300 µl/liter Silwet L-77. Plants approximately 1 month old were dipped into the media for 15 seconds, being sure to submerge the newest inflorescence. The plants were then laid down on their sides and covered (transparent or opaque) for 24 hours, then washed with water, and placed upright. The plants were grown at 22° C, with a 16-hour light/8-hour dark photoperiod. Approximately 4 weeks after dipping, the seeds were harvested.

[00216] 7.4 – Selection of transformed plants.

[00217] Freshly harvested T₁ seed [*AAD-12 (v1)* gene] was allowed to dry for 7 days at room temperature. T₁ seed was sown in 26.5 x 51-cm germination trays (T.O. Plastics Inc., Clearwater, MN), each receiving a 200 mg aliquots of stratified T₁ seed (~10,000 seed) that had previously been suspended in 40 ml of 0.1% agarose solution and stored at 4° C for 2 days to complete dormancy requirements and ensure synchronous seed germination.

[00218] Sunshine Mix LP5 (Sun Gro Horticulture Inc., Bellevue, WA) was covered with fine vermiculite and subirrigated with Hoagland's solution until wet, then allowed to gravity drain. Each 40 ml aliquot of stratified seed was sown evenly onto the vermiculite with a pipette and covered with humidity domes (KORD Products, Bramalea, Ontario, Canada) for 4-5 days. Domes were removed 1 day prior to initial transformant selection using glufosinate postemergence spray (selecting for the co-transformed *PAT* gene).

[00219] Seven days after planting (DAP) and again 11 DAP, T₁ plants (cotyledon and 2-4-leaf stage, respectively) were sprayed with a 0.2% solution of Liberty herbicide (200 g ai/L glufosinate, Bayer Crop Sciences, Kansas City, MO) at a spray volume of 10 ml/tray (703 L/ha) using a DeVilbiss compressed air spray tip to deliver an effective rate of 280 g ai/ha glufosinate per application. Survivors (plants actively growing) were identified 4-7 days after the final spraying and transplanted individually into 3-inch pots prepared with potting media (Metro Mix 360). Transplanted plants were covered with humidity domes for 3-4 days and placed in a 22° C growth chamber as before or moved to directly to the greenhouse. Domes were subsequently removed and plants reared in the greenhouse (22±5° C, 50±30% RH, 14 h light:10 dark, minimum 500 µE/m²s⁻¹ natural + supplemental light) at least 1 day prior to testing for the ability of *AAD-12 (v1)* (plant optimized gene) to provide phenoxy auxin herbicide resistance.

[00220] T₁ plants were then randomly assigned to various rates of 2,4-D. For *Arabidopsis*, 50 g ae/ha 2,4-D is an effective dose to distinguish sensitive plants from ones with meaningful levels of resistance. Elevated rates were also applied to determine relative levels of resistance (50, 200, 800, or 3200g ae/ha). Tables 10 and 11 show comparisons drawn to an aryloxyalkanoate herbicide resistance gene (*AAD-1 (v3)*) previously described in PCT/US2005/014737.

[00221] All auxin herbicide applications were made using the DeVilbiss sprayer as described above to apply 703 L/ha spray volume (0.4 ml solution/3-inch pot) or applied by track sprayer in a 187 L/ha spray volume. 2,4-D used was either technical grade (Sigma, St. Louis, MO) dissolved in DMSO and diluted in water (<1% DMSO final concentration) or the commercial dimethylamine salt formulation (456 g ae/L, NuFarm, St Joseph, MO). Dichlorprop used was commercial grade formulated as potassium salt of R-dichlorprop (600 g ai/L, AH Marks). As herbicide rates increased beyond 800 g ae/ha, the pH of the spray solution became exceedingly acidic, burning the leaves of young, tender *Arabidopsis* plants and complicating evaluation of the primary effects of the herbicides. It became standard practice to apply these high rates of herbicides in 200 mM HEPES buffer, pH 7.5.

[00222] Some T₁ individuals were subjected to alternative commercial herbicides instead of a phenoxy auxin. One point of interest was determining whether the pyridyloxyacetate auxin herbicides, triclopyr and fluroxypyr, could be effectively degraded *in planta*. Herbicides

were applied to T₁ plants with use of a track sprayer in a 187 L/ha spray volume. T₁ plants that exhibited tolerance to 2,4-D DMA were further accessed in the T₂ generation.

[00223] 7.5 – Results of selection of transformed plants.

[00224] The first *Arabidopsis* transformations were conducted using *AAD-12 (v1)* (plant optimized gene). T₁ transformants were first selected from the background of untransformed seed using a glufosinate selection scheme. Over 300,000 T₁ seed were screened and 316 glufosinate resistant plants were identified (PAT gene), equating to a transformation/selection frequency of 0.10% which lies in the normal range of selection frequency of constructs where PAT + Liberty are used for selection. T₁ plants selected above were subsequently transplanted to individual pots and sprayed with various rates of commercial aryloxyalkanoate herbicides. Table 11 compares the response of *AAD-12 (v1)* and control genes to impart 2,4-D resistance to *Arabidopsis* T₁ transformants. Response is presented in terms of % visual injury 2 WAT. Data are presented as a histogram of individuals exhibiting little or no injury (<20%), moderate injury (20-40%), or severe injury (>40%). Since each T₁ is an independent transformation event, one can expect significant variation of individual T₁ responses within a given rate. An arithmetic mean and standard deviation is presented for each treatment. The range in individual response is also indicated in the last column for each rate and transformation. *PAT/Cry1F*-transformed *Arabidopsis* served as an auxin-sensitive transformed control. The *AAD-12 (v1)* gene imparted herbicide resistance to individual T₁ *Arabidopsis* plants. Within a given treatment, the level of plant response varied greatly and can be attributed to the fact each plant represents an independent transformation event. Of important note, at each 2,4-D rate tested, there were individuals that were unaffected while some were severely affected. An overall population injury average by rate is presented in Table 11 simply to demonstrate the significant difference between the plants transformed with *AAD-12 (v1)* versus the wildtype or *PAT/Cry1F*-transformed controls. Injury levels tend to be greater and the frequency of uninjured plants was lower at elevated rates up to 3,200 g ae/ha (or 6x field rate). Also at these high rates, the spray solution becomes highly acidic unless buffered. *Arabidopsis* grown mostly in the growth chamber has a very thin cuticle and severe burning effects can complicate testing at these elevated rates. Nonetheless, many individuals have survived 3,200 g ae/ha 2,4-D with little or no injury.

Table 11. *AAD-12* (v1) transformed T₁ *Arabidopsis* response to a range of 2,4-D rates applied postemergence, compared to an *AAD-1* v3 (T₄) homozygous resistant population, or a *Pat-Cry1F* transformed, auxin-sensitive control.

AAD-12 (v1) gene T₁ transformants	% Injury				% Injury	
	Averages	<20%	20-40%	>40%	Ave	Std Dev
Untreated control-buffer		6	0	0	0	0
50 g ae/ha 2,4-D		6	0	2	16	24
200 g ae/ha 2,4-D		6	1	1	11	18
800 g ae/ha 2,4-D		5	2	1	15	20
3200 g ae/ha 2,4-D		8	0	0	6	6
PAT/Cry1F (transformed control)	% Injury				% Injury Ave	Std Dev
	Averages	<20%	20-40%	>40%		
Untreated control-buffer		10	0	0	0	0
50 g ae/ha 2,4-D		4	1	5	31	16
200 g ae/ha 2,4-D		0	0	10	70	2
800 g ae/ha 2,4-D		0	0	10	81	8
3200 g ae/ha 2,4-D		0	0	10	91	2
Homozygous AAD-1 (v3) gene T₄ plants	% Injury				% Injury Ave	Std Dev
	Averages	<20%	20-40%	>40%		
Untreated control-buffer		10	0	0	0	0
50 g ae/ha 2,4-D		10	0	0	0	0
200 g ae/ha 2,4-D		10	0	0	0	0
800 g ae/ha 2,4-D		10	0	0	0	0
3200g ae/ha 2,4-D		9	1	0	2	6

[00225]

Table 12 shows a similarly conducted dose response of T₁ *Arabidopsis* to the phenoxypyropionic acid, dichlorprop. The data shows that the herbicidally active (R-) isomer of dichlorprop does not serve as a suitable substrate for AAD-12 (v1). The fact that AAD-1 will metabolize R-dichlorprop well enough to impart commercially acceptable tolerance is one distinguishing characteristic that separates the two genes. (Table 12). AAD-1 and AAD-12 are considered R- and S-specific α -ketoglutarate dioxygenases, respectively.

Table 12. T₁ *Arabidopsis* response to a range of R-dichlorprop rates applied postemergence.

AAD-12 v1 gene	% Injury				% Injury	
	Averages	<20%	20-40%	>40%	Ave	Std Dev
Untreated control		6	0	0	0	0
50 g ae/ha R-dichlorprop		0	0	8	63	7
200 g ae/ha R-dichlorprop		0	0	8	85	10
800 g ae/ha R-dichlorprop		0	0	8	96	4
3200 g ae/ha R-dichlorprop		0	0	8	98	2

BDDb01 9494151v1

PAT/Cry1F	% Injury			% Injury	
Averages	<20%	20-40%	>40%	Ave	Std Dev
Untreated control	10	0	0	0	0
50 g ae/ha R-dichlorprop	0	10	0	27	2
200 g ae/ha R-dichlorprop	0	0	10	69	3
800 g ae/ha R-dichlorprop	0	0	10	83	6
3200 g ae/ha R-dichlorprop	0	0	10	90	2

Homozygous AAD-1 (v3) gene T₄ plants	% Injury			% Injury	
	<20%	20-40%	>40%	Ave	Std Dev
Untreated control	10	0	0	0	0
50g ae/ha R-dichlorprop	10	0	0	0	0
200 g ae/ha R-dichlorprop	10	0	0	0	0
800 g ae/ha R-dichlorprop	10	0	0	0	0
3200 g ae/ha R-dichlorprop	10	0	0	0	0

[00226] 7.6 – AAD-12 (v1) as a selectable marker.

[00227] The ability to use *AAD-12 (v1)* as a selectable marker using 2,4-D as the selection agent was analyzed initially with *Arabidopsis* transformed as described above. Approximately 50 T₄ generation *Arabidopsis* seed (homozygous for *AAD-12 (v1)*) were spiked into approximately 5,000 wildtype (sensitive) seed. Several treatments were compared, each tray of plants receiving either one or two application timings of 2,4-D in one of the following treatment schemes: 7 DAP, 11 DAP, or 7 followed by 11 DAP. Since all individuals also contained the *PAT* gene in the same transformation vector, *AAD-12* selected with 2,4-D could be directly compared to *PAT* selected with glufosinate.

[00228] Treatments were applied with a DeVilbiss spray tip as previously described. Plants were identified as Resistant or Sensitive 17 DAP. The optimum treatment was 75 g ae/ha 2,4-D applied 7 and 11 days after planting (DAP), was equally effective in selection frequency, and resulted in less herbicidal injury to the transformed individuals than the Liberty selection scheme. These results indicate *AAD-12 (v1)* can be effectively used as an alternative selectable marker for a population of transformed *Arabidopsis*.

[00229] 7.7 – Heritability.

[00230] A variety of T₁ events were self-pollinated to produce T₂ seed. These seed were progeny tested by applying 2,4-D (200 g ae/ha) to 100 random T₂ siblings. Each individual T₂ plant was transplanted to 7.5-cm square pots prior to spray application (track sprayer at 187 L/ha applications rate). Seventy-five percent of the T₁ families (T₂ plants) segregated in the anticipated 3 Resistant:1 Sensitive model for a dominantly inherited single locus with Mendelian inheritance as determined by Chi square analysis ($P > 0.05$).

BDDb01 9494151v1

[00231] Seed were collected from 12 to 20 T₂ individuals (T₃ seed). Twenty-five T₃ siblings from each of eight randomly-selected T₂ families were progeny tested as previously described. Approximately one-third of the T₂ families anticipated to be homozygous (non-segregating populations) have been identified in each line. These data show *AAD-12 (v1)* is stably integrated and inherited in a Mendelian fashion to at least three generations.

[00232] 7.8 – Additional foliar applications herbicide resistance in AAD-12 *Arabidopsis*.

[00233] The ability of *AAD-12 (v1)* to provide resistance to other aryloxyalkanoate auxin herbicides in transgenic *Arabidopsis* was determined by foliar application of various substrates. T₂ generation *Arabidopsis* seed was stratified, and sown into selection trays much like that of *Arabidopsis* (Example 6.4). A transformed-control line containing *PAT* and the insect resistance gene *Cry1F* was planted in a similar manner. Seedlings were transferred to individual 3-inch pots in the greenhouse. All plants were sprayed with the use of a track sprayer set at 187 L/ha. The plants were sprayed with a range of pyridyloxyacetate herbicides: 280-2240 g ae/ha triclopyr (Garlon 3A, Dow AgroSciences) and 280-2240 g ae/ha fluroxypyr (Starane, Dow AgroSciences); and the 2,4-D metabolite resulting from AAD-12 activity, 2,4-dichlorophenol (DCP, Sigma) (at a molar equivalent to 280-2240 g ae/ha of 2,4-D, technical grade DCP was used). All applications were formulated in water. Each treatment was replicated 3-4 times. Plants were evaluated at 3 and 14 days after treatment.

[00234] There is no effect of the 2,4-D metabolite, 2,4-dichlorophenol (DCP), on transgenic non-*AAD-12* control *Arabidopsis (Pat/Cry1F)*. *AAD-12*-transformed plants were also clearly protected from the triclopyr and fluroxypyr herbicide injury that was seen in the transformed non-resistant controls (see Table 13). These results confirm that *AAD-12 (v1)* in *Arabidopsis* provides resistance to the pyridyloxyacetic auxins tested. This is the first report of an enzyme with significant activity on pyridyloxyacetic acid herbicides. No other 2,4-D degrading enzyme has been reported with similar activity.

Table 13. Comparison of T ₂ AAD-12 (v1) and transformed control <i>Arabidopsis</i> plant response to various foliar-applied auxinic herbicides.		
Pyridyloxyacetic auxins		
Herbicide Treatment	Ave % Injury 14DAT	
	Segregating T ₂ <i>AAD-12 (v1)</i> plants (pDAB724.01.120)	Pat/Cry1f - Control
280 g ae/ha Triclopyr	0	52
560 g ae/ha Triclopyr	3	58
1120 g ae/ha Triclopyr	0	75*

BDDB01 9494151v1

Table 13. Comparison of T₂ AAD-12 (v1) and transformed control *Arabidopsis* plant response to various foliar-applied auxinic herbicides.

2240 g ae/ha Triclopyr	3	75*
280 g ae/ha Fluroxypyr	0	75*
560 g ae/ha Fluroxypyr	2	75*
1120 g ae/ha Fluroxypyr	3	75*
2240 g ae/ha Fluroxypyr	5	75*
Inactive DCP metabolite		
280 g ae/ha 2,4-DCP	0	0
560 g ae/ha 2,4-DCP	0	0
1120 g ae/ha 2,4-DCP	0	0
2240 g ae/ha 2,4-DCP	0	0

* Plants in this experiment were stunted and severely epinastic, but remained green and did not receive injury ratings > 75%.

[00235] 7.9 – Molecular analysis of AAD-12 (v1) Arabidopsis.

[00236] Invader Assay (methods of Third Wave Agbio Kit Procedures) for *PAT* gene copy number analysis was performed with total DNA obtained from Qiagen DNeasy kit on multiple *AAD-12 (v1)* homozygous lines to determine stable integration of the plant transformation unit containing *PAT* and *AAD-12 (v1)*. Analysis assumed direct physical linkage of these genes as they were contained on the same plasmid.

[00237] Results showed that all 2,4-D resistant plants assayed, contained *PAT* (and thus by inference, *AAD-12 (v1)*). Copy number analysis showed total inserts ranged from 1 to 5 copies. This correlates, too, with the *AAD-12 (v1)* protein expression data indicating that the presence of the enzyme yields significantly high levels of resistance to all commercially available phenoxyacetic and pyridyloxyacetic acids.

[00238] 7.10 – Arabidopsis transformed with molecular stack of AAD-12 (v1) and a glyphosate resistance gene.

[00239] T₁ *Arabidopsis* seed was produced, as previously described, containing the pDAB3759 plasmid (*AAD-12 (v1)* + *EPSPS*) which encodes a putative glyphosate resistance trait. T₁ transformants were selected using *AAD-12 (v1)* as the selectable marker as described in example 7.6. T₁ plants (individually transformed events) were recovered from the first selection attempt and transferred to three-inch pots in the greenhouse as previously described. Three different control *Arabidopsis* lines were also tested: wildtype Columbia-0, *AAD-12 (v1)* + *PAT* T₄ homozygous lines (pDAB724-transformed), and *PAT* + *Cry1F* homozygous

BDDDB01 9494151v1

line (transformed control). The pDAB3759 and pDAB724 transformed plants were pre-selected at the seedling stage for 2,4-D tolerance. Four days after transplanting, plants were evenly divided for foliar treatment by track sprayer as previously described with 0, 26.25, 105, 420, or 1680 g ae/ha glyphosate (Glyphomax Plus, Dow AgroSciences) in water. All treatments were replicated 5 to 20 times. Plants were evaluated 7 and 14 days after treatment. [00240] Initial resistance assessment indicated plants tolerant to 2,4-D were subsequently tolerant to glyphosate when compared to the response of the three control lines. These results indicate that resistance can be imparted to plants to two herbicides with differencing modes of action, including 2,4-D and glyphosate tolerance, allowing application of both herbicides postemergence. Additionally, AAD-12 + 2,4-D was used effectively as a selectable marker for a true resistance selection.

Table 14. T₁ *Arabidopsis* response to a range of glyphosate rates applied postemergence (14 DAT).

AAD-12 v1 gene + EPSPS + HptII (pDAB3759) (Averages)	% Injury			% Injury	
	<20%	20-40%	>40%	Ave	Std Dev
Untreated control	5	0	0	0	0
26.25 g ae/ha glyphosate	13	2	1	11	16
105 g ae/ha glyphosate	10	1	5	34	38
420 g ae/ha glyphosate	5	6	5	44	37
1680 g ae/ha glyphosate	0	0	16	85	9
PAT/Cry1F	% Injury			% Injury	
Averages	<20%	20-40%	>40%	Ave	Std Dev
Untreated control	5	0	0	0	0
26.25 g ae/ha glyphosate	0	0	5	67	7
105 g ae/ha glyphosate	0	0	5	100	0
420 g ae/ha glyphosate	0	0	5	100	0
1680 g ae/ha glyphosate	0	0	5	100	0
Wildtype (Col-0)	% Injury			% Injury	
Averages	<20%	20-40%	>40%	Ave	Std Dev
Untreated control	5	0	0	0	0
26.25 g ae/ha glyphosate	0	0	5	75	13
105 g ae/ha glyphosate	0	0	5	100	0
420 g ae/ha glyphosate	0	0	5	100	0
1680 g ae/ha glyphosate	0	0	5	100	0

BDDDB01 9494151v1

pDAB724 T ₄ (PAT + AAD-12) Averages	% Injury		% Injury	Ave	Std Dev
	<20%	20-40%			
Untreated control	5	0	0	0	0
26.25 g ae/ha glyphosate	0	0	5	66	8
105 g ae/ha glyphosate	0	0	5	100	0
420 g ae/ha glyphosate	0	0	5	100	0
1680 g ae/ha glyphosate	0	0	5	100	0

[00241] 7.11 – AAD-12 Arabidopsis genetically stacked with AAD-1 to give wider spectrum of herbicide tolerance.

[00242] AAD-12 (v1) (pDAB724) and AAD-1 (v3) (pDAB721) plants were reciprocally crossed and F₁ seed was collected. Eight F₁ seeds were planted and allowed to grow to produce seed. Tissue samples were taken from the eight F₁ plants and subjected to Western analysis to confirm the presence of both genes. It was concluded that all 8 plants tested expressed both AAD-1 and AAD-12 proteins. The seed was bulked and allowed to dry for a week before planting.

[00243] One hundred F₂ seeds were sown and 280 g ai/ha glufosinate was applied. Ninety-six F₂ plants survived glufosinate selection fitting an expected segregation ration for two independently assorting loci for glufosinate resistance (15 R : 1S). Glufosinate resistant plants were then treated with 560 g ae/ha R-dichlorprop + 560 g ae/ha triclopyr, applied to the plants under the same spray regimen as used for the other testing. Plants were graded at 3 and 14 DAT. Sixty-three of the 96 plants that survived glufosinate selection also survived the herbicide application. These data are consistent with an expected segregation pattern (9R: 6S) of two independently assorting dominant traits where each gene gives resistance to only one of the auxinic herbicides (either R-dichlorprop or triclopyr). The results indicate that AAD-12 (pDAB724) can be successfully stacked with AAD-1 (pDAB721), thus increasing the spectrum herbicides that may be applied to the crop of interest [(2,4-D + R-dichlorprop) and (2,4-D + fluroxypyr + triclopyr), respectively]. This could be useful to bring 2,4-D tolerance to a very sensitive species through conventional stacking of two separate 2,4-D resistance genes. Additionally, if either gene were used as a selectable marker for a third and fourth gene of interest through independent transformation activities, then each gene pair could be brought together through conventional breeding activities and subsequently selected in the F₁ generation through paired sprays with herbicides that are exclusive between the AAD-1 and

AAD-12 enzymes (as shown with R-dichlorprop and triclopyr for AAD-1 and AAD-12, respectively, above).

[00244] Other AAD stacks are also within the scope of the subject invention. The TfdA protein discussed elsewhere herein (Streber *et al.*), for example, can be used together with the subject AAD-12 genes to impart novel spectrums of herbicide resistance in transgenic plants of the subject invention.

Example 8 –WHISKERS-mediated transformation of corn using imazethapyr selection

[00245] 8.1 – Cloning of *AAD-12 (v1)*.

[00246] The *AAD-12 (v1)* gene was cut out of the intermediate vector pDAB3283 as an NcoI/SacI fragment. This was ligated directionally into the similarly cut pDAB3403 vector containing the ZmUbi1 monocot promoter. The two fragments were ligated together using T4 DNA ligase and transformed into DH5 α cells. Minipreps were performed on the resulting colonies using Qiagen's QIA Spin mini prep kit, and the colonies were digested to check for orientation. This first intermediate construct (pDAB4100) contains the ZmUbi1 : *AAD-12 (v1)* cassette. This construct was digested with NotI and PvuI to liberate the gene cassette and digest the unwanted backbone. This was ligated to NotI cut pDAB2212, which contains the AHAS selectable marker driven by the Rice Actin promoter OsAct1. The final construct was designated pDAB4101 or pDAS1863, and contains ZmUbi1/*AAD-12 (v1)*/ZmPer5::OsAct1/AHAS /LZmLip.

[00247] 8.2 – Callus/suspension initiation.

[00248] To obtain immature embryos for callus culture initiation, F₁ crosses between greenhouse-grown Hi-II parents A and B (Armstrong *et al.* 1991) were performed. When embryos were 1.0-1.2 mm in size (approximately 9-10 days post-pollination), ears were harvested and surface sterilized by scrubbing with Liqui-Nox® soap, immersed in 70% ethanol for 2-3 minutes, then immersed in 20% commercial bleach (0.1% sodium hypochlorite) for 30 minutes.

[00249] Ears were rinsed in sterile, distilled water, and immature zygotic embryos were aseptically excised and cultured on 15Ag10 medium (N6 Medium (Chu *et al.*, 1975), 1.0 mg/L 2,4-D, 20 g/L sucrose, 100 mg/L casein hydrolysate (enzymatic digest), 25 mM L-proline, 10 mg/L AgNO₃, 2.5 g/L Gelrite, pH 5.8) for 2-3 weeks with the scutellum facing away from the medium. Tissue showing the proper morphology (Welter *et al.*, 1995) was

BDDDB01 9494151v1

selectively transferred at biweekly intervals onto fresh 15Ag10 medium for about 6 weeks, then transferred to 4 medium (N6 Medium, 1.0 mg/L 2,4-D, 20 g/L sucrose, 100 mg/L casein hydrolysate (enzymatic digest), 6 mM L-proline, 2.5 g/L Gelrite, pH 5.8) at bi-weekly intervals for approximately 2 months.

[00250] To initiate embryogenic suspension cultures, approximately 3 ml packed cell volume (PCV) of callus tissue originating from a single embryo was added to approximately 30 ml of H9CP+ liquid medium (MS basal salt mixture (Murashige and Skoog, 1962), modified MS Vitamins containing 10-fold less nicotinic acid and 5-fold higher thiamine-HCl, 2.0 mg/L 2,4-D, 2.0 mg/L α -naphthaleneacetic acid (NAA), 30 g/L sucrose, 200 mg/L casein hydrolysate (acid digest), 100 mg/L *myo*-inositol, 6 mM L-proline, 5% v/v coconut water (added just before subculture), pH 6.0). Suspension cultures were maintained under dark conditions in 125 ml Erlenmeyer flasks in a temperature-controlled shaker set at 125 rpm at 28° C. Cell lines typically became established within 2 to 3 months after initiation. During establishment, suspensions were subcultured every 3.5 days by adding 3 ml PCV of cells and 7 ml of conditioned medium to 20 ml of fresh H9CP+ liquid medium using a wide-bore pipette. Once the tissue started doubling in growth, suspensions were scaled-up and maintained in 500 ml flasks whereby 12 ml PCV of cells and 28 ml conditioned medium was transferred into 80 ml H9CP+ medium. Once the suspensions were fully established, they were cryopreserved for future use.

[00251] 8.3 – Cryopreservation and thawing of suspensions.

[00252] Two days post-subculture, 4 ml PCV of suspension cells and 4 ml of conditioned medium were added to 8 ml of cryoprotectant (dissolved in H9CP+ medium without coconut water, 1 M glycerol, 1 M DMSO, 2 M sucrose, filter sterilized) and allowed to shake at 125 rpm at 4° C for 1 hour in a 125 ml flask. After 1 hour 4.5 ml was added to a chilled 5.0 ml Corning cryo vial. Once filled individual vials were held for 15 minutes at 4° C in a controlled rate freezer, then allowed to freeze at a rate of -0.5° C/minute until reaching a final temperature of -40° C. After reaching the final temperature, vials were transferred to boxes within racks inside a Cryoplus 4 storage unit (Forma Scientific) filled with liquid nitrogen vapors.

[00253] For thawing, vials were removed from the storage unit and placed in a closed dry ice container, then plunged into a water bath held at 40-45° C until “boiling” subsided. When thawed, contents were poured over a stack of ~8 sterile 70 mm Whatman filter papers (No. 4)

BDDDB01 9494151v1

in covered 100x25 mm Petri dishes. Liquid was allowed to absorb into the filters for several minutes, then the top filter containing the cells was transferred onto GN6 medium (N6 medium, 2.0 mg/L 2,4-D, 30 g/L sucrose, 2.5 g/L Gelrite, pH 5.8) for 1 week. After 1 week, only tissue with promising morphology was transferred off the filter paper directly onto fresh GN6 medium. This tissue was subcultured every 7-14 days until 1 to 3 grams was available for suspension initiation into approximately 30 ml H9CP+ medium in 125 ml Erlenmeyer flasks. Three milliliters PCV was subcultured into fresh H9CP+ medium every 3.5 days until a total of 12 ml PCV was obtained, at which point subculture took place as described previously.

[00254] 8.4 – Stable Transformation

[00255] Approximately 24 hours prior to transformation, 12 ml PCV of previously cryopreserved embryogenic maize suspension cells plus 28 ml of conditioned medium was subcultured into 80 ml of GN6 liquid medium (GN6 medium lacking Gelrite) in a 500 ml Erlenmeyer flask, and placed on a shaker at 125 rpm at 28° C. This was repeated 2 times using the same cell line such that a total of 36 ml PCV was distributed across 3 flasks. After 24 hours the GN6 liquid media was removed and replaced with 72 ml GN6 S/M osmotic medium (N6 Medium, 2.0 mg/L 2,4-D, 30 g/L sucrose, 45.5 g/L sorbitol, 45.5 g/L mannitol, 100 mg/L *myo*-inositol, pH 6.0) per flask in order to plasmolyze the cells. The flasks were placed on a shaker shaken at 125 RPM in the dark for 30-35 minutes at 28°C, and during this time a 50 mg/ml suspension of silicon carbide whiskers was prepared by adding the appropriate volume 8.1 ml of GN6 S/M liquid medium to ~405 mg of pre-autoclaved, sterile silicon carbide whiskers (Advanced Composite Materials, Inc.).

[00256] After incubation in GN6 S/M, the contents of each flask were pooled into a 250 ml centrifuge bottle. Once all cells settled to the bottom, all but ~14 ml of GN6 S/M liquid was drawn off and collected in a sterile 1-L flask for future use. The pre-wetted suspension of whiskers was vortexed for 60 seconds on maximum speed and 8.1 ml was then added to the bottle, to which 170 µg DNA was added as a last step. The bottle was immediately placed in a modified Red Devil 5400 commercial paint mixer and agitated for 10 seconds. After agitation, the cocktail of cells, media, whiskers and DNA was added to the contents of the 1-L flask along with 125 ml fresh GN6 liquid medium to reduce the osmoticant. The cells were allowed to recover on a shaker at 125 RPM for 2 hours at 28°C before being filtered onto

Whatman #4 filter paper (5.5 cm) using a glass cell collector unit that was connected to a house vacuum line.

[00257] Approximately 2 ml of dispersed suspension was pipetted onto the surface of the filter as the vacuum was drawn. Filters were placed onto 60 x 20 mm plates of GN6 medium. Plates were cultured for 1 week at 28° C in a dark box.

[00258] After 1 week, filter papers were transferred to 60x20 mm plates of GN6 (3P) medium (N6 Medium, 2.0 mg/L 2,4-D, 30 g/L sucrose, 100 mg/L *myo*-inositol, 3 µM imazethapyr from Pursuit® DG, 2.5 g/L Gelrite, pH 5.8). Plates were placed in boxes and cultured for an additional week.

[00259] Two weeks post-transformation, the tissue was embedded by scraping all cells on the plate into 3.0 ml of melted GN6 agarose medium (N6 medium, 2.0 mg/L 2,4-D, 30 g/L sucrose, 100 mg/L *myo*-inositol, 7 g/L Sea Plaque agarose, pH 5.8, autoclaved for only 10 minutes at 121°C) containing 3 µM imazethapyr from Pursuit® DG. The tissue was broken up and the 3 ml of agarose and tissue were evenly poured onto the surface of a 100 x 15 mm plate of GN6 (3P). This was repeated for all remaining plates. Once embedded, plates were individually sealed with Nescofilm® or Parafilm M®, and then cultured until putative isolates appeared.

[00260] 8.4.1- Protocol for Isolate recovery and regeneration.

[00261] Putatively transformed events were isolated off the Pursuit®-containing embedded plates approximately 9 weeks post-transformation by transferring to fresh selection medium of the same concentration in 60 x 20 mm plates. If sustained growth was evident after approximately 2-3 weeks, the event was deemed to be resistant and was submitted for molecular analysis.

[00262] Regeneration was initiated by transferring callus tissue to a cytokinin-based induction medium, 28 (3P), containing 3 µM imazethapyr from Pursuit® DG, MS salts and vitamins, 30.0 g/L sucrose, 5 mg/L BAP, 0.25 mg/L 2,4-D, 2.5 g/L Gelrite; pH 5.7. Cells were allowed to grow in low light (13 µEm⁻²s⁻¹) for one week, then higher light (40 µEm⁻²s⁻¹) for another week, before being transferred to regeneration medium, 36 (3P), which was identical to 28 (3P) except that it lacked plant growth regulators. Small (3-5 cm) plantlets were removed and placed into 150 x 25-mm culture tubes containing selection-free SHGA medium (Schenk and Hildebrandt basal salts and vitamins, 1972; 1 g/L *myo*-inositol, 10 g/L sucrose, 2.0 g/L

Gelrite, pH 5.8). Once plantlets developed a sufficient root and shoot system, they were transplanted to soil in the greenhouse.

[00263] From 4 experiments, full plantlets, comprised of a shoot and root, were formed *in vitro* on the embedded selection plates under dark conditions without undergoing a traditional callus phase. Leaf tissue from nine of these “early regenerators” were submitted for coding region PCR and Plant Transcription Unit (PTU) PCR for the *AAD-12* gene and gene cassette, respectively. All had an intact *AAD-12* coding region, while 3 did not have a full-length PTU (Table 15). These “early regenerators” were identified as 4101 events to differentiate them from the traditionally-derived events, which were identified as “1283” events. Plants from 19 additional events, obtained via standard selection and regeneration, were sent to the greenhouse, grown to maturity and cross-pollinated with a proprietary inbred line in order to produce T₁ seed. Some of the events appear to be clones of one another due to similar banding patterns following Southern blot, so only 14 unique events were represented. T₀ plants from events were tolerant 70 g/ha imazethapyr. Invader analysis (*AHAS* gene) indicated insertion complexity ranging from 1 to >10 copies. Thirteen events contained the complete coding region for *AAD-12*; however, further analysis indicated the complete plant transformation unit had not been incorporated for nine events. None of the compromised 1863 events were advanced beyond the T₁ stage and further characterization utilized the 4101 events.

[00264] 8.5– Molecular Analysis: Maize Materials and Methods.

[00265] 8.5.1 – Tissue harvesting DNA isolation and quantification. Fresh tissue is placed into tubes and lyophilized at 4° C for 2 days. After the tissue is fully dried, a tungsten bead (Valenite) is placed in the tube and the samples are subjected to 1 minute of dry grinding using a Kelco bead mill. The standard DNeasy DNA isolation procedure is then followed (Qiagen, DNeasy 69109). An aliquot of the extracted DNA is then stained with Pico Green (Molecular Probes P7589) and read in the fluorometer (BioTek) with known standards to obtain the concentration in ng/μl.

[00266] 8.5.2 – Invader assay analysis. The DNA samples are diluted to 20 ng/μl then denatured by incubation in a thermocycler at 95° C for 10 minutes. Signal Probe mix is then prepared using the provided oligo mix and MgCl₂ (Third Wave Technologies). An aliquot of 7.5 μl is placed in each well of the Invader assay plate followed by an aliquot of 7.5 μl of controls, standards, and 20 ng/μl diluted unknown samples. Each well is overlaid with 15 μl

BDDDB01 9494151v1

of mineral oil (Sigma). The plates are then incubated at 63° C for 1 hour and read on the fluorometer (Biotek). Calculation of % signal over background for the target probe divided by the % signal over background internal control probe will calculate the ratio. The ratio of known copy standards developed and validated with Southern blot analysis is used to identify the estimated copy of the unknown events.

[00267] 8.5.3 – Polymerase chain reaction. A total of 100 ng of total DNA is used as the template. 20 mM of each primer is used with the Takara Ex Taq PCR Polymerase kit (Mirus TAKRR001A). Primers for the *AAD-12 (v1)* PTU are Forward – GAACAGTTAGACATGGTCTAAAGG (SEQ ID NO:8) and Reverse – GCTGCAACACTGATAAATGCCAACTGG (SEQ ID NO:9). The PCR reaction is carried out in the 9700 Geneamp thermocycler (Applied Biosystems), by subjecting the samples to 94° C for 3 minutes and 35 cycles of 94° C for 30 seconds, 63° C for 30 seconds, and 72° C for 1 minute and 45 seconds followed by 72° C for 10 minutes.

[00268] Primers for *AAD-12 (v1)* Coding Region PCR are Forward – ATGGCTCAGACCACTCTCCAAA (SEQ ID NO:10) and Reverse – AGCTGCATCCATGCCAGGGA (SEQ ID NO:11). The PCR reaction is carried out in the 9700 Geneamp thermocycler (Applied Biosystems), by subjecting the samples to 94° C for 3 minutes and 35 cycles of 94° C for 30 seconds, 65° C for 30 seconds, and 72° C for 1 minute and 45 seconds followed by 72° C for 10 minutes. PCR products are analyzed by electrophoresis on a 1% agarose gel stained with EtBr.

[00269] 8.5.4 – Southern blot analysis.

[00270] Southern blot analysis is performed with genomic DNA obtained from Qiagen DNeasy kit. A total of 2 µg of genomic leaf DNA or 10 µg of genomic callus DNA is subjected to an overnight digestion using BSM I and SWA I restriction enzymes to obtain PTU data .

[00271] After the overnight digestion an aliquot of ~100 ng is run on a 1% gel to ensure complete digestion. After this assurance the samples are run on a large 0.85 % agarose gel overnight at 40 volts. The gel is then denatured in 0.2 M NaOH, 0.6 M NaCl for 30 minutes. The gel is then neutralized in 0.5 M Tris HCl, 1.5 M NaCl pH of 7.5 for 30 minutes. A gel apparatus containing 20x SSC is then set up to obtain a gravity gel to nylon membrane (Millipore INYC00010) transfer overnight. After the overnight transfer the membrane is then subjected to UV light via a crosslinker (Stratagene UV stratalinker 1800) at 1200 X100

BDDDB01 9494151v1

microjoules. The membrane is then washed in 0.1% SDS, 0.1 SSC for 45 minutes. After the 45 minute wash, the membrane is baked for 3 hours at 80° C and then stored at 4° C until hybridization. The hybridization template fragment is prepared using the above coding region PCR using plasmid DNA. The product is run on a 1% agarose gel and excised and then gel extracted using the Qiagen (28706) gel extraction procedure. The membrane is then subjected to a pre-hybridization at 60°C step for 1 hour in Perfect Hyb buffer (Sigma H7033). The Prime it RmT dCTP-labeling rxn (Stratagene 300392) procedure is used to develop the p32 based probe (Perkin Elmer). The probe is cleaned up using the Probe Quant. G50 columns (Amersham 27-5335-01). Two million counts CPM are used to hybridize the southern blots overnight. After the overnight hybridization the blots are then subjected to two 20 minute washes at 65° C in 0.1% SDS, 0.1 SSC. The blots are then exposed to film overnight, incubating at -80° C.

[00272] 8.6 – Postemergence herbicide tolerance in AAD-12 transformed T₀ Corn.

[00273] Four T₀ events were allowed to acclimate in the greenhouse and were grown until 2-4 new, normal looking leaves had emerged from the whorl (i.e., plants had transitioned from tissue culture to greenhouse growing conditions). Plants were grown at 27° C under 16 hour light:8 hour dark conditions in the greenhouse. Plants were then treated with commercial formulations of either Pursuit® (imazethapyr) or 2,4-D Amine 4. Pursuit® was sprayed to demonstrate the function of the selectable marker gene present within the events tested. Herbicide applications were made with a track sprayer at a spray volume of 187 L/ha, 50-cm spray height. Plants were sprayed with either a lethal dose of imazethapyr (70 g ae/ha) or a rate of 2,4-D DMA salt capable of significant injury to untransformed corn lines (2240 g ae/ha). A lethal dose is defined as the rate that causes >95% injury to the Hi-II inbred. Hi-II is the genetic background of the transformants of the present invention.

[00274] Several individuals were safened from the herbicides to which the respective genes were to provide resistance. The individual clone '001' from event "001" (a.k.a.,4101(0)-001-001), however, did incur minor injury but recovered by 14 DAT. Three of the four events were moved forward and individuals were crossed with 5XH751 and taken to the next generation. Each herbicide tolerant plant was positive for the presence of the *AAD-12* coding region (PCR assay) or the presence of the *AHAS* gene (Invader assay) for 2,4-D and imazethapyr-tolerant plants, respectively. AAD-12 protein was detected in all 2,4-D tolerant T₀ plants events containing an intact coding region. The copy number of the transgene(s)

BDDDB01 9494151v1

(*AHAS*, and by inference *AAD-12*) varied significantly from 1 to 15 copies. Individual T_0 plants were grown to maturity and cross-pollinated with a proprietary inbred line in order to produce T_1 seed.

Table 15. Characterization of T_0 corn plants transformed with <i>AAD-12</i> .						
Event	Spray Treatment	% Injury (14 DAT)	AAD-12 ELISA (ppm TSP)	AAD12 PCR (Coding Region)	AAD12 PCR (PTU)	AHAS Copy # (Invader)
4101(0)003.001	2240 g ae/ha 2,4-D	0	146.9	+	+	1
4101(0)003.003	2240 g ae/ha 2,4-D	0	153.5	+	+	1
4101(0)005.001	2240 g ae/ha 2,4-D	0	539.7	+	+	9
4101(0)005.0012	0 g ae/ha 2,4-D	0	562.9	+	+	7
4101(0)001.001	70 g ae/ha imazethapyr	5	170.7	+	+	6
4101(0)002.001	0 g ae/ha imazethapyr	0	105.6	+	-	2
4101(0)002.002	70 g ae/ha imazethapyr	0	105.3	+	-	2
4101(0)003.002	70 g ae/ha imazethapyr	0	0	+	band smaller than expected	15

[00275] **8.7 – Verification of high 2,4-D tolerance in T_1 corn.**

[00276] T_1 *AAD-12* (v1) seed were planted into 3-inch pots containing Metro Mix media and at 2 leaf stage were sprayed with 70 g ae/ha imazethapyr to eliminate nulls. Surviving plants were transplanted to 1-gallon pots containing Metro Mix media and placed in the same growth conditions as before. At V3-V4 stage the plants were sprayed in the track sprayer set to 187 L/ha at either 560 or 2240 g ae/ha 2,4-D DMA. Plants were graded at 3 and 14 DAT and compared to 5XH751 x Hi II control plants. A grading scale of 0-10 (no injury to extreme auxin injury) was developed to distinguish brace root injury. Brace Root grades were taken on 14DAT to show 2,4-D tolerance. 2,4-D causes brace root malformation, and is a consistent indicator of auxinic herbicide injury in corn. Brace root data (as seen in the table below) demonstrates that 2 of the 3 events tested were robustly tolerant to 2240 g ae/ha 2,4-D DMA. Event “pDAB4101(0)001.001” was apparently unstable; however, the other two events were robustly tolerant to 2,4-D and 2,4-D + imazethapyr or 2,4-D + glyphosate (see Table 16).

Table 16. Brace Root injury of <i>AAD-12 (v1)</i> transformed T ₁ plants and Untransformed control corn plants. A scale of 0-10, 10 being the highest, was used for grading the 2,4-D DMA injury. Results are a visual average of four replications per treatment.				
Herbicide	Untransformed Control	<i>AAD-12 (v1)</i> pDAB4101(0)003.003	<i>AAD-12 (v1)</i> pDAB4101(0)001.001	<i>AAD-12 (v1)</i> pDAB4101(0)005.001
Average Brace Root Injury (0-10 Scale)				
0 g ae/ha 2,4-D DMA	0	0	0	0
2240 g ae/ha 2,4-D DMA	9	1	8	0

[00277] 8.8 – *AAD-12 (v1)* heritability in corn.

[00278] A progeny test was also conducted on seven *AAD-12 (v1)* T₁ families that had been crossed with 5XH751. The seeds were planted in three-inch pots as described above. At the 3 leaf stage all plants were sprayed with 70 g ae/ha imazethapyr in the track sprayer as previously described. After 14 DAT, resistant and sensitive plants were counted. Four out of the six lines tested segregated as a single locus, dominant Mendelian trait (1R:1S) as determined by Chi square analysis. Surviving plants were subsequently sprayed with 2,4-D and all plants were deemed tolerant to 2,4-D (rates $\geq$ 560 g ae/ha). *AAD-12* is heritable as a robust aryloxyalkanoate auxin resistance gene in multiple species when reciprocally crossed to a commercial hybrid.

[00279] 8.9 – Stacking of *AAD-12 (v1)* to increase herbicide spectrum

[00280] *AAD-12 (v1)* (pDAB4101) and elite Roundup Ready inbred (BE1146RR) were reciprocally crossed and F₁ seed was collected. The seed from two F₁ lines were planted and treated with 70 g ae/ha imazethapyr at the V2 stage to eliminate nulls. To the surviving plants, reps were separated and either treated with 1120 g ae/ha 2,4-D DMA + 70 g ae/ha imazethapyr (to confirm presence of AHAS gene) or 1120 g ae/ha 2,4-D DMA + 1680 g ae/ha glyphosate (to confirm the presence of the Round Up Ready gene) in a track sprayer calibrated to 187 L/ha. Plants were graded 3 and 16 DAT. Spray data showed that *AAD-12 (v1)* can be conventionally stacked with a glyphosate tolerance gene (such as the Roundup CP4-EPSPS gene) or other herbicide tolerance genes to provide an increased spectrum of herbicides that may be applied safely to corn. Likewise imidazolinone + 2,4-D + glyphosate

tolerance was observed in F₁ plants and showed no negative phenotype by the molecular or breeding stack combinations of these multiple transgenes.

Table 17. Data demonstrating increase herbicide tolerance spectrum resulting from an F ₁ stack of <i>AAD-12 (v1)</i> and BE1146RR (an elite glyphosate tolerant inbred abbreviated as AF).				
Herbicide	Untransformed Control	2P782 (Roundup Ready Control)	<i>AAD-12 (v1)</i> pDAB4101(0) 003.R003.AF	<i>AAD-12 (v1)</i> pDAB4101(0) 005.R001.AF
0 g ae/ha 2,4-D DMA	0	0	0	0
1120 g ae/ha 2,4-D DMA	21	19	0	0
1120 g ae/ha 2,4-D DMA + 70 g ae/ha imazethapyr	100	100	5	1
01120 g ae/ha 2,4-D DMA + 1680 g ae/ha glyphosate	100	71	2	5

[00281] 8.10- Field tolerance of pDAB4101 transformed corn plants to 2,4-D, triclopyr and fluroxypyr herbicides.

[00282] Field level tolerance trials were conducted on two *AAD-12 (v1)* pDAB4101 events (4101(0)003.R.003.AF and 4101(0)005.R001.AF) and one Roundup Ready (RR) control hybrid (2P782) at Fowler, Indiana and Wayside, Mississippi. Seeds were planted with cone planter on 40-inch row spacing at Wayside and 30 inch spacing at Fowler. The experimental design was a randomized complete block design with 3 replications. Herbicide treatments were 2,4-D (dimethylamine salt) at 1120, 2240 and 4480 g ae/ha, triclopyr at 840 g ae/ha, fluroxypyr at 280 g ae/ha and an untreated control. The *AAD-12 (v1)* events contained the *AHAS* gene as a selectable marker. The F₂ corn events were segregating so the *AAD-12 (v1)* plants were treated with imazethapyr at 70 g ae/ha to remove the null plants. Herbicide treatments were applied when corn reached the V6 stage using compressed air backpack sprayer delivering 187 L/ha carrier volume at 130-200 kpa pressure. Visual injury ratings were taken at 7, 14 and 21 days after treatment. Brace root injury ratings were taken at 28DAT on a scale of 0-10 with 0-1 being slight brace root fusing, 1-3 being moderate brace root swelling/wandering and root proliferation, 3-5 being moderate brace root fusing, 5-9 severe brace root fusing and malformation and 10 being total inhibition of brace roots.

[00283] *AAD-12 (v1)* event response to 2,4-D, triclopyr, and fluroxypyr at 14 days after treatment are shown in Table 18. Crop injury was most severe at 14 DAT. The RR control

BDDB01 9494151v1

corn (2P782) was severely injured (44% at 14 DAT) by 2,4-D at 4480 g ae/ha, which is 8 times (8X) the normal field use rate. The *AAD-12 (v1)* events all demonstrated excellent tolerance to 2,4-D at 14 DAT with 0% injury at the 1, 2 and 4X rates, respectively. The control corn (2P782) was severely injured (31% at 14 DAT) by the 2X rate of triclopyr (840 g ae/ha). *AAD-12 (v1)* events demonstrated tolerance at 2X rates of triclopyr with an average of 3% injury at 14 DAT across the two events. Fluroxypyr at 280 g ae/ha caused 11% visual injury to the wild-type corn at 14 DAT. *AAD-12 (v1)* events demonstrated increased tolerance with an average of 8% injury at 5 DAT.

[00284] Applications of auxinic herbicides to corn in the V6 growth stage can cause malformation of the brace roots. Table 18 shows the severity of the brace root injury caused by 2,4-D, triclopyr, and fluroxypyr. Triclopyr at 840 g ae/ha caused the most severe brace root fusing and malformation resulting in an average brace root injury score of 7 in the 2P782 control-type corn. Both *AAD-12 (v1)* corn events showed no brace root injury from the triclopyr treatment. Brace root injury in 2P782 corn increased with increasing rates of 2,4-D. At 4480 g ae/ha of 2,4-D, the *AAD-12* events showed no brace root injury; whereas, severe brace root fusing and malformation was seen in the 2P782 hybrid. Fluroxypyr caused only moderate brace root swelling and wandering in the wild-type corn with the *AAD-12 (v1)* events showing no brace root injury.

[00285] This data clearly shows that *AAD-12(v1)* conveys high level tolerance in corn to 2,4-D, triclopyr and fluroxypyr at rates far exceeding those commercially used and that cause non-*AAD-12 (v1)* corn severe visual and brace root injury.

Table 18. Visual Injury of AAD-12 events and wild-type corn following foliar applications of 2,4-D, triclopyr and fluroxypyr under field conditions.					
Treatment	Rate (g ae/ha)	%Visual Injury 14DAT			
		AAD-12 4101(0)003.R.003.AF	AAD- 124101(0)005.001.AF	2P782 control	
Untreated	0	0	0	0	
2,4-D	1120	0	0	9	
2,4-D	2240	0	1	20	
2,4-D	4480	0	1	34	
Fluroxypyr	280	1	5	11	
Triclopyr	840	3	4	31	
Dicamba	840	8	8	11	

Table 19. Brace root injury ratings for AAD-12 and wild-type corn plants in response to 2,4-D, triclopyr and fluroxypyr under field conditions.

Treatment	Brace Root Injury Rating (0-10 scale) 28DAT			
	Rate (g ae/ha)	AAD-12 event 4101(0)003.R.003.AF	AAD-12 event 4101(0)005.001.AF	Wild- type NK603
Untreated	0	0	0	0
2,4-D	1120	0	0	3
2,4-D	2240	0	0	5
2,4-D	4480	0	0	6
Fluroxypyr	280	0	0	2
Triclopyr	840	0	0	7
Dicamba	840	1	1	1

Example 9. Protein detection from transformed plants via antibody

[00286]

9.1 – Extracting AAD-12 (v1) from plant leaves.

Approximately 50 to 100 mg of leaf tissue was cut into small pieces (or 4 single-hole-punched leaf discs) and put into 2-ml cluster tubes containing 2 stainless steel BB beads (4.5 mm; Daisy Co., cat. #145462-000). Five hundred microliters of plant extraction buffer (PBS containing 0.05 % Tween 20 and 1% Bovine serum albumin) was added to each sample. The tubes were capped and secured in the Geno/Grinder (Model 2000-115, Certiprep, Metuchen, NJ) and shaken for 6 min with setting at 1x of 500 rpm. Tubes were centrifuged at 5000x g for 10 min and supernatant containing the soluble proteins were analyzed for AAD-12 (v1) using Western Blots and ELISA.

[00287]

9.2 – Enzyme linked immuno-sorbent assay (ELISA).

[00288]

The assay was conducted at room temperature unless otherwise stated. One hundred micro-liter of purified anti-AAD-12 antibody (0.5 µg/ml) was coated on 96-well microtiter well and incubated at 4° C for 16 hours. The plate was washed four times with washing buffer (100 mM phosphate buffered saline (PBS; pH 7.4) containing 0.05% Tween 20) using a plate washer, followed by blocking with 4% skim milk dissolved in PBS for 1 hour. After washing, 100 µL standard AAD-12 of known concentrations or plant extracts from different samples were incubated in the wells. For standard curve, purified AAD-12 was diluted 2-fold serially from 52 to 0.813 ng/ml in triplicates. Plant extracts were diluted 5, 10, 20, and 40-fold in PBS and analyzed in duplicates. After 1 hour incubation, the plate was washed as above. One hundred micro-liter anti-AAD-12 antibody-HRP conjugate (0.5 ug/ml) was incubated in each well for 1 hour before washing. One hundred micro-liter HRP substrate, 1-

BDDB01 9494151v1

Step™ Ultra TMB-ELISA (Pierce, Rockford, IL), was incubated in each well for 10 minutes before the reaction was stopped by adding 100 µL 0.4N H₂SO₄. The OD of each well was measured using a microplate reader at 450 nm. To determine the concentrations of AAD-12 (v1) in plant extract, the OD value of duplicates were averaged and extrapolated from the standard curve using the Softmax® Pro ver. 4.0 (Molecular Devices).

[00289] For comparison, each sample was normalized with its fresh weight and percent expression was calculated.

[00290] 9.3 – Western blotting analysis.

[00291] Plant extracts or AAD-12 standards (5 and 0.5 µg/ml) were incubated with Laemmli sample buffer at 95° C for 10 minutes and electrophoretically separated in 8-16% Tris-Glycine Precast gel. Proteins were then electro-transferred onto nitrocellulose membrane using standard protocol. After blocking in 4% skim milk in PBS, AAD-12 (v1) protein was detected by anti-AAD-12 antiserum followed by goat anti-rabbit/HRP conjugates. The detected protein was visualized by chemiluminescence substrate ECL Western Analysis Reagent (Amersham, NJ).

Example 10 – Tobacco Transformation

[00292] Tobacco transformation with *Agrobacterium tumefaciens* was carried out by a method similar, but not identical, to published methods (Horsch *et al.*, 1988). To provide source tissue for the transformation, tobacco seed (*Nicotiana tabacum* cv. KY160) was surface sterilized and planted on the surface of TOB-medium, which is a hormone-free Murashige and Skoog medium (Murashige and Skoog, 1962) solidified with agar. Plants were grown for 6-8 weeks in a lighted incubator room at 28-30° C and leaves collected sterily for use in the transformation protocol. Pieces of approximately one square centimeter were sterily cut from these leaves, excluding the midrib. Cultures of the *Agrobacterium* strains (EHA101S containing pDAB3278, aka pDAS1580, *AAD-12* (v1) + *PAT*), grown overnight in a flask on a shaker set at 250 rpm at 28° C, were pelleted in a centrifuge and resuspended in sterile Murashige & Skoog salts, and adjusted to a final optical density of 0.5 at 600 nm. Leaf pieces were dipped in this bacterial suspension for approximately 30 seconds, then blotted dry on sterile paper towels and placed right side up on TOB+ medium (Murashige and Skoog medium containing 1 mg/L indole acetic acid and 2.5 mg/L benzyladenine) and incubated in the dark at 28° C. Two days later the leaf pieces were moved to TOB+ medium containing

BDDDB01 9494151v1

250 mg/L cefotaxime (Agri-Bio, North Miami, Florida) and 5 mg/L glufosinate ammonium (active ingredient in Basta, Bayer Crop Sciences) and incubated at 28-30°C in the light. Leaf pieces were moved to fresh TOB+ medium with cefotaxime and Basta twice per week for the first two weeks and once per week thereafter. Four to six weeks after the leaf pieces were treated with the bacteria, small plants arising from transformed foci were removed from this tissue preparation and planted into medium TOB-containing 250 mg/L cefotaxime and 10 mg/L Basta in Phytatray™ II vessels (Sigma). These plantlets were grown in a lighted incubator room. After 3 weeks, stem cuttings were taken and re-rooted in the same media. Plants were ready to send out to the greenhouse after 2-3 additional weeks.

[00293] Plants were moved into the greenhouse by washing the agar from the roots, transplanting into soil in 13.75 cm square pots, placing the pot into a Ziploc® bag (SC Johnson & Son, Inc.), placing tap water into the bottom of the bag, and placing in indirect light in a 30° C greenhouse for one week. After 3-7 days, the bag was opened; the plants were fertilized and allowed to grow in the open bag until the plants were greenhouse-acclimated, at which time the bag was removed. Plants were grown under ordinary warm greenhouse conditions (30° C, 16 hour day, 8 hour night, minimum natural + supplemental light = 500 $\mu\text{E}/\text{m}^2\text{s}^1$).

[00294] Prior to propagation, T₀ plants were sampled for DNA analysis to determine the insert copy number. The *PAT* gene which was molecularly linked to *AAD-12 (v1)* was assayed for convenience. Fresh tissue was placed into tubes and lyophilized at 4° C for 2 days. After the tissue was fully dried, a tungsten bead (Valenite) was placed in the tube and the samples were subjected to 1 minute of dry grinding using a Kelco bead mill. The standard DNeasy DNA isolation procedure was then followed (Qiagen, DNeasy 69109). An aliquot of the extracted DNA was then stained with Pico Green (Molecular Probes P7589) and read in the fluorometer (BioTek) with known standards to obtain the concentration in ng/ μl .

[00295] The DNA samples were diluted to 9 ng/ μl and then denatured by incubation in a thermocycler at 95° C for 10 minutes. Signal Probe mix was then prepared using the provided oligo mix and MgCl₂ (Third Wave Technologies). An aliquot of 7.5 μl was placed in each well of the Invader assay plate followed by an aliquot of 7.5 μl of controls, standards, and 20 ng/ μl diluted unknown samples. Each well was overlaid with 15 μl of mineral oil (Sigma). The plates were then incubated at 63° C for 1.5 hours and read on the fluorometer (Biotek). Calculation of % signal over background for the target probe divided by the %

BDDDB01 9494151v1

signal over background internal control probe will calculate the ratio. The ratio of known copy standards developed and validated with southern blot analysis was used to identify the estimated copy of the unknown events.

[00296] All events were also assayed for the presence of the *AAD-12 (v1)* gene by PCR using the same extracted DNA samples. A total of 100 ng of total DNA was used as template. 20 mM of each primer was used with the Takara Ex Taq PCR Polymerase kit. Primers for the Plant Transcription Unit (PTU) PCR *AAD-12* were (SdpacodF: ATGGCTCA TGCTGCCCTCAGCC) (SEQ ID NO:12) and (SdpacodR: CGGGCAGGCCTAACTCCACC AA) (SEQ ID NO:13). The PCR reaction was carried out in the 9700 Geneamp thermocycler (Applied Biosystems), by subjecting the samples to 94° C for 3 minutes and 35 cycles of 94° C for 30 seconds, 64° C for 30 seconds, and 72° C for 1 minute and 45 seconds followed by 72° C for 10 minutes. PCR products were analyzed by electrophoresis on a 1% agarose gel stained with EtBr. Four to 12 clonal lineages from each of 18 PCR positive events with 1-3 copies of PAT gene (and presumably *AAD-12 (v1)* since these genes are physically linked) were regenerated and moved to the greenhouse.

[00297] 10.1 Postemergence herbicide tolerance in *AAD-12 (v1)* transformed T₀ tobacco

[00298] T₀ plants from each of the 19 events were challenged with a wide range of 2,4-D, triclopyr, or fluroxypyr sprayed on plants that were 3-4 inches tall. Spray applications were made as previously described using a track sprayer at a spray volume of 187 L/ha. 2,4-D dimethylamine salt (Riverside Corp) was applied at 0, 140, 560, or 2240 g ae/ha to representative clones from each event mixed in deionized water. Fluroxypyr was likewise applied at 35, 140, or 560 g ae/ha. Triclopyr was applied at 70, 280, or 1120 g ae/ha. Each treatment was replicated 1-3 times. Injury ratings were recorded 3 and 14 DAT. Every event tested was more tolerant to 2,4-D than the untransformed control line KY160. In several events, some initial auxinic herbicide-related epinasty occurred at doses of 560 g ae/ha 2,4-D or less. Some events were uninjured at 2,4-D applied at 2240 g ae/ha (equivalent to 4X field rate). On the whole, *AAD-12 (v1)* events were more sensitive to fluroxypyr, followed by triclopyr, and least affected by 2,4-D. The quality of the events with respect to magnitude of resistance was discerned using T₀ plant responses to 560 g ae/ha fluroxypyr. Events were categorized into “low” (>40% injury 14 DAT), “medium” (20-40% injury), “high” (<20% injury). Some events were inconsistent in response among replicates and were deemed “variable.”

BDDDB01 9494151v1

Table 20. Tobacco T0 events transformed with pDAS1580 (*AAD-12* (*v1*) + *PAT*)

#	Plant ID	Copy #	PTU PCR	Full PTU and	Full PTU and	Relative Herbicide Tolerance [@]
Tube		<i>PAT</i>	<i>AAD-12</i>	Under 2	1 copy	
1	1580[1]-001	6	+			Not tested
2	1580[1]-002	8	+			Not tested
3	1580[1]-003	10	+			Not tested
4	1580[1]-004	1	+	*	*	High
5	1580[1]-005	2	+	*		Variable
6	1580[1]-006	6	+			Not tested
7	1580[1]-007	4	+			Not tested
8	1580[1]-008	3	+			Variable
9	1580[1]-009	4	+			Not tested
10	1580[1]-010	8	+			Not tested
11	1580[1]-011	3	+			High
12	1580[1]-012	12	+			Not tested
13	1580[1]-013	13	+			Not tested
14	1580[1]-014	4	+			Not tested
15	1580[1]-015	2	+	*		High
16	1580[1]-016	1 ?	+	*	*	High
17	1580[1]-017	3	+			High
18	1580[1]-018	1	+	*	*	Variable
19	1580[1]-019	1	+	*	*	Variable
20	1580[1]-020	1	+	*	*	Not tested
21	1580[1]-021	1	+	*	*	Not tested
22	1580[1]-022	3	+			Variable
23	1580[1]-023	1	+	*	*	Variable
24	1580[1]-024	1	+	*	*	Variable
25	1580[1]-025	5	+			Not tested
26	1580[1]-026	3	+			Variable
27	1580[1]-027	3	+			Low
28	1580[1]-028	4	+			Not tested
29	1580[1]-029	3	+			Variable
30	1580[1]-030	1	+	*	*	High
31	1580[1]-031	1	+	*	*	High
32	1580[1]-032	2	+	*		High

[@] Distinguishing herbicide tolerance performance of events required assessment of relative tolerance when treated with 560 g ac/ha fluroxypyr where tolerance was variable across events.

[00299]

10.2 Verification of high 2,4-D tolerance in T₁ tobacco.

[00300]

Two to four T₀ individuals surviving high rates of 2,4-D and fluroxypyr were saved from each event and allowed to self fertilize in the greenhouse to give rise to T₁ seed. The T₁ seed was stratified, and sown into selection trays much like that of *Arabidopsis* (Example 7.4), followed by selective removal of untransformed nulls in this segregating population with 560 g ai/ha glufosinate (*PAT* gene selection). Survivors were transferred to individual 3-

BDDB01 9494151v1

inch pots in the greenhouse. These lines provided high levels of resistance to 2,4-D in the T₀ generation. Improved consistency of response is anticipated in T₁ plants not having come directly from tissue culture. These plants were compared against wildtype KY160 tobacco. All plants were sprayed with a track sprayer set at 187 L/ha. The plants were sprayed from a range of 140 - 2240 g ae/ha 2,4-D dimethylamine salt (DMA), 70-1120 g ae/ha triclopyr or 35-560 g ae/ha fluroxypyr. All applications were formulated in water. Each treatment was replicated 2-4 times. Plants were evaluated at 3 and 14 days after treatment. Plants were assigned injury rating with respect to stunting, chlorosis, and necrosis. The T₁ generation is segregating, so some variable response is expected due to difference in zygosity.

[00301] No injury was observed at 4X field rate (2240 g ae/ha) for 2,4-D or below. Some injury was observed with triclopyr treatments in one event line, but the greatest injury was observed with fluroxypyr. The fluroxypyr injury was short-lived and new growth on one event was nearly indistinguishable from the untreated control by 14 DAT (Table 21). It is important to note that untransformed tobacco is exceedingly sensitive to fluroxypyr. These results indicated commercial level 2,4-D tolerance can be provided by *AAD-12 (v1)*, even in a very auxin-sensitive dicot crop like tobacco. These results also show resistance can be imparted to the pyridyloxyacetic acid herbicides, triclopyr and fluroxypyr. Having the ability to prescribe treatments in an herbicide tolerant crop protected by AAD-12 with various active ingredients having varying spectra of weed control is extremely useful to growers.

Table 21. Assessment of cross tolerance of <i>AAD-12 (v1)</i> T ₁ tobacco plants' response to various phenoxy and pyridyloxy auxin herbicides.			
Herbicide	KY160 – Wildtype	1580(1)-004 (high tolerance in T₀ generation)	1580(1)-018 (high tolerance in T₀ generation)
	Average % Injury of Replicates 14 DAT		
140 g ae/ha 2,4-D DMA	45	0	0
560 g ae/ha 2,4-D DMA	60	0	0
2240 g ae/ha 2,4-D DMA	73	0	0
70 g ae/ha triclopyr	40	0	5
280 g ae/ha triclopyr	65	0	5
1120 g ae/ha triclopyr	80	0	8
35 g ae/ha fluroxypyr	85	0	8
140 g ae/ha fluroxypyr	93	0	10
560 g ae/ha fluroxypyr	100	3	18

BDDb01 9494151v1

[00302] 10.3 *AAD-12 (v1)* heritability in tobacco

[00303] A 100 plant progeny test was also conducted on seven *T₁* lines of *AAD-12 (v1)* lines. The seeds were stratified, sown, and transplanted with respect to the procedure above with the exception that null plants were not removed by Liberty selection. All plants were then sprayed with 560 g ae/ha 2,4-D DMA as previously described. After 14 DAT, resistant and sensitive plants were counted. Five out of the seven lines tested segregated as a single locus, dominant Mendelian trait (3R:1S) as determined by Chi square analysis. *AAD-12* is heritable as a robust aryloxyalkanoate auxin resistance gene in multiple species.

10.4 – Field tolerance of pDAS1580 tobacco plants to 2,4-D, dichloprop, triclopyr and fluroxypyr herbicides.

[00304] Field level tolerance trials were conducted on three *AAD-12 (v1)* lines (events pDAS1580-[1]-018.001, pDAS1580-[1]-004.001 and pDAS1580-[1]-020.016) and one wild-type line (KY160) at field stations in Indiana and Mississippi. Tobacco transplants were grown in the greenhouse by planting *T₁* seed in 72 well transplant flats (Hummert International) containing Metro 360 media according to growing conditions indicated above. The null plants were selectively removed by Liberty selection as previously described. The transplant plants were transported to the field stations and planted at either 14 or 24 inches apart using industrial vegetable planters. Drip irrigation at the Mississippi site and overhead irrigation at the Indiana site were used to keep plants growing vigorously.

[00305] The experimental design was a split plot design with 4 replications. The main plot was herbicide treatment and the sub-plot was tobacco line. The herbicide treatments were 2,4-D (dimethylamine salt) at 280, 560, 1120, 2240 and 4480 g ae/ha, triclopyr at 840 g ae/ha, fluroxypyr at 280 g ae/ha and an untreated control. Plots were one row by 25-30 ft. Herbicide treatments were applied 3-4 weeks after transplanting using compressed air backpack sprayer delivering 187 L/ha carrier volume at 130-200 kpa pressure. Visual rating of injury, growth inhibition, and epinasty were taken at 7, 14 and 21 days after treatment.

[00306] *AAD-12 (v1)* event response to 2,4-D, triclopyr, and fluroxypyr are shown in Table 22. The non-transformed tobacco line was severely injured (63% at 14 DAT) by 2,4-D at 560 g ae/ha which is considered the 1X field application rate. The *AAD-12 (v1)* lines all demonstrated excellent tolerance to 2,4-D at 14 DAT with average injury of 1, 4, and 4% injury observed at the 2, 4 and 8X rates, respectively. The non-transformed tobacco line was severely injured (53% at 14 DAT) by the 2X rate of triclopyr (840 g ae/ha); whereas, *AAD-*

BDDB01 9494151v1

I2 (v1) lines demonstrated tolerance with an average of 5% injury at 14 DAT across the three lines. Fluroxypyr at 280 g ae/ha caused severe injury (99%) to the non-transformed line at 14 DAT. *AAD-I2 (v1)* lines demonstrated increased tolerance with an average of 11% injury at 14 DAT.

[00307] These results indicate that *AAD-I2 (v1)* transformed event lines displayed a high level of tolerance to 2,4-D, triclopyr and fluroxypyr at multiples of commercial use rates that were lethal or caused severe epinastic malformations to non-transformed tobacco under representative field conditions.

Table 22. <i>AAD-I2 (v1)</i> tobacco plants response to 2,4-D, triclopyr, and fluroxypyr under field conditions.					
<u>Herbicide Treatment</u>		<u>Average % Injury across locations at 14 DAT</u>			
Active Ingredient	Rate	Wild type	pDAS1580-[1]-004.001	pDAS1580-[1]-020.016	pDAS1580-[1]-018.001
2,4-D	280 GM AE/HA	48	0	0	0
2,4-D	560 GM AE/HA	63	0	0	2
2,4-D	1120 GM AE/HA	78	1	1	2
2,4-D	2240 GM AE/HA	87	4	4	4
2,4-D	4480 GM AE/HA	92	4	4	4
Triclopyr	840 GM AE/HA	53	5	5	4
Fluroxypyr	280 GM AE/HA	99	11	11	12

[00308] 10.5 *AAD-I2 (v1)* protection against elevated 2,4-D rates

[00309] Results showing *AAD-I2 (v1)* protection against elevated rates of 2,4-D DMA in the greenhouse are shown in Table 23. *T₁ AAD-I2 (v1)* plants from an event segregating 3R:1S when selected with 560 g ai/ha Liberty using the same protocol as previously described. *T₁ AAD-I (v3)* seed was also planted for transformed tobacco controls (see PCT/US2005/014737). Untransformed KY160 was served as the sensitive control. Plants were sprayed using a track sprayer set to 187 L/ha at 140, 560, 2240, 8960, and 35840 g ae/ha 2,4-D DMA and rated 3 and 14 DAT.

[00310] *AAD-I2 (v1)* and *AAD-I (v3)* both effectively protected tobacco against 2,4-D injury at doses up to 4X commercial use rates. *AAD-I2 (v1)*, however, clearly demonstrated a marked advantage over *AAD-I (v3)* by protecting up to 64X the standard field rates.

Table 23. Results demonstrating protection provided by <i>AAD-12 (v1)</i> and <i>AAD-1 (v3)</i> against elevated rates of 2,4-D.			
	KY160 control	<i>AAD-1(v3)</i>	<i>AAD-12 (v1)</i>
Treatment	Average % injury 14 DAT		
2240 g ae/ha 2,4-D	95	4	0
8960 g ae/ha 2,4-D	99	9	0
35840 g ae/ha 2,4-D	100	32	4

[00311] 10.6 Stacking of *AAD-12* to increase herbicide spectrum

[00312] Homozygous *AAD-12 (v1)* (pDAS1580) and *AAD-1 (v3)* (pDAB721) plants (*see* PCT/US2005/014737 for the latter) were both reciprocally crossed and F₁ seed was collected. The F₁ seed from two reciprocal crosses of each gene were stratified and treated 4 reps of each cross were treated under the same spray regime as used for the other testing with one of the following treatments: 70, 140, 280 g ae/ha fluroxypyr (selective for the *AAD-12 (v1)* gene); 280, 560, 1120 g ae/ha R-dichloroprop (selective for the *AAD-1 (v3)* gene); or 560, 1120, 2240 g ae/ha 2,4-D DMA (to confirm 2,4-D tolerance). Homozygous T₂ plants of each gene were also planted for use as controls. Plants were graded at 3 and 14 DAT. Spray results are shown in Table 24.

[00313] The results confirm that *AAD-12 (v1)* can be successfully stacked with *AAD-1 (v3)*, thus increasing the spectrum herbicides that may be applied to the crop of interest (phenoxyacetic acids + phenoxypropionic acids vs phenoxyacetic acids + pyridyloxyacetic acids for *AAD-1* and *AAD-12*, respectively). The complementary nature of herbicide cross resistance patterns allows convenient use of these two genes as complementary and stackable field-selectable markers. In crops where tolerance with a single gene may be marginal, one skilled in the art recognizes that one can increase tolerance by stacking a second tolerance gene for the same herbicide. Such can be done using the same gene with the same or different promoters; however, as observed here, stacking and tracking two complementary traits can be facilitated by the distinguishing cross protection to phenoxypropionic acids [from *AAD-1 (v3)*] or pyridyloxyacetic acids [*AAD-12 (v1)*]

Table 24. Comparison of auxinic herbicide cross tolerance of *AAD-12 (v1)* (pDAS1580) and *AAD-1 (v3)* (pDAB721) T₂ plants compared to AAD-12 x AAD-1 F₁ cross and to wildtype.

Treatment	KY160 wildtype control	<i>AAD-12 (v1)</i> (pDAS1580)	<i>AAD-1(v3)</i> (pDAB721)	<i>AAD-12 (v1)</i> x <i>AAD (v3)</i> F ₁
Average % injury 14 DAT				
560 g ac/ha 2,4-D	<u>63</u>	<u>0</u>	<u>0</u>	<u>0</u>
1120 g ac/ha 2,4-D	<u>80</u>	<u>0</u>	<u>4</u>	<u>0</u>
2240 g ac/ha 2,4-D	<u>90</u>	<u>0</u>	<u>2</u>	<u>0</u>
280 g ac/ha R-dichlorprop	<u>25</u>	<u>15</u>	<u>0</u>	<u>0</u>
560 g ac/ha R-dichlorprop	<u>60</u>	<u>50</u>	<u>0</u>	<u>0</u>
1120 g ac/ha R-dichlorprop	<u>80</u>	<u>70</u>	<u>3</u>	<u>0</u>
70 g ac/ha fluroxypyr	<u>40</u>	<u>0</u>	<u>40</u>	<u>0</u>
140 g ac/ha fluroxypyr	<u>65</u>	<u>0</u>	<u>60</u>	<u>0</u>
280 g ac/ha fluroxypyr	<u>75</u>	<u>3</u>	<u>75</u>	<u>3</u>

Example 11 - Soybean Transformation

[00314] Soybean improvement via gene transfer techniques has been accomplished for such traits as herbicide tolerance (Padgett *et al.*, 1995), amino acid modification (Falco *et al.*, 1995), and insect resistance (Parrott *et al.*, 1994). Introduction of foreign traits into crop species requires methods that will allow for routine production of transgenic lines using selectable marker sequences, containing simple inserts. The transgenes should be inherited as a single functional locus in order to simplify breeding. Delivery of foreign genes into cultivated soybean by microprojectile bombardment of zygotic embryo axes (McCabe *et al.*, 1988) or somatic embryogenic cultures (Finer and McMullen, 1991), and *Agrobacterium*-mediated transformation of cotyledonary explants (Hinchee *et al.*, 1988) or zygotic embryos (Chee *et al.*, 1989) have been reported.

[00315] Transformants derived from *Agrobacterium*-mediated transformations tend to possess simple inserts with low copy number (Birch, 1991). There are benefits and disadvantages associated with each of the three target tissues investigated for gene transfer into soybean,

BDDB01 9494151v1

zygotic embryonic axis (Chee *et al.*, 1989; McCabe *et al.*, 1988), cotyledon (Hinchee *et al.*, 1988) and somatic embryogenic cultures (Finer and McMullen, 1991). The latter have been extensively investigated as a target tissue for direct gene transfer. Embryogenic cultures tend to be quite prolific and can be maintained over a prolonged period. However, sterility and chromosomal aberrations of the primary transformants have been associated with age of the embryogenic suspensions (Singh *et al.*, 1998) and thus continuous initiation of new cultures appears to be necessary for soybean transformation systems utilizing this tissue. This system needs a high level of 2,4-D, 40 mg/L concentration, to initiate the embryogenic callus and this poses a fundamental problem in using the *AAD-12 (v1)* gene since the transformed locus could not be developed further with 2,4-D in the medium. So, the meristem based transformation is ideal for the development of 2,4-D resistant plant using *AAD-12 (v1)*.

[00316] 11.1 Gateway cloning of binary constructs

[00317] The *AAD-12 (v1)* coding sequence was cloned into five different Gateway Donor vectors containing different plant promoters. The resulting *AAD-12 (v1)* plant expression cassettes were subsequently cloned into a Gateway Destination Binary vector via the LR Clonase reaction (Invitrogen Corporation, Carlsbad Ca, Cat # 11791-019).

[00318] An NcoI – SacI fragment containing the *AAD-12 (v1)* coding sequence was digested from DASPICO12 and ligated into corresponding NcoI – SacI restriction sites within the following Gateway Donor vectors: pDAB3912 (attL1 // CsVMV promoter // AtuORF23 3'UTR // attL2); pDAB3916 (attL1 // AtUbi10 promoter // AtuORF23 3'UTR // attL2); pDAB4458 (attL1 // AtUbi3 promoter // AtuORF23 3'UTR // attL2); pDAB4459 (attL1 // ZmUbi1 promoter // AtuORF23 3'UTR // attL2); and pDAB4460 (attL1 // AtAct2 promoter // AtuORF23 3'UTR // attL2). The resulting constructs containing the following plant expression cassettes were designated: pDAB4463 (attL1 // CsVMV promoter // *AAD-12 (v1)* // AtuORF23 3'UTR // attL2); pDAB4467 (attL1 // AtUbi10 promoter // *AAD-12 (v1)* // AtuORF23 3'UTR // attL2); pDAB4471 (attL1 // AtUbi3 promoter // *AAD-12 (v1)* // AtuORF23 3'UTR // attL2); pDAB4475 (attL1 // ZmUbi1 promoter // *AAD-12 (v1)* // AtuORF23 3'UTR // attL2); and pDAB4479 (attL1 // AtAct2 promoter // *AAD-12 (v1)* // AtuORF23 3'UTR // attL2). These constructs were confirmed via restriction enzyme digestion and sequencing.

[00319] The plant expression cassettes were recombined into the Gateway Destination Binary vector pDAB4484 (RB7 MARv3 // attR1 – ccdB – chloramphenicol resistance – attR2 //

BDDDB01 9494151v1

CsVMV promoter // PATv6 // *AtuORF1* 3'UTR) via the Gateway LR Clonase reaction. Gateway Technology uses lambda phage-based site-specific recombination instead of restriction endonuclease and ligase to insert a gene of interest into an expression vector. Invitrogen Corporation, Gateway Technology: A Universal Technology to Clone DNA Sequences for Functional Analysis and Expression in multiple Systems, Technical Manual, Catalog #'s 12535-019 and 12535-027, Gateway Technology Version E, 9/22/2003, #25-022. The DNA recombination sequences (attL, and attR,) and the LR Clonase enzyme mixture allows any DNA fragment flanked by a recombination site to be transferred into any vector containing a corresponding site. The attL1 site of the donor vector corresponds with attR1 of the binary vector. Likewise, the attL2 site of the donor vector corresponds with attR2 of the binary vector. Using the Gateway Technology the plant expression cassette (from the donor vector) which is flanked by the attL sites can be recombined into the attR sites of the binary vector. The resulting constructs containing the following plant expression cassettes were labeled as: pDAB4464 (RB7 MARv3 // CsVMV promoter // *AAD-12 (v1)* // *AtuORF23* 3'UTR // CsVMV promoter // PATv6 // *AtuORF1* 3'UTR); pDAB4468 (RB7 MARv3 // *AtUbi10* promoter // *AAD-12 (v1)* // *AtuORF23* 3'UTR // CsVMV promoter // PATv6 // *AtuORF1* 3'UTR); pDAB4472 (RB7 MARv3 // *AtUbi3* promoter // *AAD-12 (v1)* // *AtuORF23* 3'UTR // CsVMV promoter // PATv6 // *AtuORF1* 3'UTR); pDAB4476 (RB7 MARv3 // *ZmUbi1* promoter // *AAD-12 (v1)* // *AtuORF23* 3'UTR // CsVMV promoter // PATv6 // *AtuORF1* 3'UTR); and pDAB4480 (RB7 MARv3 // *AtAct2* promoter // *AAD-12 (v1)* // *AtuORF23* 3'UTR // CsVMV promoter // PATv6 // *AtuORF1* 3'UTR) (see Table 8). These constructs were confirmed via restriction enzyme digestion and sequencing.

[00320] 11.2 Transformation Method 1: cotyledonary node transformation of soybean mediated by *Agrobacterium tumefaciens*.

[00321] The first reports of soybean transformation targeted meristematic cells in the cotyledonary node region (Hinchee *et al.*, 1988) and shoot multiplication from apical meristems (McCabe *et al.*, 1988). In the *A. tumefaciens*-based cotyledonary node method, explant preparation and culture media composition stimulate proliferation of auxiliary meristems in the node (Hinchee *et al.*, 1988). It remains unclear whether a truly dedifferentiated, but totipotent, callus culture is initiated by these treatments. The recovery of multiple clones of a transformation event from a single explant and the infrequent recovery of chimeric plants (Clemente *et al.*, 2000; Olhoft *et al.*, 2003) indicates a single cell origin

BDDDB01 9494151v1

followed by multiplication of the transgenic cell to produce either a proliferating transgenic meristem culture or a uniformly transformed shoot that undergoes further shoot multiplication. The soybean shoot multiplication method, originally based on microprojectile bombardment (McCabe *et al.*, 1988) and, more recently, adapted for *Agrobacterium*-mediated transformation (Martinell *et al.*, 2002), apparently does not undergo the same level or type of dedifferentiation as the cotyledonary node method because the system is based on successful identification of germ line chimeras. The range of genotypes that have been transformed via the *Agrobacterium*-based cotyledonary node method is steadily growing (Olhoft and Somers, 2001). This *de novo* meristem and shoot multiplication method is less limited to specific genotypes. Also, this is a non 2,4-D based protocol which would be ideal for 2,4-D selection system. Thus, the cotyledonary node method may be the method of choice to develop 2,4-D resistant soybean cultivars. Though this method was described as early as 1988 (Hinchey *et al.*, 1988), only very recently has it been optimized for routine high frequency transformation of several soybean genotypes (Zhang *et al.*, 1999; Zeng *et al.*, 2004).

[00322] 11.2.1 – Plant transformation production of AAD-12 (v1) tolerant phenotypes. Seed derived explants of “Maverick” and the *Agrobacterium* mediated cot-node transformation protocol was used to produce AAD-12 (v1) transgenic plants.

[00323] 11.2.2– *Agrobacterium* preparation and inoculation

[00324] *Agrobacterium* strain EHA101 (Hood et al. 1986), carrying each of five binary pDAB vectors (Table 8) was used to initiate transformation. Each binary vector contains the AAD-12 (v1) gene and a plant-selectable gene (*PAT*) cassette within the T-DNA region. Each gene is driven by the promoters listed in Table 8 and these plasmids were mobilized into the EHA101 strain of *Agrobacterium* by electroporation. The selected colonies were then analyzed for the integration of genes before the *Agrobacterium* treatment of the soybean explants. Maverick seeds were used in all transformation experiments and the seeds were obtained from University of Missouri, Columbia, MO.

[00325] *Agrobacterium*-mediated transformation of soybean (*Glycine max*) using the *PAT* gene as a selectable marker coupled with the herbicide glufosinate as a selective agent was carried out followed a modified procedure of Zeng et al. (2004). The seeds were germinated on B5 basal medium (Gamborg et al. 1968) solidified with 3 g/L Phytagel (Sigma-Aldrich, St. Louis, Mo.); added l-cysteine to the co-cultivation medium at 400 mg/L and co-cultivation

BDDDB01 9494151v1

lasted 5 days (Olhoft and Somers 2001); shoot initiation, shoot elongation, and rooting media were supplemented with 50 mg/L cefotaxime, 50 mg/L timentin, 50 mg/L vancomycin, and solidified with 3 g/L Phytigel. Selected shoots were then transferred to the rooting medium. The optimal selection scheme was the use of glufosinate at 8 mg/L across the first and second shoot initiation stages in the medium and 3–4 mg/L during shoot elongation in the medium.

[00326] Prior to transferring elongated shoots (3–5 cm) to rooting medium, the excised end of the internodes were dipped in 1 mg/L indole 3-butyric acid for 1–3 min to promote rooting (Khan et al. 1994). The shoots struck roots in 25×100 mm glass culture tubes containing rooting medium and then they were transferred to soil mix for acclimatization of plantlets in Metro-mix 200 (Hummert International, Earth City, Mo.) in open Magenta boxes in Conviron. Glufosinate, the active ingredient of Liberty herbicide (Bayer Crop Science), was used for selection during shoot initiation and elongation. The rooted plantlets were acclimated in open Magenta boxes for several weeks before they were screened and transferred to the greenhouse for further acclimation and establishment.

[00327] 11.2.3 - Assay of putatively transformed plantlets, and analyses established T₀ plants in the greenhouse.

[00328] The terminal leaflets of selected leaves of these plantlets were leaf painted with 50 mg/L of glufosinate twice with a week interval to observe the results to screen for putative transformants. The screened plantlets were then transferred to the greenhouse and after acclimation the leaves were painted with glufosinate again to confirm the tolerance status of these plantlets in the GH and deemed to be putative transformants.

[00329] Plants that are transferred to the greenhouse can be assayed for the presence of an active *PAT* gene further with a non-destructive manner by painting a section of leaf of the T₀ primary transformant, or progeny thereof, with a glufosinate solution [0.05-2% v/v Liberty Herbicide, preferably 0.25-1.0% (v/v),=500-2000 ppm glufosinate, Bayer Crop Science]. Depending on the concentration used, assessment for glufosinate injury can be made 1-7 days after treatment. Plants can also be tested for 2,4-D tolerance in a non-destructive manner by selective application of a 2,4-D solution in water (0.25-1% v/v commercial 2,4-D dimethylamine salt formulation, preferably 0.5% v/v = 2280 ppm 2,4-D ae) to the terminal leaflet of the newly expanding trifoliolate one or two, preferably two, nodes below the youngest emerging trifoliolate. This assay allows assessment of 2,4-D sensitive plants 6 hours to several days after application by assessment of leaf flipping or rotation >90 degrees from

BDDB01 9494151v1

the plane of the adjacent leaflets. Plants tolerant to 2,4-D will not respond to 2,4-D. T₀ plants will be allowed to self fertilize in the greenhouse to give rise to T₁ seed. T₁ plants (and to the extent enough T₀ plant clones are produced) will be sprayed with a range of herbicide doses to determine the level of herbicide protection afforded by *AAD-12 (v1)* and *PAT* genes in transgenic soybean. Rates of 2,4-D used on T₀ plants will typically comprise one or two selective rates in the range of 100-1120 g ae/ha using a track sprayer as previously described. T₁ plants will be treated with a wider herbicide dose ranging from 50-3200 g ae/ha 2,4-D. Likewise, T₀ and T₁ plants can be screened for glufosinate resistance by postemergence treatment with 200-800 and 50-3200 g ae/ha glufosinate, respectively. Glyphosate resistance (in plants transformed with constructs that contain EPSPS) or another glyphosate tolerance gene can be assessed in the T₁ generation by postemergence applications of glyphosate with a dose range from 280-2240 g ae/ha glyphosate. Analysis of protein expression will occur as described in below. Individual T₀ plants were assessed for the presence of the coding region of the gene of interest (*AAD-12 (v1)* or *PAT v6*) and copy number. Determination of the inheritance of *AAD-12 (v1)* will be made using T₁ and T₂ progeny segregation with respect to herbicide tolerance as described in previous examples.

[00330] A subset of the initial transformants were assessed in the T₀ generation according to the methods above. Any plant confirmed as having the *AAD-12 (v1)* coding region, regardless of the promoter driving the gene did not respond to the 2,4-D leaf painting whereas wildtype Maverick soybeans did (Table Sec 11.2.3). *PAT*-only transformed plants responded the same as wildtype plants to leaf paint applications of 2,4-D

[00331] 2,4-D was applied to a subset of the plants that were of similar size to the wildtype control plants with either 560 or 1120 g ae 2,4-D. All *AAD-12 (v1)*-containing plants were clearly resistant to the herbicide application versus the wildtype Maverick soybeans. A slight level of injury (2 DAT) was observed for two *AAD-12 (v1)* plants, however, injury was temporary and no injury was observed 7 DAT. Wildtype control plants were severely injured 7-14 DAT at 560 g ae/ha 2,4-D and killed at 1120 g ae/ha. These data are consistent with the fact that *AAD-12 (v1)* can impart high tolerance (>2X field rates) to a sensitive crop like soybeans. The screened plants were then sampled for molecular and biochemical analyses for the confirmation of the *AAD12 (v1)* genes integration, copy number, and their gene expression levels as described below and reported in Table 25.

Table 25. T₀ soybean response to 2,4-D leaf paint and 2,4-D spray application.

Leaf flip assay																	
Construct (pDAB#)				Gene	Promoter	Event	Node	Spray POST over the top with 2,4-D (g ae/ha)			Stage at appl (# nodes)	ELISA] (ng/mL)	Southern Copy number	PCR coding region	% injury 2 DAT	% injury 7 DAT	% injury 14 DAT
NODE		LEAF PAINTED		N-1	N-2												
4464	AAD-12	CsVMV	D-1-14	N-1	0			0	>10	5246.83	2	+	X	X	0		
4464	AAD-12	CsVMV	D-2-9	N-2			0	0	>10	204.27	1	+	X	X	0		
4468	AAD-12	AtUbi10	D-3-7	N-2			0	0	>10	4.65	1	+	0	0	0		
4468	AAD-12	AtUbi10	D-4-11B	N-2			0	0	8	1452.84	2	+	0	0	0		
4468	AAD-12	AtUbi10	D-4-16	N-2			0	0	>10	653.21	2	+	X	X	0		
4480	AAD-12	AtAct2	D-9-1	N-2			0	0	>10	248.33	3 or 4	+	X	X	0		
4464	AAD-12	CsVMV	D-2-14	N-2			0	560	7	4917.43	2	+	0	0	0		
4468	AAD-12	AtUbi10	D-3-5	N-2			0	560	8	365.75	1	+	0	0	0		
4468	AAD-12	AtUbi10	D-3-6	N-1	0			560	5	714.79	3	+	0	0	0		
4472	AAD-12	AtUbi3	D-5-2	N-1	0			560	6	0.58	1	+	5	0	0		
4468	AAD-12	AtUbi10	D-3-9	N-2			0	1120	6	2657.26	3	+	0	0	0		
4468	AAD-12	AtUbi10	D-4-17	N-2			0	1120	7	286.14	5	+	5	0	0		
4499	PAT	CsVMV	D-2-3	N-2			1	0	>10	2.36	5	+	X	X	0		
Maverick	WT		WT-10	NT			1	ND	ND	ND	ND	ND	ND	ND	ND		
Maverick	WT		WT-2	NT			1	ND	ND	ND	ND	ND	ND	ND	ND		
Maverick	WT		WT-3	NT				0	4	ND	ND	ND	0	0	0		
Maverick	WT		WT-4	NT				0	4	ND	ND	ND	0	0	0		
Maverick	WT		WT-5	NT				560	4	ND	ND	ND	50	60	60		
Maverick	WT		WT-6	NT				560	4	ND	ND	ND	70	90	80		
Maverick	WT		WT-7	NT				560	4	ND	ND	ND	70	80	80		
Maverick	WT		WT-10	NT				1120	4	ND	ND	ND	70	90	100		
Maverick	WT		WT-8	NT				1120	4	ND	ND	ND	70	95	100		
Maverick	WT		WT-9	NT				1120	4	ND	ND	ND	70	95	100		
					1=Flip					ND=Not determined							
					0=No Flip												

BDDB01 9494151v1

[00332] 11.2.4– Molecular Analyses: Soybean

[00333] 11.2.4.1– Tissue harvesting DNA isolation and quantification. Fresh tissue is placed into tubes and lyophilized at 4° C for 2 days. After the tissue is fully dried, a tungsten bead (Valenite) is placed in the tube and the samples are subjected to 1 minute of dry grinding using a Kelco bead mill. The standard DNeasy DNA isolation procedure is then followed (Qiagen, DNeasy 69109). An aliquot of the extracted DNA is then stained with Pico Green (Molecular Probes P7589) and read in the fluorometer (BioTek) with known standards to obtain the concentration in ng/μL.

[00334] 11.2.4.2- Polymerase chain reaction. A total of 100 ng of total DNA is used as the template. 20 mM of each primer is used with the Takara Ex Taq PCR Polymerase kit (Mirus TAKRR001A). Primers for the *AAD-12 (v1)* PTU are (Forward – ATAATGCCAGC CTGTAAACGCC) (SEQ ID NO:8) and (Reverse – CTCAAGCATATGAATGACCT CGA) (SEQ ID NO:9). The PCR reaction is carried out in the 9700 Geneamp thermocycler (Applied Biosystems), by subjecting the samples to 94° C for 3 minutes and 35 cycles of 94° C for 30 seconds, 63° C for 30 seconds, and 72° C for 1 minute and 45 seconds followed by 72° C for 10 minutes. Primers for Coding Region PCR AAD-12 (v1) are (Forward – ATGGCTCATGCTGCCCTCAGCC) (SEQ ID NO:10) and (Reverse – CGGGC AGGCCTAACTCCACCAA) (SEQ ID NO:11). The PCR reaction is carried out in the 9700 Geneamp thermocycler (Applied Biosystems), by subjecting the samples to 94° C for 3 minutes and 35 cycles of 94° C for 30 seconds, 65° C for 30 seconds, and 72° C for 1 minute and 45 seconds followed by 72° C for 10 minutes. PCR products are analyzed by electrophoresis on a 1% agarose gel stained with EtBr.

[00335] 11.2.4.3- Southern blot analysis. Southern blot analysis is performed with total DNA obtained from Qiagen DNeasy kit. A total of 10 μg of genomic DNA is subjected to an overnight digestion to obtain integration data. After the overnight digestion an aliquot of ~100 ng is run on a 1% gel to ensure complete digestion. After this assurance the samples are run on a large 0.85 % agarose gel overnight at 40 volts. The gel is then denatured in 0.2 M NaOH, 0.6 M NaCl for 30 minutes. The gel is then neutralized in 0.5 M Tris HCl, 1.5 M NaCl pH of 7.5 for 30 minutes. A gel apparatus containing 20x SSC is then set up to obtain a gravity gel to nylon membrane (Millipore INYC00010) transfer overnight. After the overnight transfer the membrane is then subjected to UV light via a crosslinker (Stratagene

BDDDB01 9494151v1

UV stratalinker 1800) at 1200 X100 microjoules. The membrane is then washed in 0.1% SDS, 0.1 SSC for 45 minutes. After the 45 minute wash, the membrane is baked for 3 hours at 80° C and then stored at 4° C until hybridization. The hybridization template fragment is prepared using the above coding region PCR using plasmid DNA. The product is run on a 1% agarose gel and excised and then gel extracted using the Qiagen (28706) gel extraction procedure. The membrane is then subjected to a pre-hybridization at 60° C step for 1 hour in Perfect Hyb buffer (Sigma H7033). The Prime it RmT dCTP-labeling rxn (Stratagene 300392) procedure is used to develop the p32 based probe (Perkin Elmer). The probe is cleaned up using the Probe Quant. G50 columns (Amersham 27-5335-01). Two million counts CPM are used to hybridize the southern blots overnight. After the overnight hybridization the blots are then subjected to two 20 minute washes at 65° C in 0.1% SDS, 0.1 SSC. The blots are then exposed to film overnight, incubating at -80° C.

[00336] 11.2.5 – Biochemical Analyses: Soybean

[00337] 11.2.5.1 – Tissue Sampling and Extracting AAD-12 (v1) protein from soybean leaves.

Approximately 50 to 100 mg of leaf tissue was sampled from the N-2 leaves that were 2,4-D leaf painted, but after 1 DAT. The terminal N-2 leaflet was removed and either cut into small pieces or 2-single-hole- punched leaf discs (~0.5 cm in diameter) and were frozen on dry ice instantly. Further protein analysis (ELISA and Western analysis) was completed according to methods described in Example 9.

[00338] 11.2.6 – T₁ Progeny evaluation. T₀ plants will be allowed to self fertilize to derive T₁ families. Progeny testing (segregation analysis) will be assayed using glufosinate at 560 g ai/ha as the selection agent applied at the V1-V2 growth stage. Surviving plants will be further assayed for 2,4-D tolerance at one or more growth stages from V2-V6. Seed will be produced through self fertilization to allow broader herbicide testing on the transgenic soybean.

[00339] *AAD-12 (v1)* transgenic Maverick soybean plants have been generated thorough *Agrobacterium*- mediated cot-node transformation system. The T₀ plants obtained tolerated up to 2X levels of 2,4-D field applications and developed fertile seeds. The frequency of fertile transgenic soybean plants was up to 5.9%. The integration of the *AAD1-12 (v1)* gene into the soybean genome was confirmed by Southern blot analysis. This analysis indicated that most of the transgenic plants contained a low copy number. The plants screened with

AAD-12 (v1) antibodies showed positive for ELISA and the appropriate band in Western analysis.

[00340] 11.3 Transformation Method 2: Aerosol-beam mediated transformation of embryogenic soybean callus tissue.

[00341] Culture of embryogenic soybean callus tissue and subsequent beaming can be accomplished as described in U.S. Patent No. 6,809,232 (Held *et al.*) to create transformants using one or more constructs in Table 8.

[00342] 11.4 Transformation Method 3. Biolistic bombardment of Soybean

[00343] This can be accomplished using mature seed derived embryonic axes meristem (McCabe *et al.* (1988)). Following established methods of biolistic bombardment, one can expect recovery of transformed soybean plants. Once plants are regenerated and evaluation of events could occur as described in Example 11.2.

[00344] 11.5 Transformation Method 4. Whiskers mediated transformation.

[00345] Whisker preparation and whisker transformation can anticipated according to methods described previously by Terakawa *et al.* (2005)). Following established methods of biolistic bombardment, one can expect recovery of transformed soybean plants. Once plants are regenerated and evaluation of events could occur as described in Example 11.2.

[00346] Maverick seeds were surface-sterilized in 70% ethanol for 1 min followed by immersion in 1% sodium hypochlorite for 20 min. and then rinsed three times in sterile distilled water. The seeds were soaked in distilled water for 18–20 h. The embryonic axes were excised from seeds, and the apical meristems were exposed by removing the primary leaves. The embryonic axes were positioned in the bombardment medium [BM: MS (Murashige and Skoog 1962) basal salts medium, 3% sucrose and 0.8% phytigel Sigma, pH 5.7] with the apical region directed upwards in 5-cm culture dishes containing 12 ml culture medium.

[00347] 11.6 Transformation Method 5. Particle bombardment-mediated transformation for embryogenic callus tissue can be optimized for according to previous methods (Khalafalla *et al.*, 2005; El-Shemy *et al.*, 2004, 2006). Regenerated plants can also be assessed according to Example 11.2.

Example 12– *AAD-12 (v1)* in Cotton

[00348] 12.1 – Cotton transformation protocol.

[00349] Cotton seeds (Co310 genotype) are surface-sterilized in 95% ethanol for 1 minute, rinsed, sterilized with 50% commercial bleach for twenty minutes, and then rinsed 3 times with sterile distilled water before being germinated on G-media (Table 26) in Magenta GA-7 vessels and maintained under high light intensity of 40-60 $\mu\text{E}/\text{m}^2$, with the photoperiod set at 16 hours of light and 8 hours dark at 28° C.

[00350] Cotyledon segments (~5mm) square are isolated from 7-10 day old seedlings into liquid M liquid media (Table 26) in Petri plates (Nunc, item #0875728). Cut segments are treated with an *Agrobacterium* solution (for 30 minutes) then transferred to semi-solid M-media (Table 26) and undergo co-cultivation for 2-3 days. Following co-cultivation, segments are transferred to MG media (Table 26). Carbenicillin is the antibiotic used to kill the *Agrobacterium* and glufosinate-ammonium is the selection agent that would allow growth of only those cells that contain the transferred gene.

[00351] Agrobacterium preparation. Inoculate 35ml of Y media (Table 26) (containing streptomycin (100 mg/ml stock) and erythromycin (100 mg/ml stock)), with one loop of bacteria to grow overnight in the dark at 28° C, while shaking at 150 rpm. The next day, pour the *Agrobacterium* solution into a sterile oakridge tube (Nalge-Nunc, 3139-0050), and centrifuge for in Beckman J2-21 at 8,000 rpm for 5 minutes. Pour off the supernatant and resuspend the pellet in 25 ml of M liquid (Table 26) and vortex. Place an aliquot into a glass culture tube (Fisher, 14-961-27) for Klett reading (Klett-Summerson, model 800-3). Dilute the new suspension using M liquid media to a Klett-meter reading of 10^8 colony forming units per ml with a total volume of 40 ml.

[00352] After three weeks, callus from the cotyledon segments is isolated and transferred to fresh MG media. The callus is transferred for an additional 3 weeks on MG media. In a side-by-side comparison, MG media can be supplemented with dichlorprop (added to the media at a concentration of 0.01 and 0.05mg/L) to supplement for the degradation of the 2,4-D, since dichlorprop is not a substrate for the AAD-12 enzyme, however dichlorprop is more active on cotton than 2,4-D. In a separate comparison, segments which were plated on MG media containing no growth regulator compared to standard MG media, showed reduced callusing, but there still is callus growth. Callus is then transferred to CG-media (Table 26), and transferred again to fresh selection medium after three weeks. After another three weeks the callus tissue is transferred to D media (Table 26) lacking plant growth regulators for embryogenic callus induction. After 4-8 weeks on this media, embryogenic callus is formed,

BDDDB01 9494151v1

and can be distinguished from the non-embryogenic callus by its yellowish-white color and granular cells. Embryos start to regenerate soon after and are distinct green in color. Cotton can take time to regenerate and form embryos, one of the ways to speed up this process is to stress the tissue. Dessication is a common way to accomplish this, via changes in the microenvironment of the tissue and plate, by using less culture media and/or adopting various modes of plate enclosure (taping versus parafilm).

[00353] Larger, well-developed embryos are isolated and transferred to DK media (Table 26) for embryo development. After 3 weeks (or when the embryos have developed), germinated embryos are transferred to fresh media for shoot and root development. After 4-8 weeks, any well-developed plants are transferred into soil and grown to maturity. Following a couple of months, the plant has grown to a point that it can be sprayed to determine if it has resistance to 2,4-D.

Table 26. Media for Cotton Transformation									
Ingredients in 1 liter	G	M liquid	M	MG	CG	D	DK	Y	
LS Salts (5X)	200 ml	200 ml	200 ml	200 ml	200 ml				
Glucose		30 grams	30 grams	30 grams	30 grams	20 grams			
modified B5 vit (1000x)	1 ml	1 ml	1 ml	1 ml	1 ml	10 ml	1 ml		
kinetin (1mM)		1ml	1 ml	1 ml	4.6 ml		0.5ml		
2,4-D (1mM)		1ml	1 ml	1 ml					
Agar	8 grams		8 grams	8 grams	8 grams	8 grams	8 grams		
DKW salts (D190)						1 package	1 package		
MYO-Inositol (100x)						1 ml	10 ml		
Sucrose 3%	30 grams						30 grams	10 grams	
NAA									
Carbenicillin (250 mg/ml)				2 ml	0.4 ml				
GLA (10mg/ml)				0.5 ml	0.3 ml				
Peptone								10 grams	
Yeast Extract								10 grams	
NaCl								5 grams	

BDD801 9494151v1

[00354] 12.2 – Cell transformation.

[00355] Several experiments were initiated in which cotyledon segments were treated with *Agrobacterium* containing pDAB724. Over 2000 of the resulting segments were treated using various auxin options for the proliferation of pDAB724 cotton callus, either: 0.1 or 0.5mg/L R-dichlorprop, standard 2,4-D concentration and no auxin treatment. The callus was selected on glufosinate-ammonium, due to the inclusion of the *PAT* gene in the construct. Callus line analysis in the form of PCR and Invader will be used to determine if and to be sure the gene was present at the callus stage; then callus lines that are embryogenic will be sent for Western analysis, essentially as described in section 11.2.3. Embryogenic cotton callus was stressed using dessication techniques to improve the quality and quantity of the tissue recovered.

[00356] Almost 200 callus events have been screened for intact PTU and expression using Western analysis for the *AAD-12 (v1)* gene. Below is a subset of the data for some of the cotton callus that has been tested.

Table 26.b.

Construct	Line Number	AAD-12 PTU	AAD-12 Invader	AAD-12 ng/ml
pDAB724	1	+	+	79.89
pDAB724	2	+	+	17.34
pDAB724	3	+	+	544.80
pDAB724	4	+	+	32.63
pDAB724	5	+	+	82.77
pDAB724	83	+	+	795.50
pDAB724	84	+	+	613.35
pDAB724	85	+	+	1077.75
pDAB724	86	+	+	437.74
pDAB724	87	+	+	286.51
pDAB724	88	+	+	517.59
pDAB724	89	+	+	1250.70

[00357] 12.3 – Plant regeneration.

[00358] *AAD-12 (v1)* cotton lines that have produced plants according to the above protocol will be sent to the greenhouse. To demonstrate the *AAD-12 (v1)* gene provides resistance to 2,4-D in cotton, both the *AAD-12 (v1)* cotton plant and wild-type cotton plants will be sprayed with a track sprayer delivering 560 g ae/ha 2,4-D at a spray volume of 187 L/ha. The plants will be evaluated at 3 and 14 days after treatment. Plants surviving a selective rate of 2,4-D will be self pollinated to create T₁ seed or outcrossed with an elite cotton line to

BDDB01 9494151v1

produce F₁ seed. The subsequent seed produced will be planted and evaluated for herbicide resistance as previously described. AAD-12 (v1) events can be combined with other desired HT or IR traits as described in experiments 18, 19, 22, and 23.

Example 13 – *Agrobacterium* Transformation of Other Crops

[00359] In light of the subject disclosure, additional crops can be transformed according to the subject invention using techniques that are known in the art. For *Agrobacterium*-mediated transformation of rye, see, e.g., Popelka and Altpeter (2003). For *Agrobacterium*-mediated transformation of soybean, see, e.g., Hinchey *et al.*, 1988. For *Agrobacterium*-mediated transformation of sorghum, see, e.g., Zhao *et al.*, 2000. For *Agrobacterium*-mediated transformation of barley, see, e.g., Tingay *et al.*, 1997. For *Agrobacterium*-mediated transformation of wheat, see, e.g., Cheng *et al.*, 1997. For *Agrobacterium*-mediated transformation of rice, see, e.g., Hiei *et al.*, 1997.

[00360] The Latin names for these and other plants are given below. It should be clear that these and other (non-*Agrobacterium*) transformation techniques can be used to transform AAD-12 (v1), for example, into these and other plants, including but not limited to Maize (*Zea mays*), Wheat (*Triticum* spp.), Rice (*Oryza* spp. and *Zizania* spp.), Barley (*Hordeum* spp.), Cotton (*Abroma augusta* and *Gossypium* spp.), Soybean (*Glycine max*), Sugar and table beets (*Beta* spp.), Sugar cane (*Arenga pinnata*), Tomato (*Lycopersicon esculentum* and other spp., *Physalis ixocarpa*, *Solanum incanum* and other spp., and *Cyphomandra betacea*), Potato (*Solanum tuberosum*), Sweet potato (*Ipomoea batatas*), Rye (*Secale* spp.), Peppers (*Capsicum annuum*, *sinense*, and *frutescens*), Lettuce (*Lactuca sativa*, *perennis*, and *pulchella*), Cabbage (*Brassica* spp.), Celery (*Apium graveolens*), Eggplant (*Solanum melongena*), Peanut (*Arachis hypogea*), Sorghum (all *Sorghum* species), Alfalfa (*Medicago sativa*), Carrot (*Daucus carota*), Beans (*Phaseolus* spp. and other genera), Oats (*Avena sativa* and *strigosa*), Peas (*Pisum*, *Vigna*, and *Tetragonolobus* spp.), Sunflower (*Helianthus annuus*), Squash (*Cucurbita* spp.), Cucumber (*Cucumis sativa*), Tobacco (*Nicotiana* spp.), *Arabidopsis* (*Arabidopsis thaliana*), Turfgrass (*Lolium*, *Agrostis*, *Poa*, *Cynodon*, and other genera), Clover (*Trifolium*), Vetch (*Vicia*). Such plants, with AAD-12 (v1) genes, for example, are included in the subject invention.

[00361] AAD-12 (v1) has the potential to increase the applicability of key auxinic herbicides for in-season use in many deciduous and evergreen timber cropping systems. Triclopyr, 2,4-D, and/or fluroxypyr resistant timber species would increase the flexibility of over-the-top

BDDB01 9494151v1

use of these herbicides without injury concerns. These species would include, but not limited to: Alder (*Alnus spp.*), ash (*Fraxinus spp.*), aspen and poplar species (*Populus spp.*), beech (*Fagus spp.*), birch (*Betula spp.*), cherry (*Prunus spp.*), eucalyptus (*Eucalyptus spp.*), hickory (*Carya spp.*), maple (*Acer spp.*), oak (*Quercus spp.*), and pine (*Pinus spp.*). Use of auxin resistance for the selective weed control in ornamental and fruit-bearing species is also within the scope of this invention. Examples could include, but not be limited to, rose (*Rosa spp.*), burning bush (*Euonymus spp.*), petunia (*Petunia spp.*), begonia (*Begonia spp.*), rhododendron (*Rhododendron spp.*), crabapple or apple (*Malus spp.*), pear (*Pyrus spp.*), peach (*Prunus spp.*), and marigolds (*Tagetes spp.*).

Example 14 – Further Evidence of Surprising Results: AAD-12 vs. AAD-2

[00362] 14.1 – AAD-2 (v1) initial cloning.

[00363] Another gene was identified from the NCBI database (see the ncbi.nlm.nih.gov website; accession #AP005940) as a homologue with only 44% amino acid identity to *tfdA*. This gene is referred to herein as AAD-2 (v1) for consistency. Percent identity was determined by first translating both the AAD-2 and *tfdA* DNA sequences (SEQ ID NO:12 of PCT/US2005/014737 and GENBANK Accession No. M16730, respectively) to proteins (SEQ ID NO:13 of PCT/US2005/014737 and GENBANK Accession No. M16730, respectively), then using ClustalW in the VectorNTI software package to perform the multiple sequence alignment.

[00364] The strain of *Bradyrhizobium japonicum* containing the AAD-2 (v1) gene was obtained from Northern Regional Research Laboratory (NRRL, strain #B4450). The lyophilized strain was revived according to NRRL protocol and stored at -80° C in 20% glycerol for internal use as Dow Bacterial strain DB 663. From this freezer stock, a plate of Tryptic Soy Agar was then struck out with a loopful of cells for isolation, and incubated at 28° C for 3 days. A single colony was used to inoculate 100 ml of Tryptic Soy Broth in a 500 ml tri-baffled flask, which was incubated overnight at 28° C on a floor shaker at 150 rpm. From this, total DNA was isolated with the gram negative protocol of Qiagen's DNeasy kit (Qiagen cat. #69504). The following primers were designed to amplify the target gene from genomic DNA, Forward (SEQ ID NO:16): 5' ACT AGT AAC AAA GAA GGA GAT ATA CCA TGA CGA T 3' [(brjap 5'(speI) SEQ ID NO:14 of PCT/US2005/014737 (added Spe I restriction site and Ribosome Binding Site (RBS))] and Reverse (SEQ ID NO:17): 5' TTC

BDDDB01 9494151v1

TCG AGC TAT CAC TCC GCC GCC TGC TGC TGC 3' [(br jap 3' (xhoI) SEQ ID NO:15 of PCT/US2005/014737 (added a Xho I site)].

[00365] Fifty microliter reactions were set up as follows: Fail Safe Buffer 25 µl, ea. primer 1 µl (50 ng/µl), gDNA 1 µl (200 ng/µl), H₂O 21 µl, Taq polymerase 1 µl (2.5 units/µl). Three Fail Safe Buffers—A, B, and C—were used in three separate reactions. PCR was then carried out under the following conditions: 95° C 3.0 minutes heat denature cycle; 95° C 1.0 minute, 50° C 1.0 minute, 72° C 1.5 minutes, for 30 cycles; followed by a final cycle of 72° C 5 minutes, using the FailSafe PCR System (Epicenter cat. #FS99100). The resulting ~1 kb PCR product was cloned into pCR 2.1 (Invitrogen cat. #K4550-40) following the included protocol, with chemically competent TOP10F' *E. coli* as the host strain, for verification of nucleotide sequence.

[00366] Ten of the resulting white colonies were picked into 3 µl Luria Broth + 1000 µg/ml Ampicillin (LB Amp), and grown overnight at 37° C with agitation. Plasmids were purified from each culture using Nucleospin Plus Plasmid Miniprep Kit (BD Biosciences cat. #K3063-2) and following included protocol. Restriction digestion of the isolated DNA's was completed to confirm the presence of the PCR product in the pCR2.1 vector. Plasmid DNA was digested with the restriction enzyme EcoRI (New England Biolabs cat. #R0101S). Sequencing was carried out with Beckman CEQ Quick Start Kit (Beckman Coulter cat. #608120) using M13 Forward [5' GTA AAA CGA CGG CCA G 3'] (SEQ ID NO:6) and Reverse [5' CAG GAA ACA GCT ATG AC 3'] (SEQ ID NO:7) primers, per manufacturers instructions. This gene sequence and its corresponding protein was given a new general designation *AAD-2 (v1)* for internal consistency.

[00367] 14.2 – Completion of *AAD-2 (v1)* binary vector.

[00368] The *AAD-2 (v1)* gene was PCR amplified from pDAB3202. During the PCR reaction alterations were made within the primers to introduce the AflIII and SacI restriction sites in the 5' primer and 3' primer, respectively. See PCT/US2005/014737. The primers “NcoI of Brady” [5' TAT ACC ACA TGT CGA TCG CCA TCC GGC AGC TT 3'] (SEQ ID NO:14) and “SacI of Brady” [5' GAG CTC CTA TCA CTC CGC CGC CTG CTG CTG CAC 3'] (SEQ ID NO:15) were used to amplify a DNA fragment using the Fail Safe PCR System (Epicentre). The PCR product was cloned into the pCR2.1 TOPO TA cloning vector (Invitrogen) and sequence verified with M13 Forward and M13 Reverse primers using the Beckman Coulter “Dye Terminator Cycle Sequencing with Quick Start Kit” sequencing

BDDDB01 9494151v1

reagents. Sequence data identified a clone with the correct sequence (pDAB716). The AflIII/SacI *AAD-2 (v1)* gene fragment was then cloned into the NcoI/SacI pDAB726 vector. The resulting construct (pDAB717); AtUbi10 promoter: Nt OSM 5'UTR: *AAD-2 (v1)*: Nt OSM3'UTR: ORF1 polyA 3'UTR was verified with restriction digests (with NcoI/SacI). This construct was cloned into the binary pDAB3038 as a NotI – NotI DNA fragment. The resulting construct (pDAB767); AtUbi10 promoter: Nt OSM5'UTR: *AAD-2 (v1)*: Nt OSM 3'UTR: ORF1 polyA 3'UTR: CsVMV promoter: *PAT*: ORF25/26 3'UTR was restriction digested (with NotI, EcoRI, HindIII, NcoI, PvuII, and SalI) for verification of the correct orientation. The completed construct (pDAB767) was then used for transformation into *Agrobacterium*.

[00369] 14.3 – Evaluation of transformed *Arabidopsis*.

[00370] Freshly harvested T₁ seed transformed with a plant optimized *AAD-12 (v1)* or native *AAD-2 (v1)* gene were planted and selected for resistance to glufosinate as previously described. Plants were then randomly assigned to various rates of 2,4-D (50-3200 g ae/ha). Herbicide applications were applied by track sprayer in a 187 L/ha spray volume. 2,4-D used was the commercial dimethylamine salt formulation (456 g ae/L, NuFarm, St Joseph, MO) mixed in 200 mM Tris buffer (pH 9.0) or 200 mM HEPES buffer (pH7.5).

[00371] *AAD-12 (v1)* and *AAD-2 (v1)* did provide detectable 2,4-D resistance versus the transformed and untransformed control lines; however, individual constructs were widely variable in their ability to impart 2,4-D resistance to individual T₁ *Arabidopsis* plants. Surprisingly, *AAD-2 (v1)* and *AAD-2 (v2)* transformants were far less resistant to 2,4-D than the *AAD-12 (v1)* gene, both from a frequency of highly tolerant plants as well as overall average injury. No plants transformed with *AAD-2 (v1)* survived 200 g ae/ha 2,4-D relatively uninjured (<20% visual injury), and overall population injury was about 83% (see PCT/US2005/014737). Conversely, *AAD-12 (v1)* had a population injury average of about 6% when treated with 3,200 g ae/ha 2,4-D (Table 11). Tolerance improved slightly for plant-optimized *AAD-2 (v2)* versus the native gene; however, comparison of both *AAD-12* and *AAD-2* plant optimized genes indicates a significant advantage for *AAD-12 (v1)* *in planta*.

[00372] These results are unexpected given that the *in vitro* comparison of *AAD-2 (v1)* (see PCT/US2005/014737) and *AAD-12 (v2)* indicated both were highly efficacious at degrading 2,4-D and both shared an S-type specificity with respect to chiral aryloxyalkanoate substrates. *AAD-2 (v1)* is expressed in individual T₁ plants to varying levels; however, little protection

BDDDB01 9494151v1

from 2,4-D injury is afforded by this expressed protein. No substantial difference was evident in protein expression level (*in planta*) for the native and plant optimized *AAD-2* genes (see PCT/US2005/014737). These data corroborate earlier findings that make the functional expression of *AAD-12 (v1)* *in planta*, and resulting herbicide resistance to 2,4-D and pyridyloxyacetate herbicides, unexpected.

Example 15 – Preplant Burndown Applications

[00373] This and the following Examples are specific examples of novel herbicide uses made possible by the subject AAD-12 invention.

[00374] Preplant burndown herbicide applications are intended to kill weeds that have emerged over winter or early spring prior to planting a given crop. Typically these applications are applied in no-till or reduced tillage management systems where physical removal of weeds is not completed prior to planting. An herbicide program, therefore, must control a very wide spectrum of broadleaf and grass weeds present at the time of planting. Glyphosate, gramoxone, and glufosinate are examples of non-selective, non-residual herbicides widely used for preplant burndown herbicide applications. Some weeds, however, are difficult to control at this time of the season due to one or more of the following: inherent insensitivity of the weed species or biotype to the herbicide, relatively large size of winter annual weeds, and cool weather conditions limiting herbicide uptake and activity. Several herbicide options are available to tankmix with these herbicides to increase spectrum and activity on weeds where the non-selective herbicides are weak. An example would be 2,4-D tankmix applications with glyphosate to assist in the control of *Conyza canadensis* (horseweed). Glyphosate can be used from 420 to 1680 g ae/ha, more typically 560 to 840 g ae/ha, for the preplant burndown control of most weeds present; however, 280 – 1120 g ae/ha of 2,4-D can be applied to aid in control of many broadleaf weed species (*e.g.*, horseweed). 2,4-D is an herbicide of choice because it is effective on a very wide range of broadleaf weeds, effective even at low temperatures, and extremely inexpensive. However, if the subsequent crop is a sensitive dicot crop, 2,4-D residues in the soil (although short-lived) can negatively impact the crop. Soybeans are a sensitive crop and require a minimum time period of 7 days (for 280 g ae/ha 2,4-D rate) to at least 30 days (for 2,4-D applications of 1120 g ae/ha) to occur between burndown applications and planting. 2,4-D is prohibited as a burndown treatment prior to cotton planting (see federal labels, most are available through

BDDB01 9494151v1

CPR, 2005 or online at cdms.net/manuf/manuf.asp). With *AAD-12 (v1)* transformed cotton or soybeans, these crops should be able to survive 2,4-D residues in the soil from burndown applications applied right up to and even after planting before emergence of the crop. The increased flexibility and reduced cost of tankmix (or commercial premix) partners will improve weed control options and increase the robustness of burndown applications in important no-till and reduced tillage situations. This example is one of many options that will be available. Those skilled in the art of weed control will note a variety of other applications including, but not limited to gramoxone + 2,4-D or glufosinate + 2,4-D by utilizing products described in federal herbicide labels (CPR, 2005) and uses described in Agrilience Crop Protection Guide (2005), as examples. Those skilled in the art will also recognize that the above example can be applied to any 2,4-D-sensitive (or other phenoxy auxin herbicide) crop that would be protected by the *AAD-12 (v1)* gene if stably transformed. Likewise, the unique attributes of AAD-12 allowing degradation of triclopyr and fluroxypyr increase utility by allowing substitution or tank mixes of 70-1120 or 35-560 g ae/ha of triclopyr and fluroxypyr, respectively, to increase spectrum and/or increase the ability to control perennial or viney weed species.

Example 16 – In-Crop Use of Phenoxy Auxins Herbicides in Soybeans, Cotton, and Other Dicot Crops Transformed Only with *AAD-12 (v1)*

[00375] *AAD-12 (v1)* can enable the use of phenoxy auxin herbicides (e.g., 2,4-D and MCPA) and pyridyloxy auxins (triclopyr and fluroxypyr) for the control of a wide spectrum of broadleaf weeds directly in crops normally sensitive to 2,4-D. Application of 2,4-D at 280 to 2240 g ae/ha would control most broadleaf weed species present in agronomic environments. More typically, 560 – 1120 g ae/ha is used. For triclopyr, application rates would typically range from 70-1120 g ae/ha, more typically 140-420 g ae/ha. For fluroxypyr, application rates would typically range from 35-560 g ae/ha, more typically 70-280 ae/ha.

[00376] An advantage to this additional tool is the extremely low cost of the broadleaf herbicide component and potential short-lived residual weed control provided by higher rates of 2,4-D, triclopyr, and fluroxypyr when used at higher rates, whereas a non-residual herbicide like glyphosate would provide no control of later germinating weeds. This tool also provides a mechanism to combine herbicide modes of action with the convenience of HTC as an integrated herbicide resistance and weed shift management strategy.

BDDDB01 9494151v1

[00377] A further advantage this tool provides is the ability to tankmix broad spectrum broadleaf weed control herbicides (e.g., 2,4-D, triclopyr and fluroxypyr) with commonly used residual weed control herbicides. These herbicides are typically applied prior to or at planting, but often are less effective on emerged, established weeds that may exist in the field prior to planting. By extending the utility of these aryloxy auxin herbicides to include at-plant, preemergence, or pre-plant applications, the flexibility of residual weed control programs increases. One skilled in the art would recognize the residual herbicide program will differ based on the crop of interest, but typical programs would include herbicides of the chloracetamide and dinitroaniline herbicide families, but also including herbicides such as clomazone, sulfentrazone, and a variety of ALS-inhibiting PPO-inhibiting, and HPPD-inhibiting herbicides.

[00378] Further benefits could include tolerance to 2,4-D, triclopyr or fluroxypyr required before planting following aryloxyacetic acid auxin herbicide application (*see* previous example); and fewer problems from contamination injury to dicot crops resulting from incompletely cleaned bulk tanks that had contained 2,4-D, triclopyr or fluroxypyr. Dicamba (and many other herbicides) can still be used for the subsequent control of *AAD-12 (v1)*-transformed dicot crop volunteers.

[00379] Those skilled in the art will also recognize that the above example can be applied to any 2,4-D-sensitive (or other aryloxy auxin herbicide) crop that would be protected by the *AAD-12 (v1)* gene if stably transformed. One skilled in the art of weed control will now recognize that use of various commercial phenoxy or pyridyloxy auxin herbicides alone or in combination with a herbicide is enabled by *AAD-12 (v1)* transformation. Specific rates of other herbicides representative of these chemistries can be determined by the herbicide labels compiled in the CPR (Crop Protection Reference) book or similar compilation or any commercial or academic crop protection references such as the Crop Protection Guide from Agrilience (2005). Each alternative herbicide enabled for use in HTC by *AAD-12 (v1)*, whether used alone, tank mixed, or sequentially, is considered within the scope of this invention.

Example 17 - In-Crop Use of Phenoxy Auxin and Pyridyloxy Auxin Herbicides in *AAD-12 (v1)* Only Transformed Corn, Rice, and Other Monocot Species

[00380] In an analogous fashion, transformation of grass species (such as, but not limited to, corn, rice, wheat, barley, or turf and pasture grasses) with *AAD-12 (v1)* would allow the use of highly efficacious phenoxy and pyridyloxy auxins in crops where normally selectivity is not certain. Most grass species have a natural tolerance to auxinic herbicides such as the phenoxy auxins (i.e., 2,4-D,.). However, a relatively low level of crop selectivity has resulted in diminished utility in these crops due to a shortened window of application timing or unacceptable injury risk. *AAD-12 (v1)*-transformed monocot crops would, therefore, enable the use of a similar combination of treatments described for dicot crops such as the application of 2,4-D at 280 to 2240 g ae/ha to control most broadleaf weed species. More typically, 560 – 1120 g ae/ha is used. For triclopyr, application rates would typically range from 70-1120 g ae/ha, more typically 140-420 g ae/ha. For fluroxypyr, application rates would typically range from 35-560 g ae/ha, more typically 70-280 ae/ha.

[00381] An advantage to this additional tool is the extremely low cost of the broadleaf herbicide component and potential short-lived residual weed control provided by higher rates of 2,4-D, triclopyr, or fluroxypyr. In contrast, a non-residual herbicide like glyphosate would provide no control of later-germinating weeds. This tool would also provide a mechanism to rotate herbicide modes of action with the convenience of HTC as an integrated-herbicide-resistance and weed-shift-management strategy in a glyphosate tolerant crop/*AAD-12 (v1)* HTC combination strategy, whether one rotates crops species or not.

[00382] A further advantage this tool provides is the ability to tankmix broad spectrum broadleaf weed control herbicides (e.g., 2,4-D, triclopyr and fluroxypyr) with commonly used residual weed control herbicides. These herbicides are typically applied prior to or at planting, but often are less effective on emerged, established weeds that may exist in the field prior to planting. By extending the utility of these aryloxy auxin herbicides to include at-plant, preemergence, or pre-plant applications, the flexibility of residual weed control programs increases. One skilled in the art would recognize the residual herbicide program will differ based on the crop of interest, but typical programs would include herbicides of the chloracetmide and dinitroaniline herbicide families, but also including herbicides such as clomazone, sulfentrazone, and a variety of ALS-inhibiting PPO-inhibiting, and HPPD-inhibiting herbicides.

[00383] The increased tolerance of corn, rice, and other monocots to the phenoxy or pyridyloxy auxins shall enable use of these herbicides in-crop without growth stage

restrictions or the potential for crop leaning, unfurling phenomena such as “rat-tailing,” crop leaning, growth regulator-induced stalk brittleness in corn, or deformed brace roots. Each alternative herbicide enabled for use in HTC by *AAD-12 (v1)*, whether used alone, tank mixed, or sequentially, is considered within the scope of this invention.

Example 18 – *AAD-12 (v1)* Stacked With Glyphosate Tolerance Trait in Any Crop

[00384]

The vast majority of cotton, canola, corn, and soybean acres planted in North America contain a glyphosate tolerance (GT) trait, and adoption of GT corn is on the rise. Additional GT crops (*e.g.*, wheat, rice, sugar beet, and turf) have been under development but have not been commercially released to date. Many other glyphosate resistant species are in experimental to development stage (*e.g.*, alfalfa, sugar cane, sunflower, beets, peas, carrot, cucumber, lettuce, onion, strawberry, tomato, and tobacco; forestry species like poplar and sweetgum; and horticultural species like marigold, petunia, and begonias; isb.vt.edu/cfdocs/fieldtests1.cfm, 2005 on the World Wide Web). GTC's are valuable tools for the sheer breadth of weeds controlled and convenience and cost effectiveness provided by this system. However, glyphosate's utility as a now-standard base treatment is selecting for glyphosate resistant weeds. Furthermore, weeds that glyphosate is inherently less efficacious on are shifting to the predominant species in fields where glyphosate-only chemical programs are being practiced. By stacking *AAD-12 (v1)* with a GT trait, either through conventional breeding or jointly as a novel transformation event, weed control efficacy, flexibility, and ability to manage weed shifts and herbicide resistance development could be improved. As mentioned in previous examples, by transforming crops with *AAD-12 (v1)*, monocot crops will have a higher margin of phenoxy or pyridyloxy auxin safety, and phenoxy auxins can be selectively applied in dicot crops. Several scenarios for improved weed control options can be envisioned where *AAD-12 (v1)* and a GT trait are stacked in any monocot or dicot crop species:

- a) Glyphosate can be applied at a standard postemergent application rate (420 to 2160 g ae/ha, preferably 560 to 840 g ae/ha) for the control of most grass and broadleaf weed species. For the control of glyphosate resistant broadleaf weeds like *Conyza canadensis* or weeds inherently difficult to control with glyphosate (*e.g.*, *Commelina* spp, *Ipomoea* spp, etc), 280-2240 g ae/ha (preferably 560-1120 g ae/ha) 2,4-D can be applied sequentially, tank mixed,

BDDB01 9494151v1

or as a premix with glyphosate to provide effective control. For triclopyr, application rates would typically range from 70-1120 g ae/ha, more typically 140-420 g ae/ha. For fluroxypyr, application rates would typically range from 35-560 g ae/ha, more typically 70-280 ae/ha.

- b) Currently, glyphosate rates applied in GTC's generally range from 560 to 2240 g ae/ha per application timing. Glyphosate is far more efficacious on grass species than broadleaf weed species. *AAD-12 (v1)* + GT stacked traits would allow grass-effective rates of glyphosate (105-840 g ae/ha, more preferably 210-420 g ae/ha). 2,4-D (at 280-2240 g ae/ha, more preferably 560-1120 g ae/ha) could then be applied sequentially, tank mixed, or as a premix with grass-effective rates of glyphosate to provide necessary broadleaf weed control. Triclopyr and fluroxypyr at rates mentioned above would be acceptable components in the treatment regimen. The low rate of glyphosate would also provide some benefit to the broadleaf weed control; however, primary control would be from the 2,4-D, triclopyr, or fluroxypyr.

[00385] One skilled in the art of weed control will recognize that use of one or more commercial aryloxy auxin herbicides alone or in combination (sequentially or independently) is enabled by *AAD-12 (v1)* transformation into crops. Specific rates of other herbicides representative of these chemistries can be determined by the herbicide labels compiled in the CPR (Crop Protection Reference) book or similar compilation, labels compiled online (e.g., cdms.net/manuf/manuf.asp), or any commercial or academic crop protection guides such as the Crop Protection Guide from Agrilience (2005). Each alternative herbicide enabled for use in HTC's by *AAD-12 (v1)*, whether used alone, tank mixed, or sequentially, is considered within the scope of this invention.

Example 19 - *AAD-12 (v1)* Stacked with Glufosinate Tolerance Trait in Any Crop

[00386] Glufosinate tolerance (*PAT* or *bar*) is currently present in a number of crops planted in North America either as a selectable marker for an input trait like insect resistance proteins or specifically as an HTC trait. Crops include, but are not limited to, glufosinate tolerant canola, corn, and cotton. Additional glufosinate tolerant crops (e.g., rice, sugar beet, soybeans, and turf) have been under development but have not been commercially released to date. Glufosinate, like glyphosate, is a relatively non-selective, broad spectrum grass and

BDDDB01 9494151v1

broadleaf herbicide. Glufosinate's mode of action differs from glyphosate. It is faster acting, resulting in desiccation and "burning" of treated leaves 24-48 hours after herbicide application. This is advantageous for the appearance of rapid weed control. However, this also limits translocation of glufosinate to meristematic regions of target plants resulting in poorer weed control as evidenced by relative weed control performance ratings of the two compounds in many species (Agrilience, 2005).

[00387] By stacking *AAD-12 (v1)* with a glufosinate tolerance trait, either through conventional breeding or jointly as a novel transformation event, weed control efficacy, flexibility, and ability to manage weed shifts and herbicide resistance development could be improved. Several scenarios for improved weed control options can be envisioned where *AAD-12 (v1)* and a glufosinate tolerance trait are stacked in any monocot or dicot crop species:

- a) Glufosinate can be applied at a standard postemergent application rate (200 to 1700 g ae/ha, preferably 350 to 500 g ae/ha) for the control of many grass and broadleaf weed species. To date, no glufosinate-resistant weeds have been confirmed; however, glufosinate has a greater number of weeds that are inherently more tolerant than does glyphosate.
- i) Inherently tolerant broadleaf weed species (e.g., *Cirsium arvensis*, *Apocynum cannabinum*, and *Conyza canadensis*) could be controlled by tank mixing 280-2240 g ae/ha, more preferably 560-2240 g ae/ha, 2,4-D for effective control of these more difficult-to-control perennial species and to improve the robustness of control on annual broadleaf weed species. Triclopyr and fluroxypyr would be acceptable components to consider in the weed control regimen. For triclopyr, application rates would typically range from 70-1120 g ae/ha, more typically 140-420 g ae/ha. For fluroxypyr, application rates would typically range from 35-560 g ae/ha, more typically 70-280 g ae/ha.
- b) A multiple combination of glufosinate (200-500 g ae/ha) +/- 2,4-D (280-1120 g ae/ha) +/- triclopyr or fluroxypyr (at rates listed above), for example, could provide more robust, overlapping weed control spectrum. Additionally, the overlapping spectrum provides an additional mechanism for the management or delay of herbicide resistant weeds.

BDDDB01 9494151v1

[00388] One skilled in the art of weed control will recognize that use of one or more commercial aryloxyacetic auxin herbicides alone or in combination (sequentially or independently) is enabled by *AAD-12 (v1)* transformation into crops. Specific rates of other herbicides representative of these chemistries can be determined by the herbicide labels compiled in the CPR (Crop Protection Reference) book or similar compilation, labels compiled online (e.g., cdms.net/manuf/manuf.asp), or any commercial or academic crop protection guides such as the Crop Protection Guide from Agrilience (2005). Each alternative herbicide enabled for use in HTC by *AAD-12 (v1)*, whether used alone, tank mixed, or sequentially, is considered within the scope of this invention.

Example 20 - *AAD-12 (v1)* Stacked with *AHAS* Trait in Any Crop

[00389] Imidazolinone herbicide tolerance (*AHAS*, *et al.*) is currently present in a number of crops planted in North America including, but not limited to, corn, rice, and wheat. Additional imidazolinone tolerant crops (e.g., cotton and sugar beet) have been under development but have not been commercially released to date. Many imidazolinone herbicides (e.g., imazamox, imazethapyr, imazaquin, and imazapic) are currently used selectively in various conventional crops. The use of imazethapyr, imazamox, and the non-selective imazapyr has been enabled through imidazolinone tolerance traits like *AHAS et al.* This chemistry class also has significant soil residual activity, thus being able to provide weed control extended beyond the application timing, unlike glyphosate or glufosinate-based systems. However, the spectrum of weeds controlled by imidazolinone herbicides is not as broad as glyphosate (Agrilience, 2005). Additionally, imidazolinone herbicides have a mode of action (inhibition of acetolactate synthase, ALS) to which many weeds have developed resistance (Heap, 2005). By stacking *AAD-12 (v1)* with an imidazolinone tolerance trait, either through conventional breeding or jointly as a novel transformation event, weed control efficacy, flexibility, and ability to manage weed shifts and herbicide resistance development could be improved. As mentioned in previous examples, by transforming crops with *AAD-12 (v1)*, monocot crops will have a higher margin of phenoxy or pyridyloxy auxin safety, and these auxins can be selectively applied in dicot crops. Several scenarios for improved weed control options can be envisioned where *AAD-12 (v1)* and an imidazolinone tolerance trait are stacked in any monocot or dicot crop species:

- a) Imazethapyr can be applied at a standard postemergent application rate of (35 to 280 g ae/ha, preferably 70-140 g ae/ha) for the control of many grass and broadleaf weed species.
 - i) ALS-inhibitor resistant broadleaf weeds like *Amaranthus rudis*, *Ambrosia trifida*, *Chenopodium album* (among others, Heap, 2005) could be controlled by tank mixing 280-2240 g ae/ha, more preferably 560-1120 g ae/ha, 2,4-D. For triclopyr, application rates would typically range from 70-1120 g ae/ha, more typically 140-420 g ae/ha. For fluroxypyr, application rates would typically range from 35-560 g ae/ha, more typically 70-280 ae/ha.
 - ii) Inherently more tolerant broadleaf species to imidazolinone herbicides like *Ipomoea spp.* can also be controlled by tank mixing 280-2240 g ae/ha, more preferably 560-1120 g ae/ha, 2,4-D. See rates above for triclopyr or fluroxypyr.
- b) A multiple combination of imazethapyr (35 to 280 g ae/ha, preferably 70-140 g ae/ha) +/- 2,4-D (280-1120 g ae/ha) +/- triclopyr or fluroxypyr (at rates listed above), for example, could provide more robust, overlapping weed control spectrum. Additionally, the overlapping spectrum provides an additional mechanism for the management or delay of herbicide resistant weeds.

[00390] One skilled in the art of weed control will recognize that use of any of various commercial imidazolinone herbicides, phenoxyacetic or pyridyloxyacetic auxin herbicides, alone or in multiple combinations, is enabled by *AAD-12 (v1)* transformation and stacking with any imidazolinone tolerance trait either by conventional breeding or genetic engineering. Specific rates of other herbicides representative of these chemistries can be determined by the herbicide labels compiled in the CPR (Crop Protection Reference) book or similar compilation, labels compiled online (e.g., cdms.net/manuf/manuf.asp), or any commercial or academic crop protection guides such as the Crop Protection Guide from Agrilience (2005). Each alternative herbicide enabled for use in HTC by *AAD-12 (v1)*, whether used alone, tank mixed, or sequentially, is considered within the scope of this invention.

Example 21 – *AAD-12 (v1)* in Rice

[00391] 21.1 – Media description.

BDDDB01 9494151v1

[00392] Culture media employed were adjusted to pH 5.8 with 1 M KOH and solidified with 2.5 g/L Phytigel (Sigma). Embryogenic calli were cultured in 100 x 20 mm Petri dishes containing 40 ml semi-solid medium. Rice plantlets were grown on 50 ml medium in Magenta boxes. Cell suspensions were maintained in 125-ml conical flasks containing 35 ml liquid medium and rotated at 125 rpm. Induction and maintenance of embryogenic cultures took place in the dark at 25–26° C, and plant regeneration and whole-plant culture took place in a 16-h photoperiod (Zhang *et al.* 1996).

[00393] Induction and maintenance of embryogenic callus took place on NB basal medium as described previously (Li *et al.* 1993), but adapted to contain 500 mg/L glutamine. Suspension cultures were initiated and maintained in SZ liquid medium (Zhang *et al.* 1998) with the inclusion of 30 g/L sucrose in place of maltose. Osmotic medium (NBO) consisted of NB medium with the addition of 0.256 M each of mannitol and sorbitol. Hygromycin-B-resistant callus was selected on NB medium supplemented with 50 mg/L hygromycin B for 3–4 weeks. Pre-regeneration took place on medium (PRH50) consisting of NB medium without 2,4-dichlorophenoxyacetic acid (2,4-D), but with the addition of 2 mg/L 6-benzylaminopurine (BAP), 1 mg/L α -naphthaleneacetic acid (NAA), 5 mg/L abscisic acid (ABA) and 50 mg/L hygromycin B for 1 week. Regeneration of plantlets followed via culture on regeneration medium (RNH50) comprising NB medium without 2,4-D, and supplemented with 3 mg/L BAP, 0.5 mg/L NAA, and 50 mg/L hygromycin B until shoots regenerated. Shoots were transferred to rooting medium with half-strength Murashige and Skoog basal salts and Gamborg's B5 vitamins, supplemented with 1% sucrose and 50 mg/L hygromycin B (1/2MSH50).

[00394] 21.2 – Tissue culture development.

[00395] Mature desiccated seeds of *Oryza sativa* L. japonica cv. Taipei 309 were sterilized as described in Zhang *et al.* 1996. Embryogenic tissues were induced by culturing sterile mature rice seeds on NB medium in the dark. The primary callus approximately 1 mm in diameter, was removed from the scutellum and used to initiate cell suspension in SZ liquid medium. Suspensions were then maintained as described in Zhang 1995. Suspension-derived embryogenic tissues were removed from liquid culture 3–5 days after the previous subculture and placed on NBO osmotic medium to form a circle about 2.5 cm across in a Petri dish and cultured for 4 h prior to bombardment. Sixteen to 20 h after bombardment, tissues were transferred from NBO medium onto NBH50 hygromycin B selection medium, ensuring that

BDDDB01 9494151v1

the bombarded surface was facing upward, and incubated in the dark for 14–17 days. Newly formed callus was then separated from the original bombarded explants and placed nearby on the same medium. Following an additional 8–12 days, relatively compact, opaque callus was visually identified, and transferred to PRH50 pre-regeneration medium for 7 days in the dark. Growing callus, which became more compact and opaque was then subcultured onto RNH50 regeneration medium for a period of 14–21 days under a 16-h photoperiod. Regenerating shoots were transferred to Magenta boxes containing ½ MSH50 medium. Multiple plants regenerated from a single explant are considered siblings and were treated as one independent plant line. A plant was scored as positive for the hph gene if it produced thick, white roots and grew vigorously on ½ MSH50 medium. Once plantlets had reached the top of Magenta boxes, they were transferred to soil in a 6-cm pot under 100% humidity for a week, then moved to a growth chamber with a 14-h light period at 30° C and in the dark at 21° C for 2–3 weeks before transplanting into 13-cm pots in the greenhouse. Seeds were collected and dried at 37° C for one week, prior to storage.

[00396] 21.3 – Microprojectile bombardment.

[00397] All bombardments were conducted with the Biolistic PDS-1000/He™ system (Bio-Rad, Laboratories, Inc.). Three milligrams of 1.0 micron diameter gold particles were washed once with 100% ethanol, twice with sterile distilled water and resuspended in 50 µl water in a siliconized Eppendorf tube. Five micrograms plasmid DNA representing a 1:6 molar ratio of pDOW3303(*Hpt*-containing vector) to pDAB4101 (*AAD-12 (v1)* + *AHAS*), 20 µl spermidine (0.1 M) and 50 µl calcium chloride (2.5 M) were added to the gold suspension. The mixture was incubated at room temperature for 10 min, pelleted at 10000 rpm for 10 s, resuspended in 60 µl cold 100% ethanol and 8–9 µl was distributed onto each macrocarrier. Tissue samples were bombarded at 1100 psi and 27 in of Hg vacuum as described by Zhang *et al.* (1996).

[00398] 21.4 – Postemergence herbicide tolerance in *AAD-12 (v1)* transformed T₀ Rice

[00399] Rice plantlets at the 3-5 leaf stage were sprayed with a lethal dose of 0.16% (v/v) solution of Pursuit (to confirm the presence of the *AHAS* gene) containing 1% Sunit II (v/v) and 1.25% UAN (v/v) using a track sprayer calibrated to 187 L/ha. Rating for sensitivity or resistance was performed at 36 days after treatment (DAT). Ten of the 33 events sent to the greenhouse were robustly tolerant to the Pursuit; others suffered varying levels of herbicide injury. Plants were sampled (according to section 21.7 below) and molecular characterization

was performed as previously described in Example 8 that identified seven of these 10 events as containing both the *AAD-12 (v1)* PTU and the entire *AHAS* coding region.

[00400] 21.5 – Heritability of AAD-12 (v1) in T₁ rice

[00401] A 100-plant progeny test was conducted on five T₁ lines of *AAD-12 (v1)* lines that contained both the *AAD-12 (v1)* PTU and *AHAS* coding region. The seeds were planted with respect to the procedure above and sprayed with 140 g ae/ha imazethapyr using a track sprayer as previously described. After 14 DAT, resistant and sensitive plants were counted. Two out of the five lines tested segregated as a single locus, dominant Mendelian trait (3R:1S) as determined by Chi square analysis. AAD-12 coseregated with the *AHAS* selectable marker as determined by 2,4-D tolerance testing below.

[00402] 21.6 – Verification of high 2,4-D tolerance in T₁ Rice.

[00403] The following T₁ *AAD-12 (v1)* single segregating locus lines were planted into 3-inch pots containing Metro Mix media: pDAB4101(20)003 and pDAB4101(27)002. At 2-3 leaf stage were sprayed with 140 g ae/ha imazethapyr. Nulls were eliminated and individuals were sprayed at V3-V4 stage in the track sprayer set to 187 L/ha at 1120, 2240 or 4480 g ae/ha 2,4-D DMA (2X, 4X, and 8X typical commercial use rates, respectively). Plants were graded at 7 and 14 DAT and compared to untransformed commercial rice cultivar, ‘Lamont,’ as negative control plants.

[00404] Injury data (Table 27) shows that the *AAD-12 (v1)*-transformed lines are more tolerant to high rates of 2,4-D DMA than the untransformed controls. The line pDAB4101(20)003 was more tolerant to high levels of 2,4-D than the line pDAB4101(27)002. The data also demonstrates that tolerance of 2,4-D is stable for at least two generations.

Table 27. T ₁ <i>AAD-12 (v1)</i> and untransformed control response to varying levels of 2,4-D DMA.			
	Lemont Untransformed Control	pDAB4101(20)003	pDAB4101(27)002
Herbicide	Average % Injury 14 DAT		
1120 g ae/ha 2,4-D DMA	20	10	10
2240 g ae/ha 2,4-D DMA	35	15	30
4480 g ae/ha 2,4-D DMA	50	23	40

BDDDB01 9494151v1

[00405] 21.7 – Tissue harvesting, DNA isolation and quantification.

[00406] Fresh tissue was placed into tubes and lyophilized at 4° C for 2 days. After the tissue was fully dried, a tungsten bead (Valenite) was placed in the tube and the samples were subjected to 1 minute of dry grinding using a Kelco bead mill. The standard DNeasy DNA isolation procedure was then followed (Qiagen, Dneasy 69109). An aliquot of the extracted DNA was then stained with Pico Green (Molecular Probes P7589) and scanned in the fluorometer (BioTek) with known standards to obtain the concentration in ng/μl.

[00407] 21.8 – AAD-12 (v1) expression.

[00408] Sample preparation and analysis conditions were as described previously. All 33 T₀ transgenic rice lines and 1 non-transgenic control were analyzed for AAD-12 expression using ELISA blot. AAD-12 was detected in the clones of 20 lines, but not in line Taipai 309 control plant. Twelve of the 20 lines that had some of the clones tolerant to imazethapyr were expressing AAD-12 protein, were AAD-12 PCR PTU positive, and AHAS coding region positive. Expression levels ranged from 2.3 to 1092.4 ppm of total soluble protein.

[00409] 21.9– Field tolerance of pDAB4101 rice plants to 2,4-D and triclopyr herbicides.

[00410] A field level tolerance trial was conducted with *AAD-12 (v1)* event pDAB4101[20] and one wild-type rice (Clearfield 131) at Wayside, Mississippi (a non-transgenic imidazolinone-resistant variety). The experimental design was a randomized complete block design with a single replication. Herbicide treatments were 2X rates of 2,4-D (dimethylamine salt) at 2240 g ae/ha and triclopyr at 560 g ae/ha plus an untreated control. Within each herbicide treatment, two rows of T₁ generation pDAB4101[20] and two rows of Clearfield rice were planted using a small plot drill with 8-inch row spacing. The pDAB4101[20] rice contained the *AHAS* gene as a selectable marker for the *AAD-12(v1)* gene. Imazethapyr was applied at the one leaf stage as selection agent to remove any *AAD-12 (v1)* null plants from the plots. Herbicide treatments were applied when the rice reached the 2 leaf stage using compressed air backpack sprayer delivering 187 L/ha carrier volume at 130-200 kpa pressure. Visual ratings of injury were taken at 7, 14 and 21 days after application.

[00411] *AAD-12 (v1)* event response to 2,4-D and triclopyr are shown in Table 28. The non-transformed rice line (Clearfield) was severely injured (30% at 7DAT and 35% at 15DAT) by 2,4-D at 2240 g ae/ha which is considered the 4X commercial use rate. The *AAD-12 (v1)*

BDDB01 9494151v1

event demonstrated excellent tolerance to 2,4-D with no injury observed at 7 or 15DAT. The non-transformed rice was significantly injured (15% at 7DAT and 25% at 15DAT) by the 2X rate of triclopyr (560 g ae/ha). The *AAD-12 (v1)* event demonstrated excellent tolerance to the 2X rates of triclopyr with no injury observed at either 7 or 15DAT.

[00412] These results indicate that the *AAD-12 (v1)* transformed rice displayed a high level of resistance to 2,4-D and triclopyr at rates that caused severe visual injury to the Clearfield rice. It also demonstrates the ability to stack multiple herbicide tolerance genes with AAD-12 I multiple species to provide resistance to a wider spectrum of effective chemistries

Table 28. AAD-12 T ₁ generation rice plants response to 2,4-D and triclopyr under field conditions.					
Herbicide Treatment		% Visual Injury			
Active Ingredient	Rate	7DAT		15DAT	
		AAD-12 event pDAB4101[20]	Wild-type Clearfield	AAD-12 event pDAB4101[20]	Wild-type Clearfield
2,4-D	2240 GM AE/HA	0	15	0	35
Triclopyr	840 GM AE/HA	0	30	0	25
Untreated		0	0	0	0

Example 22 – *AAD-12 (v1)* in Canola

[00413] 22.1 – Canola transformation.

[00414] The *AAD-12 (v1)* gene conferring resistance to 2,4-D was used to transform *Brassica napus* var. Nexera* 710 with *Agrobacterium*-mediated transformation and plasmid pDAB3759. The construct contained *AAD-12 (v1)* gene driven by CsVMV promoter and Pat gene driven by AtUbi10 promoter and the EPSPS glyphosate resistance trait driven by AtUbi10 promoter (*see* section 2.4).

[00415] Seeds were surface-sterilized with 10% commercial bleach for 10 minutes and rinsed 3 times with sterile distilled water. The seeds were then placed on one half concentration of MS basal medium (Murashige and Skoog, 1962) and maintained under growth regime set at 25° C, and a photoperiod of 16 hrs light/8 hrs dark.

BDDB01 9494151v1

[00416] Hypocotyl segments (3-5 mm) were excised from 5 - 7 day old seedlings and placed on callus induction medium K1D1 (MS medium with 1 mg/L kinetin and 1 mg/L 2,4-D) for 3 days as pre-treatment. The segments were then transferred into a petri plate, treated with *Agrobacterium* Z707S or LBA4404 strain containing pDAB3759. The *Agrobacterium* was grown overnight at 28° C in the dark on a shaker at 150 rpm and subsequently re-suspended in the culture medium.

[00417] After 30 min treatment of the hypocotyl segments with *Agrobacterium*, these were placed back on the callus induction medium for 3 days. Following co-cultivation, the segments were placed on K1D1TC (callus induction medium containing 250 mg/L Carbenicillin and 300 mg/L Timentin) for one week or two weeks of recovery. Alternately, the segments were placed directly on selection medium K1D1H1 (above medium with 1 mg/L Herbiace). Carbenicillin and Timentin were the antibiotics used to kill the *Agrobacterium*. The selection agent Herbiace allowed the growth of the transformed cells.

[00418] Callused hypocotyl segments were then placed on B3Z1H1 (MS medium, 3 mg/L benzylamino purine, 1 mg/L Zeatin, 0.5 gm/L MES [2-(N-morpholino) ethane sulfonic acid], 5 mg/L silver nitrate, 1 mg/L Herbiace, Carbenicillin and Timentin) shoot regeneration medium. After 2-3 weeks shoots started regenerating. Hypocotyl segments along with the shoots are transferred to B3Z1H3 medium (MS medium, 3 mg/L benzylamino purine, 1 mg/L Zeatin, 0.5 gm/L MES [2-(N-morpholino) ethane sulfonic acid], 5 mg/L silver nitrate, 3 mg/L Herbiace, Carbenicillin and Timentin) for another 2-3 weeks.

[00419] Shoots were excised from the hypocotyl segments and transferred to shoot elongation medium MESH5 or MES10 (MS, 0.5 gm/L MES, 5 or 10 mg/L Herbiace, Carbenicillin, Timentin) for 2-4 weeks. The elongated shoots are cultured for root induction on MSI.1 (MS with 0.1 mg/L Indolebutyric acid). Once the plants had a well established root system, these were transplanted into soil. The plants were acclimated under controlled environmental conditions in the Convicon for 1-2 weeks before transfer to the greenhouse.

[00420] 22.2 – Molecular analysis: canola materials and methods

[00421] 22.2.1 – Tissue harvesting DNA isolation and quantification. Fresh tissue was placed into tubes and lyophilized at 4° C for 2 days. After the tissue was fully dried, a tungsten bead (Valenite) was placed in the tube and the samples were subjected to 1 minute of dry grinding using a Kelco bead mill. The standard DNeasy DNA isolation procedure was then followed (Qiagen, DNeasy 69109). An aliquot of the extracted DNA was then stained with Pico Green

BDDB01 9494151v1

(Molecular Probes P7589) and read in the fluorometer (BioTek) with known standards to obtain the concentration in ng/ul.

[00422] 22.2.2 - Polymerase chain reaction. A total of 100 ng of total DNA was used as the template. 20mM of each primer was used with the Takara Ex Taq PCR Polymerase kit (Mirus TAKRR001A). Primers for Coding Region PCR *AAD-12 (v1)* were (SEQ ID NO:10) (forward) and (SEQ ID NO:11) (reverse). The PCR reaction was carried out in the 9700 Geneamp thermocycler (Applied Biosystems), by subjecting the samples to 94°C for 3 minutes and 35 cycles of 94°C for 30 seconds, 65°C for 30 seconds, and 72°C for 2 minutes followed by 72°C for 10 minutes. PCR products were analyzed by electrophoresis on a 1% agarose gel stained with EtBr. 35 samples from 35 plants with *AAD-12 (v1)* events tested positive. Three negative control samples tested negative.

[00423] 22.2.3 – ELISA.

[00424] Using established ELISA described in previous section, AAD-12 protein was detected in 5 different canola transformation plant events. Expression levels ranged from 14 to over 700 ppm of total soluble protein (TSP). Three different untransformed plant samples were tested in parallel with no signal detected, indicating that the antibodies used in the assay have minimal cross reactivity to the canola cell matrix. These samples were also confirmed positive by Western analysis. A summary of the results is presented in Table 29.

Table 29. Expression of <i>AAD-12 (v1)</i> in Canola plants				
Sample #	[TSP] (µg/ml)	[AAD-12] (ng/ml)	Expression (ppm TSP) (ELISA)	Western
31	5614.96	1692.12	301.36	++++
33	4988.26	2121.52	425.30	++++
38	5372.25	3879.09	722.06	++++
39	2812.77	41.36	14.71	+
40	3691.48	468.74	126.98	+++
Control 1	2736.24	0.00	0.00	-
Control 2	2176.06	0.00	0.00	-
Control 3	3403.26	0.00	0.00	-

[00425] 22.4 – Postemergence herbicide tolerance in *AAD-12(v1)* transformed T₀ Canola.

[00426] Forty-five T₀ events from the transformed with the construct pDAB3759, were sent to the greenhouse over a period of time and were allowed to acclimate in the greenhouse. The plants were grown until 2-4 new, normal looking leaves had emerged (i.e., plants had

BDDB01 9494151v1

transitioned from tissue culture to greenhouse growing conditions). Plants were then treated with a lethal dose of the commercial formulations of 2,4-D Amine 4 at a rate of 560 g ae/ha. Herbicide applications were made with a track sprayer at a spray volume of 187 L/ha, 50-cm spray height. A lethal dose is defined as the rate that causes >95% injury to the untransformed controls.

[00427] Twenty-four of the events were tolerant to the 2,4-D DMA herbicide application. Some events did incur minor injury but recovered by 14 DAT. Events were progressed to the T₁ (and T₂ generation) by selfpollination under controlled, bagged, conditions.

[00428] 22.5 – AAD-12 (v1) heritability in Canola.

[00429] A 100 plant progeny test was also conducted on 11 T₁ lines of AAD-12 (v1). The seeds were sown and transplanted to 3-inch pots filled with Metro Mix media. All plants were then sprayed with 560 g ae/ha 2,4-D DMA as previously described. After 14 DAT, resistant and sensitive plants were counted. Seven out of the 11 lines tested segregated as a single locus, dominant Mendelian trait (3R:1S) as determined by Chi-square analysis. AAD-12 is heritable as a robust aryloxyalkanoate auxin resistance gene in multiple species and can be stacked with one or more additional herbicide resistance genes.

[00430] 22.6 – Verification of high 2,4-D tolerance in T₁ Canola

[00431] For T₁ AAD-12 (v1), 5-6 mg of seed were stratified, sown, and a fine layer of Sunshine Mix # 5 media was added as a top layer of soil. Emerging plants were selected with 560 g ae/ha 2,4-D at 7 and 13 days after planting.

[00432] Surviving plants were transplanted into 3-inch pots containing Metro Mix media. Surviving plants from T₁ progenies, that were selected with 560 g ae/ha 2,4-D, were also transplanted into 3-inch pots filled with Metro Mix soil. At 2-4 leaf stage plants were sprayed with either 280, 560, 1120, or 2240 g ae/ha 2,4-D DMA. Plants were graded at 3 and 14 DAT and compared to untransformed control plants. A sampling of T₁ event injury data 14DAT may be seen in **Table 30**. Data suggests that multiple events are robustly resistant to 2240 g ae/ha 2,4-D, while other events demonstrated less robust tolerance up to 1120 g ae/ha 2,4-D. Surviving plants were transplanted to 5 1/4" pots containing Metro Mix media and placed in the same growth conditions as before and self-pollinated to produce only homozygous seed.

Table 30. T ₁ <i>AAD-12</i> (<i>v1</i>) and untransformed control response to varying rates postemergence 2,4-D DMA applications.						
	Untransformed Control	pDAB3759(33)013.001	pDAB3759(18)009.001	pDAB3759(18)022.001	pDAB3759(18)030.001	pDAB3759(18)023.001
Herbicide	Average % Injury 14DAT					
280 g ae/ha 2,4-D DMA	85	0	0	0	0	0
560 g ae/ha 2,4-D DMA	85	0	0	0	0	0
1120 g ae/ha 2,4-D DMA	90	0	0	13	5	3
2240 g ae/ha 2,4-D DMA	95	1	5	83	31	6

[00433] 22.7-Field tolerance of pDAB3759 canola plants to 2,4-D, dichloprop, triclopyr and fluroxypyr herbicides.

[00434] Field level tolerance trial was conducted on two *AAD-12* (*v1*) events 3759(20)018.001 and 3759(18)030.001 and a wild-type canola (Nex710) in Fowler, Indiana. The experimental design was a randomized complete block design with 3 replications. Herbicide treatments were 2,4-D (dimethylamine salt) at 280, 560, 1120, 2240 and 4480 g ae/ha, triclopyr at 840 g ae/ha, fluroxypyr at 280 g ae/ha and an untreated control. Within each herbicide treatment, single 20 ft row/event for event 3759(18)030.001, 3759(18)018.001 and wild-type line (Nex710) were planted with a 4 row drill on 8 inch row spacing. Herbicide treatments were applied when canola reached the 4-6 leaf stage using compressed air backpack sprayer delivering 187 L/ha carrier volume at 130-200 kpa pressure. Visual injury ratings were taken at 7, 14 and 21 days after application.

[00435] Canola response to 2,4-D, triclopyr, and fluroxypyr are shown in Table 31. The wild-type canola (Nex710) was severely injured (72% at 14DAT) by 2,4-D at 2240 g ae/ha which is considered the 4X rate. The *AAD-12* (*v1*) events all demonstrated excellent tolerance to 2,4-D at 14DAT with an average injury of 2, 3 and 2% observed at the 1, 2 and 4X rates, respectively. The wild-type canola was severely injured (25% at 14DAT) by the 2X rate of triclopyr (840 g ae/ha). *AAD-12* (*v1*) events demonstrated tolerance at 2X rates of triclopyr with an average of 6% injury at 14DAT across the two events. Fluroxypyr at 280 g ae/ha

BDDDB01 9494151v1

caused severe injury (37%) to the non-transformed line at 14DAA. *AAD-12 (v1)* events demonstrated increased tolerance with an average of 8% injury at 5DAT.

[00436] These results indicate that *AAD-12 (v1)* transformed events displayed a high level of resistance to 2,4-D, triclopyr and fluroxypyr at rates that were lethal or caused severe epinastic malformations to non-transformed canola. *AAD-12* has been shown to have relative efficacy of 2,4-D > triclopyr > fluroxypyr.

Table 31. *AAD-12* (pDAB3759) canola plants response to 2,4-D, triclopyr, and fluroxypyr under field conditions.

<u>Herbicide Treatment</u>		<u>% Visual Injury at 14 DAT</u>		
Active Ingredient	Rate	<i>AAD-12</i> event 3759(20)018.001	<i>AAD-12</i> event 3759(18)030.001	Wild Type (Nex710)
2,4-D	280 GM AE/HA	0 a	0 b	0 e
2,4-D	560 GM AE/HA	0 a	0 b	15 d
2,4-D	1120 GM AE/HA	2 a	2 ab	33 bc
2,4-D	2240 GM AE/HA	3 a	3 ab	48 a
Triclopyr	840 GM AE/HA	6 a	6 ab	25 cd
Fluroxypyr	280 GM AE/HA	7 a	8 a	37 ab

Means with a column with different letters are significantly different as defined by LSD (p=0.05).

Example 23--*AAD-12 (v1)* Stacked With Insect Resistance (IR) or Other Input Traits in Any Crop

[00437] Insect resistance in crops supplied by a transgenic trait is prevalent in corn and cotton production in North America and across the globe. Commercial products having combined IR and HT traits have been developed by multiple seed companies. These include Bt IR traits (e.g. Bt toxins listed at the website lifesci.sussex.ac.uk, 2006) and any or all of the HTC traits mentioned above. The value this offering brings is the ability to control multiple pest problems through genetic means in a single offering. The convenience of this offering will be restricted if weed control and insect control are accomplished independent of each other. *AAD-12 (v1)* alone or stacked with one or more additional HTC traits can be stacked with one or more additional input traits (e.g., insect resistance, fungal resistance, or stress tolerance, *et al.*) (isb.vt.edu/cfdocs/fieldtests1.cfm, 2005) either through conventional breeding or jointly as a novel transformation event. Benefits include the convenience and flexibility described in Examples 15-20 above, together with the ability to manage insect pests and/or other

BDDB01 9494151v1

agronomic stresses in addition to the improved weed control offered by *AAD-12* and associated herbicide tolerance. Thus, the subject invention can be used to provide a complete agronomic package of improved crop quality with the ability to flexibly and cost effectively control any number of agronomic issues.

[00438] Combined traits of IR and HT have application in most agronomic and horticultural/ornamental crops and forestry. The combination of *AAD-12* and its commensurate herbicide tolerance and insect resistance afforded by any of the number of Bt or non-Bt IR genes are can be applied to the crop species listed (but not limited to) in Example 13. One skilled in the art of weed control will recognize that use of any of various commercial herbicides described in Examples 18-20, phenoxyacetic or pyridyloxyacetic auxin herbicides, alone or in multiple combinations, is enabled by *AAD-12 (v1)* transformation and stacking with the corresponding HT trait or IR trait either by conventional breeding or genetic engineering. Specific rates of other herbicides representative of these chemistries can be determined by the herbicide labels compiled in the CPR (Crop Protection Reference) book or similar compilation, labels compiled online (e.g., cdms.net/manuf/manuf.asp), or any commercial or academic crop protection guides such as the Crop Protection Guide from Agrilience (2005). Each alternative herbicide enabled for use in HTCs by *AAD-12 (v1)*, whether used alone, tank mixed, or sequentially, is considered within the scope of this invention.

Example 24—*AAD-12 (v1)* as an *in vitro* Dicot Selectable Marker

[00439] Genetic engineering of plant cell, tissue, organ, and plant or organelle such as plastid starts with the process of inserting genes of interest into plant cells using a suitable delivery method. However, when a gene is delivered to plant cells, only an extremely small percentage of cells integrate the heterogeneous gene into their genome. In order to select those few cells that have incorporated the gene of interest, researchers link a selectable or screenable "marker gene" to the gene of interest (GOI) in the vector. Cells that contain these markers are identified from the whole population of cells/ tissue to which the DNA plasmid vector was delivered. By selecting those cells that express the marker gene, researchers are able to identify those few cells that may have incorporated the GOI into their genome.

[00440] There are a variety of selectable markers available to enable this selection process to obtain transgenic cells, callus, embryos, shoots and plantlets. The preferred selectable markers by the Ag-industry are herbicide markers that allow the ease of spraying compounds

BDDDB01 9494151v1

in the field to select the right transgenic progenies during the process of event sorting in the field situation. *AAD-12 (v1)* has been shown to efficiently serve as a selectable marker for whole plants transformed with the gene in the greenhouse and growth chamber (Example 7) with 2,4-D as the selection agent. Field selection is possible as well using 2,4-D in combination with the *AAD-12 (v1)* gene (Example 11, 22), but use *in vitro* for cell-level selection is complicated by the fact 2,4-D is used almost ubiquitously as a plant growth regulator in the plant tissue culture systems. Degradation of this important hormone by *AAD-12 (v1)* can impact the ability to use this gene as an *in vitro* selectable marker. Success of developing 2,4-D as a marker gene depends on identifying the right alternate plant growth regulator that can mimic the effect of 2,4-D in the respective culture system and at the same time possess the ability to be stable and not be degraded by the *AAD-12* enzyme when expressed in the transgenic cells. R-dichlorprop is a close analog to 2,4-D that is not a substrate for *AAD-12 (v1)* and is used as a non-metabolizable auxin substitute in tobacco cell cultures allowing 2,4-D to be used at high rates as a selection agent. This fact was used in exemplifying *AAD-12 (v1)* could be used as a selectable marker *in vitro*.

[00441] 24.1—Cell culture--Alternative auxins.

[00442] *AAD-12 (v1)* degrades 2,4-D, but not R-2,4-dichlorophenoxypropionic acid (R-dichlorprop), which has at the same time the structural requirement of an auxinic growth regulator. Other non-metabolizable plant auxin mimics that may be used in cell culture include NAA (naphthalene acetic acid), IAA (indole acetic acid), dicamba, picloram, and R-mecoprop. It was investigated if it was possible to substitute R-dichlorprop and successfully maintain two different tobacco cell cultures PHL (Petite Havanna) and BY2 suspensions. Conversely, for cotton explants R-dichlorprop, dicamba, and picloram were tested as alternative auxins and the embryogenic callus induction response in comparison to the standard growth regulator, 2,4-D was evaluated. Petite Havana tobacco (PHL) and Coker cotton cotyledons were used in their experiments.

[00443] 24.1.1—Tobacco cell suspension—2,4-D as selection agent.

[00444] A dose response study was conducted with both the R-dichlorprop habituated PHL cells and the R-dichlorprop habituated BY2 cells where R-dichlorprop was substituted directly for 2,4-D in culture media. Though the focus was on PHL, a dose response was also done with BY2 in case of possible future studies, as well as to help predict the dose response for PHL. For the dichlorprop habituated PHL dose response, the levels of 2,4-D used (on

LSBY2C medium with R-dichlorprop) were 0 (the control), 1, 2, 3, 5, 8, 10, 12, 15, 18, 20, 40, 60, 80, 100, 120 mg/L 2,4-D. There were four replications per concentration. For the R-dichlorprop habituated BY2 dose response, the levels of 2,4-D used (on LSBY2C medium) were 0 (the control), 1, 2, 3, 5, 8, 10, 20, 30, 40, mg/L 2,4-D.

[00445] The dose response was carried out showed that all the concentration of 2,4-D tested were lethal above 10 mg/ L concentrations. However, there was growth in all the concentrations up to 10-mg/L 2,4-D where a slight growth of PHL suspension was observed. The growth of the suspension colonies from 1- 8 mg/L 2,4-D concentrations was comparable to the growth in control treatments. The observation made in BY2 suspension cells were similar except the concentration at 10 mg/L was found to be lethal and the sub lethal concentration was 8 mg/L concentration.

[00446] 24.1.2—Tobacco cell transformation with *AAD-12 (v1)* and 2,4-D selection.

[00447] For tobacco transformation experiment, there were 11 treatments altogether: a control set plated on LS-BY2C + dichlorprop medium , and 10 sets of LSBY2C + dichlorprop + 2,4-D at varying concentration levels (1, 2, 3, 5, 8, 10, 12, 15, 18, 20 mg/L). There were four replications per treatment. The plasmid DNA vector used was pDAB724, and the vector used for transformation was EHA101S strain of *Agrobacterium tumefaciens*. Four ml of PHL suspension at 0.6 OD⁶⁶⁰ were mixed with 100 ul of *Agrobacterium* (either EHA101 or LBA4404 strains) suspension at 1.0 OD⁶⁶⁰ in a sterile Petri plate and were mixed thoroughly and co-cultivated together in a non-shake condition at a dark growth chamber for 3 days at 25°C . After the co-cultivation period 1.5 ml of the Agro-tobacco suspension mixture was plated to the 11 set of plates above. The experiment was repeated with 13 treatments: a control of LS-BY2C + dichlorprop media (no 2,4-D), and LS-BY2C + dichlorprop + 2,4-D (1, 2, 3, 5, 8, 10, 12, 15, 18, 20 mg/L); LSBY2C + 1mg/L 2,4-D + B10 (Bialophos); LSBY2C + 10 2,4-D + B10 + R-dichlorprop. Again, there were four replicates per treatment, as well as a positive and negative control. All media contain 500 mg/L Carbenicillin (C) to control to contain *Agrobacterium* growth in the selection media.

[00448] The plasmid used in these experiments is pDAB724 and it has *PAT* selectable marker as well. So, control transformation experiments were initiated using R-dichlorprop habituated PHL in the presence of 10 mg/L bialophos following the standard protocol described above. The treatments were done side by side with 4 replicates to see if the bialophos selection in these suspension is normal.

BDDB01 9494151v1

[00449] There was little growth observed in all selection concentrations of 2,4D tested above 10 mg/L; however several fast growing colonies were found in 2, 5, and 8 mg/L 2,4-D concentration and representative sample was transferred to fresh selection at 10 mg/L selection to bulk the callus. Also, several putative colonies were selected in from 12, 15, 18 and 20 mg/L 2,4-D, but when compared to 10 mg/L there were only few colonies in these selection plate. Control treatment conducted with bialophos selection showed normal colony development. It appears that 10 mg/L 2,4-D is the sub-lethal and above this concentration 2,4-D appears to be lethal to the non-transformed cells. All the identified colonies were transferred to fresh medium with 10 mg/L selection and were probed for the presence of transgene by PCR as described in Example 10. The colonies selected and bulked had the transgenes as determined by PCR and expression of the genes as established by the Western analyses (as described in example 10). Several colonies were identified as actively growing and transferred to fresh selection medium with 10 mg/L 2,4-D to bulk the callus.

[00450] The bulked calluses were then transferred to higher level of 2,4-D to test the tolerance level *in vitro*. The levels of 2,4-D used were 20, 40, 60, 80, 100, and 120 mg/L 2,4-D. However the callus did not grow beyond 20 mg/L 2, 4-D concentrations indicating a threshold concentration higher than 20 mg/L may exist.

[00451] 24.2.1— Cotton explants—auxin alternatives

[00452] A dose response study was initiated to test multiple auxin alternatives as a substitute for the use of 2,4-D as a growth regulator in cotton. The alternative auxin tested were 2,4-dichloroprop, dicamba, and picloram. These compounds were tested at 0.2, 2.0, and 20.0 uM concentrations respectively. 2,4-D was used as the control treatment at 0.02 uM concentration. The medium used is the base medium for cotton callus induction (Example 12). Beyond the initial phase of culture, auxin is removed from the medium to prod the tissue toward the regeneration process.

[00453] R-dichloroprop was not effective in callus induction of cotyledonary segments and appears toxic to cotton cells at the lowest concentration tested (0.02 uM). Dicamba effectively induces callus growth at all concentrations tested (0.02-20 uM) and has no apparent toxic effects in this concentration range. Callus induction with picloram increased up to a maximum when explants were treated with 0.2 uM to 20 uM. Quality of the callus was consistent with the standard 2,4-D treatment at the 2 uM picloram concentration. At the

highest concentration (20 uM) 2,4-D was also inhibitory to cotton callus generation and growth.

[00454] Cotton has shown initial ability to respond effectively to alternative auxins (to 2,4-D) in culture. At high enough concentrations, 2,4-D is toxic to cotton cotyledonary explants. R-dichlorprop is surprisingly significantly more toxic to cotton than 2,4-D or other auxins. 2,4-D may be used as a selection agent and in combination with *AAD-12 (v1)* as the selectable marker gene. Other non-metabolizable auxin surrogates (e.g., dicamba, picloram, R-mecoprop, NAA, or IAA) would allow the use of AAD-12 as a selectable marker in dicots with 2,4-D as the selection agent.

BDDb01 9494151v1

References

- Adang, M.J., M.J. Staver, T.A. Rocheleau, J. Leighton, R.F. Barker, and D.V. Thompson.** 1985. Characterized full-length and truncated plasmid clones of the crystal protein of *Bacillus thuringiensis* subsp *kurstaki* HD-73 and their toxicity to *Manduca sexta*. *Gene* 36:289-300.
- Agrilience Crop Protection Guide.** 2005. Agrilience, LLC. St Paul, MN. 614 p.
- Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D.J. Lipman.** 1990. Basic local alignment search tool. *J. Mol. Biol.* 215:403-410.
- Altschul, S. F., T.L. Madden, A.A. Schaffer, J. Zhang, Z. Zhang, W. Miller, and D.J. Lipman.** 1997. Gapped BLAST and PSIBLAST: a new generation of protein databasesearch programs. *Nucl. Acids Res.* 25:3389-3402.
- An, G., B.D. Watson, S. Stachel, M.P. Gordon, E. W. Nester.** 1985. New cloning vehicles for transformation of higher plants. *EMBO J.* 4:277-284.
- Armstrong C.L., C.E. Green, R.L. Phillips.** 1991. Development and availability of germplasm with high Type II culture formation response. *Maize Genet Coop News Lett* 65:92-93.
- Beltz, G.A., K.A. Jacobs, T.H. Eickbush, P.T. Cherbas, and F.C. Kafatos.** 1983 *Methods of Enzymology*, R. Wu, L. Grossman and K. Moldave [eds.] Academic Press, New York 100:266-285
- Birch R.G. and T. Franks.** 1991. Development and optimization of microprojectile systems for plant genetic transformation. *Aust. J. Plant Physiol.* 18:453-469.
- CDMS.** Crop Data Management Systems Labels and MSDS. Online. Internet. March 13, 2004. Available at net/manuf/manuf.asp.
- Chee P.P., K.A. Foer, J.L. Slightom.** 1989. Transformation of soybean (*Glycine max*) by infecting germinating seeds with *Agrobacterium tumefaciens*. *Plant Physiol.* 91:1212-1218.
- Cheng M., J.E. Fry, S. Pang, H. Zhou, C.M. Hironaka, D.R. Duncan, T.W. Conner, and Y. Wan.** 1997. Genetic transformation of wheat mediated by *Agrobacterium tumefaciens*. *Plant Physiol* 115: 971-980.
- Chu C.C., C.C. Wang, C.S. Sun, C. Hsu, K.C. Yin, C.Y. Chu, F.Y. Bi.** 1975. Establishment of an efficient medium for anther culture of rice through comparative experiments on the nitrogen sources. *Sci. Sinica* 18:659-668.
- Clemente T.E., B.J. LaVallee, A.R. Howe, D. Conner-Ward, R.J. Rozman, P.E. Hunter, D.L. Broyles, D.S. Kasten, M.A. Hinchee.** 2000. Progeny analysis of glyphosate selected transgenic soybeans derived from *Agrobacterium*-mediated transformation. *Crop Sci* 40: 797-803.

BDDB01 9494151v1

- CPR: Crop Protection Reference.** 2005 Chemical and Pharmaceutical Press, New York, NY. 2647 p.
- Devine, M. D.** 2005. Why are there not more herbicide-tolerant crops? *Pest Manag. Sci.* 61:312-317.
- Dietrich, Gabriele Elfriede** (1998) Imidazolinone resistant AHAS mutants. U.S. Patent 5,731,180.
- Didierjean L, L. Gondet, R. Perkins, S.M. Lau, H. Schaller, D.P. O'Keefe, D. Werck-Reichhart.** 2002. Engineering Herbicide Metabolism in Tobacco and *Arabidopsis* with CYP76B1, a Cytochrome P450 Enzyme from Jerusalem Artichoke. *Plant Physiol* 2002, 130:179-189.
- Ditta, G. S. Stranfield, D. Corbin, and D.R. Helinski.** 1980. Broad host range DNA cloning system for Gram-negative bacteria: Construction of a gene bank of *Rhizobium leililoti*. *PNAS* 77:7347-7351.
- Edwards, R. A., L. H. Keller, and D. M. Schifferli.** 1998. Improved allelic exchange vectors and their use to analyze 987P fimbria gene expression. *Gene* 207:149-157.
- El-Shemy A, M.Teraishi, M. Khalafalla, T. Katsube-Tanaka, S. Utsumi, M. Ishimoto.** 2004. Isolation of soybean plants with stable transgene expression by visual selection based on green fluorescent protein *Molecular Breeding* 14: 227-238.
- El-Shemy A, M. Khalafalla, K. Fujita, M. Ishimoto.** 2006. Molecular control of gene co-suppression of transgenic soybean. *J. Biochem. and Mole. Biol.* 39: 61-67.
- Falco S.C., T. Guida, M. Locke, J. Mauvais, C. Sanders, R.T. Ward, P. Webber.** 1995. Transgenic canola and soybean seeds with increased lysine. *Bio/Technology* 13:577-582.
- Finer J. and M. McMullen.** 1991. Transformation of soybean via particle bombardment of embryogenic suspension culture tissue. *In Vitro Cell. Dev. Biol.* 27P:175-182.
- Fraley, R.T., D.G. Rogers, and R. B. Horsch.** 1986. Genetic transformation in higher plants. *Crit. Rev. Plant Sci.* 4:1-46.
- Frame B.R., P.R. Drayton, S.V. Bagnall, C.J. Lewnau, W.P. Bullock, H.M. Wilson, J.M. Dunwell, J.A. Thompson, and K. Wang.** 1994. Production of fertile maize plants by silicon carbide whisker-mediated transformation. *Plant J.* 6:941-948.
- Fukumori, F., and R.P. Hausinger.** 1993. Purification and characterization of 2,4-dichlorophenoxyacetate/ α -ketoglutarate dioxygenase. *J. Biol. Chem.* 268: 24311-24317.
- Gamborg, O.L., R. A. Miller, and K. Ojima.** 1968. Nutrient requirements of suspensions of cultures of soybean root cells. *Exp. Cell Res.* 50:151-158.

- Gay, P., D. Le Coq, M. Steinmetz, E. Ferrari, and J. A. Hoch.** 1983. Cloning structural gene *sacB*, which codes for exoenzyme levansucrase of *Bacillus subtilis*: expression of the gene in *Escherichia coli*. *J. Bacteriol.* 153:1424-1431.
- Gianessi, L. R.** 2005 Economic and herbicide use impacts of glyphosate-resistant crops. *Pest. Manag. Sci.* 61:241-245.
- Heap, I.** The International Survey of Herbicide Resistant Weeds. Online. Internet. March 18, 2005. Available at weedscience.com.
- Hiei Y., T. Komari, and T. Kubo.** 1997. Transformation of rice mediated by *Agrobacterium tumefaciens*. *Plant Mol. Biol.* 35:205-218.
- Hiei, Y., T. Komari** (1997) Method for Transforming Monocotyledons. U.S. Patent 5,591,616.
- Hinchee M.A.W., D.V. Conner-Ward, C.A. Newell, R.E. McDonnell, S.J. Sato, C.S. Gasser, D.A. Fischhoff, D.B. Re, R.T. Fraley, R.B. Horsch.** 1988. Production of transgenic soybean plants using *Agrobacterium*-mediated DNA transfer. *Bio/Technology* 6:915-922.
- Höfte, H. and H. R. Whiteley.** 1989. Insecticidal cristal proteins of *Bacillus thuringiensis*. 1989. *Microbiol. Rev.* 53:242-255.
- Hoekema, A.** 1985. In: *The Binary Plant Vector System*, Offset-drukkerij Kanters B.V., Alblasterdam, Chapter 5.
- Hogan, D.A.; S.R. Smith, E.A. Saari, J. McCracken, R.P. Hausinger.** 2000. Site-directed mutagenesis of 2,4-dichlorophenoxyacetic acid/a-ketoglutarate dioxygenase. Identification of residues involved in metallocenter formation and substrate binding. *J. Biol. Chem.* 275:12400-12409.
- Holsters, M., D. De Waele, A. Depicker, E. Messens, M. Van Montagu, and J. Schell.** 1978. Transfection and transformation of *Agrobacterium tumefaciens*. *Mol Gen. Genet.* 163:181-187.
- Horsch, R., J. Fry, N. Hoffman, J. Neidermeyer, S. Rogers, and R. Fraley.** 1988. In *Plant Molecular Biology Manual*, S. Gelvin *et al.*, eds., Kluwer Academic Publishers, Boston
- Horvath, M., G. Ditzelmüller, M. Lodl, and F. Streichsbier.** 1990. Isolation and characterization of a 2-(2,4-dichlorophenoxy)propionic acid-degrading soil bacterium. *Appl. Microbiol Biotechnol.* 33:213-216.
- Jefferson, R. A. M. Bevan, and T. Kavanagh.** 1987. The use of *Escherichia coli* β -glucuronidase gene as a gene fusion marker for studies of gene expression in higher plants. *Biochem. Soc. Trans.* 15: 17-19.
- Karlin, S. and S.F. Altschul.** 1990. Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes. *PNAS* 87:2264-2268.

BDDb01 9494151v1

- Karlin, S. and S.F. Altschul.** 1993. Applications and statistics for multiple high-scoring segments in molecular sequences. *PNAS* 90:5873-5877
- Keller, G.H., and M.M. Manak.** 1987. *DNA Probes*. Stockton Press, New York, NY, pp. 169-170.
- Khalafalla M, S. Rahman, H. El-Shemy, Y. Nakamoto, K. Wakasa, M. Ishimoto.** 2005. Optimization of particle bombardment conditions by monitoring of transient sGFP(S65T) expression in transformed soybean. *Breeding Sci.* 55:257-263.
- Khan M, L. Table, L. Heath , D. Spencer, T. Higgins.** 1994. *Agrobacterium*-mediated transformation of subterranean clover (*Trifolium subterraneum* L.). *Plant Physiol* 105:81-88.
- Kohler, H.P.E.** 1999. *Delftia acidovorans* MH: a versatile phenoxyalkanoic acid herbicide degrader. *J. Ind Microbiol and Biotech.* 23:336-340.
- Li L, Qu R, Kochko A de, Fauquet CM, Beachy RN** (1993) An improved rice transformation system using the biolistic method. *Plant Cell Rep* 12:250-255
- Linsmaier, E.M. and F. Skoog** (1965) Organic growth factor requirements of tobacco tissue cultures. *Physiol. Plant.* 18:100-127.
- Lorraine-Colwill, D. F., S. B. Powles, T. R. Hoawkes, P.H. Hollingshead, S.A.J. Arner, and C. Preston.** 2003. Investigations into the mechanism of glyphosate resistance in *Lolium rigidum*. *Pestic. Biochem. Physiol.* 74:62-73.
- Luo , H., Q. Hu, K. Nelson, C. Longo, A. P. Kausch, J. M. Chandlee, J. K. Wipff and C. R. Fricker.** 2004. *Agrobacterium tumefaciens*-mediated creeping bentgrass (*Agrostis stolonifera* L.) transformation using phosphinothricin selection results in a high frequency of single-copy transgene integration. *Plant Cell Reports* 22: 645-652.
- Lyon, B.R., D. J. Llewellyn, J. L. Huppertz, E. S. Dennis, and W. J. Peacock.** 1989. Expression of a bacterial gene in transgenic tobacco confers resistance to the herbicide 2,4-dichlorophenoxyacetic acid. *Plant Mol. Bio.* 13:533-540.
- Lyon, B.R., Y. L. Cousins, D. J. Llewellyn, and E. S. Dennis.** 1993. Cotton plants transformed with a bacterial degradation gene are protected from accidental spray drift damage by the herbicide 2,4-dichlorophenoxyacetic acid. *Transgenic Res.* 2: 166-169.
- Maniatis, T., E.F. Fritsch, J. Sambrook.** 1982. *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
- Martin, J.R. and W.W. Witt.** 2002. Response of glyphosate tolerant and susceptible biotypes of horseweed (*Conyza canadensis*) to foliar applied herbicides. *Proc.North Cent.Weed Sci.Soc.* 57:185.
- Martinell B.J., L.S. Julson, C.A. Emler, H. Yong, D.E. McCabe, E.J. Williams.** 2002. Soybean *Agrobacterium* transformation method. U.S. Patent Application No. 6384301

BDDB01 9494151v1

- McCabe D.E., W.F. Swain, B.J. Martinell, P. Christou.** 1988. Stable transformation of soybean (*Glycine max*) by particle acceleration. *Bio/Technology* 6:923-926.
- Miller S.D., P.W. Stahlman, P. Westra, G.W. Wicks, R.G. Wilson, J.M. Tichota.** 2003. Risks of weed spectrum shifts and herbicide resistance in glyphosate-resistant cropping systems. *Proc.West.Soc.Weed Sci.* 56:61-62.
- Muller R, S. Jorks, S. Kleinsteuber, W. Babel.** 1999. *Comamonas acidovorans* strain MC1: a new isolate capable of degrading the chiral herbicides dichlorprop and mecoprop and the herbicides 2,4-D and MCPA. *Microbiol. Res.* 154:241-246.
- Muller T, S. Byrde, C. Werlen, J. Roelof van der Meer, H-P. Kohler.** 2004. Genetic Analysis of Phenoxyalkanoic Acid Degradation in *Sphingomonas herbicidovorans* MH. *Appl. Environ. Microbiol.* 70(10):6066-6075.
- Muller T, T. Fleischmann, J. Roelof van der Meer, H-P. Kohler.** 2006. Purification and Characterization of Two Enantioselective α -Ketoglutarate-Dependent Dioxygenases, RdpA and SpdA from *Sphingomonas herbicidovorans* MH. *Appl. Environ. Microbiol.* 72(7):4853-4861.
- Muller T, M. Zavodszky, M. Feig, L. Kuhn, R. Hausinger.** 2006. Structural basis for the enantiospecificities of R- and S-specific phenoxypropionate/ α -ketoglutarate dioxygenases. *Protein Sci.* 15:1356-1368.
- Murashige T. and F. Skoog.** 1962. A revised medium for rapid growth and bioassays with tobacco tissue cultures. *Physiol. Plant.* 15:473-497.
- Murphy G.P., T.E. Dutt, R.F. Montgomery, T.S. Willard, G.A. Elmore.** 2002. Control of horseweed with glyphosate. *Proc.North Cent.Weed Sci.Soc.* 57:194.
- Ng, C.H., R. Wickneswari, S. Salmigah, Y.T. Teng, and B.S. Ismail.** 2003. Gene polymorphisms in glyphosate-resistant and -susceptible biotypes of *Eleusine indica* from Malaysia. *Weed Res.* 43:108-115.
- Olhofs P.M. and D.A. Somers.** 2001. L-Cysteine increases *Agrobacterium*-mediated T-DNA delivery into soybean cotyledonary-node cells. *Plant Cell Rep* 20: 706-711
- Olhofs, P.M., L.E. Fligel, C.M. Donovan, and D.A. Somers.** 2003. Efficient soybean transformation using hygromycin B selection in the cotyledonary-node method. *Planta* 216:723-735
- Padgett S.R., K.H. Kolacz, X. Delannay, D.B. Re, B.J. LaVallee, C.N. Tinius, W.K. Rhodes, Y.I. Otero, G.F. Barry, D.A. Eichholtz, V.M. Peschke, D.L. Nida, N.B. Taylor, and G.M. Kishore.** 1995. Development, identification, and characterization of a glyphosate-tolerant soybean line. *Crop Sci.* 1995;35:1451-1461.
- Parrott W.A., J. N. All, M.J. Adang, M.A. Bailey, H.R. Boerma, and C.N. Stewart, Jr.** 1994. Recovery and evaluation of soybean plants transgenic for a *Bacillus thuringiensis* var. kurstaki insecticidal gene. *In Vitro Cell. Dev. Biol.* 30P:144-149.

- Popelka, J. C. and F. Altpeter** 2003. *Agrobacterium tumefaciens*-mediated genetic transformation of rye (*Secale cereale* L) Mol. Breed 11:203-211
- Powles, S.B. and C. Preston.** 2006. Evolved glyphosate resistance in plants: biochemical and genetic basis of resistance. Weed Tech 20:282-289.
- Saari, R.E., D.A. Hogan, and R.P. Hausinger.** 1999. Stereospecific degradation of the phenoxypropionate herbicide dichlorprop. J. Mol. Catal. B: Enz. 6:421-428.
- Saiki, R. K., S. Scharf, F. Faloona, K.B. Mullis, G.T. Horn, H.A. Erlich, and N. Arnheim.** 1985. Enzymatic Amplification of β -Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell Anemia. *Science* 230:1350-1354.
- Sambrook, J., E.F. Fritsch, and T. Maniatis.** 1989. Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press.
- Sambrook, J. and D.W. Russell.** 2000. *Molecular Cloning*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- Schenk, R.U. and A.C. Hildebrandt** (1972) Methods and techniques for induction and growth of monocotyledonous and dicotyledonous plant cell cultures. Can. J. Bot. 50:199-204.
- Sfiligoj, E.** 2004. Spreading resistance. Crop Life. March issue.
- Simarmata, M., J.E. Kaufmann, and D. Penner.** 2003. Potential basis of glyphosate resistance in California rigid ryegrass (*Lolium rigidum*). Weed Sci. 51:678-682.
- Singh R.J., T.M. Klein, C.J. Mauvais, S. Knowlton, T. Hymowitz, C.M. Kostow.** Cytological characterization of transgenic soybean. Theor. Appl. Genet. 1998; 96:319-324.
- Smejkal, C.W., T. Vallaey, S.K. Burton, and H.M. Lappin-Scott.** 2001. Substrate specificity of chlorophenoxyalkanoic acid-degrading bacteria is not dependent upon phylogenetically related tfdA gene types. Biol. Fertil. Sols 33:507-513.
- Streber, W. and L. Willmitzer.** 1989. Transgenic tobacco plants expressing a bacterial detoxifying enzyme are resistant to 2,4-D. Bio/Technology 7:811-816.
- Streber, W.R., K.N. Timmis, and M. H. Zenk.** 2000. Microorganisms and plasmids for 2,4-dichlorophenoxyacetic acid (2,4-D) monooxygenase formation and process for the production of these plasmids and strains. US Pat. 6,153,401.
- Streber, W.R., K.N. Timmis, and M.H. Zenk.** 1987. Analysis, cloning, and high-level expression of 2,4-dichlorophenoxyacetic monooxygenase gene tfdA of *Alcaligenes eutrophus* JMP134. J. Bacteriol. 169:2950-2955.

- Suggs, S.V., T. Miyake, E.H. Kawashime, M.J. Johnson, K. Itakura, and R.B. Wallace.** 1981. *ICN-UCLA Symp. Dev. Biol. Using Purified Genes*, D.D. Brown [ed.], Academic Press, New York, 23:683-693.
- Terakawa T, H. Hisakazu, Y. Masanori.** 2005. Efficient whiskermediated gene transformation in a combination with supersonic treatment. *Breeding science* 55: 456-358.
- Tingay, S., D. McElroy, R. Kalla, S. Fieg, W. Mingbo, S. Thornton, and R. Bretell.** 1997. *Agrobacterium tumefaciens*-mediated barley transformation. *Plant J.* 11:1369-1376.
- Weigel, D. and J. Glazebrook.** 2002. *Arabidopsis: A Laboratory Manual*. Cold Spring Harbor Lab Press, Cold Spring Harbor, N. Y. 358 pp.
- Weising, K., J. Schell, and G. Kahl.** 1988. Foreign genes in plants: transfer, structure, expression and applications. *Ann. Rev. Genet.* 22:421-477.
- Welter, M.E., D.S. Clayton, M.A. miler, and J.F. Petolino.** 1995. Morphotypes of friable embryogenic maize callus. *Plant Cell Rep.* 14:725-729.
- Westendorf A., D. Benndorf, R. Muller, W. Babel.** 2002. The two enantiospecific dichlorprop/ α -ketoglutarate-dioxygenases from *Delftia acidovorans* MC1-protein and sequence data of *Rdpa* and *SdpA*. *Microbiol. Res.* 157:317-22.
- Westendorf, A., R.H. Muller, and W. Babel.** 2003. Purification and characterization of the enantiospecific dioxygenases from *Delftia acidovorans* MC1 initiating the degradation of phenoxypropionates and phenoxyacetate herbicides. *Acta Biotechnol.* 23: 3-17.
- WSSA.** 2002. *Herbicide Handbook* (8th ed). Weed Science Society of America. Lawrence, KS 492 pp.
- Zeng P, D. Vadnais, Z. Zhang, and J. Polacco.** 2004. Refined glufosinate selection in *Agrobacterium*-mediated transformation of soybean [*Glycine max* (L.) Merr.]. *Plant Cell Rep.* 22: 478 – 482.
- Zhang S** (1995) Efficient plant regeneration from indica (group 1) rice protoplasts of one advanced breeding line and three varieties. *Plant Cell Rep* 15:68–71
- Zhang S, Chen L, Qu R, Marmey P, Beachy RN, Fauquet CM** (1996) Efficient plant regeneration from indica (group 1) rice protoplasts of one advanced breeding line and three varieties. *Plant Cell Rep* 15:465–469.
- Zhang S, Song W, Chen L, Ruan D, Taylor N, Ronald P, Beachy RN, Fauquet CM** (1998) Transgenic elite Indica rice varieties, resistant to *Xanthomonas oryzae* pv. *oryzae*. *Mol Breed* 4:551-558.
- Zhang, Z., A. Xing, P.E. Staswick, and T. E. Clemente.** 1999. The use of glufosinate as a selective agent in *Agrobacterium*-mediated transformation of soybean. *Plant Cell, Tissue, and Organ Culture* 56:37-46.

BDDB01 9494151v1

- Zhao, Z.Y., T. Cai, L. Tagliani, M. Miller, N. Wang, H. Pang, M. Rudert, S. Schroeder, D. Hondred, J. Seltzer, and D. Pierce.** 2000. *Agrobacterium*-mediated sorghum transformation, Plant Mol. Biol. 44:789-798.
- Zipper, C., M. Bunk, A. Zehnder, H. Kohler.** 1998. Enantioselective uptake and degradation of the chiral herbicide dichlorprop [(RS)-2-(2,4-dichlorophenoxy) propanoic acid] by *Delftia acidovorans* MH. J. Bact. 13:3368-3374

Claims

We claim:

1. A transgenic plant cell comprising a recombinant polynucleotide that encodes a protein having an activity that catalyzes degradation of a herbicidal compound selected from the group consisting of a phenoxypropionic auxin and a phenoxyacetic auxin, wherein said protein has at least 95% amino acid sequence identity with a sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:4.
2. The plant cell of claim 1 wherein said plant cell is selected from the group consisting of soybean, cotton, *Arabidopsis*, tobacco and canola.
3. A transgenic plant cell comprising a recombinant polynucleotide that encodes a protein that confers tolerance on said plant cell to a pyridyloxy acetate herbicide, wherein said protein has at least 95% amino acid sequence identity with a sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:4.
4. The cell of claim 3 wherein said pyridyloxy acetate herbicide is selected from the group consisting of triclopyr and fluroxypyr.
5. A method of producing a herbicide tolerant plant, said method comprising introducing a polynucleotide into a plant cell, wherein said polynucleotide encodes a protein having an activity that catalyzes degradation of a herbicidal compound selected from the group consisting of a phenoxypropionic auxin and a phenoxyacetic auxin, wherein said protein has at least 95% amino acid sequence identity with a sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:4, and regenerating a plant from said cell.
6. The method of claim 5 further comprising selecting transformed plant tissue that produces said protein.

BDDDB01 9494151v1

7. The cell of claim 1, wherein said protein confers tolerance to 2,4-D to said cell.
8. The plant cell of claim 1, further comprising at least one different polynucleotide that encodes a protein that confers tolerance to the plant cell to a herbicide selected from the group consisting of glyphosate, glufosinate, HPPD-inhibitors, and dicamba.
9. The plant cell of claim 8, wherein the plant cell is selected from the group consisting of soybean, cotton, or canola.
10. The plant cell of claim 8, wherein the plant cell is a soybean cell and the herbicide is selected from the group consisting of glyphosate and dicamba.
11. The plant cell of claim 8, wherein the plant cell is a soybean cell and the herbicide is selected from the group consisting of glyphosate and glufosinate.
12. The plant cell of claim 1, further comprising a second polynucleotide that encodes a gene product having an insecticidal activity.
13. The plant cell of claim 12, wherein said gene product encoded by said second polynucleotide is selected from the group consisting of Cry1F and Cry1Ac.
14. The plant cell of claim 1 further comprising an output trait.
15. The plant cell of claim 1 further comprising an input trait.
16. A plant comprising a plurality of cells of claim 1.
17. A part, progeny, seed or asexual propagate of the plant of claim 17, wherein said part, progeny, seed or propagate comprises said polynucleotide.

18. A method for selectively controlling weeds in a field, said field containing a crop, said crop comprising plant cells of claim 1, said method comprising applying an aryloxyalkanoate herbicide to at least a portion of the crop and the weeds in the field to control the weeds.
19. A method of controlling volunteer plants of a crop comprising the plant cells of claim 1, said method comprising applying to said volunteer plants a herbicide selected from the group consisting of ACCase inhibitors, HPPD inhibitors, ALS inhibitors, and dicamba.
20. The method of claim 19 wherein the herbicide is selected from sethoxydim and clethodim.

Abstract

[00455] The subject invention provides novel plants that are not only resistant to 2,4-D, but also to pyridyloxyacetate herbicides. Heretofore, there was no expectation or suggestion that a plant with both of these advantageous properties could be produced by the introduction of a single gene. The subject invention also includes plants that produce one or more enzymes of the subject invention “stacked” together with one or more other herbicide resistance genes. The subject invention enables novel combinations of herbicides to be used in new ways. Furthermore, the subject invention provides novel methods of preventing the development of, and controlling, strains of weeds that are resistant to one or more herbicides such as glyphosate. The preferred enzyme and gene for use according to the subject invention are referred to herein as *AAD-12* (AryloxyAlkanoate Dioxygenase). This highly novel discovery is the basis of significant herbicide tolerant crop trait and selectable marker opportunities.

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Terry R. Wright et al.)
)
Filed:)
)
Title: Novel Herbicide Resistance Genes)
)
Docket No. DAS-P0129-03-US-E)
)
Customer No.: 83067)

STATEMENT IN SUPPORT OF SEQUENCE SUBMISSION
UNDER 37 C.F.R. §§1.821-1.825

Sir:

Electronically transmitted herewith is a patent application, including a sequence listing in computer readable form (attached .txt file) in compliance with 37 C.F.R. §§1.821 through 1.825. The undersigned hereby states that the sequence listing submitted herewith for the subject continuation application contains the same sequence information as was filed for the parent application.

Respectfully submitted,



Jay M. Sanders
Registration No. 39,355
Attorney for Applicant

Faegre Baker Daniels
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204
Telephone: 317-237-1245
Facsimile: 317-237-1000

Date Submitted: October 8, 2012

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	DAS-P0129-03-US-E
		Application Number	
Title of Invention	NOVEL HERBICIDE RESISTANCE GENES		
<p>The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.</p> <p>This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.</p>			

Secrecy Order 37 CFR 5.2

☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
--

Inventor Information:

Inventor 1						Remove	
Legal Name							
Prefix	Given Name	Middle Name	Family Name			Suffix	
	Terry	R.	Wright				
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service							
City	Carmel	State/Province	IN	Country of Residence	US		
Mailing Address of Inventor:							
Address 1		14162 Charity Chase Circle					
Address 2							
City	Carmel	State/Province			IN		
Postal Code		46074	Country		US		
Inventor 2						Remove	
Legal Name							
Prefix	Given Name	Middle Name	Family Name			Suffix	
	Justin	M.	Lira				
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service							
City	Zionsville	State/Province	IN	Country of Residence	US		
Mailing Address of Inventor:							
Address 1		8974 Windpointe Pass					
Address 2							
City	Zionsville	State/Province			IN		
Postal Code		46077	Country		US		
Inventor 3						Remove	
Legal Name							
Prefix	Given Name	Middle Name	Family Name			Suffix	
	Terence	Anthony	Walsh				
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service							

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number		DAS-P0129-03-US-E	
		Application Number			
Title of Invention		NOVEL HERBICIDE RESISTANCE GENES			
City	Zionsville	State/Province	IN	Country of Residence	US
Mailing Address of Inventor:					
Address 1		11638 Promontory Trail			
Address 2					
City	Zionsville	State/Province	IN		
Postal Code	46077	Country i	US		
Inventor 4					Remove
Legal Name					
Prefix	Given Name	Middle Name	Family Name	Suffix	
	Donald		Merlo		
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service					
City	Carmel	State/Province	IN	Country of Residence	US
Mailing Address of Inventor:					
Address 1		11845 Durbin Drive			
Address 2					
City	Carmel	State/Province	IN		
Postal Code	46032	Country i	US		
Inventor 5					Remove
Legal Name					
Prefix	Given Name	Middle Name	Family Name	Suffix	
	Pon Samuel		Jayakumar		
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service					
City	Carmel	State/Province	IN	Country of Residence	US
Mailing Address of Inventor:					
Address 1		3336 Kilkenny Circle			
Address 2					
City	Carmel	State/Province	IN		
Postal Code	46032	Country i	US		
Inventor 6					Remove
Legal Name					
Prefix	Given Name	Middle Name	Family Name	Suffix	
	Gaofeng		Lin		
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service					
City	Zionsville	State/Province	IN	Country of Residence	US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	DAS-P0129-03-US-E	
		Application Number		
Title of Invention	NOVEL HERBICIDE RESISTANCE GENES			
Mailing Address of Inventor:				
Address 1	981 Franklin Trace			
Address 2				
City	Zionsville	State/Province	IN	
Postal Code	46077	Country	US	
All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the Add button.				

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below. For further information see 37 CFR 1.33(a).			
☐ An Address is being provided for the correspondence information of this application.			
Customer Number	83067		
Email Address	intear@faegrebd.com	Add Email	Remove Email
Email Address	cynthia.payson@faegrebd.com	Add Email	Remove Email

Application Information:

Title of the Invention	NOVEL HERBICIDE RESISTANCE GENES		
Attorney Docket Number	DAS-P0129-03-US-E	Small Entity Status Claimed	☐
Application Type	Nonprovisional		
Subject Matter	Utility		
Suggested Class (if any)		Sub Class (if any)	
Suggested Technology Center (if any)			
Total Number of Drawing Sheets (if any)	3	Suggested Figure for Publication (if any)	

Publication Information:

☐ Request Early Publication (Fee required at time of Request 37 CFR 1.219)
☐ Request Not to Publish. I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

<p>Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number will be used for the Representative Information during processing.</p>
--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	DAS-P0129-03-US-E
		Application Number	
Title of Invention	NOVEL HERBICIDE RESISTANCE GENES		
Please Select One:	☒ Customer Number	☐ US Patent Practitioner	☐ Limited Recognition (37 CFR 11.9)
Customer Number	83067		

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c) or indicate National Stage entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.

Prior Application Status	Pending	Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)
	Continuation of	12091896	2008-11-03
Prior Application Status	Pending	Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)
12091896	a 371 of international	PCTUS2006042133	2006-10-27
Prior Application Status	Expired	Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)
PCTUS2006042133	non provisional of	60731044	2005-10-28

Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the **Add** button.

Foreign Priority Information:

This section allows for the applicant to claim benefit of foreign priority and to identify any prior foreign application for which priority is not claimed. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(a).

Remove		
Application Number	Country ¹	Filing Date (YYYY-MM-DD)
		Priority Claimed ☐ Yes ☒ No

Additional Foreign Priority Data may be generated within this form by selecting the **Add** button.

Authorization to Permit Access:

☐ Authorization to Permit Access to the Instant Application by the Participating Offices

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	DAS-P0129-03-US-E
		Application Number	
Title of Invention	NOVEL HERBICIDE RESISTANCE GENES		

If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and any other intellectual property offices in which a foreign application claiming priority to the instant patent application is filed access to the instant patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority to the instant patent application is filed to have access to the instant patent application.

In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the instant patent application with respect to: 1) the instant patent application-as-filed; 2) any foreign application to which the instant patent application claims priority under 35 U.S.C. 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the instant patent application; and 3) any U.S. application-as-filed from which benefit is sought in the instant patent application.

In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing this Authorization.

Applicant Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.			
Applicant 1			
If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed. The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be identified in this section.			
☒ Assignee		☐ Legal Representative under 35 U.S.C. 117	
☐ Person to whom the inventor is obligated to assign.		☐ Person who shows sufficient proprietary interest	
If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:			
Name of the Deceased or Legally Incapacitated Inventor : <input type="text"/>			
If the Assignee is an Organization check here. ☒			
Organization Name		Dow AgroSciences LLC	
Mailing Address Information:			
Address 1		9330 Zionsville Road	
Address 2			
City		Indianapolis	State/Province
Country		US	Postal Code
Phone Number			Fax Number


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DAS-P0129-03-US-E
	Application Number	
Title of Invention	NOVEL HERBICIDE RESISTANCE GENES	

Email Address	
---------------	--

Additional Applicant Data may be generated within this form by selecting the Add button.

Signature:

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications					
Signature				Date (YYYY-MM-DD)	2012-10-08
First Name	Jay M.	Last Name	Sanders	Registration Number	39355
Additional Signature may be generated within this form by selecting the Add button.					

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Electronic Patent Application Fee Transmittal				
Application Number:				
Filing Date:				
Title of Invention:		NOVEL HERBICIDE RESISTANCE GENES		
First Named Inventor/Applicant Name:		Terry R. Wright		
Filer:		Jay M. Sanders/Lisa Schodrowski		
Attorney Docket Number:		DAS-P0129-03-US-E		
Filed as Large Entity				
Utility under 35 USC 111(a) Filing Fees				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Utility application filing	1011	1	390	390
Utility Search Fee	1111	1	620	620
Utility Examination Fee	1311	1	250	250
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Miscellaneous:				
Total in USD (\$)				1260

Electronic Acknowledgement Receipt	
EFS ID:	13931247
Application Number:	13647081
International Application Number:	
Confirmation Number:	1022
Title of Invention:	NOVEL HERBICIDE RESISTANCE GENES
First Named Inventor/Applicant Name:	Terry R. Wright
Customer Number:	83067
Filer:	Jay M. Sanders/Lisa Schodrowski
Filer Authorized By:	Jay M. Sanders
Attorney Docket Number:	DAS-P0129-03-US-E
Receipt Date:	08-OCT-2012
Filing Date:	
Time Stamp:	16:37:30
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$1260
RAM confirmation Number	19716
Deposit Account	020390
Authorized User	
<p>The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)</p>	

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Drawings-only black and white line drawings	Figures.pdf	121580	no	3
			5d0ccaffe91d9c046a028d0211351b3f8225b18		
Warnings:					
Information:					
2	Sequence Listing (Text File)	DAS-129XC1-ST25.txt	11878	no	0
Warnings:					
Information:					
3		Specification.pdf	948285	yes	147
			e09c8006e3cf1dcbaa33572e6fe7515d0e6139fd		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Specification		1	143	
	Claims		144	146	
	Abstract		147	147	
Warnings:					
Information:					
4	CRF Statement Paper and CRF are the same	Sequence-Stmt.pdf	41623	no	1
			021fe2fd7a2ec680a8f371908eb963231b493499		
Warnings:					
Information:					
5	Application Data Sheet	ADS.pdf	563672	no	6
			12a8ce16867230e983583620089759ba378fdb05		
Warnings:					
Information:					
This is not an USPTO supplied ADS fillable form					
6	Fee Worksheet (SB06)	fee-info.pdf	33271	no	2
			9630f278de76a23479ea9b1c825e5359be8e9d37		
Warnings:					
Information:					
Total Files Size (in bytes):			1720309		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

=====
Sequence Listing was accepted.
See attached Validation Report.
If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).
Reviewer: Durreshwar Anjum
Timestamp: [year=2012; month=10; day=18; hr=14; min=41; sec=13; ms=491;
]
=====

Application No: 13647081 Version No: 1.0

Input Set:

Output Set:

Started: 2012-10-08 16:38:09.715
 Finished: 2012-10-08 16:38:10.986
 Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 271 ms
 Total Warnings: 17
 Total Errors: 1
 No. of SeqIDs Defined: 17
 Actual SeqID Count: 17

Error code	Error Description
E 201	Mandatory field data missing in <140>
W 402	Undefined organism found in <213> in SEQ ID (1)
W 402	Undefined organism found in <213> in SEQ ID (2)
W 402	Undefined organism found in <213> in SEQ ID (3)
W 402	Undefined organism found in <213> in SEQ ID (4)
W 402	Undefined organism found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)

SEQUENCE LISTING

<110> Wright, Terry R.
Lira, Justin M.
Walsh, Terence A.
Merlo, Donald J.
Jayakumar, Pon Samuel
Lin, Gaofeng

<120> Novel Herbicide Resistance Genes

<130> DAS-P0129-02-US-e

<140> US 13/647,081

<141> 2012-10-08

<150> US 60/731,044

<151> 2005-10-28

<150> PCT/US2006/042133

<151> 2006-10-27

<160> 17

<170> PatentIn version 3.3

<210> 1

<211> 879

<212> DNA

<213> Delftia acidovorans

<400> 1

```
atgcagacga cgctgcagat tccccccaca ggcgccaccc tgggcgccac cgtcaccggc      60
gtgcacctgg ccacgctgga cgacgcgggc ttgcgcgcc tgcacgcgc ctggtgcag      120
catgcctgct tgatcttccc cggccagcac ctacagcaac accagcagat cacttttgcc      180
aaacgcttcg gcgcgatcga gcgcctcggc ggcggcgaca tcgtggccat ctccaatgtc      240
aaggccgatg gcacggtgcg ccagcacagc cccgccgagt gggacgacat gatgaaggtc      300
atcgtcggca acatggcctg gcatgccgac agcacctaca tgccggtgat ggcgcagggc      360
gcggtgttct cggccgaagt ggtgcccgca gtgggcgggc gcacctgctt cgccgacatg      420
cgcgccgcct acgacgcgct ggacgaggcc acccgcgccc tgggtcacca gcgctcggcg      480
cggcattcgc tgggtgtattc gcagagcaag ctgggccatg tgcagcaggc cggctcggcc      540
tacatcggtt acggcatgga caccaccgcc acgccccctg gcccgctggt caaggtgcat      600
cccgagaccg gcgcgccctc gctgctgata ggccgccatg cccatgccat cccgggcatg      660
gacgcgcgcc aatccgagcg ctctctggaa ggccgtggtc actgggcctg ccaggcgccg      720
cgggtgcatg cccaccaatg ggcgcggcgc gacgtggtgg tgtgggacaa ccgctgctg      780
```

ctgcaccgcg ccgagccctg ggatttcaag ctgccgcggg tgatgtggca cagccgectg 840

gccggccgcc ccgagaccga gggcgccgcc ctggtgtaa 879

<210> 2

<211> 292

<212> PRT

<213> Delftia acidovorans

<400> 2

Met Gln Thr Thr Leu Gln Ile Thr Pro Thr Gly Ala Thr Leu Gly Ala
1 5 10 15

Thr Val Thr Gly Val His Leu Ala Thr Leu Asp Asp Ala Gly Phe Ala
20 25 30

Ala Leu His Ala Ala Trp Leu Gln His Ala Leu Leu Ile Phe Pro Gly
35 40 45

Gln His Leu Ser Asn Asp Gln Gln Ile Thr Phe Ala Lys Arg Phe Gly
50 55 60

Ala Ile Glu Arg Ile Gly Gly Gly Asp Ile Val Ala Ile Ser Asn Val
65 70 75 80

Lys Ala Asp Gly Thr Val Arg Gln His Ser Pro Ala Glu Trp Asp Asp
85 90 95

Met Met Lys Val Ile Val Gly Asn Met Ala Trp His Ala Asp Ser Thr
100 105 110

Tyr Met Pro Val Met Ala Gln Gly Ala Val Phe Ser Ala Glu Val Val
115 120 125

Pro Ala Val Gly Gly Arg Thr Cys Phe Ala Asp Met Arg Ala Ala Tyr
130 135 140

Asp Ala Leu Asp Glu Ala Thr Arg Ala Leu Val His Gln Arg Ser Ala
145 150 155 160

Arg His Ser Leu Val Tyr Ser Gln Ser Lys Leu Gly His Val Gln Gln
165 170 175

Ala Gly Ser Ala Tyr Ile Gly Tyr Gly Met Asp Thr Thr Ala Thr Pro

180	185	190
Leu Arg Pro Leu Val Lys Val His Pro Glu Thr Gly Arg Pro Ser Leu		
195	200	205
Leu Ile Gly Arg His Ala His Ala Ile Pro Gly Met Asp Ala Ala Glu		
210	215	220
Ser Glu Arg Phe Leu Glu Gly Leu Val Asp Trp Ala Cys Gln Ala Pro		
225	230	235 240
Arg Val His Ala His Gln Trp Ala Ala Gly Asp Val Val Val Trp Asp		
245	250	255
Asn Arg Cys Leu Leu His Arg Ala Glu Pro Trp Asp Phe Lys Leu Pro		
260	265	270
Arg Val Met Trp His Ser Arg Leu Ala Gly Arg Pro Glu Thr Glu Gly		
275	280	285
Ala Ala Leu Val		
290		

<210> 3
 <211> 882
 <212> DNA
 <213> Delftia acidovorans

<400> 3	
atggctcaga ccactctcca aatcacaccc actggtgcc ccttgggtgc cacagtcaact	60
ggtgttcacc ttgccacact tgacgatgct ggtttcgctg ccctccatgc agcctggcctt	120
caacatgcac tcttgatctt ccttgggcaa cacctcagca atgaccaaca gattaccttt	180
gctaaacgct ttggagcaat tgagaggatt ggcggagggtg acattgttgc catatccaat	240
gtcaaggcag atggcacagt gcgccagcac tctctgctg agtgggatga catgatgaag	300
gtcattgtgg gcaacatggc ctggcacgcc gactcaacct acatgccagt catggctcaa	360
ggagctgtgt tcagcgcaga agttgtccca gcagttgggg gcagaacctg ctttgetgac	420
atgagggcag cctacgatgc ctttgatgag gcaaccctg ctcttgttca ccaaaggtct	480
gtcgtcact cccttgtgta ttctcagagc aagttgggac atgtccaaca ggccgggtca	540
gcctacatag gttatggcat ggacaccact gcaactctc tcagaccatt ggtcaagggtg	600

catcctgaga ctggaaggcc cagcctcttg atcgcccgcc atgcccattgc catccctggc 660
atggatgcag ctgaatcaga gcgcttcctt gaaggacttg ttgactgggc ctgccaggct 720
cccagagtcc atgctcacca atgggctgct ggagatgtgg ttgtgtggga caaccgctgt 780
ttgctccacc gtgctgagcc ctgggatttc aagttgccac gtgtgatgtg gcactecaga 840
ctcgcgtggac gccacagaaac tgagggtgct gccttggttt ga 882

<210> 4
<211> 293
<212> PRT
<213> Delftia acidovorans

<400> 4

Met Ala Gln Thr Thr Leu Gln Ile Thr Pro Thr Gly Ala Thr Leu Gly
1 5 10 15

Ala Thr Val Thr Gly Val His Leu Ala Thr Leu Asp Asp Ala Gly Phe
20 25 30

Ala Ala Leu His Ala Ala Trp Leu Gln His Ala Leu Leu Ile Phe Pro
35 40 45

Gly Gln His Leu Ser Asn Asp Gln Gln Ile Thr Phe Ala Lys Arg Phe
50 55 60

Gly Ala Ile Glu Arg Ile Gly Gly Gly Asp Ile Val Ala Ile Ser Asn
65 70 75 80

Val Lys Ala Asp Gly Thr Val Arg Gln His Ser Pro Ala Glu Trp Asp
85 90 95

Asp Met Met Lys Val Ile Val Gly Asn Met Ala Trp His Ala Asp Ser
100 105 110

Thr Tyr Met Pro Val Met Ala Gln Gly Ala Val Phe Ser Ala Glu Val
115 120 125

Val Pro Ala Val Gly Gly Arg Thr Cys Phe Ala Asp Met Arg Ala Ala
130 135 140

Tyr Asp Ala Leu Asp Glu Ala Thr Arg Ala Leu Val His Gln Arg Ser
145 150 155 160

Ala Arg His Ser Leu Val Tyr Ser Gln Ser Lys Leu Gly His Val Gln
165 170 175

Gln Ala Gly Ser Ala Tyr Ile Gly Tyr Gly Met Asp Thr Thr Ala Thr
180 185 190

Pro Leu Arg Pro Leu Val Lys Val His Pro Glu Thr Gly Arg Pro Ser
195 200 205

Leu Leu Ile Gly Arg His Ala His Ala Ile Pro Gly Met Asp Ala Ala
210 215 220

Glu Ser Glu Arg Phe Leu Glu Gly Leu Val Asp Trp Ala Cys Gln Ala
225 230 235 240

Pro Arg Val His Ala His Gln Trp Ala Ala Gly Asp Val Val Val Trp
245 250 255

Asp Asn Arg Cys Leu Leu His Arg Ala Glu Pro Trp Asp Phe Lys Leu
260 265 270

Pro Arg Val Met Trp His Ser Arg Leu Ala Gly Arg Pro Glu Thr Glu
275 280 285

Gly Ala Ala Leu Val
290

<210> 5
<211> 882
<212> DNA
<213> Delftia acidovorans

<400> 5
atggctcaga ctaccctgca gattaccccg actggtgcga ccctgggtgc aaccgttacc 60
ggcggttcacc tggcgactct ggatgacgca ggtttcgctg cgctgcacgc ggcttggtctg 120
caacatgctc tcttgatatt cccaggtcag cacctgtcca acgaccagca aatcactttt 180
gcaaaacgct tcggtgcatc cgaacgtatc ggtggcggtg atattgtggc gatctccaac 240
gtaaaagcgg atggtactgt acgtcagcac agcccggcgg agtgggacga tatgatgaag 300
gtgatcgtag gcaacatggc atggcatgct gacagcacct acatgccggg tatggcgag 360
ggtgcggttt tctctgctga agtggttccg gcagtgggag gtcgcacctg cttcgcagac 420

atgcgtgcag cttacgacgc gttagacgaa gctacccgcg cactggtaca ccagcgtctt 480
gcgcgtcact ctctggtgta ttcccagagc aaactggggc acgttcagca agcgggctcc 540
gcataatcgc gctacggtat ggataccact gcgacccgcg tgcgtccgct ggtaaaagtg 600
catccgaaaa ccggccgtcc gtctctcctg atcggcgcgc acgctcatgc gattccgggt 660
atggacgcgg cagaatccga gcgtttcctg gaaggtctgg ttgattgggc ttgtcaggcg 720
ccgcgtgtgc atgctacca gtgggcagct ggcgacgtgg ttgtatggga taaccgctgc 780
ctgcttcacc gtgcagaacc gtgggacttt aagctgccac gtgttatgtg gcacagccgt 840
ctggcaggcc gcccagaaac cgagggcgcg gctctggttt aa 882

<210> 6
<211> 16
<212> DNA
<213> Artificial sequence

<220>
<223> Chemically synthesized M13 forward sequencing primer

<400> 6
gtaaaacgac ggccag 16

<210> 7
<211> 17
<212> DNA
<213> Artificial sequence

<220>
<223> Chemically synthesized M13 reverse sequencing primer

<400> 7
caggaaacag ctatgac 17

<210> 8
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Chemically synthesized forward AAD-12 (v1) PTU primer

<400> 8
gaacagttag acatggtcta aagg 24

<210> 9
<211> 27
<212> DNA
<213> Artificial sequence

<220>
 <223> Chemically synthesized reverse AAD-12 (v1) PTU primer

<400> 9
 gctgcaacac tgataaatgc caactgg 27

<210> 10
 <211> 22
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Chemically synthesized forward AAD-12 (v1) coding PCR primer

<400> 10
 atggctcaga ccactctcca aa 22

<210> 11
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Chemically synthesized reverse AAD-12 (v1) coding PCR primer

<400> 11
 agctgcatcc atgccaggga 20

<210> 12
 <211> 22
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Chemically synthesized SdpacodF: AAD-12 (v1) forward coding region primer

<400> 12
 atggctcatg ctgccctcag cc 22

<210> 13
 <211> 22
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Chemically synthesized SdpacodR: AAD-12 (v1) reverse coding region primer

<400> 13
 cgggcaggcc taactccacc aa 22

<210> 14
 <211> 32
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Chemically synthesized primer "NcoI of Brady"

 <400> 14
 tataccacat gtcgatcgcc atccggcagc tt 32

 <210> 15
 <211> 33
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Chemically synthesized primer "SacI of Brady"

 <400> 15
 gagctcctat cactccgccg cctgctgctg cac 33

 <210> 16
 <211> 34
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Primer brjap 5'(speI)

 <400> 16
 actagtaaca aagaaggaga tataccatga cgat 34

 <210> 17
 <211> 33
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Primer br jap 3' (xhoI)

 <400> 17
 ttctcgagct atcactccgc cgctgctgc tgc 33

=====
Sequence Listing was accepted.
See attached Validation Report.
If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).
Reviewer: Durreshwar Anjum
Timestamp: [year=2012; month=10; day=18; hr=14; min=41; sec=42; ms=767;
]
=====

=====
Sequence Listing was accepted.
See attached Validation Report.
If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).
Reviewer: Durreshwar Anjum
Timestamp: [year=2012; month=10; day=18; hr=14; min=41; sec=13; ms=491;
]
=====

Application No: 13647081 Version No: 1.0

Input Set:

Output Set:

Started: 2012-10-08 16:38:09.715
 Finished: 2012-10-08 16:38:10.986
 Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 271 ms
 Total Warnings: 17
 Total Errors: 1
 No. of SeqIDs Defined: 17
 Actual SeqID Count: 17

Error code	Error Description
E 201	Mandatory field data missing in <140>
W 402	Undefined organism found in <213> in SEQ ID (1)
W 402	Undefined organism found in <213> in SEQ ID (2)
W 402	Undefined organism found in <213> in SEQ ID (3)
W 402	Undefined organism found in <213> in SEQ ID (4)
W 402	Undefined organism found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)

SEQUENCE LISTING

<110> Wright, Terry R.
Lira, Justin M.
Walsh, Terence A.
Merlo, Donald J.
Jayakumar, Pon Samuel
Lin, Gaofeng

<120> Novel Herbicide Resistance Genes

<130> DAS-P0129-02-US-e

<140> US 13/647,081

<141> 2012-10-08

<150> US 60/731,044

<151> 2005-10-28

<150> PCT/US2006/042133

<151> 2006-10-27

<160> 17

<170> PatentIn version 3.3

<210> 1

<211> 879

<212> DNA

<213> Delftia acidovorans

<400> 1

atgcagacga cgctgcagat tccccccaca ggcgccaccc tgggcgccac cgtcaccggc	60
gtgcacctgg ccacgctgga cgacgcgggc ttgcgcgcc tgcacgcgc ctggtgcag	120
catgcctgc tgatcttccc cggccagcac ctacagcaac accagcagat cacttttgcc	180
aaacgcttcg gcgcgatcga gcgcctcggc ggcggcgaca tcgtggccat ctccaatgtc	240
aaggccgatg gcacggtgcg ccagcacagc cccgccgagt gggacgacat gatgaaggtc	300
atcgtcggca acatggcctg gcatgccgac agcacctaca tgccggtgat ggcgcagggc	360
gcggtgttct cggccgaagt ggtgcccgca gtgggcgggc gcacctgctt cgccgacatg	420
cgcgcgcct acgacgcgt ggacgaggcc accgcgcgcc tgggtcacca gcgctcggcg	480
cggcattcgc tgggtgattc gcagagcaag ctgggccatg tgcagcaggc cggctcggcc	540
tacatcggt acggcatgga caccaccgcc acgccccctgc gcccgctggt caaggtgcat	600
cccgagaccg gcgcgccctc gctgctgata ggccgccatg cccatgccat cccgggcatg	660
gacgcgcgcg aatccgagcg ctctctggaa ggctggctg actgggcctg ccaggcgccg	720
cgggtgcatg cccaccaatg ggcgcgcggc gacgtggtgg tgtgggacaa ccgctgctg	780

ctgcaccgcg ccgagccctg ggatttcaag ctgccgcggg tgatgtggca cagccgectg 840

gccggccgcc ccgagaccga gggcgccgcc ctggtgtaa 879

<210> 2

<211> 292

<212> PRT

<213> Delftia acidovorans

<400> 2

Met Gln Thr Thr Leu Gln Ile Thr Pro Thr Gly Ala Thr Leu Gly Ala
1 5 10 15

Thr Val Thr Gly Val His Leu Ala Thr Leu Asp Asp Ala Gly Phe Ala
20 25 30

Ala Leu His Ala Ala Trp Leu Gln His Ala Leu Leu Ile Phe Pro Gly
35 40 45

Gln His Leu Ser Asn Asp Gln Gln Ile Thr Phe Ala Lys Arg Phe Gly
50 55 60

Ala Ile Glu Arg Ile Gly Gly Gly Asp Ile Val Ala Ile Ser Asn Val
65 70 75 80

Lys Ala Asp Gly Thr Val Arg Gln His Ser Pro Ala Glu Trp Asp Asp
85 90 95

Met Met Lys Val Ile Val Gly Asn Met Ala Trp His Ala Asp Ser Thr
100 105 110

Tyr Met Pro Val Met Ala Gln Gly Ala Val Phe Ser Ala Glu Val Val
115 120 125

Pro Ala Val Gly Gly Arg Thr Cys Phe Ala Asp Met Arg Ala Ala Tyr
130 135 140

Asp Ala Leu Asp Glu Ala Thr Arg Ala Leu Val His Gln Arg Ser Ala
145 150 155 160

Arg His Ser Leu Val Tyr Ser Gln Ser Lys Leu Gly His Val Gln Gln
165 170 175

Ala Gly Ser Ala Tyr Ile Gly Tyr Gly Met Asp Thr Thr Ala Thr Pro

180 185 190
 Leu Arg Pro Leu Val Lys Val His Pro Glu Thr Gly Arg Pro Ser Leu
 195 200 205

 Leu Ile Gly Arg His Ala His Ala Ile Pro Gly Met Asp Ala Ala Glu
 210 215 220

 Ser Glu Arg Phe Leu Glu Gly Leu Val Asp Trp Ala Cys Gln Ala Pro
 225 230 235 240

 Arg Val His Ala His Gln Trp Ala Ala Gly Asp Val Val Val Trp Asp
 245 250 255

 Asn Arg Cys Leu Leu His Arg Ala Glu Pro Trp Asp Phe Lys Leu Pro
 260 265 270

 Arg Val Met Trp His Ser Arg Leu Ala Gly Arg Pro Glu Thr Glu Gly
 275 280 285

 Ala Ala Leu Val
 290

<210> 3
 <211> 882
 <212> DNA
 <213> Delftia acidovorans

<400> 3
 atggctcaga ccactctcca aatcacaccc actggtgcc ccttgggtgc cacagtcact 60

 ggtgttcacc ttgccacact tgacgatgct ggtttcgctg ccctccatgc agcctggcctt 120

 caacatgcac tcttgatctt ccttgggcaa cacctcagca atgaccaaca gattaccttt 180

 gctaaacgct ttggagcaat tgagaggatt ggcggagggtg acattgttgc catatccaat 240

 gtcaaggcag atggcacagt gcgccagcac tctcctgctg agtgggatga catgatgaag 300

 gtcattgtgg gcaacatggc ctggcacgcc gactcaacct acatgccagt catggctcaa 360

 ggagctgtgt tcagcgcaga agttgtccca gcagttgggg gcagaacctg ctttgetgac 420

 atgagggcag cctacgatgc ctttgatgag gcaaccctgt ctcttgttca ccaaaggctct 480

 gctcgtcact cccttgtgta ttctcagagc aagttgggac atgtccaaca ggccgggtca 540

 gcctacatag gttatggcat ggacaccact gcaactctc tcagaccatt ggtcaagggtg 600

catcctgaga ctggaaggcc cagcctcttg atcgcccgcc atgcccatgc catccctggc 660
atggatgcag ctgaatcaga gcgcttcctt gaaggacttg ttgactgggc ctgccagget 720
cccagagtcc atgctcacca atgggctgct ggagatgtgg ttgtgtggga caaccgctgt 780
ttgctccacc gtgctgagcc ctgggatttc aagttgccac gtgtgatgtg gcactecaga 840
ctcgctggac gccacagaaac tgagggtgct gccttggttt ga 882

<210> 4
<211> 293
<212> PRT
<213> Delftia acidovorans

<400> 4

Met Ala Gln Thr Thr Leu Gln Ile Thr Pro Thr Gly Ala Thr Leu Gly
1 5 10 15

Ala Thr Val Thr Gly Val His Leu Ala Thr Leu Asp Asp Ala Gly Phe
20 25 30

Ala Ala Leu His Ala Ala Trp Leu Gln His Ala Leu Leu Ile Phe Pro
35 40 45

Gly Gln His Leu Ser Asn Asp Gln Gln Ile Thr Phe Ala Lys Arg Phe
50 55 60

Gly Ala Ile Glu Arg Ile Gly Gly Gly Asp Ile Val Ala Ile Ser Asn
65 70 75 80

Val Lys Ala Asp Gly Thr Val Arg Gln His Ser Pro Ala Glu Trp Asp
85 90 95

Asp Met Met Lys Val Ile Val Gly Asn Met Ala Trp His Ala Asp Ser
100 105 110

Thr Tyr Met Pro Val Met Ala Gln Gly Ala Val Phe Ser Ala Glu Val
115 120 125

Val Pro Ala Val Gly Gly Arg Thr Cys Phe Ala Asp Met Arg Ala Ala
130 135 140

Tyr Asp Ala Leu Asp Glu Ala Thr Arg Ala Leu Val His Gln Arg Ser
145 150 155 160

Ala Arg His Ser Leu Val Tyr Ser Gln Ser Lys Leu Gly His Val Gln
165 170 175

Gln Ala Gly Ser Ala Tyr Ile Gly Tyr Gly Met Asp Thr Thr Ala Thr
180 185 190

Pro Leu Arg Pro Leu Val Lys Val His Pro Glu Thr Gly Arg Pro Ser
195 200 205

Leu Leu Ile Gly Arg His Ala His Ala Ile Pro Gly Met Asp Ala Ala
210 215 220

Glu Ser Glu Arg Phe Leu Glu Gly Leu Val Asp Trp Ala Cys Gln Ala
225 230 235 240

Pro Arg Val His Ala His Gln Trp Ala Ala Gly Asp Val Val Val Trp
245 250 255

Asp Asn Arg Cys Leu Leu His Arg Ala Glu Pro Trp Asp Phe Lys Leu
260 265 270

Pro Arg Val Met Trp His Ser Arg Leu Ala Gly Arg Pro Glu Thr Glu
275 280 285

Gly Ala Ala Leu Val
290

<210> 5
<211> 882
<212> DNA
<213> Delftia acidovorans

<400> 5
atggctcaga ctaccctgca gattaccccg actggtgcga ccctgggtgc aaccgttacc 60
ggcggttcacc tggcgactct ggatgacgca ggtttcgctg cgctgcacgc ggcttggtctg 120
caacatgctc tcctgatattt ccaggtcag cacctgtcca acgaccagca aatcactttt 180
gcaaaacgct tcggtgcat cgaacgtatc ggtggcggtg atattgtggc gatctccaac 240
gtaaaagcgg atggtactgt acgtcagcac agcccggcgg agtgggacga tatgatgaag 300
gtgatcgtag gcaacatggc atggcatgct gacagcacct acatgccggg tatggcgag 360
ggtgcggttt tctctgctga agtggttccg gcagtgggag gtcgcacctg ettcgcagac 420

atgcgtgcag cttacgacgc gttagacgaa gctacccgcg cactggtaca ccagcgtctt 480
gcgcgtcact ctctggtgta ttcccagagc aaactggggc acgttcagca agcgggctcc 540
gcataatcgc gctacggtat ggataccact gcgacccgcg tgcgtccgct ggtaaaagtg 600
catccgaaaa ccggccgtcc gtctctcctg atcggcgcgc acgctcatgc gattccgggt 660
atggacgcgg cagaatccga gcgtttcctg gaaggtctgg ttgattgggc ttgtcaggcg 720
ccgcgtgtgc atgctacca gtgggcagct ggcgacgtgg ttgtatggga taaccgctgc 780
ctgcttcacc gtgcagaacc gtgggacttt aagctgccac gtgttatgtg gcacagccgt 840
ctggcaggcc gcccagaaac cgagggcgcg gctctggttt aa 882

<210> 6
<211> 16
<212> DNA
<213> Artificial sequence

<220>
<223> Chemically synthesized M13 forward sequencing primer

<400> 6
gtaaaacgac ggccag 16

<210> 7
<211> 17
<212> DNA
<213> Artificial sequence

<220>
<223> Chemically synthesized M13 reverse sequencing primer

<400> 7
caggaaacag ctatgac 17

<210> 8
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Chemically synthesized forward AAD-12 (v1) PTU primer

<400> 8
gaacagttag acatggtcta aagg 24

<210> 9
<211> 27
<212> DNA
<213> Artificial sequence

<220>
 <223> Chemically synthesized reverse AAD-12 (v1) PTU primer

<400> 9
 gctgcaacac tgataaatgc caactgg 27

<210> 10
 <211> 22
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Chemically synthesized forward AAD-12 (v1) coding PCR primer

<400> 10
 atggctcaga ccactctcca aa 22

<210> 11
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Chemically synthesized reverse AAD-12 (v1) coding PCR primer

<400> 11
 agctgcatcc atgccaggga 20

<210> 12
 <211> 22
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Chemically synthesized SdpacodF: AAD-12 (v1) forward coding region primer

<400> 12
 atggctcatg ctgccctcag cc 22

<210> 13
 <211> 22
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Chemically synthesized SdpacodR: AAD-12 (v1) reverse coding region primer

<400> 13
 cgggcaggcc taactccacc aa 22

<210> 14
<211> 32
<212> DNA
<213> Artificial sequence

<220>
<223> Chemically synthesized primer "NcoI of Brady"

<400> 14
tataccacat gtcgatcgcc atccggcagc tt 32

<210> 15
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> Chemically synthesized primer "SacI of Brady"

<400> 15
gagctcctat cactccgccg cctgctgctg cac 33

<210> 16
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer brjap 5'(speI)

<400> 16
actagtaaca aagaaggaga tataccatga cgat 34

<210> 17
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer br jap 3' (xhoI)

<400> 17
ttctcgagct atcactccgc cgctgctgc tgc 33

SEQUENCE LISTING

<110> Wright, Terry R.
Lira, Justin M.
Walsh, Terence A.
Merlo, Donald J.
Jayakumar, Pon Samuel
Lin, Gaofeng

<120> Novel Herbicide Resistance Genes

<130> DAS-P0129-02-US-e

<140> US 13/647,081

<141> 2012-10-08

<150> US 60/731,044

<151> 2005-10-28

<150> PCT/US2006/042133

<151> 2006-10-27

<160> 17

<170> PatentIn version 3.3

<210> 1

<211> 879

<212> DNA

<213> Delftia acidovorans

<400> 1

atgcagacga cgctgcagat tccccccaca ggcgccaccc tgggcgccac cgtcaccggc	60
gtgcacctgg ccacgctgga cgacgcgggc ttgcgcgcc tgcacgcgc ctggctgcag	120
catgcctgct tgatcttccc cggccagcac ctccagcaac accagcagat cacttttgcc	180
aaacgcttcg gcgcgatcga gcgcctcggc ggcggcgaca tcgtggccat ctccaatgtc	240
aaggccgatg gcacggtgct ccagcacagc cccgccgagt gggacgacat gatgaaggct	300
atcgtcggca acatggcctg gcatgccgac agcacctaca tgccggtgat ggcgcagggc	360
gcggtgttct cggccgaagt ggtgcccgca gtgggcgggc gcacctgctt cgccgacatg	420
cgcgcgcct acgacgcgct ggacgaggcc accgcgcgcc tgggtgcacca gcgctcggcg	480
cggcattcgc tgggtgtatt gcagagcaag ctgggccatg tgcagcaggc cggctcggcc	540
tacatcggt acggcatgga caccaccgcc acgccccctgc gcccgctggt caaggtgcat	600
cccgagaccg gcgcgccctc gctgctgata ggccgccatg cccatgccat cccgggcatg	660
gacgcgcgcg aatccgagcg ctctctggaa ggctggctg actgggcctg ccaggcgccg	720
cgggtgcatg cccaccaatg ggcgcgcggc gacgtggtgg tgtgggacaa ccgctgctg	780

ctgcaccgcg ccgagccctg ggatttcaag ctgccgcggg tgatgtggca cagccgectg 840

gccggccgcc ccgagaccga gggcgccgcc ctggtgtaa 879

<210> 2

<211> 292

<212> PRT

<213> Delftia acidovorans

<400> 2

Met Gln Thr Thr Leu Gln Ile Thr Pro Thr Gly Ala Thr Leu Gly Ala
1 5 10 15

Thr Val Thr Gly Val His Leu Ala Thr Leu Asp Asp Ala Gly Phe Ala
20 25 30

Ala Leu His Ala Ala Trp Leu Gln His Ala Leu Leu Ile Phe Pro Gly
35 40 45

Gln His Leu Ser Asn Asp Gln Gln Ile Thr Phe Ala Lys Arg Phe Gly
50 55 60

Ala Ile Glu Arg Ile Gly Gly Gly Asp Ile Val Ala Ile Ser Asn Val
65 70 75 80

Lys Ala Asp Gly Thr Val Arg Gln His Ser Pro Ala Glu Trp Asp Asp
85 90 95

Met Met Lys Val Ile Val Gly Asn Met Ala Trp His Ala Asp Ser Thr
100 105 110

Tyr Met Pro Val Met Ala Gln Gly Ala Val Phe Ser Ala Glu Val Val
115 120 125

Pro Ala Val Gly Gly Arg Thr Cys Phe Ala Asp Met Arg Ala Ala Tyr
130 135 140

Asp Ala Leu Asp Glu Ala Thr Arg Ala Leu Val His Gln Arg Ser Ala
145 150 155 160

Arg His Ser Leu Val Tyr Ser Gln Ser Lys Leu Gly His Val Gln Gln
165 170 175

Ala Gly Ser Ala Tyr Ile Gly Tyr Gly Met Asp Thr Thr Ala Thr Pro

180	185	190
Leu Arg Pro Leu Val Lys Val His Pro Glu Thr Gly Arg Pro Ser Leu		
195	200	205
Leu Ile Gly Arg His Ala His Ala Ile Pro Gly Met Asp Ala Ala Glu		
210	215	220
Ser Glu Arg Phe Leu Glu Gly Leu Val Asp Trp Ala Cys Gln Ala Pro		
225	230	235 240
Arg Val His Ala His Gln Trp Ala Ala Gly Asp Val Val Val Trp Asp		
245	250	255
Asn Arg Cys Leu Leu His Arg Ala Glu Pro Trp Asp Phe Lys Leu Pro		
260	265	270
Arg Val Met Trp His Ser Arg Leu Ala Gly Arg Pro Glu Thr Glu Gly		
275	280	285
Ala Ala Leu Val		
290		

<210> 3
 <211> 882
 <212> DNA
 <213> Delftia acidovorans

<400> 3	
atggctcaga ccactctcca aatcacaccc actggtgcc ccttgggtgc cacagtcaact	60
ggtgttcacc ttgccacact tgacgatgct ggtttcgctg ccctccatgc agcctggcctt	120
caacatgcac tcttgatctt ccttgggcaa cacctcagca atgaccaaca gattaccttt	180
gctaaacgct ttggagcaat tgagaggatt ggcggagggtg acattgttgc catatccaat	240
gtcaaggcag atggcacagt gcgccagcac tctctgctg agtgggatga catgatgaag	300
gtcattgtgg gcaacatggc ctggcacgcc gactcaacct acatgccagt catggctcaa	360
ggagctgtgt tcagcgcaga agttgtccca gcagttgggg gcagaacctg ctttgetgac	420
atgagggcag cctacgatgc ctttgatgag gcaaccctg ctcttgttca ccaaaggctct	480
gtcgtcact cccttgtgta ttctcagagc aagttgggac atgtccaaca ggccgggtca	540
gcctacatag gttatggcat ggacaccact gcaactctc tcagaccatt ggtcaagggtg	600

catcctgaga ctggaaggcc cagcctcttg atcgcccgcc atgcccattgc catccctggc 660
atggatgcag ctgaatcaga gcgcttcctt gaaggacttg ttgactgggc ctgccaggct 720
cccagagtcc atgctcacca atgggctgct ggagatgtgg ttgtgtggga caaccgctgt 780
ttgctccacc gtgctgagcc ctgggatttc aagttgccac gtgtgatgtg gcactecaga 840
ctcgcgtggac gccacagaaac tgagggtgct gccttggttt ga 882

<210> 4
<211> 293
<212> PRT
<213> Delftia acidovorans

<400> 4

Met Ala Gln Thr Thr Leu Gln Ile Thr Pro Thr Gly Ala Thr Leu Gly
1 5 10 15

Ala Thr Val Thr Gly Val His Leu Ala Thr Leu Asp Asp Ala Gly Phe
20 25 30

Ala Ala Leu His Ala Ala Trp Leu Gln His Ala Leu Leu Ile Phe Pro
35 40 45

Gly Gln His Leu Ser Asn Asp Gln Gln Ile Thr Phe Ala Lys Arg Phe
50 55 60

Gly Ala Ile Glu Arg Ile Gly Gly Gly Asp Ile Val Ala Ile Ser Asn
65 70 75 80

Val Lys Ala Asp Gly Thr Val Arg Gln His Ser Pro Ala Glu Trp Asp
85 90 95

Asp Met Met Lys Val Ile Val Gly Asn Met Ala Trp His Ala Asp Ser
100 105 110

Thr Tyr Met Pro Val Met Ala Gln Gly Ala Val Phe Ser Ala Glu Val
115 120 125

Val Pro Ala Val Gly Gly Arg Thr Cys Phe Ala Asp Met Arg Ala Ala
130 135 140

Tyr Asp Ala Leu Asp Glu Ala Thr Arg Ala Leu Val His Gln Arg Ser
145 150 155 160

Ala Arg His Ser Leu Val Tyr Ser Gln Ser Lys Leu Gly His Val Gln
165 170 175

Gln Ala Gly Ser Ala Tyr Ile Gly Tyr Gly Met Asp Thr Thr Ala Thr
180 185 190

Pro Leu Arg Pro Leu Val Lys Val His Pro Glu Thr Gly Arg Pro Ser
195 200 205

Leu Leu Ile Gly Arg His Ala His Ala Ile Pro Gly Met Asp Ala Ala
210 215 220

Glu Ser Glu Arg Phe Leu Glu Gly Leu Val Asp Trp Ala Cys Gln Ala
225 230 235 240

Pro Arg Val His Ala His Gln Trp Ala Ala Gly Asp Val Val Val Trp
245 250 255

Asp Asn Arg Cys Leu Leu His Arg Ala Glu Pro Trp Asp Phe Lys Leu
260 265 270

Pro Arg Val Met Trp His Ser Arg Leu Ala Gly Arg Pro Glu Thr Glu
275 280 285

Gly Ala Ala Leu Val
290

<210> 5
<211> 882
<212> DNA
<213> Delftia acidovorans

<400> 5
atggctcaga ctaccctgca gattaccccg actggtgcga ccctgggtgc aaccgttacc 60
ggcggttcacc tggcgactct ggatgacgca ggtttcgctg cgctgcacgc ggcttggtctg 120
caacatgctc tcttgatatt cccaggtcag cacctgtcca acgaccagca aatcactttt 180
gcaaaacgct tcggtgcatc cgaacgtatc ggtggcggtg atattgtggc gatctccaac 240
gtaaaagcgg atggtactgt acgtcagcac agcccggcgg agtgggacga tatgatgaag 300
gtgatcgtag gcaacatggc atggcatgct gacagcacct acatgccggt tatggcgag 360
ggtgcggttt tctctgctga agtgggtccg gcagtgggag gtcgcacctg cttcgcagac 420

atgcgtgcag cttacgacgc gttagacgaa gctaccgcgc cactggtaca ccagcgcctct 480
gcgcgtcact ctctggtgta ttcccagagc aaactggggc acgttcagca agcgggctcc 540
gcataatcgc gctacggtat ggataccact gcgacccgcg tgcgtccgct ggtaaaagtg 600
catccgaaaa ccggccgtcc gtctctcctg atcggcgcgc acgctcatgc gattccgggt 660
atggacgcgg cagaatccga gcgtttcctg gaaggtctgg ttgattgggc ttgtcaggcg 720
ccgcgtgtgc atgctacca gtgggcagct ggcgacgtgg ttgtatggga taaccgctgc 780
ctgcttcacc gtgcagaacc gtgggacttt aagctgccac gtgttatgtg gcacagccgt 840
ctggcaggcc gcccagaaac cgagggcgcg gctctggttt aa 882

<210> 6
<211> 16
<212> DNA
<213> Artificial sequence

<220>
<223> Chemically synthesized M13 forward sequencing primer

<400> 6
gtaaaacgac ggccag 16

<210> 7
<211> 17
<212> DNA
<213> Artificial sequence

<220>
<223> Chemically synthesized M13 reverse sequencing primer

<400> 7
caggaaacag ctatgac 17

<210> 8
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Chemically synthesized forward AAD-12 (v1) PTU primer

<400> 8
gaacagttag acatggtcta aagg 24

<210> 9
<211> 27
<212> DNA
<213> Artificial sequence

<220>
 <223> Chemically synthesized reverse AAD-12 (v1) PTU primer

<400> 9
 gctgcaacac tgataaatgc caactgg 27

<210> 10
 <211> 22
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Chemically synthesized forward AAD-12 (v1) coding PCR primer

<400> 10
 atggctcaga ccactctcca aa 22

<210> 11
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Chemically synthesized reverse AAD-12 (v1) coding PCR primer

<400> 11
 agctgcatcc atgccaggga 20

<210> 12
 <211> 22
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Chemically synthesized SdpacodF: AAD-12 (v1) forward coding region primer

<400> 12
 atggctcatg ctgccctcag cc 22

<210> 13
 <211> 22
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Chemically synthesized SdpacodR: AAD-12 (v1) reverse coding region primer

<400> 13
 cgggcaggcc taactccacc aa 22

<210> 14
<211> 32
<212> DNA
<213> Artificial sequence

<220>
<223> Chemically synthesized primer "NcoI of Brady"

<400> 14
tataccacat gtcgatcgcc atccggcagc tt 32

<210> 15
<211> 33
<212> DNA
<213> Artificial sequence

<220>
<223> Chemically synthesized primer "SacI of Brady"

<400> 15
gagctcctat cactccgccg cctgctgctg cac 33

<210> 16
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer brjap 5'(speI)

<400> 16
actagtaaca aagaaggaga tataccatga cgat 34

<210> 17
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer br jap 3' (xhoI)

<400> 17
ttctcgagct atcactccgc cgctgctgc tgc 33



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	TOT CLAIMS	IND CLAIMS
13/647,081	10/08/2012	1638	1710	DAS-P0129-03-US-E	20	3

CONFIRMATION NO. 1022

83067

Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204

FILING RECEIPT



OC000000057360801

Date Mailed: 11/02/2012

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections**

Inventor(s)

Terry R. Wright, Camel, IN;
Justin M. Lira, Zionsville, IN;
Terence Anthony Walsh, Zionsville, IN;
Donald Merto, Camel, IN;
Pon Samuel Jayakumar, Camel, IN;
Gaofeng Lin, Zionsville, IN;

Applicant(s)

Dow AgroSciences LLC, Indianapolis, IN

Assignment For Published Patent Application

Dow AgroSciences LLC, Indianapolis, IN

Power of Attorney: None

Domestic Priority data as claimed by applicant

This application is a CON of 12/091,896 11/03/2008 PAT 8283522
which is a 371 of PCT/US06/42133 10/27/2006
which claims benefit of 60/731,044 10/28/2005

Foreign Applications (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see <http://www.uspto.gov> for more information.)

If Required, Foreign Filing License Granted: 10/23/2012

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 13/647,081**

Projected Publication Date: 02/07/2013

page 1 of 3

Non-Publication Request: No

Early Publication Request: No
Title

NOVEL HERBICIDE RESISTANCE GENES

Preliminary Class

800

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage, facilitate, and accelerate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875						Application or Docket Number 13/647,081				
APPLICATION AS FILED - PART I										
(Column 1)		(Column 2)		SMALL ENTITY		OR OTHER THAN SMALL ENTITY				
FOR	NUMBER FILED	NUMBER EXTRA	RATE(\$)	FEE(\$)		RATE(\$)	FEE(\$)			
BASIC FEE <small>(37 CFR 1.16(a), (b), or (c))</small>	N/A	N/A	N/A			N/A	390			
SEARCH FEE <small>(37 CFR 1.16(k), (l), or (m))</small>	N/A	N/A	N/A			N/A	620			
EXAMINATION FEE <small>(37 CFR 1.16(o), (p), or (q))</small>	N/A	N/A	N/A			N/A	250			
TOTAL CLAIMS <small>(37 CFR 1.16(i))</small>	20	minus 20 = *				x 62 =	0.00			
INDEPENDENT CLAIMS <small>(37 CFR 1.16(h))</small>	3	minus 3 = *				x 250 =	0.00			
APPLICATION SIZE FEE <small>(37 CFR 1.16(s))</small>	If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).						320			
MULTIPLE DEPENDENT CLAIM PRESENT <small>(37 CFR 1.16(j))</small>							0.00			
			TOTAL			TOTAL	1580			
* If the difference in column 1 is less than zero, enter "0" in column 2.										
APPLICATION AS AMENDED - PART II										
(Column 1)		(Column 2)		(Column 3)		SMALL ENTITY		OR OTHER THAN SMALL ENTITY		
AMENDMENT A		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE(\$)	ADDITIONAL FEE(\$)		RATE(\$)	ADDITIONAL FEE(\$)
	Total <small>(37 CFR 1.16(i))</small>	*	Minus	**	=	x	=		x	=
	Independent <small>(37 CFR 1.16(h))</small>	*	Minus	***	=	x	=		x	=
	Application Size Fee <small>(37 CFR 1.16(s))</small>									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM <small>(37 CFR 1.16(j))</small>									
						TOTAL ADD'L FEE			TOTAL ADD'L FEE	
AMENDMENT B		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE(\$)	ADDITIONAL FEE(\$)		RATE(\$)	ADDITIONAL FEE(\$)
	Total <small>(37 CFR 1.16(i))</small>	*	Minus	**	=	x	=		x	=
	Independent <small>(37 CFR 1.16(h))</small>	*	Minus	***	=	x	=		x	=
	Application Size Fee <small>(37 CFR 1.16(s))</small>									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM <small>(37 CFR 1.16(j))</small>									
						TOTAL ADD'L FEE			TOTAL ADD'L FEE	
* If the entry in column 1 is less than the entry in column 2, write "0" in column 3. ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20". *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest Number Previously Paid For" (Total or Independent) is the highest found in the appropriate box in column 1.										



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
13/647,081	10/08/2012	Terry R. Wright	DAS-P0129-03-US-E

CONFIRMATION NO. 1022

83067

Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204

NOTICE



Date Mailed: 11/02/2012

INFORMATIONAL NOTICE TO APPLICANT

Applicant is notified that the above-identified application contains the deficiencies noted below. No period for reply is set forth in this notice for correction of these deficiencies. However, if a deficiency relates to the inventor's oath or declaration, the applicant must file an oath or declaration in compliance with 37 CFR 1.63, or a substitute statement in compliance with 37 CFR 1.64, executed by or with respect to each actual inventor no later than the expiration of the time period set in the "Notice of Allowability" to avoid abandonment. See 37 CFR 1.53(f).

The item(s) indicated below are also required and should be submitted with any reply to this notice to avoid further processing delays.

- A properly executed inventor's oath or declaration has not been received for the following inventor(s):
all

Applicant may submit the inventor's oath or declaration at any time before the Notice of Allowance and Fee(s) Due, PTOL-85, is mailed.

To: inteas@faegrebd.com,cynthia.payson@faegrebd.com,
From: PAIR_eOfficeAction@uspto.gov
Cc: PAIR_eOfficeAction@uspto.gov
Subject: Private PAIR Correspondence Notification for Customer Number 83067

Nov 02, 2012 05:20:24 AM

Dear PAIR Customer:

Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204
UNITED STATES

The following USPTO patent application(s) associated with your Customer Number, 83067 , have new outgoing correspondence. This correspondence is now available for viewing in Private PAIR.

The official date of notification of the outgoing correspondence will be indicated on the form PTOL-90 accompanying the correspondence.

Disclaimer:

The list of documents shown below is provided as a courtesy and is not part of the official file wrapper. The content of the images shown in PAIR is the official record.

Application	Document	Mailroom Date	Attorney Docket No.
13647081	APP.FILE.REC	11/02/2012	DAS-P0129-03-US-E
	M327	11/02/2012	DAS-P0129-03-US-E

To view your correspondence online or update your email addresses, please visit us anytime at <https://sportal.uspto.gov/secure/myportal/privatepair>.

If you have any questions, please email the Electronic Business Center (EBC) at EBC@uspto.gov with 'e-Office Action' on the subject line or call 1-866-217-9197 during the following hours:

Monday - Friday 6:00 a.m. to 12:00 a.m.

Thank you for prompt attention to this notice,

UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT APPLICATION INFORMATION RETRIEVAL SYSTEM

Electronic Acknowledgement Receipt	
EFS ID:	13931247
Application Number:	13647081
International Application Number:	
Confirmation Number:	1022
Title of Invention:	NOVEL HERBICIDE RESISTANCE GENES
First Named Inventor/Applicant Name:	Terry R. Wright
Customer Number:	83067
Filer:	Jay M. Sanders/Lisa Schodrowski
Filer Authorized By:	Jay M. Sanders
Attorney Docket Number:	DAS-P0129-03-US-E
Receipt Date:	08-OCT-2012
Filing Date:	
Time Stamp:	16:37:30
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes	10/23/2012 MTEKLEMT 00000061 020390 13647081
Payment Type	Deposit Account	01 FC:1051 130.00 DA
Payment was successfully received in RAM	\$1260	
RAM confirmation Number	19716	
Deposit Account	020390	
Authorized User		
<p>The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)</p>		

Electronic Acknowledgement Receipt	
EFS ID:	13931247
Application Number:	13647081
International Application Number:	
Confirmation Number:	1022
Title of Invention:	NOVEL HERBICIDE RESISTANCE GENES
First Named Inventor/Applicant Name:	Terry R. Wright
Customer Number:	83067
Filer:	Jay M. Sanders/Lisa Schodrowski
Filer Authorized By:	Jay M. Sanders
Attorney Docket Number:	DAS-P0129-03-US-E
Receipt Date:	08-OCT-2012
Filing Date:	
Time Stamp:	16:37:30
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes	10/29/2012 MTEKLEMI 00000006 020390 13647081
Payment Type	Deposit Account	01 FC:1081 320.00 DA
Payment was successfully received in RAM	\$1260	
RAM confirmation Number	19716	
Deposit Account	020390	
Authorized User		
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)		

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875					Application or Docket Number 13/647,081		Filing Date 10/08/2012		☐ To be Mailed	
APPLICATION AS FILED – PART I										
(Column 1)			(Column 2)			SMALL ENTITY ☐ OR		OTHER THAN SMALL ENTITY		
FOR	NUMBER FILED	NUMBER EXTRA	RATE (\$)	FEE (\$)	OR	RATE (\$)	FEE (\$)			
☒ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A			N/A	390			
☒ SEARCH FEE (37 CFR 1.16(k), (j), or (m))	N/A	N/A	N/A			N/A	620			
☒ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A			N/A	250			
TOTAL CLAIMS (37 CFR 1.16(i))	20 minus 20 =	* 0	X \$ =		OR	X \$62 =	0			
INDEPENDENT CLAIMS (37 CFR 1.16(h))	3 minus 3 =	* 0	X \$ =			X \$250 =	0			
☒ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).						320			
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))										
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL			TOTAL	1580			
APPLICATION AS AMENDED – PART II										
(Column 1)			(Column 2)			SMALL ENTITY OR		OTHER THAN SMALL ENTITY		
AMENDMENT	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE (\$)	ADDITIONAL FEE (\$)	OR	RATE (\$)	ADDITIONAL FEE (\$)		
	Total (37 CFR 1.16(i))	*	Minus	**	=		X \$ =			
	Independent (37 CFR 1.16(h))	*	Minus	***	=		X \$ =			
	☐ Application Size Fee (37 CFR 1.16(s))									
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))									
			TOTAL ADD'L FEE			OR	TOTAL ADD'L FEE			
(Column 1)			(Column 2)			SMALL ENTITY OR		OTHER THAN SMALL ENTITY		
AMENDMENT	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE (\$)	ADDITIONAL FEE (\$)	OR	RATE (\$)	ADDITIONAL FEE (\$)		
	Total (37 CFR 1.16(i))	*	Minus	**	=		X \$ =			
	Independent (37 CFR 1.16(h))	*	Minus	***	=		X \$ =			
	☐ Application Size Fee (37 CFR 1.16(s))									
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))									
			TOTAL ADD'L FEE			OR	TOTAL ADD'L FEE			
<p>* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.</p> <p>** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".</p> <p>*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".</p> <p>The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.</p>										

Legal Instrument Examiner:
/EVA GILLIS/

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
13/647,081	10/08/2012	Terry R. Wright	DAS-P0129-03-US-E

CONFIRMATION NO. 1022

PUBLICATION NOTICE



OC000000059153829

83067
Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204

Title:NOVEL HERBICIDE RESISTANCE GENES

Publication No.US-2013-0035233-A1

Publication Date:02/07/2013

NOTICE OF PUBLICATION OF APPLICATION

The above-identified application will be electronically published as a patent application publication pursuant to 37 CFR 1.211, et seq. The patent application publication number and publication date are set forth above.

The publication may be accessed through the USPTO's publicly available Searchable Databases via the Internet at www.uspto.gov. The direct link to access the publication is currently <http://www.uspto.gov/patft/>.

The publication process established by the Office does not provide for mailing a copy of the publication to applicant. A copy of the publication may be obtained from the Office upon payment of the appropriate fee set forth in 37 CFR 1.19(a)(1). Orders for copies of patent application publications are handled by the USPTO's Office of Public Records. The Office of Public Records can be reached by telephone at (703) 308-9726 or (800) 972-6382, by facsimile at (703) 305-8759, by mail addressed to the United States Patent and Trademark Office, Office of Public Records, Alexandria, VA 22313-1450 or via the Internet.

In addition, information on the status of the application, including the mailing date of Office actions and the dates of receipt of correspondence filed in the Office, may also be accessed via the Internet through the Patent Electronic Business Center at www.uspto.gov using the public side of the Patent Application Information and Retrieval (PAIR) system. The direct link to access this status information is currently <http://pair.uspto.gov/>. Prior to publication, such status information is confidential and may only be obtained by applicant using the private side of PAIR.

Further assistance in electronically accessing the publication, or about PAIR, is available by calling the Patent Electronic Business Center at 1-866-217-9197.

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

To: inteas@faegrebd.com,cynthia.payson@faegrebd.com,
From: PAIR_eOfficeAction@uspto.gov
Cc: PAIR_eOfficeAction@uspto.gov
Subject: Private PAIR Correspondence Notification for Customer Number 83067

Feb 08, 2013 05:38:33 AM

Dear PAIR Customer:

Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204
UNITED STATES

The following USPTO patent application(s) associated with your Customer Number, 83067 , have new outgoing correspondence. This correspondence is now available for viewing in Private PAIR.

The official date of notification of the outgoing correspondence will be indicated on the form PTOL-90 accompanying the correspondence.

Disclaimer:

The list of documents shown below is provided as a courtesy and is not part of the official file wrapper. The content of the images shown in PAIR is the official record.

Application	Document	Mailroom Date	Attorney Docket No.
13647081	NTC.PUB	02/07/2013	DAS-P0129-03-US-E

To view your correspondence online or update your email addresses, please visit us anytime at <https://sportal.uspto.gov/secure/myportal/privatepair>.

If you have any questions, please email the Electronic Business Center (EBC) at EBC@uspto.gov with 'e-Office Action' on the subject line or call 1-866-217-9197 during the following hours:

Monday - Friday 6:00 a.m. to 12:00 a.m.

Thank you for prompt attention to this notice,

UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT APPLICATION INFORMATION RETRIEVAL SYSTEM



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/647,081	10/08/2012	Terry R. Wright	DAS-P0129-03-US-E	1022
83067	7590	03/01/2013		
Faegre Baker Daniels LLP- Dow AgroSciences 300 North Meridian Street, Suite 2700 Indianapolis, IN 46204			EXAMINER KRUSE, DAVID H	
			ART UNIT 1638	PAPER NUMBER
			NOTIFICATION DATE 03/01/2013	DELIVERY MODE ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

intcas@faegrebd.com
cynthia.payson@faegrebd.com

Office Action Summary	Application No.	Applicant(s)	
	13/647,081	WRIGHT ET AL.	
	Examiner	Art Unit	
	DAVID H. KRUSE	1638	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on ____; the restriction requirement and election have been incorporated into this action.
- 4) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 5) ☒ Claim(s) 1-20 is/are pending in the application.
- 5a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 6) ☐ Claim(s) ____ is/are allowed.
- 7) ☒ Claim(s) 1-20 is/are rejected.
- 8) ☐ Claim(s) ____ is/are objected to.
- 9) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.

Application Papers

- 10) ☒ The specification is objected to by the Examiner.
- 11) ☒ The drawing(s) filed on 08 October 2012 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) ☒ Notice of References Cited (PTO-892) | 3) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____. |
| 2) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date ____. | 4) ☐ Other: ____. |

DETAILED ACTION

Information Disclosure Statement

1. The listing of references on pages 136-143 of the specification is not a proper information disclosure statement. 37 CFR § 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered.

Specification

2. The disclosure is objected to because of the following informalities:

Figure 2 fails to comply with the Sequence Rules because said figure does not contain sequence identifiers, nor does the brief description on page 7 of the specification.

Appropriate correction is required.

Claim Objections

3. The claim 17 is objected to because of the following informalities: Claim 17 depends from itself, the claim appears to depend from claim 16. Appropriate correction is required.

Claim Rejections - 35 USC § 112

4. The following is a quotation of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.

The following is a quotation of 35 U.S.C. 112 (pre-AIA), first paragraph:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claim 14 is rejected under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Applicant claims a transgenic plant cell comprising a recombinant polynucleotide that encodes a protein having an activity that catalyzes degradation of a herbicidal compound selected from a phenoxypropionic auxin and a phenoxyacetic auxin, and further comprising an “output trait”.

Applicant does not describe any “output trait” as the limitation “output trait” lacks antecedence in the instant specification.

Hence, it is unclear that Applicant had possession of the invention as claimed.

6. The following is a quotation of 35 U.S.C. 112(b):

(B) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.

The following is a quotation of 35 U.S.C. 112 (pre-AIA), second paragraph:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

7. Claim 14 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention.

The instant specification does not define or mention the limitation "output trait", and it unclear if the one of skill in the instant art would understand the metes and bounds of this limitation. Hence, the metes and bounds of the claim are unclear.

Claim Rejections - 35 USC § 103

8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

9. Claims 1-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kaphammer (U.S. Patent 5,608,147) in view of Schleinitz *et al* (September 2004, Applied and Environmental Microbiology 70(9): 5357-5365) and Pallett *et al* (U.S. Patent 7,250,561 B1, § 371(c)(1) date of 15 June 1998) and in further view of Malvar *et al* (U.S. Patent 6,645,497).

Kaphammer teaches a plant cell comprising a polynucleotide that encodes a protein having aryloxyalkanoate dioxygenase activity, resistance to 2,4-dichlorophenoxyacetate (2,4-D) at claim 11, and a plant regenerated therefrom at claim 15. Kaphammer teaches an isolated polynucleotide that encodes a protein having aryloxyalkanoate dioxygenase activity at SEQ ID NO: 1. Kaphammer teaches

Art Unit: 1638

transforming a soybean cell at Example 11, columns 21-22. Kaphammer teaches a method of controlling weeds by applying 2,4-D herbicide to a crop field at column 2, lines 26-28. Kaphammer teaches that a transgene that confers resistance to glyphosate can also be introduced into the plant cell (column 3, lines 11-6).

Kaphammer does not teach an isolated nucleic acid encoding instant SEQ ID NO: 2 or having the nucleotide sequence of instant SEQ ID NO: 1. Kaphammer does not teach introducing a polynucleotide that confers glufosinate resistance.

Schleinitz *et al* teach an isolated polynucleotide comprising instant SEQ ID NO: 1 at GenBank accession number AY327575 (page 5359, right column, 5th paragraph) encoding instant SEQ ID NO: 2 (RdpA). The encoded protein (see FIG 2 on page 5360) would naturally have aryloxyalkanoate dioxygenase activity. Schleinitz *et al* teach that RdpA degrades the herbicide dichlorprop to 2,4-DCP which is not herbicidal (Fig 1 on page 5358).

Pallett *et al* teach introducing polynucleotides to a transformed plant cell that renders said plant cell resistant to multiple herbicides including glyphosate (column 1, lines 62-64) and glufosinate (column 2, lines 27-29).

Malvar *et al* teach combining a recombinant Cry1A or Cry1F protein (claim 1) in combination with an herbicide resistance protein (claim 7). Malvar *et al* teach a transgenic plant which expresses a gene or gene segment encoding one or more of the novel polypeptide compositions disclosed (column 8, lines 43-59).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of Applicants' invention to modify the teachings of Kaphammer to introduce a

Art Unit: 1638

polynucleotide encoding instant SEQ ID NO: 2 as taught by Schleinitz *et al* in addition to a polynucleotide encoding resistance to glyphosate and glufosinate as suggested Pallett *et al*. The tdfA taught by Kaphammer and the RdpA taught by Schleinitz *et al* would be considered functional equivalents since both degrade chlorinated phenoxyalkanoic acid herbicides. Given the success of Pallett *et al*, and Kaphammer one of ordinary skill in the art would have had a reasonable expectation of success. Given dichlorprop was a known herbicide as taught by Schleinitz *et al* (page 5357, left column, 1st paragraph), one of ordinary skill in the art would have been motivated to introduce said polynucleotide encoding instant SEQ ID NO: 2 into a plant cell. Combining herbicide resistance with a Cry insect resistance would have been obvious in view of the teachings of Malvar *et al*.

The catalytic properties of the RdpA taught by Schleinitz *et al* would be a natural consequence of its structure. The method of instant claim 20 would appear to be obvious as a design choice since the herbicides sethoxydim and clethodim are lipid inhibitor herbicides that are selective for grasses. The method of instant claim 18 would appear to be obvious because grasses tend to be resistant to aryloxyalkanoate herbicides like 2,4-D, thus it would be obvious to control broadleaf weeds in a crop comprising plant cells of claim 1 if said plant cells are of a monocot.

Double Patenting

10. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent

Art Unit: 1638

and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

11. Claims 1-20 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-14 of U.S. Patent No. 8,283,522.

Although the conflicting claims are not identical, they are not patentably distinct from

Art Unit: 1638

each other because the instantly claimed invention would at least be a subgenus of the '522 patent.

Conclusion

12. No claims are allowed.

Notice of References Cited	Application/Control No. 13/647,081	Applicant(s)/Patent Under Reexamination WRIGHT ET AL.	
	Examiner DAVID H. KRUSE	Art Unit 1638	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-8,283,522	10-2012	Wright et al.	800/300
*	B	US-7,250,561	07-2007	Pallett et al.	800/300
*	C	US-5,608,147	03-1997	Kaphammer, Bryan J.	800/294
*	D	US-6,645,497	11-2003	Malvar et al.	424/184.1
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Schleinitz et al 2004, Applied and Environmental Microbiology 70(9): 5357-5365
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

EAST Search History**EAST Search History (Prior Art)**

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	5	((("5608147") or ("7205561"))).PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2013/02/20 13:26
L2	4	((("5608147") or ("7250561"))).PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2013/02/20 13:27
L3	290	plant and tfdA and herbicide	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2013/02/20 13:28
L4	42	plant and AAD-12 and herbicide	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2013/02/20 13:28

EAST Search History (Interference)

< This search history is empty >

2/ 20/ 2013 1:29:47 PM**C:\ Users\ dkruse\ Documents\ EAST\ Workspaces\ 13647081.wsp**

**Localization and Characterization of Two
Novel Genes Encoding Stereospecific
Dioxygenases Catalyzing
2(2,4-Dichlorophenoxy)propionate
Cleavage in *Delftia acidovorans* MC1**

**Kathleen M. Schleinitz, Sabine Kleinstaub, Tatiana
Vallaey and Wolfgang Babel**

***Appl. Environ. Microbiol.* 2004, 70(9):5357. DOI:
10.1128/AEM.70.9.5357-5365.2004.**

Updated information and services can be found at:
<http://aem.asm.org/content/70/9/5357>

These include:

REFERENCES

This article cites 57 articles, 24 of which can be accessed free
at: <http://aem.asm.org/content/70/9/5357#ref-list-1>

CONTENT ALERTS

Receive: RSS Feeds, eTOCs, free email alerts (when new
articles cite this article), [more»](#)

CORRECTIONS

An erratum has been published regarding this article. To view
this page, please click [here](#)

Information about commercial reprint orders: <http://journals.asm.org/site/misc/reprints.xhtml>
To subscribe to to another ASM Journal go to: <http://journals.asm.org/site/subscriptions/>

Journals.ASM.org

Localization and Characterization of Two Novel Genes Encoding Stereospecific Dioxygenases Catalyzing 2(2,4-Dichlorophenoxy)propionate Cleavage in *Delftia acidovorans* MC1

Kathleen M. Schleinitz,¹ Sabine Kleinstaubert,^{1*} Tatiana Vallaey,^{2,3} and Wolfgang Babel¹

Department of Environmental Microbiology, UFZ Centre for Environmental Research Leipzig-Halle, Leipzig, Germany,¹ and Institut National de la Recherche Agronomique² and Laboratoire de Génétique des Microorganismes Pathogène, Institut Pasteur,³ Paris, France

Received 11 March 2004/Accepted 20 May 2004

Two novel genes, *rdpA* and *sdpA*, encoding the enantiospecific α -ketoglutarate dependent dioxygenases catalyzing *R,S*-dichlorprop cleavage in *Delftia acidovorans* MC1 were identified. Significant similarities to other known genes were not detected, but their deduced amino acid sequences were similar to those of other α -ketoglutarate dioxygenases. RdpA showed 35% identity with TauD of *Pseudomonas aeruginosa*, and SdpA showed 37% identity with TfdA of *Ralstonia eutropha* JMP134. The functionally important amino acid sequence motif HX(D/E)X₂₃₋₂₆(T/S)X₁₁₄₋₁₈₃HX₁₀₋₁₃R/K, which is highly conserved in group II α -ketoglutarate-dependent dioxygenases, was present in both dichlorprop-cleaving enzymes. Transposon mutagenesis of *rdpA* inactivated *R*-dichlorprop cleavage, indicating that it was a single-copy gene. Both *rdpA* and *sdpA* were located on the plasmid pMC1 that also carries the lower pathway genes. Sequencing of a 25.8-kb fragment showed that the dioxygenase genes were separated by a 13.6-kb region mainly comprising a Tn501-like transposon. Furthermore, two copies of a sequence similar to IS91-like elements were identified. Hybridization studies comparing the wild-type plasmid and that of the mutant unable to cleave dichlorprop showed that *rdpA* and *sdpA* were deleted, whereas the lower pathway genes were unaffected, and that deletion may be caused by genetic rearrangements of the IS91-like elements. Two other dichlorprop-degrading bacterial strains, *Rhodospirillum rubrum* sp. strain P230 and *Sphingobium herbicidovorans* MH, were shown to carry *rdpA* genes of high similarity to *rdpA* from strain MC1, but *sdpA* was not detected. This suggested that *rdpA* gene products are involved in the degradation of *R*-dichlorprop in these strains.

Chlorinated phenoxyalkanoic acids such as 2,4-dichlorophenoxyacetate (2,4-D), 2-methyl-4-chlorophenoxyacetate (MCPA), 2(2,4-dichlorophenoxy)propionate (dichlorprop), and 2(2-methyl-4-chlorophenoxy)propionate (mecoprop) have been widely used as broad leaf herbicides since their introduction in the 1940s. The ability to degrade the phenoxyacetate herbicides is widespread among bacteria (16). In contrast, breakdown of the structurally very similar chiral phenoxypropionate derivatives is far less widespread, and only few strains able to mineralize these compounds have been described (9, 21, 30, 35, 42, 50).

Degradation of phenoxyalkanoate herbicides is initiated by the etherolytic cleavage of the side chain yielding the respective phenol (Fig. 1). Subsequently, conversion into intermediates of the tricarboxylic acid cycle takes place via the modified *ortho*-pathway (16). Side chain cleaving specificity is crucial and determines the range of substrates that can be mineralized by a given microorganism.

Thus far, two types of 2,4-D-cleaving enzymes have been described. In *Ralstonia eutropha* JMP134, 2,4-D cleavage is catalyzed by a well-studied Fe(II) and α -ketoglutarate (α KG)-dependent dioxygenase, which is encoded by *tfdA* (13, 20, 39, 45, 59). The presence of the functionally essential motif HX(D/

E)X₂₃₋₂₆(T/S)X₁₁₄₋₁₈₃HX₁₀₋₁₃R/K indicates that TfdA is related to several other (referred to as group II) α KG-dependent dioxygenases (18). Recently, a three-dimensional model of the active site was proposed (10) on the basis of predictions made from site-directed mutagenesis studies (20) and secondary structure predictions (10). The identity of the suggested substrate-binding residues was confirmed by site-directed mutagenesis and inactivation studies (8). The *tfdA* genes are widespread among bacteria (17, 31, 33, 36, 39, 42, 47, 53, 54, 55, 56), also among strains unable to degrade 2,4-D (19). Recently, several α -proteobacterial strains were shown to carry *tfdA* α genes, which are *tfdA*-like, showing between 46 and 60% nucleotide identity to the canonical *tfdA* genes and forming a phylogenetic clade distinct from *tfdA* (22, 23). Three other genes, clustered as *cadABC*, were found to encode a second type of 2,4-D-cleaving enzyme, a putative monooxygenase responsible for 2,4-D cleavage in *Bradyrhizobium* sp. strain HW13 (24).

Studies on *Sphingobium* (formerly *Sphingomonas* [48]) *herbicidovorans* MH and *Delftia acidovorans* MC1 indicated that enantiospecific dichlorprop and mecoprop cleavage is catalyzed by Fe(II)- and α KG-dependent dioxygenases (35, 38). The enzymes have been biochemically characterized (34, 38, 57, 58), but no data regarding the genetic background are yet available. Thus far, the dioxygenases have been assumed to be *tfdA* gene products (39), because some dichlorprop- and mecoprop-degrading strains carry *tfdA* genes (36, 39) and cell extracts of *R. eutropha* strain JMP134 showed some specificity

* Corresponding author. Mailing address: UFZ Centre for Environmental Research Leipzig-Halle, Department of Environmental Microbiology, Permoserstr. 15, 04318 Leipzig, Germany. Phone: 49-341-235-2191. Fax: 49-341-235-2247. E-mail: sabine.kleinstaubert@ufz.de.




FIG. 1. Modified *ortho*-pathway for the degradation of chlorinated phenoxyalkanoate herbicides. 2,4-D, 2,4-dichlorophenoxyacetate; R-DP and S-DP, *R*- and *S*-enantiomers of 2(2,4-dichlorophenoxy)propionate, respectively; 2,4-DCP, 2,4-dichlorophenol; 3,5-DCC, 3,5-dichlorocatechol; TCA, tricarboxylate.

toward cleaving *S*-dichlorprop (39). However, no activity for *S*-mecoprop or the *R*-enantiomers was detected in strain JMP134, and the organism was unable to grow on phenoxypropionate herbicides. Recently, available N-terminal and internal amino acid sequences of the enantiospecific dioxygenases from *D. acidovorans* MC1 showed only low similarities to TfdA enzymes (57), and *tfdA* genes were not detected in this strain (36). This suggested that genes other than *tfdA* are involved in dichlorprop degradation in strain MC1.

In *D. acidovorans* MC1 the first step in dichlorprop degradation was found to be highly unstable and easily lost under nonselective conditions (36). Loss of dichlorprop-cleaving activity was correlated with a deletion in the plasmid pMC1, and it was therefore hypothesized that the deleted fragment contains the genes encoding dichlorprop cleavage (36).

Based on the recently available peptide sequences of the *R*- and *S*-dichlorprop-cleaving dioxygenases, we investigated the genetic background of dichlorprop cleavage in *D. acidovorans* MC1. Two novel genes encoding the *R*- and *S*-dichlorprop-cleaving dioxygenases in *D. acidovorans* MC1 were identified and localized. The phylogenetic relationship of the *R,S*-dichlorprop-cleaving dioxygenases to other α -ketoglutarate-dependent dioxygenases was analyzed. The organization of these genes within the genome of strain MC1, as well as in a mutant deficient in dichlorprop cleavage, was investigated with regard to implications for the instability of this trait.

MATERIALS AND METHODS

Strains, plasmids, and culture conditions. *D. acidovorans* MC1 and *Rhodospirillum rubrum* strain P230, isolated from contaminated building rubble (9, 35), *D. acidovorans* MC1-DP⁻ (a mutant of strain MC1 arisen by spontaneous loss of dichlorprop-cleaving ability), and *S. herbicidovorans* MH, isolated from soil (21), were all grown on MM agar (36) containing 0.5 mM dichlorprop at 30°C. *Escherichia coli* TOP10F⁺ (pCR2.1; Invitrogen) was used for cloning PCR products. The cosmid library was constructed in *E. coli* XL1-Blue MR (Stratagene). *E. coli* XL1-Blue MRF⁺ (Stratagene) was used for maintaining pScosPA1. The vector pScosPA1 is a new broad-host-range cosmid identical to pSBC1 (43) except for a gentamicin resistance instead of the tetracycline resistance (*E. Mahenthiralingam*, unpublished data). A shotgun library of a cosmid was constructed by using the vector pcDNA2.1 (Invitrogen). *E. coli* S17-1 (pAG408::gfp [46]) was used in transposon mutagenesis experiments. *E. coli* strains were cultivated on Luria-Bertani (LB) agar at 37°C with the addition of appropriate antibiotics. Overnight cultures were prepared in liquid LB medium containing appropriate antibiotics at 37°C (*E. coli* strains) or 30°C (dichlorprop-degrading

strains) on a rotary shaker. Antibiotics and dichlorprop were filter sterilized through a 0.2- μ m-pore-size Minisart cellulose acetate filter (Sartorius) and added at a concentration of 100 μ g/ml.

Mercury resistance was examined on LB agar plates containing 0.1 mM HgCl₂, incubated at 30°C for 48 h. *R. eutropha* JMP134(pJP4) and *R. eutropha* JM222 were used as positive and negative controls, respectively.

Construction of gene libraries. A genomic library of *D. acidovorans* MC1 was constructed by using cosmid pScosPA1, as described elsewhere (43). The average insert size of library clones was 34 kb. A total of 2,592 clones were picked into 96-well plates. After overnight growth 8% (vol/vol) dimethyl formamide was added, and the cosmid library was stored at -80°C.

A shotgun library of cosmid pScos-R5 was constructed in pcDNA2.1 according to the method of Buchrieser et al. (4) by using cosmid DNA isolated as described elsewhere (2, 3).

Transposon mutagenesis. The transposon of the suicide vector pAG408, a miniTn5 derivative, carries a promoterless *gfp* gene (46) and was used for transposon mutagenesis of strain MC1. Mutagenesis was performed according to standard procedures (40). Overnight cultures of the donor and the recipient grown in LB medium supplemented with antibiotics (donor) were centrifuged, washed, and resuspended in LB medium to a final optical density at 600 nm (OD₆₀₀) of 1.0. Equal volumes of the donor and the recipient were mixed, and 100 μ l of the mixture was plated out on LB agar, followed by incubation at 30°C for 6 h. The bacterial lawn was then washed from the plates with MM medium. Dilution series were prepared in MM and 100 μ l of the 10⁻³ to the 10⁻⁵ dilutions was plated on selective MM agar plates containing 100 μ g of gentamicin/ml, 27.8 mM fructose, and 0.5 mM dichlorprop. After incubation at 30°C for 6 days green fluorescing mutants were isolated and tested for dichlorprop degradation by high-pressure liquid chromatography as described elsewhere (60). In mutant clones able to degrade one of the enantiomers but not the other the region flanking the transposon was PCR amplified and sequenced.

DNA amplification. Degenerate primers (Table 1) were designed from N-terminal and internal peptide sequences of the enantiospecific dioxygenases of *D. acidovorans* MC1 (57) for PCR amplification of *rdpA* and *sdpA*. According to preliminary alignments of these peptide sequences with TfdA and Taud, the expected PCR fragment sizes were ca. 350 bp (*R*-dichlorprop dioxygenase gene) and 540 bp (*S*-dichlorprop dioxygenase gene). All primers were synthesized by MWG Biotech. Total genomic DNA used as a template was prepared from colonies grown on LB agar as described elsewhere (25). PCR was performed by using the *Taq* PCR Mastermix kit (Qiagen) and a PTC-200 thermal cycler (MJ Research). First, 100 pmol of each degenerate primer was added to 25 μ l of PCR sample. The temperature gradient program involved an initial denaturation step at 94°C for 3 min, followed by 36 cycles of 94°C for 45 s, 50 to 70°C for 45 s, and 72°C for 2 min, with a final elongation step of 72°C for 6 min. Amplification of an *rdpA* gene fragment with the primers rdp.fg and rdp.r involved an initial denaturation step at 94°C for 3 min, followed by 36 cycles of 94°C for 45 s, 54°C for 45 s, and 72°C for 1 min, with a final elongation step of 72°C for 6 min. Amplification of an *sdpA* gene fragment with the primers sdp.ft and sdp.ra was the same as for *rdpA* amplification, except that the annealing step was performed at 60°C and that elongation lasted 90 s.

The *rdpA* genes from *S. herbicidovorans* MH and *Rhodospirillum rubrum* strain P230 were amplified with primers rdp.f_{forw} (5'-atg gta ggt ctc aaA TGC ATG CTG CAC TGT CCC CC-3'; lowercase letters denote a linker sequence) and rdp.r_{rev} (5'-atg gta ggt ctc agc gct CTA GCG CGC CGG GCG GCG G-3'). Amplification was the same as for the *rdpA* fragment except for the annealing step being performed at 60°C for 30 s.

Regions flanking Tn5 transposon insertion sites were amplified by ST-PCR (6). To each sample either Tn5.outF (5'-GGC AGA TCT GAT CAA GAG-3' [27]) annealing to the I end of the transposon or Tn5.outR (5'-CCG CAC TTG TGT ATA AGA GTC-3') designed from the O end of the transposon were added as specific primers. Either of the following FP primers (44) was added as a random primer: FP-1, 5'-AGT TCA AGC TTG TCC AGG AAT TC(N); GGC CT-3'; FP-2, 5'-AGT TCA AGC TTG TCC AGG AAT TC(N); GCG CT-3'; FP-3, 5'-AGT TCA AGC TTG TCC AGG AAT TC(N); CCG GT-3'; and FP-4, 5'-AGT TCA AGC TTG TCC AGG AAT TC(N); CGC GT-3'.

PCR products for the use as hybridization probes were generated as follows: the *mer* operon was partially amplified with primers mer.f (5'-CAC CAG TTC AGA CAG CAC G-3') and mer.r (5'-ACC GGT GAA ACC AAG TCC-3') amplifying a 1,450-bp fragment. The IS91-like element was partially amplified by using the primers IS.f (5'-ATG TCA GCC ACT TCC AAG C-3') and IS.r (5'-GGA GGC AGT ATG CAT TTG G-3') amplifying a 1,622-bp fragment. The PCR program for both fragments involved an initial denaturation step of 94°C for 3 min, followed by 36 cycles of 94°C for 45 s, 60°C for 45 s, and 72°C for 2 min, with a final elongation step of 72°C for 6 min. Amplification of *tfdB*, *tfdC*, and

TABLE 1. Degenerate primers designed for the amplification of *rdpA* and *sdpA*

Peptide or primer	Sequence ^a	Position ^b
RDP_internal sequence 2 rdp_r	W E T L S P T M Q A T I E G L N 3'-AC GTY CGN TGN TAI CTY CC-5'	162-177
RDP_internal sequence 3 rdp_fA ^c rdp_fG ^c	N E I L D A F H T Y Q V I Y F P 5'-GCI TTY CAY ACN TAY CAA GT-3' 5'-GCI TTY CAY ACN TAY CAG GT-3'	43-58
SDP_N terminus sdp_fC ^c sdp_fI ^c	M Q T T L Q I T P T G A T L G A 5'-ATG CAR ACI ACI CTG CAR ATC AC-3' 5'-ATG CAR ACI ACI CTG CAR ATT AC-3'	1-16
SDP_internal sequence 1 sdp_rA ^c sdp_rG ^c	L G H V Q Q A G S A Y I 3'-GTA CAN GTY GTY CGN CC-5' 3'-GTA CAN GTY GTY CGN CC-5'	193-204

^a As described previously (57). IUPAC ambiguity codes: R = A or G, Y = C or T, N = any base, I = inosine.^b Alignment is shown in Fig. 2.^c To avoid degeneracy near the 3' end, two pools of primers were designed from some peptides (sequence differences are indicated in boldface).

tfpD gene fragments was performed as described in reference 35. Fragments of *tfpD* and *tfpF* were amplified according to the method of Hoffmann et al. (17).

Sequencing and sequence analysis. For sequencing, PCR products were ligated to pCR2.1 and transformed into *E. coli* TOP10F' by using the TA cloning kit (Invitrogen). Cycle sequencing was performed by using the ABI Prism BigDye Terminator v2.0 cycle sequencing ready reaction kit (PE Applied Biosystems). M13 primers were used for amplifying and sequencing cloned PCR fragments. After amplification with M13 primers and electrophoretic separation, fragments were extracted with the E.Z.N.A gel extraction kit (Peqlab Biotechnologie). Sequencing reactions (total volume, 10 µl) contained 2 µl of premix, 10 pmol primer, and 10 to 50 ng of template DNA. Primer walking on cosmid DNA was performed with primers designed from the sequences of the *rdpA* and *sdpA* PCR products. Sequencing reactions (total volume, 20 µl) contained 6 µl of premix, 20 pmol of primer, and 500 ng of cosmid DNA. After 25 cycles of 96°C for 30 s, 55°C for 15 s, and 60°C for 4 min, the DNA was precipitated by adding 80 µl of H₂O, 10 µl of 3 M sodium acetate (pH 4.6), and 250 µl of ethanol; washed with 70% ethanol; vacuum dried; and redissolved in 20 µl of template suppression reagent (PE Applied Biosystems). Sequencing from cosmid DNA involved an additional purification step prior to the ethanol precipitation by using Centri-Sep spin columns (Princeton Separations). After denaturation at 90°C/2 min the sample was chilled on ice. Electrophoresis, data collection, and analysis were carried out on an ABI Prism 310 genetic analyzer (PE Applied Biosystems). Both strands were sequenced. Sequencing data were analyzed with the Sequence Navigator software, contigs were assembled by using the Autoassembler software (PE Applied Biosystems), and the BLASTn and BLASTx programs (version 2.2.2. [1]) were used to search for similar sequences in nucleotide and protein sequence databases. Sequences were aligned by using the programs CLUSTAL W (51) or MultAlign (7). Phylogenetic analysis was performed by using the protml tool of the ARB package (29) when the maximum-likelihood method was applied and MEGA2.1 (26) when trees were constructed with the neighbor-joining or maximum-parsimony method.

Recombinant pcDNA2.1 DNA was isolated as described elsewhere (2, 3). A Perkin-Elmer 9700 thermocycler was used for cycle sequencing. Sequencing reactions (total volume, 10 µl) contained ca. 300 ng of template, 1.5 µl of ABI Prism BigDye Terminator v1.1 Cycle Sequencing RR-100 mix, 1.2 µl of 5× sequencing buffer, and 2.4 pmol of primer T7 or M13. The sequencing program involved an initial denaturation step (94°C for 60 s), followed by 70 cycles of 96°C for 10 s, 50°C for 5 s, and 60°C for 4 min. Sequencing reactions were precipitated with 40 µl of 76% ethanol for 30 min, washed with 70% ethanol, and resuspended in 10 µl of 0.3 mM EDTA buffer. Electrophoresis, data collection, and analysis were performed by using an ABI Prism 3700 genetic analyzer (PE Applied Biosystems). Automatic sequence assembly was carried out by using PHRED (11, 12), PHRAP (P. Green, unpublished data), and the Autoassembler software. When gaps were closed between contigs, cosmid DNA was used as a template and custom-made oligonucleotides were added as primers. The sequence was edited by using CONSED (15) and annotated by using Vector NTI Advance (InforMax). Similarity searches were carried out as mentioned above.

DNA-DNA hybridization. Screening of the cosmid library was done by replica plating 12 96-well grids onto positively charged nylon membranes (Roche) that

had been placed on selective agar. Cells of strain MC1 (positive control) and *E. coli* XLI-Blue MRF' (pScosPA1) (negative control), as well as strains MH and P230, were smeared onto the nylon membrane placed on LB agar. After overnight growth, DNA was immobilized onto the membranes according to the manufacturer's guidelines.

Genomic DNA of strain MC1 was isolated as described by Sokol et al. (43). The low-copy plasmid pMC1 was isolated with a Nucleobond AX100 kit (Macherey-Nagel). Plasmid and genomic DNA were PstI digested according to standard procedures (40), separated electrophoretically in 0.8% agarose, blotted onto positively charged nylon membrane according to the manufacturer's guidelines, and cross-linked by UV irradiation for 1 min.

Cosmid and plasmid DNA was isolated from 20 ml of LB medium by using the Nucleobond AX100 kit (Macherey-Nagel). Next, 5 µl of cosmid DNA was applied to positively charged nylon membrane and cross-linked by UV irradiation for 1 min. then, 100 µl of plasmid DNA was PstI or EcoRI/XmaI digested according to standard procedures (40), ethanol precipitated, separated, blotted, and UV cross-linked as described above.

PCR fragments were digoxigenin labeled by using the DIG DNA labeling kit (Roche). For hybridization and immunodetection, the DIG Easy Hyb Wash and Block buffer set and the DIG nucleic acid detection kit (Roche) were used according to the manufacturer's guidelines. Hybridizations were performed at 50°C (*tfpD*, *tfpD*, *tfpE*, and *tfpF* probes), 55°C (*rdpA* probe), 60°C (probes against *tfpD*, the *mer* operon, and the IS91 element), or 62°C (*sdpA* probe). Stripping was carried out according to the manufacturer's instructions.

Nucleotide accession numbers. The nucleotide sequences determined in the present study were deposited in the GenBank, EMBL, and DDBJ databases under accession numbers AY327575, AF516751, and AF516752.

RESULTS

Identification, sequencing, and analysis of dichlorprop-cleaving dioxygenase genes in *D. acidovorans* MC1. Degenerate primers were designed from N-terminal and internal peptide sequences of both enantiospecific dioxygenases of *D. acidovorans* MC1. Primers with a degeneracy near the 3' end proved to be nonspecific; therefore, two pools of primers were synthesized to avoid degeneracy at such positions (Table 1). PCR with the primer pairs rdp_fG-rdp_r (*rdpA*-specific primers) and sdp_fT-sdp_rA (*sdpA*-specific primers) yielded fragments of 339 and 532 bp, respectively, whereas all other primer combinations did not produce specific fragments. The two PCR fragments were cloned and sequenced. The deduced amino acid sequences of both fragments contained sequences at their N and C termini, respectively, that correctly corresponded to the peptide sequences used for designing the prim-

TABLE 2. Sequence identities of the dichlorprop-cleaving enzymes RdpA and SdpA to other group II α KG-dependent dioxygenases

α -KG dioxygenase ^a	Strain, accession no.	% Identities ^b to	
		RdpA	SdpA
TfdA	<i>Ralstonia eutropha</i> , A27082	32/279	37/244
TauD	<i>Pseudomonas aeruginosa</i> , NP_252624	35/279	27/258
AtsK	<i>Pseudomonas putida</i> , AAD31784	31/296	31/296
YSD	<i>Saccharomyces cerevisiae</i> , Q12358	29/279	27/304
PvcB	<i>Pseudomonas aeruginosa</i> , AAC21672	20/298	21/277
SyrI	<i>Pseudomonas syringae</i> , AAB63253	17/323	18/308
CarC	<i>Pectobacterium carotovorum</i> , AAD38231	16/285	17/275
γ -BBH	<i>Pseudomonas</i> sp. strain AK-1, P80193	16/309	17/291
CS2	<i>Streptomyces clavuligerus</i> , AAA26723	16/208	17/275

^a TfdA, 2,4-D/ α KG dioxygenase; TauD, taurine/ α KG dioxygenase; AtsK, putative α KG-dependent alkylsulfatase; YSD, sulfonate/ α KG dioxygenase; PvcB, pyoverdine biosynthesis enzyme; SyrI, syringomycin biosynthesis enzyme I; CarC, carbapenem biosynthesis enzyme C; γ -BBH, γ -butyrobetaine hydroxylase; CS2, clavaminic synthase 2.

^b That is, the percent sequence identity over the total number of amino acids examined.

ers. In screens of a genomic cosmid library of strain MC1 10 of 1,152 clones hybridized with the *rdpA* gene probe. Of these 10, 4 hybridized with the *sdpA* gene probe, but PCR with the *sdpA*-specific primers yielded a product with only 1 of these 4 clones, designated pScos-R5. Both dioxygenase genes were then completely sequenced from this clone. The coding regions of the *R*-dichlorprop and *S*-dichlorprop dioxygenase genes were 888 and 879 bp, respectively. No significant sequence similarities to other known genes were found searching nucleotide databases. However, the deduced amino acid sequences of RdpA and SdpA both shared significant similarities to other α KG-dependent dioxygenases ranging between 37 and 16% (Table 2). RdpA and SdpA shared 26% sequence identities. Furthermore, similarities to a number of putative dioxygenases belonging to the genera *Pseudomonas*, *Yersinia*, *Ralstonia*, *Streptomyces*, *Bordetella*, *Bradyrhizobium*, *Azotobacter*, *Shigella*, *Chromobacterium*, *Burkholderia*, and *Mycobacterium* were found and ranged between 31 and 16%.

The amino acid sequences of both dioxygenases were analyzed on the basis of the alignment shown in Fig. 2. It shows that an internal sequence tentatively aligned to positions 257 to 287 of TfdA by Westendorf et al. (57), comprises positions 85 to 131 of RdpA.

Transposon mutagenesis. Of 959 green fluorescing transposon mutants, 2 were found to carry the transposon insertion in *rdpA*. In clone MC1-T270, the insertion was located after bp 627; in clone MC1-T647, the mini-Tn5 had inserted after bp 814. Both mutants had lost the ability to cleave *R*-dichlorprop but were still able to grow on the *S*-enantiomer.

Organization of *rdpA* and *sdpA* within the genome of *D. acidovorans* MC1. The 25,768-bp sequence of the genomic fragment from strain MC1 containing *rdpA* and *sdpA* in cosmid pScos-R5 is represented in Fig. 3A. The assembly was verified by PCR of selected regions (data not shown). The *rdpA* and *sdpA* genes were separated by 13.6 kb, which mainly comprised an 8.7-kb putative transposon, organized in a way characteristic for the Tn501 subgroup of the Tn3 transposon family (28). It was flanked by 38-bp inverted repeats that were flanked by 5-bp direct repeats generated during insertion. The open reading frames (ORFs) for the putative transposase and resolvase




FIG. 2. Sequence alignment of RdpA and SdpA with other group II α KG-dependent dioxygenases. TfdA, *R. eutropha* 2,4-D/ α KG dioxygenase (accession no. A27082); TauD, *P. aeruginosa* taurine/ α KG dioxygenase (accession no. NP_252624). Conserved Fe(II)- and α KG-binding residues are shaded in black; other conserved regions are shaded in gray. Black arrows indicate 2,4-D binding residues in TfdA; gray arrows indicate residues undergoing posttranslational hydroxylation in TauD or TfdA. Amino acid positions numbers are shown to the right of each line. The alignment was created with CLUSTAL W.

genes *tnpA* and *tnpR* had an outward direction with the ORF for *tnpA* proceeding 5 bp into the inverted repeat. The *res* site, at which cointegrate resolution during transposition takes place, was located upstream of *tnpR*. The remaining part of the transposon was occupied by a mercury resistance gene cluster. The *merR* gene had a direction divergent from the *merTP* *CADE* operon. A putative *urf2M* was located adjacent to the *mer* operon. The putative Tn501 transposon showed 81% nucleotide sequence identity to a putative Tn3 family transposon of *Nitrosomonas europaea* ATCC 19718 (accession no. BX321858.1). The deduced amino acid sequences of the identified ORFs showed between 82 and 97% identity to proteins involved in transposition and mercury resistance (Table 3). The functionality and mobility of this transposon were not tested, but strain MC1 was found to be resistant to 0.1 mM HgCl₂. Mercury resistance was not lost when dichlorprop-cleaving activity was lost, but these mutants were still able to grow in the presence of 0.1 mM HgCl₂. In Southern hybridizations the *mer* operon of the plasmid was localized on a 4.4-kb fragment of pMC1 (Fig. 4C). This copy was deleted in the plasmid of the mutant MC1-DP⁻. However, in hybridizations against genomic DNA, another signal at 2.8 kb was detected that was present in the wild-type strain as well as in strain MC1-DP⁻ (data not shown), suggesting that strain MC1 carries a second copy of the *mer* operon on the chromosome that is not lost when the dichlorprop-cleaving ability is lost. It is possible that the chromosomal copy of the *mer* operon confers mercury resistance to strains MC1 and MC1-DP⁻, whereas the copy on the plasmid may lack functionality.




FIG. 3. Organization of *rdpA* and *sdpA* within the genome of strain MC1. (A) Genetic map of the genomic fragment containing *rdpA* and *sdpA*. For ORFs showing a high degree of similarity to other genes (>80% identity of the deduced amino acid sequence) the respective names are given. The gene designations are as follows: *tnpA/tnpA*(Tn), putative transposases; *sdpA*, *S*-dichlorprop/ α -ketoglutarate dioxygenase; *merR*, putative mercury resistance operon transcriptional regulator; *merT*, *merP* and *merC*, putative mercury ion transport genes; *merA*, putative mercury reductase; *merD*, putative secondary regulator; *merE* and *urf2M*, conserved ORF of unknown function; *tnpR*, putative site-specific resolvase; and *rdpA*, *R*-dichlorprop/ α -ketoglutarate dioxygenase. ORF1 through ORF5 and ORF19 show significant similarities to genes encoding the proteins as follows: ORF1, carboxymuconolactone decarboxylase; ORF2, potassium/proton antiporter; ORF3, bacterioferritin; ORF4, LysR type regulator; ORF5, dihydroxyacid dehydratase; and ORF19, MFS transporter. The positions of the following features are indicated: IR, 38-bp inverted repeat flanking the Tn501-like transposon, DR, 5-bp direct repeat. Two putative IS91-like elements are shown as black boxes; the positions of the *oriIS* are indicated as arrows above the sequence. The right IS91-like element is interrupted by a Tn501-like transposon. Its left partial sequence is not drawn to scale. Single letters denote the following restriction sites: E, EcoRI; P, PstI; and X, XmaI. In the case of multiple PstI restriction sites within less than 100 bp, only the most left site is given and the number of sites is indicated in brackets. (B) Comparison of the sequence at the right end of the putative IS elements with the IS91 family *oriIS* consensus sequence. Conserved nucleotides are shown in bold uppercase letters.

Furthermore, two copies of a putative IS element resembling the IS91/IS801 family of insertion elements were identified. Members of this family of IS elements do not contain inverted repeats and do not create duplications of the target sequence (14). Insertion of this family of elements is site specific, and replication utilizes the rolling circle mechanism; therefore, an *oriIS*, the origin of replication, and a *terIS*, the termination sequence, are found at either end of these IS elements (14). The two copies of the putative IS elements in strain MC1 were essentially identical except for a 9-bp deletion and a 47-bp deletion in the left, intact copy. The element next to ORF19 was interrupted by the Tn501-like element (Fig. 3A). The elements were 2,037 bp (intact copy) and 2,084 bp (interrupted copy) and contained an IS801-like transposase gene showing 99% sequence identity to the homologues on the atrazine catabolic plasmid pADP-1 (Table 3 [32]) and a transposase associated with chlorobenzene degradation genes in *Ralstonia* sp. strain JS705 (37). At the right end of both elements a

sequence was identified, that matched the consensus sequence for origin of replication *oriIS* of this group of insertion elements (49) in all but the first nucleotide (Fig. 3B). Neither the termination sequence *terIS* nor the tetramers GTTC/CTTG for which IS91 family elements show site specificity were detected.

ORF19, located upstream of *rdpA* showed significant similarities to aromatic compound major facilitator superfamily (MFS) transporters. A 29% identity to the 2,4-D transporters CadK of *Bradyrhizobium* sp. strain HW13 and TfdK of *Achromobacter xylosoxidans* subsp. *denitrificans* and *R. eutropha* JMP134 was detected. A putative Shine-Dalgarno sequence was found 7 bp upstream of the start codon.

Another five ORFs, ORF1 to ORF5, were identified at the left end side of the insert.

Localization of *rdpA* and *sdpA* within the genome of *D. acidovorans* MC1 and comparison of the wild-type plasmid pMC1 with that of the mutant MC1-DP⁻. Southern hybridizations showed that both *rdpA* and *sdpA* were located on the

TABLE 3. Localization and predicted function of ORFs in the genomic region of strain MC1 containing *rdpA* and *sdpA*

ORF	Coordinates (bp)	Coding strand ^a	Function of closest match	Source microorganism	% Amino acid identity ^b	No. of amino acids MC1/match ^c	Accession no.
1	574-966	d	Carboxymuconolactone decarboxylase family protein	<i>Shewanella oneidensis</i> MIR-1	65 (81/124)	130/128	AA553170.1
2	1006-2799	c	Glutathione-regulated potassium-proton antiporter	<i>Pseudomonas putida</i> KT2440	69 (385/556)	597/581	AEO16523.1
3	3018-3494	d	Putative bacterioferritin	<i>Delftia acidovorans</i>	70 (112/158)	158/158	CAC83620.1
4	3701-4642	c	Hypothetical protein, similar to LysR-type regulators	<i>Ralstonia metallidurans</i>	51 (161/314)	313/360	ZP_0002245.1
5	4745-6438	d	Putative dihydroxy acid dehydratase	<i>Ralstonia solanacearum</i>	76 (420/555)	564/557	CAD16119.1
6	7981-9528	d	Putative transposase, similar to IS801 transposase	<i>Pseudomonas</i> sp. strain ADP	99 (512/515)	515/515	AAK50272.1
7	9836-10714	d	2,4-D dioxygenase (TfdA)	<i>Ralstonia eutropha</i> JMP134	37 (92/249)	292/287	A27082
8	12107-12541	c	Mercury resistance regulatory protein (MerR)	<i>Enterobacter aerogenes</i>	97 (140/144)	144/144	CAA83896.1
9	12613-12963	d	Mercury uptake protein (MerF)	<i>Alcaligenes</i> sp.	96 (112/116)	116/116	CAA70196.1
10	12977-13251	d	Mercury uptake protein (MerP)	<i>Nitrosomonas europaea</i> ATCC 19718	94 (86/91)	91/91	CAA70197.1
11	13279-13701	d	Mercury uptake protein (MerC)	<i>Nitrosomonas europaea</i> ATCC 19718	86 (121/140)	140/140	CAD84751.1
12	13741-15426	d	Mercury ion reductase (MerA)	<i>Klebsiella pneumoniae</i>	88 (494/561)	561/561	AAM44226.1
13	15444-15809	d	Mercury resistance secondary regulatory protein (MerD)	<i>Pseudomonas</i> sp. strain ADP	95 (115/121)	121/121	AAK50284.1
14	15806-16042	d	Putative protein (MerE)	<i>Pseudomonas</i> sp. strain ADP	91 (71/78)	78/78	AAK50283.1
15	16093-17028	d	Putative protein, similar to Urf2M	<i>Ralstonia metallidurans</i>	88 (274/310)	311/329	CAD97548.1
16	17245-17718	d	Resolvase (TnpR)	<i>Nitrosomonas europaea</i> ATCC 19718	98 (154/157)	158/186	CAD84747.1
17	17721-20690	d	Tn3 family transposase (TnpA)	<i>Nitrosomonas europaea</i> ATCC 19718	95 (945/989)	989/989	CAD84746.1
18	21024-22571	d	Putative transposase, similar to IS801 transposase	<i>Pseudomonas</i> sp. strain ADP	99 (511/515)	515/515	AAK50727.1
19	22752-24137	c	Putative aromatic compound MFS transporter	<i>Pseudomonas putida</i> KT2440	73 (318/433)	461/450	AAAG9258.1
20	24330-25217	d	Taurine dioxygenase (TauD)	<i>Pseudomonas aeruginosa</i> PA01	35 (100/284)	295/279	NP_252624

^a c, complementary strand; d, direct strand.^b Values in parentheses refer to numbers of identical amino acids over the total number examined.^c Number of amino acids in strain MC1 ORF/number in the closest match.

plasmid pMC1 (Fig. 4A). Distinct signals of the expected fragment sizes of 3.5 kb (*rdpA*) and 1.9 kb (*sdpA*) were observed with plasmid DNA (Fig. 4A, lane 1). Much fainter signals of the same fragment sizes were obtained with the genomic DNA, making visible the plasmid content of this. Loss of dichlorprop cleavage in strain MC1-DP⁻ was associated with a deletion of both dioxygenase genes from pMC1-DP⁻ (Fig. 4B). Furthermore, the *mer* operon and most of the numerous copies of the IS91-like elements were also deleted in the mutant MC1-DP⁻ (Fig. 4C). In contrast, the lower pathway genes *tfdB-F* remained unaffected (data not shown).

Screening for *rdpA* and *sdpA* in other dichlorprop-degrading bacteria. Southern hybridizations with *rdpA* and *sdpA* probes showed that neither *S. herbicidovorans* MH nor *Rhodospirillum rubrum* strain P230 carried *sdpA*-like genes, but both strains gave signals with the *rdpA* gene probe (data not shown). The genes were PCR amplified and sequenced. The *rdpA* gene of strain P230 was identical to that of strain MC1; the one of strain MH contained one neutral base substitution.

DISCUSSION

Two novel genes encoding the enantiospecific dichlorprop and mecoprop cleaving dioxygenases RdpA and SdpA in *D. acidovorans* MC1 were identified. The characterization of genes shown to be involved in the cleavage of these chiral herbicides has not previously been reported. To date, *tfdA* genes or genes closely related in sequence to *tfdA* were proposed to be involved in *R*-dichlorprop cleavage in *Alcaligenes denitrificans* (39). This suggestion was based on the observations that a *tfdA* gene is present in *Alcaligenes denitrificans* and that dichlorprop cleavage is catalyzed by an α KG-dependent dioxygenase in this strain as well as in *S. herbicidovorans* MH (38). However, it was not supported by *tfdA* expression studies or amino acid sequences of the *R*-dichlorprop cleaving dioxygenase. The *rdpA* and *sdpA* genes of strain MC1 showed no significant nucleotide similarities to *tfdA*. However, the significant degree of identity of their deduced amino acid sequences to group II α KG-dependent dioxygenases and the distribution of these identities throughout the whole of the primary sequence (Fig. 2) supported the view that RdpA and SdpA are homologous to dioxygenases of this family. The functionally important motif HX(D/E)X₂₃₋₂₆(T/S)X₁₁₄₋₁₈₃HX₁₀₋₁₃R/K, which is conserved throughout group II α KG-dependent dioxygenases (18), is present in both RdpA and SdpA. In TfdA of *R. eutropha* it includes the three Fe(II)-binding residues His114, Asp116, and His263, and the two α KG-binding residues Thr141 and Arg274 (Fig. 2). All of these residues were conserved in RdpA and SdpA, representing the putative Fe(II) and α KG-binding residues in these enzymes. Arg278, His214, Ser117, Lys95, and Lys71 of TfdA are known to interact with 2,4-D (8, 10). Ser117 homologues were identified in both dichlorprop-cleaving enzymes. A homologue for Arg278 was present only in RdpA, one for His214 was found in SdpA. The tryptophan residues Trp126, Trp238, and Trp246 undergoing posttranslational hydroxylation in TauD and Trp113 undergoing posttranslational hydroxylation in TfdA form a hydrophobic cluster around the active site (10). In RdpA and SdpA all of these residues were conserved or substituted by other hydrophobic amino acids. The basis of the enantiospecificity of




FIG. 4. Localization of *rdpA* and *sdpA* within the genome of *D. acidovorans* MC1 and comparison of plasmid pMC1 with pMC1-DP⁻, the plasmid of mutant MC1-DP⁻. (A) Localization of *rdpA* and *sdpA* within the genome of strain MC1. Plasmid DNA (lane 1) and genomic DNA (lane 2) was digested with PstI, separated electrophoretically in 0.8% agarose (A1), and hybridized (A2). Gene probes are given at the bottom. (B and C) Comparison of plasmid pMC1 of the wild-type strain of MC1 (lane 2) with pMC1-DP⁻, the plasmid of the mutant unable to cleave dichlorprop (lane 1). PstI-digested plasmid DNA was separated electrophoretically in 0.8% agarose (B1) and hybridized against *rdpA* and *sdpA* gene probes (B2). EcoRI/XmaI-digested plasmid DNA was separated electrophoretically in 0.8% agarose (C1) and hybridized against probes for the *mer* operon and the IS91 element (C2).

the dichlorprop-cleaving enzymes is not known. It is known that the tertiary structure of homologous proteins showing at least 20% identity of amino acid sequence is conserved (41). Among group II α KG dioxygenases a high degree of structural conservation was observed between clavamate synthase and TauD, which share as little as 7.7% primary sequence identity (10). It is therefore likely that 2,4-D and dichlorprop-cleaving enzymes are structurally very similar and that substrate specificity is determined by only a few amino acids. Site-specific mutagenesis studies are needed to reveal the molecular basis of the substrate specificity and stereospecificity of RdpA and SdpA.

Phylogenetic trees calculated by different methods (data not shown) consistently grouped RdpA in one clade with TauD enzymes, but the assignment of SdpA could not be determined precisely. The primary sequence of SdpA most closely resembled that of TfdA and, like this dioxygenase, SdpA is characterized by a relatively broad substrate specificity (34). TfdA has greatest activity with 2,4-D but shows some activity toward *S*-mecoprop (38). SdpA shows greatest activity with the *S*-enantiomers of mecoprop and dichlorprop but has some activity toward 2,4-D (34). These observations suggested that SdpA is most closely related to 2,4-D-cleaving enzymes, which was also consistent with the position of SdpA in trees constructed without an outgroup. However, when PvcB was used as an outgroup SdpA was represented as a sister group of both the TfdA/TfdA α and the RdpA/TauD clades. At present, the database is too small to determine more precisely the phylogenetic relationship between SdpA and other members of the α KG dioxygenase family.

Transposon mutagenesis inactivation of *rdpA* indicated that it was a single-copy gene and gave a further proof of its func-

tionality and role in strain MC1, besides previous characterization of RdpA and SdpA (34, 57, 58).

An *rdpA* gene identical to that of strain MC1 was identified in *Rhodospirillum* sp. strain P230, and one nearly identical was found in *S. herbicidovorans* MH, but neither of these strains carried *sdpA* genes, as indicated by Southern hybridizations allowing ca. 20% mismatches. The *rdpA* genes could be involved in *R*-dichlorprop degradation in strains P230 and MH. Further investigations are necessary to study their role to determine whether *rdpA* genes are generally more widely distributed than *sdpA* genes, as these limited data suggest, and to identify the genes encoding the *S*-dichlorprop-cleaving dioxygenases of strains MH and P230.

In *S. herbicidovorans* MH, three transport proteins specific for 2,4-D, *R*-dichlorprop, and *S*-dichlorprop were identified (60). In strain MC1, ORF19 encodes a putative transport protein (Fig. 4 and Table 3). It was in close proximity to *rdpA*, and the significant similarity of the deduced protein sequence to TfdK and CadK suggested an involvement in *R*-dichlorprop transport. No other potential transporters were detected. Likewise, no genes encoding transcriptional regulators of dichlorprop cleavage were identified. This is in accordance with previous studies which found *rdpA* and *sdpA* to be constitutively expressed (36). ORF4, which shows significant similarities to LysR-type transcriptional regulators, probably regulates the expression of ORF5 rather than that of *sdpA* or *rdpA*.

The ability to degrade dichlorprop in *D. acidovorans* MC1 is spontaneously and irreversibly lost at high frequencies under nonselective conditions, whereas the degradation of dichlorophenol is a stable trait (36). This indicated that the ability to cleave the phenoxyalkanoate herbicides is unstable in strain MC1, which would be consistent with recent acquisition of the

rdpA and *sdpA* genes. The localization and organization of the initial step in dichlorprop degradation imply that its evolution and recruitment took place independently of the lower pathway. Cases and de Lorenzo (5) postulated that degradative pathways for substrates only very recently found in the environment are often poorly regulated, probably reflecting an early step in the optimization of the corresponding metabolic route, and that biodegradative operons evolve from constitutive expression to substrate-responsive and metabolically controlled transcription. The evolution of the dichlorprop cleavage pathway in strain MC1 is an example supporting this hypothesis, since *rdpA* and *sdpA* are constitutively expressed, whereas the consecutive degradation of the intermediate dichlorophenol is inducible (36).

Previously, the loss of genes involved in etherolytic cleavage of dichlorprop was hypothesized to be caused by a deletion within plasmid pMC1, which occurs concomitantly with loss of dichlorprop cleavage (36). In the present study, both dioxygenase genes were shown to be located on the plasmid and to be deleted in the MC1-DP⁻ mutant, proving this hypothesis to be correct. Moreover, the *mer* operon was deleted, and the copy number of the IS91-like element was found to be considerably reduced. This suggests that recombination between IS91 elements could lead to the deletion of one or both dioxygenase genes and the Tn501-like transposon. Although IS91-like elements do not cause deletion of regions adjacent to them, a deletion of a genomic fragment flanked by IS91-like elements was observed in *Shigella flexneri* (52). In strain MC1, recombination between the interrupted IS element and the intact IS copy downstream of ORF5 would lead to the deletion of the region between the elements, including *sdpA*. Likewise, the IS elements may have played a role in the acquisition of dichlorprop cleavage in strain MC1. In *Ralstonia* sp. strain JS705 the *clc* genes are flanked by an intact and a partial copy of an insertion element highly similar to the ones identified in strain MC1. These IS elements were proposed to have captured the *clc* genes and made possible the gene transfer from *Ralstonia* sp. strain JS745 to strain JS705 (37). Characterization of the region downstream of *rdpA* and comparison of the MC1-DP⁻ mutant genotype with the MC1 wild-type will further the understanding of processes having lead to the acquisition and causing instability of the degradative trait.

ACKNOWLEDGMENTS

We thank Esh Mahenthalingam (Cardiff University) for the gift of pScosPA1. The construction of the cosmid library was carried out by KMS in Andrew Weightman's lab at Cardiff University, and we are very grateful to Andrew Weightman, Esh Mahenthalingam, and Li Ling Lee for advice and discussions. We thank Ute Lohse and Anett Heidtmann for skillful technical support.

K.M.S. was supported by Deutsche Bundesstiftung Umwelt grant 20000/99.

REFERENCES

- Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D. J. Lipman. 1990. Basic local alignment search tool. *J. Mol. Biol.* 215:403–410.
- Birnboim, H. C., and J. Doly. 1979. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. *Nucleic Acids Res.* 7:1513–1523.
- Brosch, R., S. V. Gordon, A. Billault, T. Garnier, K. Eiglmeyer, C. Soravito, B. G. Barrell, and S. T. Cole. 1998. Use of a *Mycobacterium tuberculosis* H37Rv bacterial artificial chromosome library for genome mapping, sequencing and comparative genomics. *Infect. Immun.* 66:2221–2229.
- Buchrieser, C., C. Rusniok, L. Frangeul, E. Couve, A. Billault, F. Kunst, E. Carniel, and P. Glaser. 1999. The 102-kilobase *pgm* locus of *Yersinia pestis*: sequence analysis and comparison of selected regions among different *Yersinia pestis* and *Yersinia pseudotuberculosis* strains. *Infect. Immun.* 67:4851–4861.
- Cases, I., and V. de Lorenzo. 2001. The black cat/white cat principle of signal integration in bacterial promoters. *The EMBO J.* 20:1–11.
- Chun, K. T., H. J. Edenberg, M. R. Kelley, and M. G. Goebel. 1997. Rapid amplification of uncharacterized transposon-tagged DNA sequences from genomic DNA. *Yeast* 13:233–240.
- Corpet, F. 1988. Multiple sequence alignment with hierarchical clustering. *Nucleic Acids Res.* 16:10881–10890.
- Dunning-Hotopp, J. C., and R. P. Hausinger. 2002. Probing the 2,4-dichlorophenoxyacetate/ α -ketoglutarate dioxygenase substrate-binding site by site-directed mutagenesis and mechanism-based inactivation. *Biochemistry* 41:9787–9794.
- Ehrig, A., R. H. Müller, and W. Babel. 1997. Isolation of phenoxyherbicide-degrading *Rhodospirillum rubrum* species from contaminated building material. *Acta Biotechnol.* 17:351–356.
- Elkins, J. M., M. J. Ryle, I. J. Clifton, J. C. Dunning-Hotopp, J. S. Lloyd, N. I. Burzlaff, J. E. Baldwin, R. P. Hausinger, and P. L. Roach. 2002. X-ray crystal structure of *Escherichia coli* taurine/ α -ketoglutarate dioxygenase complexed to ferrous iron and substrates. *Biochemistry* 41:5185–5192.
- Ewing, B., and P. Green. 1998. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. *Genome Res.* 8:175–185.
- Ewing, B., and P. Green. 1998. Base-calling of automated sequencer traces using phred. II. Error probabilities. *Genome Res.* 8:186–198.
- Fukumori, F., and R. P. Hausinger. 1993. Purification and characterization of 2,4-dichlorophenoxyacetate/ α -ketoglutarate dioxygenase. *J. Biol. Chem.* 268:24311–24317.
- Garcillán-Barcia, M. P., and F. de la Cruz. 2002. Distribution of IS91 family insertion sequences in bacterial genomes: evolutionary implications. *FEMS Microbiol. Ecol.* 42:303–313.
- Gordon, D., C. Abajian, and P. Green. 1998. Consed: a graphical tool for sequence fishing. *Genome Res.* 8:195–202.
- Häggblom, M. M. 1992. Microbial breakdown of halogenated aromatic pesticides and related compounds. *FEMS Microb. Rev.* 103:29–72.
- Hoffmann, D., S. Kleinstaub, R. H. Müller, and W. Babel. 2001. Development and application of PCR primers for the detection of the *tfd* genes in *Dehalobacterium* P4a involved in the degradation of 2,4-D. *Acta Biotechnol.* 21:321–331.
- Hogan, D. A. 1999. Characterization and function of 2,4-dichlorophenoxyacetic acid/ α -ketoglutarate dioxygenase and related enzymes. Ph.D. thesis. Michigan State University, East Lansing.
- Hogan, D. A., D. H. Buckley, C. H. Nakatsu, T. M. Schmidt, and R. P. Hausinger. 1997. Distribution of the *tfdA* gene in soil bacteria that do not degrade 2,4-dichlorophenoxyacetic acid (2,4-D). *Microb. Ecol.* 34:90–96.
- Hogan, D. A., S. R. Smith, E. A. Saari, J. McCracken, and R. P. Hausinger. 2000. Site-directed mutagenesis of 2,4-dichlorophenoxyacetic acid/ α -ketoglutarate dioxygenase. *J. Biol. Chem.* 275:12400–12409.
- Horvath, M., G. Dietzelmüller, M. Loidl, and F. Streichsbier. 1990. Isolation and characterization of a 2-(2,4-dichlorophenoxy)propionic acid-degrading soil bacterium. *Appl. Microbiol. Biotechnol.* 33:213–216.
- Itoh, K., R. Kanda, Y. Sumita, H. Kim, Y. Kamagata, K. Suyama, H. Yamamoto, R. P. Hausinger, and J. M. Tiedje. 2002. *tfdA*-like genes in 2,4-dichlorophenoxyacetic acid-degrading bacteria belonging to the *Bradyrhizobium-Agromonas-Nitrobacter-Azospira* cluster in α -Proteobacteria. *Appl. Environ. Microbiol.* 68:3449–3454.
- Itoh, K., K. Y. Tashiro, Uobe, Y. Kamagata, K. Suyama, and H. Yamamoto. 2004. Root nodule *Bradyrhizobium* spp. harbor *tfdA* and *cdaA*, homologous with genes encoding 2,4-dichlorophenoxyacetic acid-degrading proteins. *Appl. Environ. Microbiol.* 70:2110–2118.
- Kitagawa, W., S. Takami, K. Miyauchi, E. Masai, Y. Kamagata, J. M. Tiedje, and M. Fukuda. 2002. Novel 2,4-dichlorophenoxyacetic acid degradation genes from oligotrophic *Bradyrhizobium* sp. strain HW13 isolated from a pristine environment. *J. Bacteriol.* 184:509–518.
- Kleinstaub, S., D. Hoffmann, R. H. Müller, and W. Babel. 1998. Detection of chlorocatechol 1,2-dioxygenase genes in proteobacteria by PCR and gene probes. *Acta Biotechnol.* 18:231–240.
- Kumar, S., K. Tamura, I. B. Jakobsen, and M. Nei. 2001. MEGA2: molecular evolutionary genetics analysis software. *Bioinformatics* 17:1244–1245.
- Kwon, Y. M., and S. C. Rhee. 2000. Efficient amplification of multiple transposon-flanking sequences. *J. Microbiol. Methods* 41:195–199.
- Liebert, C. A., R. M. Hall, and A. O. Summers. 1999. Transposon Tn21, flagship of the floating genome. *Microbiol. Mol. Biol. Rev.* 63:507–522.
- Ludwig, W., O. Strunk, R. Westram, L. Richter, H. Meier, Yadhukumar, A. Buchner, T. Lai, S. Steppi, G. Jobb, W. Forster, I. Brettske, S. Gerber, A. W. Ginhart, O. Gross, S. Grumann, S. Hermann, R. Jost, A. König, T. Liss, R. Lussmann, M. May, B. Nonhoff, B. Reichel, R. Strehlow, A. Stamatakis, N. Stuckmann, A. Vilbig, M. Lenke, T. Ludwig, A. Bode, and K. H. Schleifer. 2004. ARB: a software environment for sequence data. *Nucleic Acids Res.* 32:1363–1371.
- Mai, P., O. S. Jacobsen, and J. Aamand. 2001. Mineralization and cometabolic degradation of phenoxyalkanoic acid herbicides by a pure bacte-

- rial culture isolated from an aquifer. Appl. Microbiol. Biotechnol. 56:486–490.
31. Maltseva, O., C. McGowan, R. Fulthorpe, and P. Oriel. 1996. Degradation of 2,4-dichlorophenoxyacetic acid by haloalkaliphilic bacteria. Microbiology 142:1115–1122.
 32. Martinez, B., J. Tomkins, L. P. Wackett, R. Wing, and M. J. Sadowsky. 2001. Complete nucleotide sequence and organization of the atrazine catabolic plasmid pADP-1 from *Pseudomonas* sp. strain ADP. J. Bacteriol. 183:5684–5697.
 33. McGowan, C., R. Fulthorpe, A. Wright, and J. M. Tiedje. 1998. Evidence for interspecies gene transfer in the evolution of 2,4-dichlorophenoxyacetic acid degraders. Appl. Environ. Microbiol. 64:4089–4092.
 34. Müller, R. H., and W. Babel. 1999. Separation of two dichlorprop/α-ketoglutarate dioxygenases with enantiospecific properties from *Comamonas acidovorans* MCI. Acta Biotechnol. 19:349–355.
 35. Müller, R. H., S. Jorks, S. Kleinstaub, and W. Babel. 1999. *Comamonas acidovorans* strain MCI: a new isolate capable of degrading the chiral herbicides dichlorprop and mecoprop and the herbicides 2,4-D and MCPA. Microbiol. Res. 154:241–246.
 36. Müller, R. H., S. Kleinstaub, and W. Babel. 2001. Physiological and genetic characteristics of two bacterial strains utilizing phenoxypropionate and phenoxyacetate herbicides. Microbiol. Res. 156:121–131.
 37. Müller, T. A., C. Werlen, J. Spain, and J. R. van der Meer. 2003. Evolution of a chlorobenzene degradative pathway among bacteria in a contaminated groundwater mediated by a genomic island in *Ralstonia*. Environ. Microbiol. 5:163–173.
 38. Nickel, K., Suter, M. J. F., and H. P. E. Kohler. 1997. Involvement of two α-ketoglutarate-dependent dioxygenases in enantioselective degradation of (R)- and (S)-mecoprop by *Sphingomonas herbicidovorans* MH. J. Bacteriol. 179:6674–6679.
 39. Saari, R. E., D. A. Hogan, and R. P. Hausinger. 1999. Stereospecific degradation of the phenoxypropionate herbicide dichlorprop. J. Mol. Cat. B 6:421–428.
 40. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
 41. Schulz, G. E., and R. H. Schirmer. 1979. Principles of protein structure. Springer, New York, N.Y.
 42. Smejkal, C. W., T. Vallaes, F. A. Seymour, S. K. Burton, and H. M. Lappin-Scott. 2001. Characterization of (R/S)-mecoprop [2-(2-methyl-4-chlorophenoxy)propionic acid]-degrading *Alcaligenes* sp. CS1 and *Ralstonia* sp. CS2 isolated from agricultural soils. Environ. Microbiol. 3:288–293.
 43. Sokol, P. A., P. Darling, D. E. Woods, E. Mahenthiralingam, and C. Kooi. 1999. Role of ornibactin biosynthesis in the virulence of *Burkholderia cepacia*: characterization of *pvdA*, the gene encoding L-ornithine N⁵-oxygenase. Infect. Immun. 67:4443–4455.
 44. Sorensen, A. B., M. Duch, and F. S. Pedersen. 1999. Isolation of unknown flanking DNA by a simple two-step polymerase chain reaction method. DYNALogue 99:2–3.
 45. Streber, W. R., K. N. Timmis, and M. H. Zenk. 1987. Analysis, cloning, and high-level expression of 2,4-dichlorophenoxyacetate monooxygenase gene *tfdA* of *Alcaligenes eutrophus* JMP134. J. Bacteriol. 169:2950–2955.
 46. Suarez, A., A. Güttler, M. Strätz, L. H. Staendner, K. N. Timmis, and C. A. Guzmán. 1997. Green fluorescent protein-based reporter systems for genetic analysis of bacteria including monocopy applications. Gene 196:69–74.
 47. Suwa, Y., A. D. Wright, F. Fukimori, K. A. Nummy, R. P. Hausinger, W. E. Holben, and L. J. Forney. 1996. Characterization of a chromosomally encoded 2,4-dichlorophenoxyacetic acid/α-ketoglutarate dioxygenase from *Burkholderia* sp. strain RASC. Appl. Environ. Microbiol. 62:2464–2469.
 48. Takeuchi, M., K. Hamana, and A. Hiraishi. 2001. Proposal of the genus *Sphingomonas* sensu stricto and three new genera, *Sphingobium*, *Novoshingobium*, and *Sphingopyxis*, on the basis of phylogenetic and chemotaxonomic analyses. Int. J. Syst. Evol. Microbiol. 51:1405–1417.
 49. Tavakoli, N., A. Comanducci, H. M. Dodd, M. C. Lett, B. Albiger, and P. Bennett. 2000. IS1294, a DNA element that transposes by RC transposition. Plasmid 44:66–84.
 50. Tett, V. A., A. J. Willets, and H. M. Lappin-Scott. 1994. Enantioselective degradation of the herbicide mecoprop [2-(2-methyl-4-chlorophenoxy)propionic acid] by mixed and pure bacterial cultures. FEMS Microb. Ecol. 14:191–200.
 51. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673–4680.
 52. Turner, S. A., S. N. Luck, H. Sakellaris, K. Rajakumar, and B. Adler. 2001. Nested deletions of the SRL pathogenicity island of *Shigella flexneri* 2a. J. Bacteriol. 183:5535–5543.
 53. Vallaes, T., R. R. Fulthorpe, A. M. Wright, and G. Soulas. 1996. The metabolic pathway of 2,4-dichlorophenoxyacetic acid degradation involves different families of *tfdA* and *tfdB* genes according to PCR-RFLP analysis. FEMS Microbiol. Ecol. 20:163–172.
 54. Vallaes, T., F. Persello-Carreaux, N. Rouard, C. Lers, G. Laguerre, and G. Soulas. 1997. RCR-RFLP analysis of 16S rRNA, *tfdA*, and *tfdB* genes reveals a diversity of 2,4-D degraders in soil aggregates. FEMS Microbiol. Ecol. 24:269–278.
 55. Vallaes, T., L. Albino, G. Soulas, A. D. Wright, and A. J. Weightman. 1998. Isolation and characterization of a stable 2,4-dichlorophenoxyacetic acid degrading bacterium, *Variovorax paradoxus*, using chemostat culture. Biotechnol. Lett. 20:1073–1076.
 56. Vedler, E., V. Koiv, and A. Heinaru. 2000. Analysis of the 2,4-dichlorophenoxyacetic acid-degradative plasmid pEST4011 of *Achromobacter xylosoxidans* subsp. *denitrificans* strain EST4002. Gene 255:281–288.
 57. Westendorf, A., D. Benndorf, R. H. Müller, and W. Babel. 2002. The two enantiospecific dichlorprop/α-ketoglutarate-dioxygenases from *Delftia acidovorans* MCI: protein and sequence data of RdpA and SdpA. Microbiol. Res. 157:317–322.
 58. Westendorf, A., R. H. Müller, and W. Babel. 2003. Purification and characterisation of the enantiospecific dioxygenases from *Delftia acidovorans* MCI initiating the degradation of phenoxypropionate and phenoxyacetate herbicides. Acta Biotechnol. 23:3–17.
 59. Whiting, A. K., L. Que, R. E. Saari, R. P. Hausinger, M. A. Fredrick, and J. McCracken. 1997. Metal coordination environment of a Cu(II)-substituted α-keto acid-dependent dioxygenase that degrades the herbicide 2,4-D. J. Am. Chem. Soc. 119:3413–3414.
 60. Zipper, C., M. Bunk, and A. J. B. Zehnder. 1998. Enantioselective uptake and degradation of the chiral herbicide dichlorprop [(R/S)-2-(2,4-dichlorophenoxy)propanoic acid] by *Sphingomonas herbicidovorans* MH. J. Bacteriol. 180:3368–3374.

ERRATUM

Localization and Characterization of Two Novel Genes Encoding Stereospecific Dioxygenases Catalyzing 2(2,4-Dichlorophenoxy)propionate Cleavage in *Delftia acidovorans* MC1

Kathleen M. Schleinitz,^{1*} Sabine Kleinsteuber,¹ Tatiana Vallaeys,^{2,3} and Wolfgang Babel¹

*Department of Environmental Microbiology, UFZ Centre for Environmental Research Leipzig-Halle, Leipzig,
Germany,¹ and Institut National de la Recherche Agronomique² and Laboratoire de Génomique des
Microorganismes Pathogène, Institut Pasteur,³ Paris, France*

Volume 70, no. 9, p. 5357–5365, 2004. Page 5357: The byline should appear as shown above, and the corresponding author footnote should appear as shown below.

* Corresponding author. Mailing address: Department of Environmental Microbiology, UFZ Centre for Environmental Research Leipzig-Halle, Permoserstr. 15, 04318 Leipzig, Germany. Phone: 49-341-235-2190. Fax: 49-341-235-2247. E-mail: kathleen.schleinitz@ufz.de.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 1022

SERIAL NUMBER	FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.		
13/647,081	10/08/2012	800	1638	DAS-P0129-03-US-E		
RULE						
APPLICANTS Terry R. Wright, Camel, IN; Justin M. Lira, Zionsville, IN; Terence Anthony Walsh, Zionsville, IN; Donald Merto, Camel, IN; Pon Samuel Jayakumar, Camel, IN; Gaofeng Lin, Zionsville, IN; Dow AgroSciences LLC, Indianapolis, IN						
** CONTINUING DATA ***** This application is a CON of 12/091,896 11/03/2008 PAT 8,283,522 which is a 371 of PCT/US06/42133 10/27/2006 /DK/ which claims benefit of 60/731,044 10/28/2005						
** FOREIGN APPLICATIONS ***** NONE /DK/						
** IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** 10/23/2012						
Foreign Priority claimed ☐ Yes ☒ No 35 USC 119(a-d) conditions met ☐ Yes ☒ No Verified and /DAVID H KRUSE/ Acknowledged Examiner's Signature		☐ Met after Allowance /DK/ Initials	STATE OR COUNTRY IN	SHEETS DRAWINGS 3	TOTAL CLAIMS 20	INDEPENDENT CLAIMS 3
ADDRESS Faegre Baker Daniels LLP- Dow AgroSciences 300 North Meridian Street, Suite 2700 Indianapolis, IN 46204 UNITED STATES						
TITLE NOVEL HERBICIDE RESISTANCE GENES						
FILING FEE RECEIVED 1710	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:			☐ All Fees ☐ 1.16 Fees (Filing) ☐ 1.17 Fees (Processing Ext. of time) ☐ 1.18 Fees (Issue) ☐ Other _____ ☐ Credit		

Search Notes 	Application/Control No. 13647081	Applicant(s)/Patent Under Reexamination WRIGHT ET AL.
	Examiner DAVID H KRUSE	Art Unit 1638

CPC- SEARCHED		
Symbol	Date	Examiner

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner
EAST	EAST	2/20/2013	/DK/

SEARCH NOTES		
Search Notes	Date	Examiner
Inventor Name Search	2/20/2013	/DK/
EAST: USPAT, USPGPUB, EPO, JPO, DERWENT	2/20/2013	/DK/
STN: AGRICOLA, BIOSIS, CAPLUS, EMBASE, CABA	2/20/2013	/DK/
Sequence Search of SEQ ID NO: 2 and 4, included interference search	1/16/2013	/DK/

INTERFERENCE SEARCH			
US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner

	/DAVID H KRUSE/ Primary Examiner.Art Unit 1638
--	---

13647081

(FILE 'HOME' ENTERED AT 13:30:18 ON 20 FEB 2013)

FILE 'AGRICOLA, CAPLUS, EMBASE, CABA, BIOSIS' ENTERED AT 13:33:02 ON 20
FEB 2013

L1	60 S PLANT AND TFDA AND HERBICIDE
L2	32 DUP REM L1 (28 DUPLICATES REMOVED)
L3	20 S PLANT AND AAD-12 AND HERBICIDE
L4	17 DUP REM L3 (3 DUPLICATES REMOVED)

To: inteias@faegrebd.com,cynthia.payson@faegrebd.com,
From: PAIR_eOfficeAction@uspto.gov
Cc: PAIR_eOfficeAction@uspto.gov
Subject: Private PAIR Correspondence Notification for Customer Number 83067

Mar 01, 2013 05:24:12 AM

Dear PAIR Customer:

Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204
UNITED STATES

The following USPTO patent application(s) associated with your Customer Number, 83067 , have new outgoing correspondence. This correspondence is now available for viewing in Private PAIR.

The official date of notification of the outgoing correspondence will be indicated on the form PTOL-90 accompanying the correspondence.

Disclaimer:

The list of documents shown below is provided as a courtesy and is not part of the official file wrapper. The content of the images shown in PAIR is the official record.

Application	Document	Mailroom Date	Attorney Docket No.
13647081	CTNF	03/01/2013	DAS-P0129-03-US-E
	892	03/01/2013	DAS-P0129-03-US-E

To view your correspondence online or update your email addresses, please visit us anytime at <https://sportal.uspto.gov/secure/myportal/privatepair>.

If you have any questions, please email the Electronic Business Center (EBC) at EBC@uspto.gov with 'e-Office Action' on the subject line or call 1-866-217-9197 during the following hours:

Monday - Friday 6:00 a.m. to 12:00 a.m.

Thank you for prompt attention to this notice,

UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT APPLICATION INFORMATION RETRIEVAL SYSTEM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

App. No. : 13/647,081 Confirmation No. 1022
Applicants : Terry R. Wright, et al.
Filed : October 8, 2012
Title : NOVEL HERBICIDE RESISTANCE GENES
Docket No. : DAS-P0129-03-US-E

**REQUEST FOR CORRECTED
PATENT APPLICATION PUBLICATION**

Applicant hereby requests that the above listed patent application with publication number US 2013/0035233 A1, published on February 7 2013, be corrected under 37 C.F.R. 1.221(b). Applicant contends that the Patent Office made errors in the publication of this application. Specifically, the following errors were noted in the published application:

In the listing of Inventors, Inventor DONALD MERLO's name is incorrectly misspelled as DONALD MERTO. A copy of the first page of the published application, with the requested correction handwritten thereon, and a copy of the previously submitted ADS showing the correct spelling is attached for the Patent Office's convenience.

No fee is believed to be necessary for correction of the Patent Office's error or republication of the patent application.

It is believed that no fees are due in connection with this Request. If any fees are due with this paper, the Office is authorized to charge these fees to Faegre Baker Daniels' Deposit Account No. 02-0390. Any such deposit account charge should not include the payment of any issue fees. The Patent Office is invited to contact the undersigned at (317) 237-0300 if there are any questions concerning this submission.

Respectfully submitted,
/Patrick M. Bickley/
Patrick M. Bickley, Reg. No. 68,575
FAEGRE BAKER DANIELS LLP
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204
Telephone: (317) 237-0300



US 20130035233A1

(19) **United States**(12) **Patent Application Publication**
Wright et al.(10) Pub. No.: **US 2013/0035233 A1**(43) Pub. Date: **Feb. 7, 2013**(54) **NOVEL HERBICIDE RESISTANCE GENES**(71) Applicant: **Dow AgroSciences LLC**, Indianapolis,
IN (US)(72) Inventors: **Terry R. Wright**, Camel, IN (US);
Justin M. Lira, Zionsville, IN (US);
Terence Anthony Walsh, Zionsville, IN
(US); **Donald Merlo**, Camel, IN (US);
Pon Samuel Jayakumar, Camel, IN
(US); **Gaofeng Lin**, Zionsville, IN (US)*A01H 5/10* (2006.01)*A01N 43/50* (2006.01)*A01N 37/40* (2006.01)*A01P 13/00* (2006.01)*A01N 43/40* (2006.01)*A01N 57/20* (2006.01)*C12N 5/10* (2006.01)*A01N 35/10* (2006.01)(52) U.S. CL. **504/206**; 435/418; 435/414; 435/415;
800/278; 800/300; 504/344; 504/324; 504/254;
504/323; 504/253(73) Assignee: **Dow AgroSciences LLC**, Indianapolis,
IN (US)(21) Appl. No.: **13/647,081**(22) Filed: **Oct. 8, 2012****Related U.S. Application Data**(63) Continuation of application No. 12/091,896, filed on
Nov. 3, 2008, now Pat. No. 8,283,522, filed as appli-
cation No. PCT/US06/42133 on Oct. 27, 2006.(60) Provisional application No. 60/731,044, filed on Oct.
28, 2005.**Publication Classification**(51) Int. Cl.
C12N 15/82 (2006.01)
A01H 5/00 (2006.01)(57) **ABSTRACT**

The subject invention provides novel plants that are not only resistant to 2,4-D, but also to pyridyloxyacetate herbicides. Heretofore, there was no expectation or suggestion that a plant with both of these advantageous properties could be produced by the introduction of a single gene. The subject invention also includes plants that produce one or more enzymes of the subject invention "stacked" together with one or more other herbicide resistance genes. The subject invention enables novel combinations of herbicides to be used in new ways. Furthermore, the subject invention provides novel methods of preventing the development of, and controlling, strains of weeds that are resistant to one or more herbicides such as glyphosate. The preferred enzyme and gene for use according to the subject invention are referred to herein as AAD-12 (AryloxyAlkanonate Dioxygenase). This highly novel discovery is the basis of significant herbicide tolerant crop trait and selectable marker opportunities.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	DAS-P0129-03-US-E
		Application Number	
Title of Invention	NOVEL HERBICIDE RESISTANCE GENES		
The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76. This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.			

Secrecy Order 37 CFR 5.2

☐	Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
--------------------------	---

Inventor Information:

Inventor 1					Remove
Legal Name					
Prefix	Given Name	Middle Name	Family Name	Suffix	
	Terry	R.	Wright		
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service					
City	Carmel	State/Province	IN	Country of Residence	
				US	
Mailing Address of Inventor:					
Address 1		14162 Charity Chase Circle			
Address 2					
City	Carmel	State/Province	IN		
Postal Code	46074	Country	US		
Inventor 2					Remove
Legal Name					
Prefix	Given Name	Middle Name	Family Name	Suffix	
	Justin	M.	Lira		
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service					
City	Zionsville	State/Province	IN	Country of Residence	
				US	
Mailing Address of Inventor:					
Address 1		8974 Windpointe Pass			
Address 2					
City	Zionsville	State/Province	IN		
Postal Code	46077	Country	US		
Inventor 3					Remove
Legal Name					
Prefix	Given Name	Middle Name	Family Name	Suffix	
	Terence	Anthony	Walsh		
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service					

Application Data Sheet 37 CFR 1.76		Attorney Docket Number		DAS-P0129-03-US-E	
		Application Number			
Title of Invention		NOVEL HERBICIDE RESISTANCE GENES			
City	Zionsville	State/Province	IN	Country of Residence	US
Mailing Address of Inventor:					
Address 1		11638 Promontory Trail			
Address 2					
City	Zionsville	State/Province	IN		
Postal Code	46077	Country i	US		
Inventor 4					Remove
Legal Name					
Prefix	Given Name	Middle Name	Family Name	Suffix	
	Donald		Merlo		
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service					
City	Carmel	State/Province	IN	Country of Residence	US
Mailing Address of Inventor:					
Address 1		11845 Durbin Drive			
Address 2					
City	Carmel	State/Province	IN		
Postal Code	46032	Country i	US		
Inventor 5					Remove
Legal Name					
Prefix	Given Name	Middle Name	Family Name	Suffix	
	Pon Samuel		Jayakumar		
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service					
City	Carmel	State/Province	IN	Country of Residence	US
Mailing Address of Inventor:					
Address 1		3336 Kilkenny Circle			
Address 2					
City	Carmel	State/Province	IN		
Postal Code	46032	Country i	US		
Inventor 6					Remove
Legal Name					
Prefix	Given Name	Middle Name	Family Name	Suffix	
	Gaofeng		Lin		
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service					
City	Zionsville	State/Province	IN	Country of Residence	US

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	DAS-P0129-03-US-E	
		Application Number		
Title of Invention	NOVEL HERBICIDE RESISTANCE GENES			
Mailing Address of Inventor:				
Address 1	981 Franklin Trace			
Address 2				
City	Zionsville	State/Province	IN	
Postal Code	46077	Country	US	
All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the Add button. Add				

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below. For further information see 37 CFR 1.33(a).			
☐ An Address is being provided for the correspondence information of this application.			
Customer Number	83067		
Email Address	intear@faegrebd.com	Add Email	Remove Email
Email Address	cynthia.payson@faegrebd.com	Add Email	Remove Email

Application Information:

Title of the Invention	NOVEL HERBICIDE RESISTANCE GENES		
Attorney Docket Number	DAS-P0129-03-US-E	Small Entity Status Claimed ☐	
Application Type	Nonprovisional		
Subject Matter	Utility		
Suggested Class (if any)		Sub Class (if any)	
Suggested Technology Center (if any)			
Total Number of Drawing Sheets (if any)	3	Suggested Figure for Publication (if any)	

Publication Information:

☐ Request Early Publication (Fee required at time of Request 37 CFR 1.219)
☐ Request Not to Publish. I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

Representative Information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number will be used for the Representative Information during processing.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	DAS-P0129-03-US-E
		Application Number	
Title of Invention	NOVEL HERBICIDE RESISTANCE GENES		
Please Select One:	☒ Customer Number	☐ US Patent Practitioner	☐ Limited Recognition (37 CFR 11.9)
Customer Number	83067		

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c) or indicate National Stage entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.

Prior Application Status	Pending	Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)
	Continuation of	12091896	2008-11-03
Prior Application Status	Pending	Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)
12091896	a 371 of International	PCTUS2006042133	2006-10-27
Prior Application Status	Expired	Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)
PCTUS2006042133	non provisional of	60731044	2005-10-28

Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the **Add** button.

Foreign Priority Information:

This section allows for the applicant to claim benefit of foreign priority and to identify any prior foreign application for which priority is not claimed. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(a).

Remove			
Application Number	Country ¹	Filing Date (YYYY-MM-DD)	Priority Claimed
			☐ Yes ☒ No

Additional Foreign Priority Data may be generated within this form by selecting the **Add** button.

Authorization to Permit Access:

☐ Authorization to Permit Access to the Instant Application by the Participating Offices

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	DAS-P0129-03-US-E
		Application Number	
Title of Invention	NOVEL HERBICIDE RESISTANCE GENES		

If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and any other intellectual property offices in which a foreign application claiming priority to the instant patent application is filed access to the instant patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority to the instant patent application is filed to have access to the instant patent application.

In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the instant patent application with respect to: 1) the instant patent application-as-filed; 2) any foreign application to which the instant patent application claims priority under 35 U.S.C. 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the instant patent application; and 3) any U.S. application-as-filed from which benefit is sought in the instant patent application.

In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing this Authorization.

Applicant Information:


Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.			
Applicant 1			
If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed. The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be identified in this section.			
☒ Assignee	☐ Legal Representative under 35 U.S.C. 117		
☐ Person to whom the inventor is obligated to assign.	☐ Person who shows sufficient proprietary interest		
If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:			
Name of the Deceased or Legally Incapacitated Inventor: <input type="text"/>			
If the Assignee is an Organization check here. ☒			
Organization Name	Dow AgroSciences LLC		
Mailing Address Information:			
Address 1	9330 Zionsville Road		
Address 2			
City	Indianapolis	State/Province	IN
Country	US	Postal Code	46268
Phone Number		Fax Number	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	DAS-P0129-03-US-E
		Application Number	
Title of Invention	NOVEL HERBICIDE RESISTANCE GENES		

Email Address	
Additional Applicant Data may be generated within this form by selecting the Add button.	

Signature:

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications					
Signature			Date (YYYY-MM-DD)	2012-10-08	
First Name	Jay M.	Last Name	Sanders	Registration Number	39355
Additional Signature may be generated within this form by selecting the Add button.					

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Electronic Acknowledgement Receipt	
EFS ID:	16079213
Application Number:	13647081
International Application Number:	
Confirmation Number:	1022
Title of Invention:	NOVEL HERBICIDE RESISTANCE GENES
First Named Inventor/Applicant Name:	Terry R. Wright
Customer Number:	83067
Filer:	Patrick M. Bickley
Filer Authorized By:	
Attorney Docket Number:	DAS-P0129-03-US-E
Receipt Date:	19-JUN-2013
Filing Date:	08-OCT-2012
Time Stamp:	10:00:32
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request/Corrected Patent Application Publications	das-p0129-03.pdf	1487481 <small>452c0b516a9bab0a456201af7d7146dfa2428158</small>	no	8

Warnings:

Information:

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

SCORE Placeholder Sheet for IFW Content

Application Number: 13647081

Document Date: 08/01/2013

The presence of this form in the IFW record indicates that the following document type was received in electronic format on the date identified above. This content is stored in the SCORE database.

- **Sequence Listing**

Since this was an electronic submission, there is no physical artifact folder, no artifact folder is recorded in PALM, and no paper documents or physical media exist. The TIFF images in the IFW record were created from the original documents that are stored in SCORE.

At the time of document entry (noted above):

- Examiners may access SCORE content via the eDAN interface using the Supplemental Content tab.
- Other USPTO employees can bookmark the current SCORE URL (<http://es/ScoreAccessWeb/>).
- External customers may access SCORE content via the Public and Private PAIR interfaces using the Supplemental Content tab.

Form Revision Date: August 3, 2011

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Ref. : DAS-P0129-03-US-E
Applicants : Terry R. Wright *et al.*
Serial No. : 13/647,081
Conf. No. : 1022
Filed : October 8, 2012
Examiner : Kruse, David H
Title : NOVEL HERBICIDE RESISTANCE GENES

RESPONSE

Authorization for a two -month extension of time accompanies this Response.

This is a Response to the office action dated March 1, 2013. Reconsideration is respectfully requested.

AMENDMENTS TO THE SPECIFICATION begin on page 2 of this Response.

AMENDMENTS TO THE CLAIMS begin on page 3 of this Response.

REMARKS begin on page 6 of this Response.

Application Serial No. 13/647,081
Attorney Ref. DAS-0129-03-US-E
Reply to OA dated 3/1/2013

IN THE SPECIFICATION

A supplement sequence listing including SEQ ID NOs:18-21 is submitted herewith along with a supporting statement. No new matter is introduced.

Please replace the description of Figure 2 on page 7 with the following:

Figure 2 is an amino acid sequence alignment of an exemplified AAD-12 protein (SEQ ID NO:2), TfdA (SEQ ID NO:18), AAD-2 (SEQ ID NO:19), AAD-1 (SEQ ID NO:20), and Tau D (SEQ ID NO:21).

IN THE CLAIMS

1. (original) A transgenic plant cell comprising a recombinant polynucleotide that encodes a protein having an activity that catalyzes degradation of a herbicidal compound selected from the group consisting of a phenoxypropionic auxin and a phenoxyacetic auxin, wherein said protein has at least 95% amino acid sequence identity with a sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:4.
2. (original) The plant cell of claim 1 wherein said plant cell is selected from the group consisting of soybean, cotton, *Arabidopsis*, tobacco and canola.
3. (original) A transgenic plant cell comprising a recombinant polynucleotide that encodes a protein that confers tolerance on said plant cell to a pyridyloxy acetate herbicide, wherein said protein has at least 95% amino acid sequence identity with a sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:4.
4. (original) The cell of claim 3 wherein said pyridyloxy acetate herbicide is selected from the group consisting of triclopyr and fluroxypyr.
5. (original) A method of producing a herbicide tolerant plant, said method comprising introducing a polynucleotide into a plant cell, wherein said polynucleotide encodes a protein having an activity that catalyzes degradation of a herbicidal compound selected from the group consisting of a phenoxypropionic auxin and a phenoxyacetic auxin, wherein said protein has at least 95% amino acid sequence identity with a sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:4, and regenerating a plant from said cell.
6. (original) The method of claim 5 further comprising selecting transformed plant tissue that produces said protein.
7. (original) The cell of claim 1, wherein said protein confers tolerance to 2,4-D to said cell.
8. (original) The plant cell of claim 1, further comprising at least one different polynucleotide that encodes a protein that confers tolerance to the plant cell to a herbicide

selected from the group consisting of glyphosate, glufosinate, HPPD-inhibitors, and dicamba.

9. (original) The plant cell of claim 8, wherein the plant cell is selected from the group consisting of soybean, cotton, or canola.
10. (original) The plant cell of claim 8, wherein the plant cell is a soybean cell and the herbicide is selected from the group consisting of glyphosate and dicamba.
11. (original) The plant cell of claim 8, wherein the plant cell is a soybean cell and the herbicide is selected from the group consisting of glyphosate and glufosinate.
12. (original) The plant cell of claim 1, further comprising a second polynucleotide that encodes a gene product having an insecticidal activity.
13. (original) The plant cell of claim 12, wherein said gene product encoded by said second polynucleotide is selected from the group consisting of Cry1F and Cry1Ac.
14. (original) The plant cell of claim 1 further comprising an output trait.
15. (original) The plant cell of claim 1 further comprising an input trait.
16. (original) A plant comprising a plurality of cells of claim 1.
17. (currently amended) A part, progeny, seed or asexual propagate of the plant of claim 4716, wherein said part, progeny, seed or propagate comprises said polynucleotide.
18. (original) A method for selectively controlling weeds in a field, said field containing a crop, said crop comprising plant cells of claim 1, said method comprising applying an aryloxyalkanoate herbicide to at least a portion of the crop and the weeds in the field to control the weeds.

Application Serial No. 13/647,081
Attorney Ref. DAS-0129-03-US-E
Reply to OA dated 3/1/2013

19. (original) A method of controlling volunteer plants of a crop comprising the plant cells of claim 1, said method comprising applying to said volunteer plants a herbicide selected from the group consisting of ACCase inhibitors, HPPD inhibitors, ALS inhibitors, and dicamba.
20. (original) The method of claim 19 wherein the herbicide is selected from sethoxydim and clethodim.

REMARKS

Claims Status:

Claims 1-20 were the subject of the Office Action dated March 1, 2013. These claims are again presented for further consideration.

Specification:

Sequence identifiers are now presented in the Brief Description of Figure 2, and corresponding sequences for SEQ ID NOs: 18-21 are now included in the attached supplemental sequence listing.

Claim Objection:

Claim 17 is amended to correct its dependency.

Claim rejection under 35 USC §112 (a) and (b)

Claim 14 stands rejected under 35 USC §112(a) and (b) or 35 USC 112 (pre-AIA) first and second paragraphs in light of the use of the term "output trait." The applicants respectfully traverse these rejections.

This term is well-known in the art, and basis is provided in the specification. For example, the specification on page 12, paragraph 49, line 3-4, states:

"...output (e.g., increased yield, improved oil profile, improved fiber quality, et al.) traits."

In light of foregoing, Applicant respectfully request the withdrawal of these rejections of claim 14.

Claim rejection under 35 USC §103 (a)

Claims 1-20 stand rejected as being obvious in view of Kaphammer, Schleinitz et al, Pallet et al, and Malvar et al. The applicants respectfully traverse this rejection.

Kaphammer relates to tfdA, which shares only about 31% identity with SEQ ID NO:2 (AAD-12). The examiner admits on page 5 of the office action that this reference does not teach the subject genes and proteins, nor does it teach introducing a gene that confers glufosinate resistance.

Schleinitz relates to bacterial genes.

Pallett is cited as teaching plant transformation in general.

Malvar is cited as teaching stacking with insect resistance genes in general.

The examiner states that it would have thus been obvious to introduce the gene of Schleinitz into a plant with a reasonable expectation of success. The applicants respectfully traverse this rejection.

Example 1 of the subject specification states as follows (emphasis added):

As a way to identify genes which possess herbicide degrading activities *in planta*, it is possible to mine current public databases such as NCBI (National Center for Biotechnology Information). To begin the process, it is necessary to have a functional gene sequence already identified that encodes a protein with the desired characteristics (*i.e.*, α -ketoglutarate dioxygenase activity). This protein sequence is then used as the input for the BLAST (Basic Local Alignment Search Tool) (Altschul *et al.*, 1997) algorithm to compare against available NCBI protein sequences deposited. **Using default settings, this search returns upwards of 100 homologous protein sequences at varying levels. These range from highly identical (85-98%) to very low identity (23-32%) at the amino acid level.** Traditionally only sequences with high homology would be expected to retain similar properties to the input sequence. In this case, only sequences with $\leq 50\%$ homology were chosen. As exemplified herein, cloning and recombinantly expressing homologues with as little as 31% amino acid conservation (relative to *tfdA* from *Ralstonia eutropha*) can be used to impart commercial levels of resistance not only to the intended herbicide, but also to substrates never previously tested with these enzymes.

A single gene (*sdpA*) was identified from the NCBI database (see the ncbi.nlm.nih.gov website; accession #AF516752) as a homologue **with only 31% amino acid identity to *tfdA*.** Percent identity was determined by first translating both the *sdpA* and *tfdA* DNA sequences deposited in the database to proteins, then using ClustalW in the VectorNTI software package to perform the multiple sequence alignment.

Thus, the gene/protein of SEQ ID NO:2 was selected from many possible options (over 100).

In addition, Example 14 (entitled "Further Evidence of Surprising Results: AAD-12 versus AAD-2") of the subject specification states (with emphasis added):

Another gene was identified from the NCBI database (see the ncbi.nlm.nih.gov website; accession #AP005940) as a homologue with only 44% amino acid identity to *tfdA*. This gene is referred to herein as *AAD-2 (v1)* for consistency. Percent identity was determined by first translating both the *AAD-2* and *tfdA* DNA sequences (SEQ ID NO:12 of PCT/US2005/014737 and GENBANK Accession No. M16730, respectively) to proteins (SEQ ID NO:13 of PCT/US2005/014737 and GENBANK Accession No. M16730, respectively), then using ClustalW in the VectorNTI software package to perform the multiple sequence alignment...

...*AAD-12 (v1)* and *AAD-2 (v1)* did provide detectable 2,4-D resistance versus the transformed and untransformed control lines; however, individual constructs were widely variable in their ability to impart 2,4-D resistance to individual T₁ *Arabidopsis* plants. **Surprisingly, *AAD-2 (v1)* and *AAD-2 (v2)* transformants were far less**

resistant to 2,4-D than the AAD-12 (v1) gene, both from a frequency of highly tolerant plants as well as overall average injury. No plants transformed with AAD-2 (v1) survived 200 g ae/ha 2,4-D relatively uninjured (<20% visual injury), and overall population injury was about 83% (see PCT/US2005/014737). Conversely, AAD-12 (v1) had a population injury average of about 6% when treated with 3,200 g ae/ha 2,4-D (Table 11). Tolerance improved slightly for plant-optimized AAD-2 (v2) versus the native gene; however, comparison of both AAD-12 and AAD-2 plant optimized genes indicates a significant advantage for AAD-12 (v1) in planta.

These results are unexpected given that the *in vitro* comparison of AAD-2 (v1) (see PCT/US2005/014737) and AAD-12 (v2) indicated both were highly efficacious at degrading 2,4-D and both shared an S-type specificity with respect to chiral aryloxyalkanoate substrates. AAD-2 (v1) is expressed in individual T₁ plants to varying levels; however, little protection from 2,4-D injury is afforded by this expressed protein. No substantial difference was evident in protein expression level (*in planta*) for the native and plant optimized AAD-2 genes (see PCT/US2005/014737). These data corroborate earlier findings that make the functional expression of AAD-12 (v1) *in planta*, and resulting herbicide resistance to 2,4-D and pyridyloxyacetate herbicides, unexpected.

Thus, it is clear that the subject AAD-12 surprisingly performed much better in plants than AAD-2 (which had little if any activity in plants), even though AAD-2 had a higher level of identity to the cited tfdA gene/protein of Klaphammer.

The above results show that the behavior and activity of a herbicide-tolerance bacterial gene in plants cannot be predicted based on its behavior and activity in bacteria (the *in vitro* results were in *E. coli*). AAD-2 is *more* related at the sequence level to the cited tfdA than is the subject AAD-12. While both genes/proteins were active in bacteria, AAD-2 was essentially inactive in plants, and the subject AAD-12 was surprisingly very active in plants.

This shows that herbicidal activity of bacterial genes in plants is unpredictable and that the results in bacteria cannot readily be used to predict *in planta* behavior. Again, there were over a hundred choices to begin with. If AAD-2 were used as a point of reference (again, AAD-2 is *more* related to tfdA at the sequence level than is AAD-12), one would have expected *no* activity in plants for AAD-12.

The foregoing should show that there was no reasonable prediction or expectation of successfully producing herbicide-tolerant plants using the subject AAD-12. In addition, nothing pointed to using AAD-12 over the 100+ other choices, such as AAD-2.

In light of these surprising and unexpected results, the withdrawal of this rejection for obviousness is respectfully requested.

Application Serial No. 13/647,081
Attorney Ref. DAS-0129-03-US-E
Reply to OA dated 3/1/2013

Double Patenting:

Claim 1-20 stand rejected on the ground of nonstatutory obviousness type double patenting as being unpatentable over claims 1-4 of US Patent No. 8,283,522. Should the subject application be allowed, the applicants may file a terminal disclaimer to overcome such rejection.


Conclusion:

In light of foregoing, the application is believed to be in condition for allowance, and such action is respectfully requested.

This response is being filed with an authorization for a two-month extension of time. This fee and any additional fees due in connection with this response are hereby authorized to be charged to Deposit Account No. 02-0390 but not to include any issue fees.

August 1, 2013

Respectfully submitted,



Jay M. Sanders, Reg. No. 39,355
Faegre Baker Daniels LLP
300 N. Meridian Street, Suite 2700
Indianapolis, Indiana 46204
Telephone: (317) 237-1245
Fax: (317) 237-1000

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Dow AgroSciences LLC	) Customer No.:83067
		)
Filed:	Concurrent filing	)
		)
Title:	Novel Herbicide Resistance Genes	)
		)
Docket No.	DAS-P0129-03-US-E	)
		)
Application No.:	13/647,081	)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT IN SUPPORT OF SEQUENCE LISTING


Pursuant to 37 C.F.R. § 1.821 (c), (e), and (f), and in response to Office Action dated March 1st, 2013, Applicant hereby submits a supplemental sequence listing that includes the sequences and corresponding sequence identifiers for Figure 2. The attached sequence listing (in Computer Readable Form) is otherwise the same as the previously submitted sequence listing.

Concurrent to this submission, applicant has requested to amend the Specification's Figure 2 brief description on Page 7 to include the sequence identifiers. Please enter this supplement sequence listing and the amendment to Figure 2 description into the specification.

This submission contains no new matter.

If the Examiner has any questions regarding this submission, the Examiner is invited to contact the undersigned, Mr. Jay Sanders, at 317-237-1245.

Respectfully submitted,



Jay M. Sanders, Reg. #39,355
Faegre Baker Daniels LLP
300 N. Meridian Street, Suite 2700
Indianapolis, Indiana 46204
Telephone: (317) 237-1245
Fax: (317) 237-1000

Date Submitted: August 1, 2013

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)		Docket Number (Optional) DAS-P0129-03-US-E																																		
Application Number 13/647,081	Filed October 8, 2012																																			
For NOVEL HERBICIDE RESISTANCE GENES																																				
Art Unit 1638	Examiner David H. Kruse																																			
<p>This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above-identified application.</p> <p>The requested extension and fee are as follows (check time period desired and enter the appropriate fee below):</p> <table style="width: 100%; border-collapse: collapse;"><thead><tr><th></th><th style="text-align: center;"><u>Fee</u></th><th style="text-align: center;"><u>Small Entity Fee</u></th><th style="text-align: center;"><u>Micro Entity Fee</u></th><th></th></tr></thead><tbody><tr><td>☐ One month (37 CFR 1.17(a)(1))</td><td style="text-align: center;">\$200</td><td style="text-align: center;">\$100</td><td style="text-align: center;">\$50</td><td>\$ _____</td></tr><tr><td>☒ Two months (37 CFR 1.17(a)(2))</td><td style="text-align: center;">\$600</td><td style="text-align: center;">\$300</td><td style="text-align: center;">\$150</td><td>\$ 600.00</td></tr><tr><td>☐ Three months (37 CFR 1.17(a)(3))</td><td style="text-align: center;">\$1,400</td><td style="text-align: center;">\$700</td><td style="text-align: center;">\$350</td><td>\$ _____</td></tr><tr><td>☐ Four months (37 CFR 1.17(a)(4))</td><td style="text-align: center;">\$2,200</td><td style="text-align: center;">\$1,100</td><td style="text-align: center;">\$550</td><td>\$ _____</td></tr><tr><td>☐ Five months (37 CFR 1.17(a)(5))</td><td style="text-align: center;">\$3,000</td><td style="text-align: center;">\$1,500</td><td style="text-align: center;">\$750</td><td>\$ _____</td></tr></tbody></table> <p>☐ Applicant asserts small entity status. See 37 CFR 1.27.</p> <p>☐ Applicant certifies micro entity status. See 37 CFR 1.29. Form PTO/SB/15A or B or equivalent must either be enclosed or have been submitted previously.</p> <p>☐ A check in the amount of the fee is enclosed.</p> <p>☐ Payment by credit card. Form PTO-2038 is attached.</p> <p>☐ The Director has already been authorized to charge fees in this application to a Deposit Account.</p> <p>☒ The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number <u>020390</u>.</p> <p>☐ Payment made via EFS-Web.</p> <p>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p> <p>I am the</p> <p>☐ applicant.</p> <p>☒ attorney or agent of record. Registration number <u>39,355</u>.</p> <p>☐ attorney or agent acting under 37 CFR 1.34. Registration number _____.</p> <table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 50%; vertical-align: bottom;">/Jay M. Sanders/ _____ Signature</td><td style="width: 50%; vertical-align: bottom;">August 1, 2013 _____ Date</td></tr><tr><td style="vertical-align: bottom;">Jay M. Sanders _____ Typed or printed name</td><td style="vertical-align: bottom;">(317) 237-1245 _____ Telephone Number</td></tr></table> <p>NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications. Submit multiple forms if more than one signature is required, see below*.</p>				<u>Fee</u>	<u>Small Entity Fee</u>	<u>Micro Entity Fee</u>		☐ One month (37 CFR 1.17(a)(1))	\$200	\$100	\$50	\$ _____	☒ Two months (37 CFR 1.17(a)(2))	\$600	\$300	\$150	\$ 600.00	☐ Three months (37 CFR 1.17(a)(3))	\$1,400	\$700	\$350	\$ _____	☐ Four months (37 CFR 1.17(a)(4))	\$2,200	\$1,100	\$550	\$ _____	☐ Five months (37 CFR 1.17(a)(5))	\$3,000	\$1,500	\$750	\$ _____	/Jay M. Sanders/ _____ Signature	August 1, 2013 _____ Date	Jay M. Sanders _____ Typed or printed name	(317) 237-1245 _____ Telephone Number
	<u>Fee</u>	<u>Small Entity Fee</u>	<u>Micro Entity Fee</u>																																	
☐ One month (37 CFR 1.17(a)(1))	\$200	\$100	\$50	\$ _____																																
☒ Two months (37 CFR 1.17(a)(2))	\$600	\$300	\$150	\$ 600.00																																
☐ Three months (37 CFR 1.17(a)(3))	\$1,400	\$700	\$350	\$ _____																																
☐ Four months (37 CFR 1.17(a)(4))	\$2,200	\$1,100	\$550	\$ _____																																
☐ Five months (37 CFR 1.17(a)(5))	\$3,000	\$1,500	\$750	\$ _____																																
/Jay M. Sanders/ _____ Signature	August 1, 2013 _____ Date																																			
Jay M. Sanders _____ Typed or printed name	(317) 237-1245 _____ Telephone Number																																			
<div style="border: 1px solid black; padding: 5px;">☒ * Total of <u>1</u> forms are submitted.</div>																																				

This collection of information is required by 37 CFR 1.136(a). The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 6 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Patent Application Fee Transmittal				
Application Number:		13647081		
Filing Date:		08-Oct-2012		
Title of Invention:		NOVEL HERBICIDE RESISTANCE GENES		
First Named Inventor/Applicant Name:		Terry R. Wright		
Filer:		Jay M. Sanders/Cindy Cohen-Katz		
Attorney Docket Number:		DAS-P0129-03-US-E		
Filed as Large Entity				
Utility under 35 USC 111(a) Filing Fees				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Extension - 2 months with \$0 paid	1252	1	600	600

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
Total in USD (\$)				600

Electronic Acknowledgement Receipt	
EFS ID:	16480667
Application Number:	13647081
International Application Number:	
Confirmation Number:	1022
Title of Invention:	NOVEL HERBICIDE RESISTANCE GENES
First Named Inventor/Applicant Name:	Terry R. Wright
Customer Number:	83067
Filer:	Jay M. Sanders/Cindy Cohen-Katz
Filer Authorized By:	Jay M. Sanders
Attorney Docket Number:	DAS-P0129-03-US-E
Receipt Date:	01-AUG-2013
Filing Date:	08-OCT-2012
Time Stamp:	17:09:56
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$600
RAM confirmation Number	4335
Deposit Account	020390
Authorized User	
<p>The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)</p>	

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Amendment/Req. Reconsideration-After Non-Final Reject	DAS_P0129_03_US_Response.pdf	108547	no	9
			c620b6214a0d107448a2cc4c196419fcbcb ba25e		
Warnings:					
Information:					
2	CRF Statement Paper and CRF are the same	DAS_P0129_03_US_Statement_SL.pdf	19352	no	2
			6bb426fa877da2acb025d324914d8d2d486 5050e		
Warnings:					
Information:					
3	Extension of Time	DAS-P0129_03_US_EXT.pdf	151177	no	2
			dfb1c24d202f5da1279509a4534da8534d5 0d8f4		
Warnings:					
Information:					
4	Sequence Listing (Text File)	DAS_P0129_03_US_ST25_updated.txt	22031	no	0
Warnings:					
Information:					
5	Fee Worksheet (SB06)	fee-info.pdf	30835	no	2
			3d9bae9344e77046bccce13d707f799f43d 5cb4		
Warnings:					
Information:					
Total Files Size (in bytes):			331942		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					

=====
Sequence Listing was accepted.
If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).
Reviewer: Durreshwar Anjum
Timestamp: [year=2013; month=8; day=6; hr=13; min=53; sec=52; ms=790;]
=====

Application No: 13647081 Version No: 2.0

Input Set:

Output Set:

Started: 2013-08-01 17:11:17.541
 Finished: 2013-08-01 17:11:18.255
 Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 714 ms
 Total Warnings: 21
 Total Errors: 0
 No. of SeqIDs Defined: 21
 Actual SeqID Count: 21

Error code	Error Description
W 402	Undefined organism found in <213> in SEQ ID (1)
W 402	Undefined organism found in <213> in SEQ ID (2)
W 402	Undefined organism found in <213> in SEQ ID (3)
W 402	Undefined organism found in <213> in SEQ ID (4)
W 402	Undefined organism found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)
W 402	Undefined organism found in <213> in SEQ ID (18)
W 402	Undefined organism found in <213> in SEQ ID (19)
W 402	Undefined organism found in <213> in SEQ ID (20)

Input Set:

Output Set:

Started: 2013-08-01 17:11:17.541
Finished: 2013-08-01 17:11:18.255
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 714 ms
Total Warnings: 21
Total Errors: 0
No. of SeqIDs Defined: 21
Actual SeqID Count: 21

Error code	Error Description
W 402	Undefined organism found in <213> in SEQ ID (21)

SEQUENCE LISTING

<110> Wright, Terry R.
Lira, Justin M.
Walsh, Terence A.
Merlo, Donald J.
Jayakumar, Pon Samuel
Lin, Gaofeng

<120> Novel Herbicide Resistance Genes

<130> DAS-P0129-02-US-e

<140> US 13/647,081

<141> 2012-10-08

<150> US 60/731,044

<151> 2005-10-28

<150> PCT/US2006/042133

<151> 2006-10-27

<160> 21

<170> PatentIn version 3.3

<210> 1

<211> 879

<212> DNA

<213> Delftia acidovorans

<400> 1

atgcagacga cgctgcagat tccccccaca ggcgccaccc tgggcgccac cgtcaccggc	60
gtgcacctgg ccacgctgga cgacgcgggc ttgcgcgcc tgcacgcgc ctggctgcag	120
catgcctgct tgatcttccc cggccagcac ctacagcaac accagcagat cacttttgcc	180
aaacgcttcg gcgcgatcga gcgcctcggc ggcggcgaca tcgtggccat ctccaatgtc	240
aaggccgatg gcacggtgcg ccagcacagc cccgccgagt gggacgacat gatgaaggtc	300
atcgtcggca acatggcctg gcatgccgac agcacetaca tgccggtgat ggcgcagggc	360
gcggtgttct cggccgaagt ggtgcccgca gtgggcgggc gcacctgctt cgccgacatg	420
cgcgcgcct acgacgcgct ggacgaggcc acccgcgcc tgggtcacca gcgctcggcg	480
cggcattcgc tgggtgtattc gcagagcaag ctgggccatg tgcagcaggc cggctcggcc	540
tacatcggt acggcatgga caccaccgcc acgccccctgc gcccgctggt caaggtgcat	600
cccgagaccg gcgcgccctc gctgctgata ggccgccatg cccatgccat cccgggcatg	660
gacgcgcgcg aatccgagcg ctctctggaa ggctggctg actgggcctg ccaggcgccg	720
cgggtgcatg cccaccaatg ggcgcgcggc gacgtggtgg tgtgggacaa ccgctgctg	780

ctgcaccgcg ccgagccctg ggatttcaag ctgccgcggg tgatgtggca cagccgectg 840

gccggccgcc ccgagaccga gggcgccgcc ctggtgtaa 879

<210> 2

<211> 292

<212> PRT

<213> Delftia acidovorans

<400> 2

Met Gln Thr Thr Leu Gln Ile Thr Pro Thr Gly Ala Thr Leu Gly Ala
1 5 10 15

Thr Val Thr Gly Val His Leu Ala Thr Leu Asp Asp Ala Gly Phe Ala
20 25 30

Ala Leu His Ala Ala Trp Leu Gln His Ala Leu Leu Ile Phe Pro Gly
35 40 45

Gln His Leu Ser Asn Asp Gln Gln Ile Thr Phe Ala Lys Arg Phe Gly
50 55 60

Ala Ile Glu Arg Ile Gly Gly Gly Asp Ile Val Ala Ile Ser Asn Val
65 70 75 80

Lys Ala Asp Gly Thr Val Arg Gln His Ser Pro Ala Glu Trp Asp Asp
85 90 95

Met Met Lys Val Ile Val Gly Asn Met Ala Trp His Ala Asp Ser Thr
100 105 110

Tyr Met Pro Val Met Ala Gln Gly Ala Val Phe Ser Ala Glu Val Val
115 120 125

Pro Ala Val Gly Gly Arg Thr Cys Phe Ala Asp Met Arg Ala Ala Tyr
130 135 140

Asp Ala Leu Asp Glu Ala Thr Arg Ala Leu Val His Gln Arg Ser Ala
145 150 155 160

Arg His Ser Leu Val Tyr Ser Gln Ser Lys Leu Gly His Val Gln Gln
165 170 175

Ala Gly Ser Ala Tyr Ile Gly Tyr Gly Met Asp Thr Thr Ala Thr Pro

180 185 190
 Leu Arg Pro Leu Val Lys Val His Pro Glu Thr Gly Arg Pro Ser Leu
 195 200 205

 Leu Ile Gly Arg His Ala His Ala Ile Pro Gly Met Asp Ala Ala Glu
 210 215 220

 Ser Glu Arg Phe Leu Glu Gly Leu Val Asp Trp Ala Cys Gln Ala Pro
 225 230 235 240

 Arg Val His Ala His Gln Trp Ala Ala Gly Asp Val Val Val Trp Asp
 245 250 255

 Asn Arg Cys Leu Leu His Arg Ala Glu Pro Trp Asp Phe Lys Leu Pro
 260 265 270

 Arg Val Met Trp His Ser Arg Leu Ala Gly Arg Pro Glu Thr Glu Gly
 275 280 285

 Ala Ala Leu Val
 290

<210> 3
 <211> 882
 <212> DNA
 <213> Delftia acidovorans

<400> 3
 atggctcaga ccactctcca aatcacaccc actggtgcc ccttgggtgc cacagtcaact 60

 ggtgttcacc ttgccacact tgacgatgct ggtttcgctg ccctccatgc agcctggcctt 120

 caacatgcac tcttgatctt ccttgggcaa cacctcagca atgaccaaca gattaccttt 180

 gctaaacgct ttggagcaat tgagaggatt ggcggagggtg acattgttgc catatccaat 240

 gtcaaggcag atggcacagt gcgccagcac tctctgctg agtgggatga catgatgaag 300

 gtcattgtgg gcaacatggc ctggcacgcc gactcaacct acatgccagt catggctcaa 360

 ggagctgtgt tcagcgaga agttgtccca gcagttgggg gcagaacctg ctttgetgac 420

 atgagggcag cctacgatgc ctttgatgag gcaaccgtg ctcttgttca ccaaaggctct 480

 gtcgctcact cccttgtgta ttctcagagc aagttgggac atgtccaaca ggccgggtca 540

 gcctacatag gttatggcat ggacaccact gcaactctc tcagaccatt ggtcaagggtg 600

catcctgaga ctggaaggcc cagcctcttg atcgcccgcc atgcccattgc catccctggc 660
atggatgcag ctgaatcaga gcgcttcctt gaaggacttg ttgactgggc ctgccagget 720
cccagagtcc atgctcacca atgggctgct ggagatgtgg ttgtgtggga caaccgctgt 780
ttgctccacc gtgctgagcc ctgggatttc aagttgccac gtgtgatgtg gcactecaga 840
ctcgctggac gccagaaaac tgagggtgct gccttggttt ga 882

<210> 4
<211> 293
<212> PRT
<213> Delftia acidovorans

<400> 4

Met Ala Gln Thr Thr Leu Gln Ile Thr Pro Thr Gly Ala Thr Leu Gly
1 5 10 15

Ala Thr Val Thr Gly Val His Leu Ala Thr Leu Asp Asp Ala Gly Phe
20 25 30

Ala Ala Leu His Ala Ala Trp Leu Gln His Ala Leu Leu Ile Phe Pro
35 40 45

Gly Gln His Leu Ser Asn Asp Gln Gln Ile Thr Phe Ala Lys Arg Phe
50 55 60

Gly Ala Ile Glu Arg Ile Gly Gly Gly Asp Ile Val Ala Ile Ser Asn
65 70 75 80

Val Lys Ala Asp Gly Thr Val Arg Gln His Ser Pro Ala Glu Trp Asp
85 90 95

Asp Met Met Lys Val Ile Val Gly Asn Met Ala Trp His Ala Asp Ser
100 105 110

Thr Tyr Met Pro Val Met Ala Gln Gly Ala Val Phe Ser Ala Glu Val
115 120 125

Val Pro Ala Val Gly Gly Arg Thr Cys Phe Ala Asp Met Arg Ala Ala
130 135 140

Tyr Asp Ala Leu Asp Glu Ala Thr Arg Ala Leu Val His Gln Arg Ser
145 150 155 160

Ala Arg His Ser Leu Val Tyr Ser Gln Ser Lys Leu Gly His Val Gln
165 170 175

Gln Ala Gly Ser Ala Tyr Ile Gly Tyr Gly Met Asp Thr Thr Ala Thr
180 185 190

Pro Leu Arg Pro Leu Val Lys Val His Pro Glu Thr Gly Arg Pro Ser
195 200 205

Leu Leu Ile Gly Arg His Ala His Ala Ile Pro Gly Met Asp Ala Ala
210 215 220

Glu Ser Glu Arg Phe Leu Glu Gly Leu Val Asp Trp Ala Cys Gln Ala
225 230 235 240

Pro Arg Val His Ala His Gln Trp Ala Ala Gly Asp Val Val Val Trp
245 250 255

Asp Asn Arg Cys Leu Leu His Arg Ala Glu Pro Trp Asp Phe Lys Leu
260 265 270

Pro Arg Val Met Trp His Ser Arg Leu Ala Gly Arg Pro Glu Thr Glu
275 280 285

Gly Ala Ala Leu Val
290

<210> 5
<211> 882
<212> DNA
<213> Delftia acidovorans

<400> 5
atggctcaga ctaccctgca gattaccccg actggtgcga ccctgggtgc aaccgttacc 60
ggcggttcacc tggcgactct ggatgacgca ggtttcgctg cgctgcacgc ggcttggtctg 120
caacatgctc tcctgatattt ccaggtcag cacctgtcca acgaccagca aatcactttt 180
gcaaaacgct tcggtgcat cgaacgtatc ggtggcggtg atattgtggc gatctccaac 240
gtaaaagcgg atggtactgt acgtcagcac agcccggcgg agtgggacga tatgatgaag 300
gtgatcgtag gcaacatggc atggcatgct gacagcacct acatgccggt tatggcgag 360
ggtgcggttt tctctgctga agtggttccg gcagtgggag gtcgcacctg cttcgcagac 420

atgcgtgcag cttacgacgc gttagacgaa gctaccgcgc cactggtaca ccagcgcctct 480
gcgcgtcact ctctggtgta ttcccagagc aaactggggc acgttcagca agcgggctcc 540
gcataatcgc gctacggtat ggataccact gcgacccgcg tgcgtccgct ggtaaaagtg 600
catccgaaaa ccggccgtcc gtctctcctg atcggcgcgc acgctcatgc gattccgggt 660
atggacgcgg cagaatccga gcgtttcctg gaaggtctgg ttgattgggc ttgtcaggcg 720
ccgcgtgtgc atgtcacca gtgggcagct ggcgacgtgg ttgtatggga taaccgctgc 780
ctgcttcacc gtgcagaacc gtgggacttt aagctgccac gtgttatgtg gcacagccgt 840
ctggcaggcc gcccagaaac cgagggcgcg gctctggttt aa 882

<210> 6
<211> 16
<212> DNA
<213> Artificial sequence

<220>
<223> Chemically synthesized M13 forward sequencing primer

<400> 6
gtaaaacgac ggccag 16

<210> 7
<211> 17
<212> DNA
<213> Artificial sequence

<220>
<223> Chemically synthesized M13 reverse sequencing primer

<400> 7
caggaaacag ctatgac 17

<210> 8
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Chemically synthesized forward AAD-12 (v1) PTU primer

<400> 8
gaacagttag acatggtcta aagg 24

<210> 9
<211> 27
<212> DNA
<213> Artificial sequence

<220>
 <223> Chemically synthesized reverse AAD-12 (v1) PTU primer

<400> 9
 gctgcaacac tgataaatgc caactgg 27

<210> 10
 <211> 22
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Chemically synthesized forward AAD-12 (v1) coding PCR primer

<400> 10
 atggctcaga ccactctcca aa 22

<210> 11
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Chemically synthesized reverse AAD-12 (v1) coding PCR primer

<400> 11
 agctgcatcc atgccaggga 20

<210> 12
 <211> 22
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Chemically synthesized SdpacodF: AAD-12 (v1) forward coding region primer

<400> 12
 atggctcatg ctgccctcag cc 22

<210> 13
 <211> 22
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Chemically synthesized SdpacodR: AAD-12 (v1) reverse coding region primer

<400> 13
 cgggcaggcc taactccacc aa 22

<210> 14
 <211> 32
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Chemically synthesized primer "NcoI of Brady"

 <400> 14
 tataccacat gtcgatcgcc atccggcagc tt 32

 <210> 15
 <211> 33
 <212> DNA
 <213> Artificial sequence

 <220>
 <223> Chemically synthesized primer "SacI of Brady"

 <400> 15
 gagctcctat cactccgccg cctgctgctg cac 33

 <210> 16
 <211> 34
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Primer brjap 5'(speI)

 <400> 16
 actagtaaca aagaaggaga tataccatga cgat 34

 <210> 17
 <211> 33
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Primer br jap 3' (xhoI)

 <400> 17
 ttctcgagct atcactccgc cgctgctgc tgc 33

 <210> 18
 <211> 287
 <212> PRT
 <213> Ralstonia eutropha JMP134

 <400> 18

Met Ser Val Val Ala Asn Pro Leu His Pro Leu Phe Ala Ala Gly Val
 1 5 10 15
 Glu Asp Ile Asp Leu Arg Glu Ala Leu Gly Ser Thr Glu Val Arg Glu
 20 25 30
 Ile Glu Arg Leu Met Asp Glu Lys Ser Val Leu Val Phe Arg Gly Gln
 35 40 45
 Pro Leu Ser Gln Asp Gln Gln Ile Ala Phe Ala Arg Asn Phe Gly Pro
 50 55 60
 Leu Glu Gly Gly Phe Ile Lys Val Asn Gln Arg Pro Ser Arg Phe Lys
 65 70 75 80
 Tyr Ala Glu Leu Ala Asp Ile Ser Asn Val Ser Leu Asp Gly Lys Val
 85 90 95
 Ala Gln Arg Asp Ala Arg Glu Val Val Gly Asn Phe Ala Asn Gln Leu
 100 105 110
 Trp His Ser Asp Ser Ser Phe Gln Gln Pro Ala Ala Arg Tyr Ser Met
 115 120 125
 Leu Ser Ala Val Val Val Pro Pro Ser Gly Gly Asp Thr Glu Phe Cys
 130 135 140
 Asp Met Arg Ala Ala Tyr Asp Ala Leu Pro Arg Asp Leu Gln Ser Glu
 145 150 155 160
 Leu Glu Gly Leu Arg Ala Glu His Tyr Ala Leu Asn Ser Arg Phe Leu
 165 170 175
 Leu Gly Asp Thr Asp Tyr Ser Glu Ala Gln Arg Asn Ala Met Pro Pro
 180 185 190
 Val Asn Trp Pro Leu Val Arg Thr His Ala Gly Ser Gly Arg Lys Phe
 195 200 205
 Leu Phe Ile Gly Ala His Ala Ser His Val Glu Gly Leu Pro Val Ala
 210 215 220
 Glu Gly Arg Met Leu Leu Ala Glu Leu Leu Glu His Ala Thr Gln Arg

225 230 235 240

 Glu Phe Val Tyr Arg His Arg Trp Asn Val Gly Asp Leu Val Met Trp
 245 250 255

 Asp Asn Arg Cys Val Leu His Arg Gly Arg Arg Tyr Asp Ile Ser Ala
 260 265 270

 Arg Arg Glu Leu Arg Arg Ala Thr Thr Leu Asp Asp Ala Val Val
 275 280 285

 <210> 19
 <211> 289
 <212> PRT
 <213> Bradyrhizobium japonicum USDA 110

 <400> 19

 Met Thr Ile Ala Ile Arg Gln Leu Gln Thr His Phe Val Gly Gln Val
 1 5 10 15

 Ser Gly Leu Asp Leu Arg Lys Pro Leu Thr Pro Gly Glu Ala Arg Glu
 20 25 30

 Val Glu Ser Ala Met Asp Lys Tyr Ala Val Leu Val Phe His Asp Gln
 35 40 45

 Asp Ile Thr Asp Glu Gln Gln Met Ala Phe Ala Leu Asn Phe Gly Gln
 50 55 60

 Arg Glu Asp Ala Arg Gly Gly Thr Val Thr Lys Glu Lys Asp Tyr Arg
 65 70 75 80

 Leu Gln Ser Gly Leu Asn Asp Val Ser Asn Leu Gly Lys Asp Gly Lys
 85 90 95

 Pro Leu Ala Lys Asp Ser Arg Thr His Leu Phe Asn Leu Gly Asn Cys
 100 105 110

 Leu Trp His Ser Asp Ser Ser Phe Arg Pro Ile Pro Ala Lys Phe Ser
 115 120 125

 Leu Leu Ser Ala Arg Val Val Asn Pro Thr Gly Gly Asn Thr Glu Phe
 130 135 140

Ala Asp Met Arg Ala Ala Tyr Asp Ala Leu Asp Asp Glu Thr Lys Ala
145 150 155 160

Glu Ile Glu Asp Leu Val Cys Glu His Ser Leu Met Tyr Ser Arg Gly
165 170 175

Ser Leu Gly Phe Thr Glu Tyr Thr Asp Glu Glu Lys Gln Met Phe Lys
180 185 190

Pro Val Leu Gln Arg Leu Val Arg Thr His Pro Val His Arg Arg Lys
195 200 205

Ser Leu Tyr Leu Ser Ser His Ala Gly Lys Ile Ala Ser Met Ser Val
210 215 220

Pro Glu Gly Arg Leu Leu Leu Arg Asp Leu Asn Glu His Ala Thr Gln
225 230 235 240

Pro Glu Phe Val Tyr Val His Lys Trp Lys Leu His Asp Leu Val Met
245 250 255

Trp Asp Asn Arg Gln Thr Met His Arg Val Arg Arg Tyr Asp Gln Ser
260 265 270

Gln Pro Arg Asp Met Arg Arg Ala Thr Val Ala Gly Thr Glu Pro Thr
275 280 285

Val

<210> 20
<211> 295
<212> PRT
<213> Sphingobium herbicidovorans

<400> 20

Met His Ala Ala Leu Ser Pro Leu Ser Gln Arg Phe Glu Arg Ile Ala
1 5 10 15

Val Gln Pro Leu Thr Gly Val Leu Gly Ala Glu Ile Thr Gly Val Asp
20 25 30

Leu Arg Glu Pro Leu Asp Asp Ser Thr Trp Asn Glu Ile Leu Asp Ala

35

40

45

Phe His Thr Tyr Gln Val Ile Tyr Phe Pro Gly Gln Ala Ile Thr Asn
50 55 60

Glu Gln His Ile Ala Phe Ser Arg Arg Phe Gly Pro Val Asp Pro Val
65 70 75 80

Pro Leu Leu Lys Ser Ile Glu Gly Tyr Pro Glu Val Gln Met Ile Arg
85

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875					Application or Docket Number 13/647,081		Filing Date 10/08/2012		☐ To be Mailed	
ENTITY: ☒ LARGE ☐ SMALL ☐ MICRO										
APPLICATION AS FILED – PART I										
(Column 1)		(Column 2)								
FOR		NUMBER FILED		NUMBER EXTRA		RATE (\$)		FEE (\$)		
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))		N/A		N/A		N/A				
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))		N/A		N/A		N/A				
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))		N/A		N/A		N/A				
TOTAL CLAIMS (37 CFR 1.16(i))		minus 20 =		*		X \$ =				
INDEPENDENT CLAIMS (37 CFR 1.16(h))		minus 3 =		*		X \$ =				
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))		If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).								
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))										
* If the difference in column 1 is less than zero, enter "0" in column 2.						TOTAL				
APPLICATION AS AMENDED – PART II										
(Column 1)		(Column 2)		(Column 3)						
AMENDMENT	08/01/2013	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE (\$)		ADDITIONAL FEE (\$)		
	Total (37 CFR 1.16(i))	* 20	Minus	** 20	= 0	X \$80 =		0		
	Independent (37 CFR 1.16(h))	* 2	Minus	***3	= 0	X \$420 =		0		
	☐ Application Size Fee (37 CFR 1.16(s))									
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))									
						TOTAL ADD'L FEE		0		
(Column 1)		(Column 2)		(Column 3)						
AMENDMENT		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE (\$)		ADDITIONAL FEE (\$)		
	Total (37 CFR 1.16(i))	*	Minus	**	=	X \$ =				
	Independent (37 CFR 1.16(h))	*	Minus	***	=	X \$ =				
	☐ Application Size Fee (37 CFR 1.16(s))									
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))									
						TOTAL ADD'L FEE				
* If the entry in column 1 is less than the entry in column 2, write "0" in column 3. ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20". *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.										

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Faegre Baker Daniels LLP- Dow Agro Sciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204

MAILED

SEP 03 2013

OFFICE OF PETITIONS

Inventor(s): Wright et al.	:	
Application No. 13/647,081	:	
Filing Date: October 8, 2012	:	Decision on Request
Attorney Docket No. DAS-P0129-03-US-E	:	
Pub. No. US 2013/0035233 A1	:	
Pub. Date: February 7, 2013	:	

This is a decision on the request for a corrected patent application publication under 37 C.F.R. § 1.221(b) filed June 19, 2013.

The request is **dismissed**.

37 C.F.R. § 1.221(b) states a “request for a corrected or revised patent application publication other than as provided in paragraph (a) of this section must be filed within two months from the date of the patent application publication.” The instant request for corrected publication was filed June 19, 2013, which is more than two months after the application published. Therefore, the request is untimely, and the request is hereby dismissed.

Applicants are advised that a “request for republication of an application previously published” may be filed under 37 C.F.R. § 1.221(a). The request must include a copy of the application, which complies with the Office’s electronic filing system requirements, the publication fee set forth in 37 C.F.R. § 1.18(d), and the required processing fee set forth in 37 C.F.R. § 1.17(i).

If the request for republication does not comply with the electronic filing system requirements, the republication will not take place and the publication fee set forth in 37 C.F.R. § 1.18(d) will be refunded. However, the processing fee will be retained.

Guidance for filing a request for a Pre-Grant Publication, such as a request for republication, may be found at the links below:

<http://www.uspto.gov/patents/process/file/efs/guidance/index.jsp>

http://www.uspto.gov/ebc/portal/efs/pgpub_quickstart.pdf

Any request for republication under 37 C.F.R. § 1.221(a), must be submitted via the EFS system as a "Pre-Grant Publication" and questions or any request for reconsideration of the instant decision should be addressed as follows:

By mail to: Mail Stop PGPUB
Commissioner for Patents
P.O. Box 1450
Alexandria, Va. 22313-1450

Telephone inquiries regarding this communication should be directed to Senior Petitions Attorney Steven Brantley at (571) 272-3203.



Christopher Bottorff
Petitions Examiner
Office of Petitions



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/647,081	10/08/2012	Terry R. Wright	DAS-P0129-03-US-E	1022
83067	7590	09/09/2013		
Faegre Baker Daniels LLP- Dow AgroSciences 300 North Meridian Street, Suite 2700 Indianapolis, IN 46204			EXAMINER KRUSE, DAVID H	
			ART UNIT 1638	PAPER NUMBER
			NOTIFICATION DATE 09/09/2013	DELIVERY MODE ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

intcas@faegrebd.com
cynthia.payson@faegrebd.com

Office Action Summary	Application No. 13/647,081	Applicant(s) WRIGHT ET AL.	
	Examiner DAVID H. KRUSE	Art Unit 1638	AIA (First Inventor to File) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 1 August 2013.
☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on ____.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on ____; the restriction requirement and election have been incorporated into this action.
- 4) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 5) ☒ Claim(s) 1-20 is/are pending in the application.
5a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 6) ☐ Claim(s) ____ is/are allowed.
- 7) ☒ Claim(s) 1-20 is/are rejected.
- 8) ☐ Claim(s) ____ is/are objected to.
- 9) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.

Application Papers

- 10) ☐ The specification is objected to by the Examiner.
- 11) ☒ The drawing(s) filed on 10/8/2012 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

- a) ☐ All b) ☐ Some * c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) ☐ Notice of References Cited (PTO-892) | 3) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____. |
| 2) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date ____. | 4) ☐ Other: ____. |

STATUS OF THE APPLICATION

1. This Office action is in response to the Amendment and Remarks filed on 1 August 2013.
2. The objection to the specification is withdrawn in view of Applicant's amendment.
3. The objection of claim 17 is withdrawn in view of Applicant's amendment.
4. The rejections of claim 14 under 35 U.S.C. 112, first and second paragraphs, are withdrawn in view of Applicant's response, page 6.
5. The rejection of claims 1-20 under 35 U.S.C. 103(a) is withdrawn in view of Applicant's arguments, pages 7-8 of the Remarks.

Double Patenting

6. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438,

Art Unit: 1638

164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

7. Claims 1-20 remain rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-14 of U.S. Patent No. 8,283,522. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instantly claimed invention would at least be a subgenus of the '522 patent. Applicant states that "should the subject application be allowed, the applicants may file a terminal disclaimer to overcome such rejection" (page 9 of the Remarks). As the instant rejection is not provisional it is maintained for the reasons of record.

Conclusion

8. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

9. No claims are allowed.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to David H. Kruse, Ph.D. whose telephone number is (571) 272-0799. The examiner can normally be reached on Monday to Friday from 8:00 a.m. to 4:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisors, Anne Marie Grunberg can be reached at (571) 272-0975 or Shubo (Joe) Zhou can be reached at (571) 272-0724. The central FAX number for official correspondence is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group Receptionist whose telephone number is (571) 272-1600.

/David H Kruse/
Primary Examiner, Art Unit 1638

EAST Search History**EAST Search History (Prior Art)**

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	60	plant and AAD-12 and herbicide	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2013/09/03 14:01
S1	5	((("5608147") or ("7205561"))).PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2013/02/20 13:26
S2	4	((("5608147") or ("7250561"))).PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2013/02/20 13:27
S3	290	plant and tfdA and herbicide	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2013/02/20 13:28
S4	42	plant and AAD-12 and herbicide	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2013/02/20 13:28
S5	11	(Ory1F.clm. or "Ory1Ac.clm") and herbicide.clm.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2013/02/20 15:20
S6	3	((("6326169") or ("6017534"))).PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2013/02/20 15:42

EAST Search History (Interference)

< This search history is empty >

9/ 3/ 2013 2:02:01 PM**C:\Users\dkruse\Documents\EAST\Workspaces\13647081.wsp**

Search Notes 	Application/Control No. 13647081	Applicant(s)/Patent Under Reexamination WRIGHT ET AL.
	Examiner DAVID H KRUSE	Art Unit 1638

CPC- SEARCHED		
Symbol	Date	Examiner

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner
EAST	EAST	2/20/2013	/DK/

SEARCH NOTES		
Search Notes	Date	Examiner
Inventor Name Search	2/20/2013	/DK/
EAST: USPAT, USPGPUB, EPO, JPO, DERWENT	2/20/2013	/DK/
STN: AGRICOLA, BIOSIS, CAPLUS, EMBASE, CABA	2/20/2013	/DK/
Sequence Search of SEQ ID NO: 2 and 4, included interference search	1/16/2013	/DK/
Update EAST	9/3/2013	/DK/

INTERFERENCE SEARCH			
US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner

	/DAVID H KRUSE/ Primary Examiner.Art Unit 1638
--	---

To: inteias@faegrebd.com,cynthia.payson@faegrebd.com,
From: PAIR_eOfficeAction@uspto.gov
Cc: PAIR_eOfficeAction@uspto.gov
Subject: Private PAIR Correspondence Notification for Customer Number 83067

Sep 06, 2013 05:31:37 AM

Dear PAIR Customer:

Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204
UNITED STATES

The following USPTO patent application(s) associated with your Customer Number, 83067 , have new outgoing correspondence. This correspondence is now available for viewing in Private PAIR.

The official date of notification of the outgoing correspondence will be indicated on the form PTOL-90 accompanying the correspondence.

Disclaimer:

The list of documents shown below is provided as a courtesy and is not part of the official file wrapper. The content of the images shown in PAIR is the official record.

Application	Document	Mailroom Date	Attorney Docket No.
13647081	PETDEC	09/03/2013	DAS-P0129-03-US-E

To view your correspondence online or update your email addresses, please visit us anytime at <https://sportal.uspto.gov/secure/myportal/privatepair>.

If you have any questions, please email the Electronic Business Center (EBC) at EBC@uspto.gov with 'e-Office Action' on the subject line or call 1-866-217-9197 during the following hours:

Monday - Friday 6:00 a.m. to 12:00 a.m.

Thank you for prompt attention to this notice,

UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT APPLICATION INFORMATION RETRIEVAL SYSTEM

To: inteas@faegrebd.com,cynthia.payson@faegrebd.com,
From: PAIR_eOfficeAction@uspto.gov
Cc: PAIR_eOfficeAction@uspto.gov
Subject: Private PAIR Correspondence Notification for Customer Number 83067

Sep 09, 2013 05:34:10 AM

Dear PAIR Customer:

Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204
UNITED STATES

The following USPTO patent application(s) associated with your Customer Number, 83067 , have new outgoing correspondence. This correspondence is now available for viewing in Private PAIR.

The official date of notification of the outgoing correspondence will be indicated on the form PTOL-90 accompanying the correspondence.

Disclaimer:

The list of documents shown below is provided as a courtesy and is not part of the official file wrapper. The content of the images shown in PAIR is the official record.

Application	Document	Mailroom Date	Attorney Docket No.
13647081	CTFR	09/09/2013	DAS-P0129-03-US-E

To view your correspondence online or update your email addresses, please visit us anytime at <https://sportal.uspto.gov/secure/myportal/privatepair>.

If you have any questions, please email the Electronic Business Center (EBC) at EBC@uspto.gov with 'e-Office Action' on the subject line or call 1-866-217-9197 during the following hours:

Monday - Friday 6:00 a.m. to 12:00 a.m.

Thank you for prompt attention to this notice,

UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT APPLICATION INFORMATION RETRIEVAL SYSTEM

UNITED STATES PATENT AND TRADEMARK OFFICE
COMMISSIONER FOR PATENTS
P.O.BOX 1450
ALEXANDRIA VA 22313-1451

PRESORTED
FIRST-CLASS MAIL
U.S. POSTAGE PAID
POSTEDIGITAL
NNNNN

Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204



**Courtesy Reminder for
Application Serial No: 13/647,081**

Attorney Docket No: DAS-P0129-03-US-E
Customer Number: 83067
Date of Electronic Notification: 09/09/2013

This is a courtesy reminder that new correspondence is available for this application. If you have not done so already, please review the correspondence. The official date of notification of the outgoing correspondence will be indicated on the form PTOL-90 accompanying the correspondence.

An email notification regarding the correspondence was sent to the following email address(es) associated with your customer number:

intead@faegrebd.com
cynthia.payson@faegrebd.com

To view your correspondence online or update your email addresses, please visit us anytime at **<https://sportal.uspto.gov/secure/myportal/privatepair>**. If you have any questions, please email the Electronic Business Center (EBC) at EBC@uspto.gov or call 1-866-217-9197.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Ref. : DAS-P0129-03-US-E
Applicants : Terry R. Wright *et al.*
Serial No. : 13/647,081
Conf. No. : 1022
Filed : October 8, 2012
Examiner : Kruse, David H
Title : NOVEL HERBICIDE RESISTANCE GENES

AFTER FINAL RESPONSE

This is a Response to the Final Office Action dated September 9, 2013.
Reconsideration is respectfully requested.

A terminal disclaimer accompanies this response.

No amendment is made to the Claims in this Response.

REMARKS begin on page 5 of this Response.

IN THE CLAIMS

1. (original) A transgenic plant cell comprising a recombinant polynucleotide that encodes a protein having an activity that catalyzes degradation of a herbicidal compound selected from the group consisting of a phenoxypropionic auxin and a phenoxyacetic auxin, wherein said protein has at least 95% amino acid sequence identity with a sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:4.
2. (original) The plant cell of claim 1 wherein said plant cell is selected from the group consisting of soybean, cotton, *Arabidopsis*, tobacco and canola.
3. (original) A transgenic plant cell comprising a recombinant polynucleotide that encodes a protein that confers tolerance on said plant cell to a pyridyloxy acetate herbicide, wherein said protein has at least 95% amino acid sequence identity with a sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:4.
4. (original) The cell of claim 3 wherein said pyridyloxy acetate herbicide is selected from the group consisting of triclopyr and fluroxypyr.
5. (original) A method of producing a herbicide tolerant plant, said method comprising introducing a polynucleotide into a plant cell, wherein said polynucleotide encodes a protein having an activity that catalyzes degradation of a herbicidal compound selected from the group consisting of a phenoxypropionic auxin and a phenoxyacetic auxin, wherein said protein has at least 95% amino acid sequence identity with a sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:4, and regenerating a plant from said cell.
6. (original) The method of claim 5 further comprising selecting transformed plant tissue that produces said protein.
7. (original) The cell of claim 1, wherein said protein confers tolerance to 2,4-D to said cell.
8. (original) The plant cell of claim 1, further comprising at least one different polynucleotide that encodes a protein that confers tolerance to the plant cell to a herbicide

selected from the group consisting of glyphosate, glufosinate, HPPD-inhibitors, and dicamba.

9. (original) The plant cell of claim 8, wherein the plant cell is selected from the group consisting of soybean, cotton, or canola.
10. (original) The plant cell of claim 8, wherein the plant cell is a soybean cell and the herbicide is selected from the group consisting of glyphosate and dicamba.
11. (original) The plant cell of claim 8, wherein the plant cell is a soybean cell and the herbicide is selected from the group consisting of glyphosate and glufosinate.
12. (original) The plant cell of claim 1, further comprising a second polynucleotide that encodes a gene product having an insecticidal activity.
13. (original) The plant cell of claim 12, wherein said gene product encoded by said second polynucleotide is selected from the group consisting of Cry1F and Cry1Ac.
14. (original) The plant cell of claim 1 further comprising an output trait.
15. (original) The plant cell of claim 1 further comprising an input trait.
16. (original) A plant comprising a plurality of cells of claim 1.
17. (previously presented) A part, progeny, seed or asexual propagate of the plant of claim 16, wherein said part, progeny, seed or propagate comprises said polynucleotide.
18. (original) A method for selectively controlling weeds in a field, said field containing a crop, said crop comprising plant cells of claim 1, said method comprising applying an aryloxyalkanoate herbicide to at least a portion of the crop and the weeds in the field to control the weeds.
19. (original) A method of controlling volunteer plants of a crop comprising the plant cells of claim 1, said method comprising applying to said volunteer plants a herbicide selected

from the group consisting of ACCase inhibitors, HPPD inhibitors, ALS inhibitors, and dicamba.

20. (original) The method of claim 19 wherein the herbicide is selected from sethoxydim and clethodim.

REMARKS

Claims Status:

Claims 1-20 were the subject of the Final Office Action dated September 9, 2013. The applicants would like to thank the examiner for acknowledging the only remaining issue for this application is for nonstatutory obviousness-type double patenting. Thus, Claims 1-20 are resubmitted with a Terminal Disclaimer.

Double Patenting:

Claim 1-20 stand rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-4 of US patent No. 8,283,522. The applicants hereby file a Terminal Disclaimer executed by the attorney of record. Thus, the withdrawal of this rejection is respectfully requested.

Conclusion:

In light of foregoing, this application is in condition for allowance. Such favorable consideration is respectfully requested.

The Commissioner is hereby authorized to charge Deposit Account No. 02-0390 for the terminal disclaimer fee and any other fees associated with this application, but not to include any issue fees.

Respectfully submitted,

/Jay M. Sanders/

Jay M. Sanders, Reg. No. 39,355
Faegre Baker Daniels LLP
300 N. Meridian Street, Suite 2700
Indianapolis, Indiana 46204
Telephone: (317) 237-1245
Fax: (317) 237-1000

Date submitted: November 12, 2013

Attachment: Terminal Disclaimer

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING
REJECTION OVER A "PRIOR" PATENT**

Docket Number (Optional)
DAS-P0129-03-US

In re Application of: Terry R. Wright et al

Application No.: 13/647,081

Filed: 10/8/2012

For: NOVEL HERBICIDE RESISTANCE GENES

The owner*, DOW AGROSCIENCES, LLC, of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term **prior patent** No. 8,283,522 as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said **prior patent** is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the **prior patent** are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the **prior patent**, "as the term of said **prior patent** is presently shortened by any terminal disclaimer," in the event that said **prior patent** later:

- expires for failure to pay a maintenance fee;
- is held unenforceable;
- is found invalid by a court of competent jurisdiction;
- is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;
- has all claims canceled by a reexamination certificate;
- is reissued; or
- is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney or agent of record. Reg. No. 39,355

/Jay M. Sanders/
Signature

November 12, 2013
Date

Jay M. Sanders
Typed or printed name

317-237-1245
Telephone Number

- ☒ Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).
Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Patent Application Fee Transmittal				
Application Number:		13647081		
Filing Date:		08-Oct-2012		
Title of Invention:		NOVEL HERBICIDE RESISTANCE GENES		
First Named Inventor/Applicant Name:		Terry R. Wright		
Filer:		Jay M. Sanders/Cindy Cohen-Katz		
Attorney Docket Number:		DAS-P0129-03-US-E		
Filed as Large Entity				
Utility under 35 USC 111(a) Filing Fees				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Statutory or Terminal Disclaimer	1814	1	160	160
Extension-of-Time:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
Total in USD (\$)				160

Electronic Acknowledgement Receipt	
EFS ID:	17379416
Application Number:	13647081
International Application Number:	
Confirmation Number:	1022
Title of Invention:	NOVEL HERBICIDE RESISTANCE GENES
First Named Inventor/Applicant Name:	Terry R. Wright
Customer Number:	83067
Filer:	Jay M. Sanders/Cindy Cohen-Katz
Filer Authorized By:	Jay M. Sanders
Attorney Docket Number:	DAS-P0129-03-US-E
Receipt Date:	12-NOV-2013
Filing Date:	08-OCT-2012
Time Stamp:	15:50:15
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 160
RAM confirmation Number	2955
Deposit Account	020390
Authorized User	
<p>The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)</p>	


Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)					
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Response After Final Action	DAS_P0129_03_US_Response_Final_OA.pdf	103415	no	5
			62d22a9d9b286999be09412ef4a949510625bbbc		
Warnings:					
Information:					
2	Terminal Disclaimer Filed	DAS_P0129_03_US_TD.pdf	157580	no	2
			19a972e5ce1a3be3f7d46663c33d52172e7431c		
Warnings:					
Information:					
3	Fee Worksheet (SB06)	fee-info.pdf	30427	no	2
			bab681ba08664d26d497941ebd7a9cd33946bf7d		
Warnings:					
Information:					
Total Files Size (in bytes):			291422		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875				Application or Docket Number 13/647,081	Filing Date 10/08/2012	☐ To be Mailed
ENTITY: ☒ LARGE ☐ SMALL ☐ MICRO						
APPLICATION AS FILED – PART I						
(Column 1)		(Column 2)				
FOR	NUMBER FILED	NUMBER EXTRA				
☒ BASIC FEE <small>(37 CFR 1.16(a), (b), or (c))</small>	N/A	N/A				
☐ SEARCH FEE <small>(37 CFR 1.16(k), (i), or (m))</small>	N/A	N/A				
☐ EXAMINATION FEE <small>(37 CFR 1.16(o), (p), or (q))</small>	N/A	N/A				
TOTAL CLAIMS <small>(37 CFR 1.16(i))</small>	minus 20 =	*				
INDEPENDENT CLAIMS <small>(37 CFR 1.16(h))</small>	minus 3 =	*				
☐ APPLICATION SIZE FEE <small>(37 CFR 1.16(s))</small>	If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).					
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))						
* If the difference in column 1 is less than zero, enter "0" in column 2.						
			TOTAL	390		
APPLICATION AS AMENDED – PART II						
(Column 1)		(Column 2)		(Column 3)		
AMENDMENT	11/12/2013	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	
	Total (37 CFR 1.16(i))	* 20	Minus	** 20	= 0	
	Independent (37 CFR 1.16(h))	* 3	Minus	***3	= 0	
	☐ Application Size Fee (37 CFR 1.16(s))					
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					
						TOTAL ADD'L FEE
						0
(Column 1)		(Column 2)		(Column 3)		
AMENDMENT		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	
	Total (37 CFR 1.16(i))	*	Minus	**	=	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	
	☐ Application Size Fee (37 CFR 1.16(s))					
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					
						TOTAL ADD'L FEE
* If the entry in column 1 is less than the entry in column 2, write "0" in column 3. ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20". *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.						

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Application Number 	Application/Control No. 13/647,081	Applicant(s)/Patent under Reexamination WRIGHT ET AL.	
Document Code - DISQ		Internal Document – DO NOT MAIL	

TERMINAL DISCLAIMER	☐ APPROVED	☒ DISAPPROVED
Date Filed : 11/12/13	This patent is subject to a Terminal Disclaimer	

Approved/Disapproved by:
<p>Wrong Td form used need to used PTO/AIA/26 form.</p> <p>The person who signed the Td is not the applicant nor the attny of record, see FP 14.26.08.</p> <p>NO FEE is required.</p> <p>Angie Walker</p>

U.S. Patent and Trademark Office



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/647,081	10/08/2012	Terry R. Wright	DAS-P0129-03-US-E	1022
83067	7590	11/18/2013		
Faegre Baker Daniels LLP- Dow AgroSciences 300 North Meridian Street, Suite 2700 Indianapolis, IN 46204			EXAMINER KRUSE, DAVID H	
			ART UNIT 1638	PAPER NUMBER
			NOTIFICATION DATE 11/18/2013	DELIVERY MODE ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

intcas@faegrebd.com
cynthia.payson@faegrebd.com

Advisory Action Before the Filing of an Appeal Brief	Application No. 13/647,081	Applicant(s) WRIGHT ET AL.	
	Examiner DAVID H. KRUSE	Art Unit 1638	AIA (First Inventor to File) Status No

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 12 November 2013 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

NO NOTICE OF APPEAL FILED

1. ☒ The reply was filed after a final rejection. No Notice of Appeal has been filed. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114 if this is a utility or plant application. Note that RCEs are not permitted in design applications. The reply must be filed within one of the following time periods:

a) ☐ The period for reply expires _____ months from the mailing date of the final rejection.

b) ☒ The period for reply expires on: (1) the mailing date of this Advisory Action; or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

c) ☐ A prior Advisory Action was mailed more than 3 months after the mailing date of the final rejection in response to a first after-final reply filed within 2 months of the mailing date of the final rejection. The current period for reply expires _____ months from the mailing date of the prior Advisory Action or SIX MONTHS from the mailing date of the final rejection, whichever is earlier.

Examiner Note: If box 1 is checked, check either box (a), (b) or (c). ONLY CHECK BOX (b) WHEN THIS ADVISORY ACTION IS THE FIRST RESPONSE TO APPLICANT'S FIRST AFTER-FINAL REPLY WHICH WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. ONLY CHECK BOX (c) IN THE LIMITED SITUATION SET FORTH UNDER BOX (c). See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) or (c) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

NOTICE OF APPEAL

2. ☐ The Notice of Appeal was filed on _____. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

AMENDMENTS

3. ☐ The proposed amendments filed after a final rejection, but prior to the date of filing a brief, will not be entered because

a) ☐ They raise new issues that would require further consideration and/or search (see NOTE below);

b) ☐ They raise the issue of new matter (see NOTE below);

c) ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or

d) ☐ They present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: _____. (See 37 CFR 1.116 and 41.33(a)).

4. ☐ The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).

5. ☐ Applicant's reply has overcome the following rejection(s): _____.

6. ☐ Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).

7. ☒ For purposes of appeal, the proposed amendment(s): (a) ☒ will not be entered, or (b) ☐ will be entered, and an explanation of how the new or amended claims would be rejected is provided below or appended.

AFFIDAVIT OR OTHER EVIDENCE

8. ☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

9. ☐ The affidavit or other evidence filed after final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).

10. ☐ The affidavit or other evidence filed after the date of filing the Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing of good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).

11. ☐ The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

12. ☒ The request for reconsideration has been considered but does NOT place the application in condition for allowance because:
See Continuation Sheet.

13. ☐ Note the attached Information *Disclosure Statement*(s). (PTO/SB/08) Paper No(s). _____

14. ☐ Other: _____.

STATUS OF CLAIMS

15. The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: _____.

Claim(s) objected to: _____.

Claim(s) rejected: 1-20.

Claim(s) withdrawn from consideration: _____.

/DAVID H KRUSE/
 Primary Examiner, Art Unit 1638

Continuation of 11. does NOT place the application in condition for allowance because: The Terminal Disclaimer was submitted using the wrong form, Applicant should use PTO/AIA/26 form. In addition, the person who signed the TD is neither the applicant nor the attorney of record. The Examiner notes that there is no Power of Attorney of record in the instant application. Consequently the claims remain rejected under nonstatutory double patenting.

OK TO ENTER: /DK/ (11/13/2013)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Ref. : DAS-P0129-03-US-E
Applicants : Terry R. Wright *et al.*
Serial No. : 13/647,081
Conf. No. : 1022
Filed : October 8, 2012
Examiner : Kruse, David H
Title : NOVEL HERBICIDE RESISTANCE GENES

AFTER FINAL RESPONSE

This is a Response to the Final Office Action dated September 9, 2013.

Reconsideration is respectfully requested.

A terminal disclaimer accompanies this response.

No amendment is made to the Claims in this Response.

REMARKS begin on page 5 of this Response.

To: inteas@faegrebd.com,cynthia.payson@faegrebd.com,
From: PAIR_eOfficeAction@uspto.gov
Cc: PAIR_eOfficeAction@uspto.gov
Subject: Private PAIR Correspondence Notification for Customer Number 83067

Nov 18, 2013 05:37:00 AM

Dear PAIR Customer:

Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204
UNITED STATES

The following USPTO patent application(s) associated with your Customer Number, 83067 , have new outgoing correspondence. This correspondence is now available for viewing in Private PAIR.

The official date of notification of the outgoing correspondence will be indicated on the form PTOL-90 accompanying the correspondence.

Disclaimer:

The list of documents shown below is provided as a courtesy and is not part of the official file wrapper. The content of the images shown in PAIR is the official record.

Application	Document	Mailroom Date	Attorney Docket No.
13647081	CTAV	11/18/2013	DAS-P0129-03-US-E

To view your correspondence online or update your email addresses, please visit us anytime at <https://sportal.uspto.gov/secure/myportal/privatepair>.

If you have any questions, please email the Electronic Business Center (EBC) at EBC@uspto.gov with 'e-Office Action' on the subject line or call 1-866-217-9197 during the following hours:

Monday - Friday 6:00 a.m. to 12:00 a.m.

Thank you for prompt attention to this notice,

UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT APPLICATION INFORMATION RETRIEVAL SYSTEM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Ref. : DAS-P0129-03-US-E
Applicants : Terry R. Wright *et al.*
Serial No. : 13/647,081
Conf. No. : 1022
Filed : October 8, 2012
Examiner : Kruse, David H
Title : NOVEL HERBICIDE RESISTANCE GENES

AFTER FINAL RESPONSE

This is a Response to the Final Office Action dated September 9, 2013, and to the Advisory Action dated November 18, 2013. Reconsideration is respectfully requested.

A Terminal Disclaimer accompanies this response. A power of attorney signed by the assignee is also attached.

No amendment is made to the Claims in this Response.

REMARKS begin on page 5 of this Response.

IN THE CLAIMS

1. (original) A transgenic plant cell comprising a recombinant polynucleotide that encodes a protein having an activity that catalyzes degradation of a herbicidal compound selected from the group consisting of a phenoxypropionic auxin and a phenoxyacetic auxin, wherein said protein has at least 95% amino acid sequence identity with a sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:4.
2. (original) The plant cell of claim 1 wherein said plant cell is selected from the group consisting of soybean, cotton, *Arabidopsis*, tobacco and canola.
3. (original) A transgenic plant cell comprising a recombinant polynucleotide that encodes a protein that confers tolerance on said plant cell to a pyridyloxy acetate herbicide, wherein said protein has at least 95% amino acid sequence identity with a sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:4.
4. (original) The cell of claim 3 wherein said pyridyloxy acetate herbicide is selected from the group consisting of triclopyr and fluroxypyr.
5. (original) A method of producing a herbicide tolerant plant, said method comprising introducing a polynucleotide into a plant cell, wherein said polynucleotide encodes a protein having an activity that catalyzes degradation of a herbicidal compound selected from the group consisting of a phenoxypropionic auxin and a phenoxyacetic auxin, wherein said protein has at least 95% amino acid sequence identity with a sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:4, and regenerating a plant from said cell.
6. (original) The method of claim 5 further comprising selecting transformed plant tissue that produces said protein.
7. (original) The cell of claim 1, wherein said protein confers tolerance to 2,4-D to said cell.
8. (original) The plant cell of claim 1, further comprising at least one different polynucleotide that encodes a protein that confers tolerance to the plant cell to a herbicide

selected from the group consisting of glyphosate, glufosinate, HPPD-inhibitors, and dicamba.

9. (original) The plant cell of claim 8, wherein the plant cell is selected from the group consisting of soybean, cotton, or canola.
10. (original) The plant cell of claim 8, wherein the plant cell is a soybean cell and the herbicide is selected from the group consisting of glyphosate and dicamba.
11. (original) The plant cell of claim 8, wherein the plant cell is a soybean cell and the herbicide is selected from the group consisting of glyphosate and glufosinate.
12. (original) The plant cell of claim 1, further comprising a second polynucleotide that encodes a gene product having an insecticidal activity.
13. (original) The plant cell of claim 12, wherein said gene product encoded by said second polynucleotide is selected from the group consisting of Cry1F and Cry1Ac.
14. (original) The plant cell of claim 1 further comprising an output trait.
15. (original) The plant cell of claim 1 further comprising an input trait.
16. (original) A plant comprising a plurality of cells of claim 1.
17. (previously presented) A part, progeny, seed or asexual propagate of the plant of claim 16, wherein said part, progeny, seed or propagate comprises said polynucleotide.
18. (original) A method for selectively controlling weeds in a field, said field containing a crop, said crop comprising plant cells of claim 1, said method comprising applying an aryloxyalkanoate herbicide to at least a portion of the crop and the weeds in the field to control the weeds.
19. (original) A method of controlling volunteer plants of a crop comprising the plant cells of claim 1, said method comprising applying to said volunteer plants a herbicide selected

from the group consisting of ACCase inhibitors, HPPD inhibitors, ALS inhibitors, and dicamba.

20. (original) The method of claim 19 wherein the herbicide is selected from sethoxydim and clethodim.

REMARKS

Claims Status:

Claims 1-20 were the subject of the Final Office Action dated September 9, 2013. The applicants would like to thank the examiner for acknowledging the only remaining issue for this application is the nonstatutory obviousness-type double patenting. Thus, Claims 1-20 are resubmitted with the proper Terminal Disclaimer executed by the registered attorney of record.

Double Patenting:

Claim 1-20 stand rejected on the ground of nonstatutory obviousness type double patenting as being unpatentable over claims 1-4 of US patent No. 8,283,522. The applicants hereby files a Terminal Disclaimer executed by the attorney of record. A power of attorney signed by the assignee accompanies the Terminal Disclaimer. Thus, the withdrawal of such rejection is respectfully requested.

Conclusion:

In light of foregoing, Applicant has put the application in condition of allowance. Such favorable consideration is respectfully requested.

The Commissioner is hereby authorized to charge Deposit Account No. 02-0390 for any fees associated with this application, but not to include any issue fees.

Respectfully submitted,

/Yonghao Hou/
Yonghao Hou, Registration Number 61,391
Faegre Baker Daniels LLP
300 N. Meridian Street, Suite 2700
Indianapolis, Indiana 46204
Telephone: (317) 237-1469
Fax: (317) 237-1000

Date submitted: December 9, 2013

Doc Code: PA..
Document Description: Power of Attorney

PTO/AIA/82B (07-13)
Approved for use through 11/30/2014. OMB 0651-0051
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY BY APPLICANT

I hereby revoke all previous powers of attorney given in the application identified in either the attached transmittal letter or the boxes below.

Application Number	Filing Date
13/647,081	10/08/2012

(Note: The boxes above may be left blank if information is provided on form PTO/AIA/82A.)

- ☒ I hereby appoint the Patent Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above: 83067
- OR**
- ☐ I hereby appoint Practitioner(s) named in the attached list (form PTO/AIA/82C) as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the patent application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above. (Note: Complete form PTO/AIA/82C.)

Please recognize or change the correspondence address for the application identified in the attached transmittal letter or the boxes above to:

- ☒ The address associated with the above-mentioned Customer Number
- OR**
- ☐ The address associated with Customer Number:
- OR**

Firm or Individual Name				
Address				
City	State	Zip		
Country				
Telephone	Email			

I am the Applicant (if the Applicant is a juristic entity, list the Applicant name in the box):

Dow Agrosciences LLC

- ☐ Inventor or Joint Inventor (title not required below)
- ☐ Legal Representative of a Deceased or Legally Incapacitated Inventor (title not required below)
- ☒ Assignee or Person to Whom the Inventor is Under an Obligation to Assign (provide signer's title if applicant is a juristic entity)
- ☐ Person Who Otherwise Shows Sufficient Proprietary Interest (e.g., a petition under 37 CFR 1.46(b)(2) was granted in the application or is concurrently being filed with this document) (provide signer's title if applicant is a juristic entity)

SIGNATURE of Applicant for Patent

The undersigned (whose title is supplied below) is authorized to act on behalf of the applicant (e.g., where the applicant is a juristic entity).

Signature		Date (Optional)	December 4, 2013
Name	Andrea T. Borucki		
Title	General Patent Counsel for Dow AgroSciences LLC		

NOTE: Signature - This form must be signed by the applicant in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications. If more than one applicant, use multiple forms.

☐ Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.131, 1.32, and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) DAS-P0129-03-US
<p>In re Application of: Terry R. Wright et al</p> <p>Application No.: 13/647,081</p> <p>Filed: 10/8/2012</p> <p>For: NOVEL HERBICIDE RESISTANCE GENES</p> <p>The applicant, <u>DOW AGROSCIENCES LLC</u>, owner of <u>100</u> percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of prior patent No. <u>8,283,522</u> as the term of said prior patent is presently shortened by any terminal disclaimer. The applicant hereby agrees that any patent so granted on the instant application shall be enforceable only for any during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.</p> <p>In making the above disclaimer, the applicant does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later:</p> <ul style="list-style-type: none">expires for failure to pay a maintenance fee;is held unenforceable;is found invalid by a court of competent jurisdiction;is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;has all claims canceled by a reexamination certificate;is reissued; oris in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. <p>Check either box 1 or 2 below, if appropriate.</p> <p>1. ☐ The undersigned is the applicant. If the applicant is an assignee, the undersigned is authorized to act on behalf of the assignee.</p> <p>I hereby acknowledge that any willful false statements made are punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.</p> <p>2. ☒ The undersigned is an attorney or agent of record. Reg. No. <u>39,355</u></p> <div style="margin-top: 20px;"><div style="display: flex; justify-content: space-between;"><div style="width: 60%; text-align: center;"><u>/Jay M. Sanders/</u> Signature</div><div style="width: 35%; text-align: center;"><u>December 9, 2013</u> Date</div></div><div style="display: flex; justify-content: center; margin-top: 10px;"><u>Jay M. Sanders</u> Typed or printed name</div><div style="display: flex; justify-content: space-between; margin-top: 20px;"><div style="width: 60%; text-align: center;"><u>Attorney of Record</u> Title</div><div style="width: 35%; text-align: center;"><u>317-237-1245</u> Telephone Number</div></div></div> <p>☒ Terminal disclaimer fee under 37 CFR 1.20(d) included.</p> <p style="text-align: center;">WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>	

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Electronic Acknowledgement Receipt	
EFS ID:	17600687
Application Number:	13647081
International Application Number:	
Confirmation Number:	1022
Title of Invention:	NOVEL HERBICIDE RESISTANCE GENES
First Named Inventor/Applicant Name:	Terry R. Wright
Customer Number:	83067
Filer:	Yonghao Hou
Filer Authorized By:	
Attorney Docket Number:	DAS-P0129-03-US-E
Receipt Date:	09-DEC-2013
Filing Date:	08-OCT-2012
Time Stamp:	14:39:45
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Response After Final Action	Res_to_FOA12092013.pdf	1052905 <small>9a27201d1e2ec689b2a6da4799f57808be145983</small>	no	5

Warnings:

Information:

2	Power of Attorney	poa001_executed.pdf	124019 2e169766d5f79e55d647e8a73df1026c1423720d	no	1
Warnings:					
Information:					
3	Terminal Disclaimer Filed	aia0026_DAS_p0129_03_TD.pdf	141729 8afbe7786b654a4abe34b6260fda97212d725325	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			1318653		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875					Application or Docket Number 13/647,081		Filing Date 10/08/2012		☐ To be Mailed	
ENTITY: ☒ LARGE ☐ SMALL ☐ MICRO										
APPLICATION AS FILED – PART I										
(Column 1)		(Column 2)								
FOR		NUMBER FILED		NUMBER EXTRA		RATE (\$)		FEE (\$)		
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))		N/A		N/A		N/A				
☐ SEARCH FEE (37 CFR 1.16(k), (j), or (m))		N/A		N/A		N/A				
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))		N/A		N/A		N/A				
TOTAL CLAIMS (37 CFR 1.16(i))		minus 20 =		*		X \$ =				
INDEPENDENT CLAIMS (37 CFR 1.16(h))		minus 3 =		*		X \$ =				
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))		If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).								
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))										
* If the difference in column 1 is less than zero, enter "0" in column 2.										TOTAL
APPLICATION AS AMENDED – PART II										
(Column 1)		(Column 2)		(Column 3)						
AMENDMENT	12/09/2013	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE (\$)		ADDITIONAL FEE (\$)		
	Total (37 CFR 1.16(i))	* 20	Minus	** 20	= 0	x \$80 =		0		
	Independent (37 CFR 1.16(h))	* 3	Minus	***3	= 0	x \$420 =		0		
	☐ Application Size Fee (37 CFR 1.16(s))									
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))									
						TOTAL ADD'L FEE		0		
(Column 1)		(Column 2)		(Column 3)						
AMENDMENT		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE (\$)		ADDITIONAL FEE (\$)		
	Total (37 CFR 1.16(i))	*	Minus	**	=	X \$ =				
	Independent (37 CFR 1.16(h))	*	Minus	***	=	X \$ =				
	☐ Application Size Fee (37 CFR 1.16(s))									
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))									
						TOTAL ADD'L FEE				
* If the entry in column 1 is less than the entry in column 2, write "0" in column 3. ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20". *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.										

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
13/647,081	10/08/2012	Terry R. Wright	DAS-P0129-03-US-E

CONFIRMATION NO. 1022

POA ACCEPTANCE LETTER

83067
Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204



Date Mailed: 12/16/2013

NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 12/09/2013.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

/zabaha/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

Application Number 	Application/Control No.	Applicant(s)/Patent under Reexamination	
	13/647,081	WRIGHT ET AL.	
Document Code - DISQ		Internal Document – DO NOT MAIL	

TERMINAL DISCLAIMER	☒ APPROVED	☐ DISAPPROVED
Date Filed : 12/09/13	This patent is subject to a Terminal Disclaimer	

Approved/Disapproved by:
Felicia D. Roberts 8,283,522

U.S. Patent and Trademark Office

To: inteas@faegrebd.com,cynthia.payson@faegrebd.com,
From: PAIR_eOfficeAction@uspto.gov
Cc: PAIR_eOfficeAction@uspto.gov
Subject: Private PAIR Correspondence Notification for Customer Number 83067

Dec 16, 2013 05:38:58 AM

Dear PAIR Customer:

Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204
UNITED STATES

The following USPTO patent application(s) associated with your Customer Number, 83067 , have new outgoing correspondence. This correspondence is now available for viewing in Private PAIR.

The official date of notification of the outgoing correspondence will be indicated on the form PTOL-90 accompanying the correspondence.

Disclaimer:

The list of documents shown below is provided as a courtesy and is not part of the official file wrapper. The content of the images shown in PAIR is the official record.

Application	Document	Mailroom Date	Attorney Docket No.
13647081	N570	12/16/2013	DAS-P0129-03-US-E

To view your correspondence online or update your email addresses, please visit us anytime at <https://sportal.uspto.gov/secure/myportal/privatepair>.

If you have any questions, please email the Electronic Business Center (EBC) at EBC@uspto.gov with 'e-Office Action' on the subject line or call 1-866-217-9197 during the following hours:

Monday - Friday 6:00 a.m. to 12:00 a.m.

Thank you for prompt attention to this notice,

UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT APPLICATION INFORMATION RETRIEVAL SYSTEM



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

83067 7590 12/20/2013
Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204

EXAMINER

KRUSE, DAVID H

ART UNIT

PAPER NUMBER

1638

DATE MAILED: 12/20/2013

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/647,081	10/08/2012	Terry R. Wright	DAS-P0129-03-US-E	1022

TITLE OF INVENTION: NOVEL HERBICIDE RESISTANCE GENES

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$1780	\$300	\$0	\$2080	03/20/2014

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

**Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885**

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

83067 7590 12/20/2013
Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/647,081	10/08/2012	Terry R. Wright	DAS-P0129-03-US-E	1022

TITLE OF INVENTION: NOVEL HERBICIDE RESISTANCE GENES

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$1780	\$300	\$0	\$2080	03/20/2014

EXAMINER	ART UNIT	CLASS-SUBCLASS
KRUSE, DAVID H	1638	800-300000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

- ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
- ☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

- (1) The names of up to 3 registered patent attorneys or agents OR, alternatively,
- (2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 _____

2 _____

3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ☐ Individual ☐ Corporation or other private group entity ☐ Government

4a. The following fee(s) are submitted:

- ☐ Issue Fee
- ☐ Publication Fee (No small entity discount permitted)
- ☐ Advance Order - # of Copies _____

4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)

- ☐ A check is enclosed.
- ☐ Payment by credit card. Form PTO-2038 is attached.
- ☐ The Director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

- ☐ Applicant certifying micro entity status. See 37 CFR 1.29
- ☐ Applicant asserting small entity status. See 37 CFR 1.27
- ☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____ Date _____

Typed or printed name _____ Registration No. _____



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/647,081	10/08/2012	Terry R. Wright	DAS-P0129-03-US-E	1022
83067 7590 12/20/2013 Faegre Baker Daniels LLP- Dow AgroSciences 300 North Meridian Street, Suite 2700 Indianapolis, IN 46204			EXAMINER KRUSE, DAVID H	
			ART UNIT 1638	PAPER NUMBER

DATE MAILED: 12/20/2013

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 0 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 0 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

**Notices of Allowance and Fee(s) Due mailed between October 1, 2013 and
December 31, 2013**

(Addendum to PTOL-85)

If the "Notice of Allowance and Fee(s) Due" has a mailing date on or after October 1, 2013 and before January 1, 2014, the following information is applicable to this application.

If the issue fee is being timely paid on or after January 1, 2014, the amount due is the issue fee and publication fee in effect January 1, 2014. On January 1, 2014, the issue fees set forth in 37 CFR 1.18 decrease significantly and the publication fee set forth in 37 CFR 1.18(d)(1) decreases to \$0.

If an issue fee or publication fee has been previously paid in this application, applicant is not entitled to a refund of the difference between the amount paid and the amount in effect on January 1, 2014.

Notice of Allowability	Application No. 13/647,081	Applicant(s) WRIGHT ET AL.	
	Examiner DAVID H. KRUSE	Art Unit 1638	AIA (First Inventor to File) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the Amendment filed on 9 December 2013.
☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on ____.
2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on ____; the restriction requirement and election have been incorporated into this action.
3. ☒ The allowed claim(s) is/are 1-20. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
Certified copies:
 a) ☐ All b) ☐ Some *c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
 * Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892) 2. ☐ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date _____ 3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material 4. ☐ Interview Summary (PTO-413), Paper No./Mail Date _____	5. ☒ Examiner's Amendment/Comment 6. ☐ Examiner's Statement of Reasons for Allowance 7. ☐ Other _____.
--	--

/DAVID H KRUSE/ Primary Examiner, Art Unit 1638	
--	--

Art Unit: 1638

The present application is being examined under the pre-AIA first to invent provisions.

EXAMINER'S COMMENT

Terminal Disclaimer

The terminal disclaimer filed on 9 December 2013 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of U.S. Patent 8,283,522 has been reviewed and is accepted. The terminal disclaimer has been recorded.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David H. Kruse, Ph.D. whose telephone number is (571) 272-0799. The examiner can normally be reached on Monday to Friday from 8:00 a.m. to 4:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisors, Anne Marie Grunberg can be reached at (571) 272-0975 or Shubo (Joe) Zhou can be reached at (571) 272-0724. The central FAX number for official correspondence is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group Receptionist whose telephone number is (571) 272-1600.

/David H Kruse/
Primary Examiner, Art Unit 1638

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Ref. : DAS-P0129-03-US-E
Applicants : Terry R. Wright *et al.*
Serial No. : 13/647,081
Conf. No. : 1022
Filed : October 8, 2012
Examiner : Kruse, David H
Title : NOVEL HERBICIDE RESISTANCE GENES

OK TO ENTER: /DK/ (12/13/2013)

AFTER FINAL RESPONSE

This is a Response to the Final Office Action dated September 9, 2013, and to the Advisory Action dated November 18, 2013. Reconsideration is respectfully requested.

A Terminal Disclaimer accompanies this response. A power of attorney signed by the assignee is also attached.

No amendment is made to the Claims in this Response.

REMARKS begin on page 5 of this Response.

EAST Search History**EAST Search History (Prior Art)**

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	71	plant and AAD-12 and herbicide	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2013/12/13 13:48
S1	5	((("5608147") or ("7205561"))).PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2013/02/20 13:26
S2	4	((("5608147") or ("7205561"))).PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2013/02/20 13:27
S3	290	plant and tfdA and herbicide	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2013/02/20 13:28
S4	42	plant and AAD-12 and herbicide	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2013/02/20 13:28
S5	11	(Ory1F.clm. or "Ory1Ac.clm") and herbicide.clm.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2013/02/20 15:20
S6	3	((("6326169") or ("6017534"))).PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2013/02/20 15:42
S7	60	plant and AAD-12 and herbicide	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2013/09/03 14:01

EAST Search History (Interference)

< This search history is empty >

12/ 13/ 2013 1:49:19 PM**C:\Users\dkruse\Documents\EAST\Workspaces\13647081.wsp**

Issue Classification 	Application/Control No. 13647081	Applicant(s)/Patent Under Reexamination WRIGHT ET AL.
	Examiner DAVID H KRUSE	Art Unit 1638

US ORIGINAL CLASSIFICATION						INTERNATIONAL CLASSIFICATION													
CLASS			SUBCLASS			CLAIMED					NON-CLAIMED								
800			300			C	1	2	N	15 / 82 (2006.01.01)									
CROSS REFERENCE(S)																			
CLASS	SUBCLASS (ONE SUBCLASS PER BLOCK)																		
435	419																		
800	288	302																	
																	</		

NONE		Total Claims Allowed:	
		20	
(Assistant Examiner)	(Date)		
/DAVID H KRUSE/ Primary Examiner. Art Unit 1638	12/13/2013	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	NONE

Issue Classification 	Application/Control No. 13647081	Applicant(s)/Patent Under Reexamination WRIGHT ET AL.
	Examiner DAVID H KRUSE	Art Unit 1638

☒ Claims renumbered in the same order as presented by applicant ☐ CPA ☒ T.D. ☐ R.1.47															
Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
1	1	17	17												
2	2	18	18												
3	3	19	19												
4	4	20	20												
5	5														
6	6														
7	7														
8	8														
9	9														
10	10														
11	11														
12	12														
13	13														
14	14														
15	15														
16	16														

NONE		Total Claims Allowed:	
		20	
(Assistant Examiner)	(Date)		
/DAVID H KRUSE/ Primary Examiner. Art Unit 1638	12/13/2013	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	NONE

Search Notes 	Application/Control No. 13647081	Applicant(s)/Patent Under Reexamination WRIGHT ET AL.
	Examiner DAVID H KRUSE	Art Unit 1638

CPC- SEARCHED		
Symbol	Date	Examiner

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner
EAST	EAST	2/20/2013	/DK/

SEARCH NOTES		
Search Notes	Date	Examiner
Inventor Name Search	2/20/2013	/DK/
EAST: USPAT, USPGPUB, EPO, JPO, DERWENT	2/20/2013	/DK/
STN: AGRICOLA, BIOSIS, CAPLUS, EMBASE, CABA	2/20/2013	/DK/
Sequence Search of SEQ ID NO: 2 and 4, included interference search	1/16/2013	/DK/
Update EAST	9/3/2013	/DK/
Update EAST	12/13/2013	/DK/

INTERFERENCE SEARCH			
US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner
EAST	EAST	12/13/2013	/DK/

	/DAVID H KRUSE/ Primary Examiner.Art Unit 1638
--	---

To: inteias@faegrebd.com,cynthia.payson@faegrebd.com,
From: PAIR_eOfficeAction@uspto.gov
Cc: PAIR_eOfficeAction@uspto.gov
Subject: Private PAIR Correspondence Notification for Customer Number 83067

Dec 20, 2013 05:40:56 AM

Dear PAIR Customer:

Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204
UNITED STATES

The following USPTO patent application(s) associated with your Customer Number, 83067 , have new outgoing correspondence. This correspondence is now available for viewing in Private PAIR.

The official date of notification of the outgoing correspondence will be indicated on the form PTOL-90 accompanying the correspondence.

Disclaimer:

The list of documents shown below is provided as a courtesy and is not part of the official file wrapper. The content of the images shown in PAIR is the official record.

Application	Document	Mailroom Date	Attorney Docket No.
13647081	NOA	12/20/2013	DAS-P0129-03-US-E

To view your correspondence online or update your email addresses, please visit us anytime at <https://sportal.uspto.gov/secure/myportal/privatepair>.

If you have any questions, please email the Electronic Business Center (EBC) at EBC@uspto.gov with 'e-Office Action' on the subject line or call 1-866-217-9197 during the following hours:

Monday - Friday 6:00 a.m. to 12:00 a.m.

Thank you for prompt attention to this notice,

UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT APPLICATION INFORMATION RETRIEVAL SYSTEM



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	TOT CLAIMS	IND CLAIMS
13/647,081	10/08/2012	1638	1710	DAS-P0129-03-US-E	20	3

CONFIRMATION NO. 1022

CORRECTED FILING RECEIPT



OC000000067090493

83067

Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204

Date Mailed: 03/12/2014

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections**

Inventor(s)

Terry R. Wright, Camel, IN;
Justin M. Lira, Zionsville, IN;
Terence Anthony Walsh, Zionsville, IN;
Donald Merlo, Camel, IN;
Pon Samuel Jayakumar, Camel, IN;
Gaofeng Lin, Zionsville, IN;

Applicant(s)

DOW AGROSCIENCES LLC, Indianapolis, IN

Assignment For Published Patent Application

Dow AgroSciences LLC, Indianapolis, IN

Power of Attorney: The patent practitioners associated with Customer Number 83067

Domestic Priority data as claimed by applicant

This application is a CON of 12/091,896 11/03/2008 PAT 8283522
which is a 371 of PCT/US06/42133 10/27/2006
which claims benefit of 60/731,044 10/28/2005

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see <http://www.uspto.gov> for more information.) - None.

Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

If Required, Foreign Filing License Granted: 10/23/2012

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 13/647,081**

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

Title

NOVEL HERBICIDE RESISTANCE GENES

Preliminary Class

800

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications:

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit <http://www.SelectUSA.gov> or call +1-202-482-6800.

To: inteias@faegrebd.com,cynthia.payson@faegrebd.com,
From: PAIR_eOfficeAction@uspto.gov
Cc: PAIR_eOfficeAction@uspto.gov
Subject: Private PAIR Correspondence Notification for Customer Number 83067

Mar 12, 2014 05:41:05 AM

Dear PAIR Customer:

Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204
UNITED STATES

The following USPTO patent application(s) associated with your Customer Number, 83067 , have new outgoing correspondence. This correspondence is now available for viewing in Private PAIR.

The official date of notification of the outgoing correspondence will be indicated on the form PTOL-90 accompanying the correspondence.

Disclaimer:

The list of documents shown below is provided as a courtesy and is not part of the official file wrapper. The content of the images shown in PAIR is the official record.

Application	Document	Mailroom Date	Attorney Docket No.
13647081	APP.FILE.REC	03/12/2014	DAS-P0129-03-US-E

To view your correspondence online or update your email addresses, please visit us anytime at <https://sportal.uspto.gov/secure/myportal/privatepair>.

If you have any questions, please email the Electronic Business Center (EBC) at EBC@uspto.gov with 'e-Office Action' on the subject line or call 1-866-217-9197 during the following hours:

Monday - Friday 6:00 a.m. to 12:00 a.m.

Thank you for prompt attention to this notice,

UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT APPLICATION INFORMATION RETRIEVAL SYSTEM



03-19-14; 12:28PM;

; 1111

1/1

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: **Mail** Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or **Fax** (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advances orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

83067 7590 12/20/2013
Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

Gretchen Haley (Depositor's name)
Gretchen Haley (Signature)
3/19/14 (Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/647,081	10/08/2012	Terry R. Wright	03/19/2014 H000002 00000042 041529	1022 13647081
TITLE OF INVENTION: NOVEL HERBICIDE RESISTANCE GENES				
01 FC:1501 960.00 DA				

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$1780	\$300	\$0	\$2080	03/20/2014
EXAMINER		ART UNIT	CLASS-SUBCLASS			
KRUSE, DAVID H		1638	800-300000			

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.63).

- ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
☒ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.

2. For printing on the patent front page, list

- (1) The names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

- 1 James Daly
2 Kenneth B. Ludwig
3 Faegre Baker Daniels LLP

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Dow AgroSciences, LLC

INDIANAPOLIS, IN USA

Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☒ Corporation or other private group entity ☐ Government

4a. The following fee(s) are submitted:

- ☒ Issue Fee
☒ Publication Fee (No small entity discount permitted)
☐ Advance Order - # of Copies

4b. Payment of Fee(s): (Please first recopy any previously paid issue fee shown above)

- ☐ A check is enclosed.
☐ Payment by credit card. Form PTO-2038 is attached.
☒ The Director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number 04-1529 (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

- ☐ Applicant certifying micro entity status. See 37 CFR 1.29
☐ Applicant asserting small entity status. See 37 CFR 1.27
☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature

Date

1/10/14

Typed or printed name James Daly

Registration No. 51,209

Page 2 of 3

PTOL-85 Part B (10-13) Approved for use through 10/31/2013.

OMB 0651-0033

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

PAGE 1/1 * RCVD AT 3/19/2014 12:28:22 PM [Eastern Daylight Time] * SVR:W-PTOFAX-001/38 * DNIS:2732885 * CSID:1111 * DURATION (mm:ss):01:32

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: **Mail** Mail Stop ISSUE FEE
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 or **Fax** (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

83067 7590 12/20/2013
 Faegre Baker Daniels LLP- Dow AgroSciences
 300 North Meridian Street, Suite 2700
 Indianapolis, IN 46204



Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

Gretchen Haley (Depositor's name)
 Gretchen Haley (Signature)
 3/19/14 (Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/647,081	10/08/2012	Terry R. Wright	DAS-P0129-03-US-E	1022

TITLE OF INVENTION: NOVEL HERBICIDE RESISTANCE GENES

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$1780	\$300	\$0	\$2080	03/20/2014
EXAMINER	ART UNIT	CLASS-SUBCLASS				
KRUSE, DAVID H	1638	800-300000				

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

- ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
☒ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.

2. For printing on the patent front page, list

- (1) The names of up to 3 registered patent attorneys or agents OR, alternatively,
 (2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 James Daly
 2 Kenneth B. Ludwig
 3 Faegre Baker Daniels LLP

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Dow AgroSciences, LLC

INDIANAPOLIS, IN USA

Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☒ Corporation or other private group entity ☐ Government

4a. The following fee(s) are submitted:

- ☒ Issue Fee
☒ Publication Fee (No small entity discount permitted)
☐ Advance Order - # of Copies

4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)

- ☐ A check is enclosed.
☐ Payment by credit card. Form PTO-2038 is attached.
☒ The Director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number 04-1529 (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

- ☐ Applicant certifying micro entity status. See 37 CFR 1.29
☐ Applicant asserting small entity status. See 37 CFR 1.27
☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature James Daly
 Typed or printed name James Daly

Date 1/10/14
 Registration No. 51,209

Page 2 of 3

PTOL-85 Part B (10-13) Approved for use through 10/31/2013.

OMB 0651-0033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

**CORRECTED
NOTICE OF ALLOWANCE AND FEE(S) DUE**

83067 7590 07/14/2014
Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204

EXAMINER

KRUSE, DAVID H

ART UNIT

PAPER NUMBER

1638

DATE MAILED: 07/14/2014

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/647,081	10/08/2012	Terry R. Wright	DAS-P0129-03-US-E	1022

TITLE OF INVENTION: NOVEL HERBICIDE RESISTANCE GENES

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$0	\$0	\$960	\$0	10/14/2014

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: **Mail** Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

83067 7590 07/14/2014
Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/647,081	10/08/2012	Terry R. Wright	DAS-P0129-03-US-E	1022

TITLE OF INVENTION: NOVEL HERBICIDE RESISTANCE GENES

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$0	\$0	\$960	\$0	10/14/2014

EXAMINER	ART UNIT	CLASS-SUBCLASS
KRUSE, DAVID H	1638	800-300000

<p>1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.563).</p> <p>☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.</p> <p>☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.</p>	<p>2. For printing on the patent front page, list</p> <p>(1) The names of up to 3 registered patent attorneys or agents OR, alternatively, 1 _____</p> <p>(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. 2 _____</p> <p>3 _____</p>
---	---

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☐ Corporation or other private group entity ☐ Government

4a. The following fee(s) are submitted:

- ☐ Issue Fee
- ☐ Publication Fee (No small entity discount permitted)
- ☐ Advance Order - # of Copies _____

4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)

- ☐ A check is enclosed.
- ☐ Payment by credit card. Form PTO-2038 is attached.
- ☐ The Director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

- ☐ Applicant certifying micro entity status. See 37 CFR 1.29
- ☐ Applicant asserting small entity status. See 37 CFR 1.27
- ☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____

Date _____

Typed or printed name _____

Registration No. _____



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/647,081	10/08/2012	Terry R. Wright	DAS-P0129-03-US-E	1022
83067	7590	07/14/2014	EXAMINER	
Faegre Baker Daniels LLP- Dow AgroSciences 300 North Meridian Street, Suite 2700 Indianapolis, IN 46204			KRUSE, DAVID H	
			ART UNIT	PAPER NUMBER
			1638	
DATE MAILED: 07/14/2014				

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Letter Withdrawing the Notice of Allowance and Fee(s) Due

This application is being withdrawn from issue because an inventor's oath or declaration, executed by or with respect to each inventor, in compliance with 35 U.S.C. § 115 and 37 CFR 1.63 or 1.64 has not been submitted. While the claims remain allowed and prosecution on the merits remains closed, the Notice of Allowance and Fee(s) Due is hereby withdrawn. The Notice of Allowability is not being withdrawn. As a result, any time period set forth in the Notice of Allowability continues to run from the mailing date of the Notice of Allowability.

Oath/Declaration:

An inventor's oath or declaration in compliance with 35 U.S.C. § 115 and 37 CFR 1.63 or 1.64, executed by or with respect to each inventor **MUST be filed no later than the date on which the issue fee is paid.** See 35 U.S.C. 115(f). In this instance, a compliant inventor's oath or declaration must be submitted before, or at the time, the signed part B of the attached "Notice of Allowance and Fee(s) Due" (PTOL-85) is returned (see below). Failure to timely comply will result in ABANDONMENT of this application. To ensure compliance with 35 U.S.C. § 115 and 37 CFR 1.63 or 1.64, the Office suggests using the appropriate USPTO form(s) available on the USPTO Web site (e.g., PTO/AIA/01 for a declaration under 37 CFR 1.63 or PTO/AIA/02 for a substitute statement under 37 CFR 1.64).

An inventor's oath or declaration in compliance with 35 U.S.C. § 115 and 37 CFR 1.63 or 1.64 must include the following (in addition to meeting the other requirements of 35 U.S.C. § 115 and 37 CFR 1.63 or 1.64):

- (1) a statement that the application was made or was authorized to be made by the affiant or declarant;
- (2) a statement that such individual believes himself or herself to be the original inventor or an original joint inventor of a claimed invention in the application; and
- (3) an acknowledgment that any willful false statement made in such declaration or statement is punishable under section 1001 of title 18 by fine or imprisonment of not more than 5 years, or both.

Reapplication of Issue Fee and Publication Fee:

A new Notice of Allowance and Fee(s) Due is being issued herewith. The issue fee and any required publication fee set forth in the new Notice of Allowance and Fee(s) Due, including any fee adjustment since the fees were previously paid, must be paid within three months from the mailing date of the new Notice of Allowance and Fee(s) Due. Since fees were previously paid, applicant may request that the previously submitted issue fee and publication fee be applied toward payment of the issue fee and publication fee in the amount identified on the new Notice of Allowance and Fee(s) Due. The return of part B of the new Notice of Allowance and Fee(s) Due will be considered a request to apply any previously submitted issue fee and publication fee toward the issue fee and any publication fee now due. Failure to timely comply will result in ABANDONMENT of this application. **This three-month time period is not extendable under 37 CFR 1.136(a).**

Diane Terry
Application Assistance Unit
571-272-4200

To: inteias@faegrebd.com,cynthia.payson@faegrebd.com,
From: PAIR_eOfficeAction@uspto.gov
Cc: PAIR_eOfficeAction@uspto.gov
Subject: Private PAIR Correspondence Notification for Customer Number 83067

Jul 16, 2014 05:29:07 AM

Dear PAIR Customer:

Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204
UNITED STATES

The following USPTO patent application(s) associated with your Customer Number, 83067 , have new outgoing correspondence. This correspondence is now available for viewing in Private PAIR.

The official date of notification of the outgoing correspondence will be indicated on the form PTOL-90 accompanying the correspondence.

Disclaimer:

The list of documents shown below is provided as a courtesy and is not part of the official file wrapper. The content of the images shown in PAIR is the official record.

Application	Document	Mailroom Date	Attorney Docket No.
13647081	NOA	07/14/2014	DAS-P0129-03-US-E

To view your correspondence online or update your email addresses, please visit us anytime at <https://sportal.uspto.gov/secure/myportal/privatepair>.

If you have any questions, please email the Electronic Business Center (EBC) at EBC@uspto.gov with 'e-Office Action' on the subject line or call 1-866-217-9197 during the following hours:

Monday - Friday 6:00 a.m. to 12:00 a.m.

Thank you for prompt attention to this notice,

UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT APPLICATION INFORMATION RETRIEVAL SYSTEM

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	13/647,081
	Filing Date	October 8, 2012
	First Named Inventor	Justin M. Lira
	Art Unit	1638
	Examiner Name	David H. Kruse
Total Number of Pages in This Submission	Attorney Docket Number	DAS-P0129-03-US-E

ENCLOSURES <i>(Check all that apply)</i>		
☐ Fee Transmittal Form ☐ Fee Attached ☐ Amendment/Reply ☐ After Final ☐ Affidavits/declaration(s) ☐ Extension of Time Request ☐ Express Abandonment Request ☐ Information Disclosure Statement ☐ Certified Copy of Priority Document(s) ☐ Reply to Missing Parts/ Incomplete Application ☐ Reply to Missing Parts under 37 CFR 1.52 or 1.53	☐ Drawing(s) ☐ Licensing-related Papers ☐ Petition ☐ Petition to Convert to a Provisional Application ☐ Power of Attorney, Revocation ☐ Change of Correspondence Address ☐ Terminal Disclaimer ☐ Request for Refund ☐ CD, Number of CD(s) _____ ☐ Landscape Table on CD	☐ After Allowance Communication to TC ☐ Appeal Communication to Board of Appeals and Interferences ☐ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) ☐ Proprietary Information ☐ Status Letter ☒ Other Enclosure(s) (please identify below): Executed Declaration
<div style="border: 1px solid black; height: 20px; width: 100%;"></div> Remarks		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	FAEGRE BAKER DANIELS LLP	
Signature	/yonghao hou/	
Printed name	Yonghao Hou	
Date	August 19, 2014	Reg. No. 61,391

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:		
Signature	filed electronically	
Typed or printed name		Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Doc Code: Oath

Document Description: Oath or declaration filed

PTO/SB/01 (09-12)

Approved for use through 01/31/2014. OMB 0551-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)	Attorney Docket Number	63979A-US-PCD
	First Named Inventor	Terry R. Wright
	COMPLETE IF KNOWN	
	Application Number	13/647,081-Conf. #1022
	Filing Date	October 8, 2012
	Art Unit	1638
☐ Declaration Submitted With Initial Filing	OR	☒ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (f)) required)
Examiner Name		D. H. Kruse

I hereby declare that: (1) Each inventor's residence, mailing address, and citizenship are as stated below next to their name; and (2) I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NOVEL HERBICIDE RESISTANCE GENES

(Title of the invention)

the application of which was made or was authorized to be made by me and

☐ is attached hereto

OR

☒ was filed on (MM/DD/YYYY) 10/08/2012 as United States Application Number or PCT International

Application Number 13/647,081 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

Authorization To Permit Access To Application by Participating Offices

☐ If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and any other intellectual property offices in which a foreign application claiming priority to the above-identified patent application is filed access to the above-identified patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority to the above-identified patent application is filed to have access to the above-identified patent application.

In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the above-identified patent application with respect to: 1) the above-identified patent application-as-filed; 2) any foreign application to which the above-identified patent application claims priority under 35 USC 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the above-identified patent application; and 3) any U.S. application-as-filed from which benefit is sought in the above-identified patent application.

In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing the Authorization to Permit Access to Application by Participating Offices.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application


Claim of Foreign Priority Benefits

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking this box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.




Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			☐	☐	☐
			☐	☐	☐
			☐	☐	☐
			☐	☐	☐

☐



Additional foreign application number(s) are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

DECLARATION — Utility or Design Patent Application			
Direct all correspondence to:		☒ The address associated with Customer Number: 83067	OR ☐ Correspondence address below
Name			
Address			
City		State	ZIP
Country	Telephone	Email	
<p style="text-align: center;">WARNING:</p> <p>Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.</p> <p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.</p> <p>I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) year, or both.</p>			
NAME OF SOLE OR FIRST INVENTOR:		☐ A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Terry R.		Wright	
Inventor's Signature		Date	
		7-31-2014	
Residence: City	State	Country	Citizenship
Carmel	IN	United States of America	US
Mailing Address: 14162 Charity Chase Circle			
City	State	Zip	Country
Carmel	IN	46074	United States of America
☒ Additional inventors or a legal representative are being named on the <u>2</u> supplemental sheet(s) PTO/SB/02A or 02L/R attached hereto.			

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION		ADDITIONAL INVENTOR(S) Supplemental Sheet	
		Page 1 of 2	
Name of Additional Joint Inventor, if any:		☐ A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Justin M.		Lira	
Inventor's Signature 		Date <u>Aug 6, 2014</u>	
Residence: City	State	Country	Citizenship
Zionsville	IN	United States of America	US
Mailing Address: 8974 Windpointe Pass			
City	State	Zip	Country
Zionsville	IN	46077	United States of America
Name of Additional Joint Inventor, if any:		☐ A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Terence A.		Walsh	
Inventor's Signature 		Date <u>August 6, 2014</u>	
Residence: City	State	Country	Citizenship
Carmel	IN	United States of America	US
Mailing Address: 12443 Branford Street			
City	State	Zip	Country
Carmel	IN	46032	United States of America
Name of Additional Joint Inventor, if any:		☐ A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Donald J.		Merlo	
Inventor's Signature 		Date <u>July 31, 2014</u>	
Residence: City	State	Country	Citizenship
Carmel	IN	United States of America	US
Mailing Address: 11845 Durbin Drive			
City	State	Zip	Country
Carmel	IN	46032	United States of America

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION				ADDITIONAL INVENTOR(S) Supplemental Sheet	
				Page <u>2</u> of <u>2</u>	
Name of Additional Joint Inventor, if any:				☐ A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))				Family Name or Surname	
Jayakumar Pon				Samuel	
Inventor's Signature 				Date <u>08/18/2014</u>	
Residence: City Carmel	State IN	Country United States of America	Citizenship US		
Mailing Address: 3336 Kilkenny Circle					
City Carmel	State IN	Zip 46032	Country United States of America		
Name of Additional Joint Inventor, if any:				☐ A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))				Family Name or Surname	
Gaofeng				Lin	
Inventor's Signature 				Date <u>August 10, 2014</u>	
Residence: City Zionsville	State IN	Country United States of America	Citizenship US		
Mailing Address: 981 Franklin Trace					
City Zionsville	State IN	Zip 46077	Country United States of America		
Name of Additional Joint Inventor, if any:				☐ A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))				Family Name or Surname	
Inventor's Signature				Date	
Residence: City	State	Country	Citizenship		
Mailing Address:					
City	State	Zip	Country		

Electronic Acknowledgement Receipt	
EFS ID:	19900559
Application Number:	13647081
International Application Number:	
Confirmation Number:	1022
Title of Invention:	NOVEL HERBICIDE RESISTANCE GENES
First Named Inventor/Applicant Name:	Terry R. Wright
Customer Number:	83067
Filer:	Yonghao Hou
Filer Authorized By:	
Attorney Docket Number:	DAS-P0129-03-US-E
Receipt Date:	19-AUG-2014
Filing Date:	08-OCT-2012
Time Stamp:	12:40:20
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Transmittal Letter	DAS-P0129-03-TRANS.pdf	262172 7de0f9bb87e09ca73b1b9c37bd2f3d784507dca3	no	2

Warnings:

Information:

2	Oath or Declaration filed	DAS-P0129-03-US-DEC.pdf	230991 e1d0a8bf542dc805444b76e2ef4637b6df3e13ce	no	5
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
Total Files Size (in bytes):				493163	
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<i>Attorney</i>	}	<i>Confirmation No.</i> 1022
<i>Docket No.:</i> DAS-P0129-03-US-E	}	
<i>Applicant:</i> Terry R. Wright et al.	}	
<i>Invention:</i> NOVEL HERBICIDE RESISTANCE GENES	}	
<i>Serial No:</i> 13/647,081	}	
<i>Filed:</i> October 8, 2012	}	

**REQUEST FOR CORRECTION OF FILING RECEIPT and
SUPPLEMENTAL APPLICATION DATA SHEET**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

A Corrected Notice of Allowance, with issue fee due October 14 2014, was mailed on July 14, 2014. Attached is a Revised Application Data Sheet.

It is requested that the filing receipt be corrected as indicated on the enclosed copy thereof. Specifically, the name of the 5th inventor should be listed as:

Jayakumar P. Samuel

It is requested that a corrected filing receipt be forwarded to the undersigned. If there are any fees due with the filing of this document, the undersigned authorizes the appropriate fee be withdrawn from deposit account number 02-0390.

Respectfully submitted,

/yonghao hou /

.....
Yonghao Hou, Reg. No. 61,391
Attorney for Applicant

Faegre Baker Daniels LLP
Customer No. 83067

US.55016999.01



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	TOT CLAIMS	IND CLAIMS
13/647,081	10/08/2012	1638	1710	DAS-P0129-03-US-E	20	3

CONFIRMATION NO. 1022

83067

Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204

FILING RECEIPT



OC000000057360801

Date Mailed: 11/02/2012

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections**

Inventor(s)

Terry R. Wright, Camel, IN;
Justin M. Lira, Zionsville, IN;
Terence Anthony Walsh, Zionsville, IN;
Donald Merto, Camel, IN;
Pon-Samuel-Jayakumar, Camel, IN; Jayakumar P. Samuel
Gaofeng Lin, Zionsville, IN;

Applicant(s)

Dow AgroSciences LLC, Indianapolis, IN

Assignment For Published Patent Application

Dow AgroSciences LLC, Indianapolis, IN

Power of Attorney: None

Domestic Priority data as claimed by applicant

This application is a CON of 12/091,896 11/03/2008 PAT 8283522
which is a 371 of PCT/US06/42133 10/27/2006
which claims benefit of 60/731,044 10/28/2005

Foreign Applications (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see <http://www.uspto.gov> for more information.)

If Required, Foreign Filing License Granted: 10/23/2012

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 13/647,081**

Projected Publication Date: 02/07/2013

page 1 of 3

Non-Publication Request: No

Early Publication Request: No
Title

NOVEL HERBICIDE RESISTANCE GENES

Preliminary Class

800

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage, facilitate, and accelerate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.

Doc Code: Oath

Document Description: Oath or declaration filed

PTO/SB/01 (09-12)

Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)	Attorney Docket Number	63979A-US-PCD
	First Named Inventor	Terry R. Wright
	COMPLETE IF KNOWN	
	Application Number	13/647,081-Conf. #1022
	Filing Date	October 8, 2012
	Art Unit	1638
☐ Declaration Submitted With Initial Filing	OR	☒ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (f)) required)
Examiner Name		D. H. Kruse

I hereby declare that: (1) Each inventor's residence, mailing address, and citizenship are as stated below next to their name; and (2) I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NOVEL HERBICIDE RESISTANCE GENES

(Title of the invention)

the application of which was made or was authorized to be made by me and

☐ is attached hereto

OR

☒ was filed on (MM/DD/YYYY) 10/08/2012 as United States Application Number or PCT International

Application Number 13/647,081 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

Authorization To Permit Access To Application by Participating Offices

☐ If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and any other intellectual property offices in which a foreign application claiming priority to the above-identified patent application is filed access to the above-identified patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority to the above-identified patent application is filed to have access to the above-identified patent application.

In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the above-identified patent application with respect to: 1) the above-identified patent application-as-filed; 2) any foreign application to which the above-identified patent application claims priority under 35 USC 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the above-identified patent application; and 3) any U.S. application-as-filed from which benefit is sought in the above-identified patent application.

In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing the Authorization to Permit Access to Application by Participating Offices.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


DECLARATION — Utility or Design Patent Application**Claim of Foreign Priority Benefits**

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking this box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.




Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			☐	☐	☐
			☐	☐	☐
			☐	☐	☐
			☐	☐	☐

☐



Additional foreign application number(s) are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

DECLARATION — Utility or Design Patent Application			
Direct all correspondence to:		☒ The address associated with Customer Number: 83067	OR ☐ Correspondence address below
Name			
Address			
City		State	ZIP
Country	Telephone	Email	
<p style="text-align: center;">WARNING:</p> <p>Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.</p> <p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.</p> <p>I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) year, or both.</p>			
NAME OF SOLE OR FIRST INVENTOR:		☐ A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Terry R.		Wright	
Inventor's Signature		Date	
		7-31-2014	
Residence: City	State	Country	Citizenship
Carmel	IN	United States of America	US
Mailing Address: 14162 Charity Chase Circle			
City	State	Zip	Country
Carmel	IN	46074	United States of America
☒ Additional inventors or a legal representative are being named on the <u>2</u> supplemental sheet(s) PTO/SB/02A or 02L/R attached hereto.			

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION		ADDITIONAL INVENTOR(S) Supplemental Sheet	
		Page 1 of 2	
Name of Additional Joint Inventor, if any:		☐ A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Justin M.		Lira	
Inventor's Signature 		Date <u>Aug 6, 2014</u>	
Residence: City	State	Country	Citizenship
Zionsville	IN	United States of America	US
Mailing Address: 8974 Windpointe Pass			
City	State	Zip	Country
Zionsville	IN	46077	United States of America
Name of Additional Joint Inventor, if any:		☐ A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Terence A.		Walsh	
Inventor's Signature 		Date <u>August 6, 2014</u>	
Residence: City	State	Country	Citizenship
Carmel	IN	United States of America	US
Mailing Address: 12443 Branford Street			
City	State	Zip	Country
Carmel	IN	46032	United States of America
Name of Additional Joint Inventor, if any:		☐ A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Donald J.		Merlo	
Inventor's Signature 		Date <u>July 31, 2014</u>	
Residence: City	State	Country	Citizenship
Carmel	IN	United States of America	US
Mailing Address: 11845 Durbin Drive			
City	State	Zip	Country
Carmel	IN	46032	United States of America

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION				ADDITIONAL INVENTOR(S) Supplemental Sheet	
				Page <u>2</u> of <u>2</u>	
Name of Additional Joint Inventor, if any:			☐ A petition has been filed for this unsigned inventor		
Given Name (first and middle (if any))			Family Name or Surname		
Jayakumar Pon			Samuel		
Inventor's Signature 		Date <u>08/18/2014</u>			
Residence: City Carmel	State IN	Country United States of America	Citizenship US		
Mailing Address 3336 Kilkenny Circle					
City Carmel	State IN	Zip 46032	Country United States of America		
Name of Additional Joint Inventor, if any:			☐ A petition has been filed for this unsigned inventor		
Given Name (first and middle (if any))			Family Name or Surname		
Gaofeng			Lin		
Inventor's Signature 		Date <u>August 10, 2014</u>			
Residence: City Zionsville	State IN	Country United States of America	Citizenship US		
Mailing Address 981 Franklin Trace					
City Zionsville	State IN	Zip 46077	Country United States of America		
Name of Additional Joint Inventor, if any:			☐ A petition has been filed for this unsigned inventor		
Given Name (first and middle (if any))			Family Name or Surname		
Inventor's Signature		Date			
Residence: City	State	Country	Citizenship		
Mailing Address:					
City	State	Zip	Country		

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	DAS-P0129-03-US-E
		Application Number	
Title of Invention	NOVEL HERBICIDE RESISTANCE GENES		
<p>The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.</p> <p>This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.</p>			

Secrecy Order 37 CFR 5.2

☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
--

Inventor Information:

Inventor 1						Remove	
Legal Name							
Prefix	Given Name	Middle Name	Family Name			Suffix	
	Terry	R.	Wright				
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service							
City	Carmel	State/Province	IN	Country of Residence	US		
Mailing Address of Inventor:							
Address 1		14162 Charity Chase Circle					
Address 2							
City	Carmel	State/Province	IN				
Postal Code	46074	Country	US				
Inventor 2						Remove	
Legal Name							
Prefix	Given Name	Middle Name	Family Name			Suffix	
	Justin	M.	Lira				
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service							
City	Zionsville	State/Province	IN	Country of Residence	US		
Mailing Address of Inventor:							
Address 1		8974 Windpointe Pass					
Address 2							
City	Zionsville	State/Province	IN				
Postal Code	46077	Country	US				
Inventor 3						Remove	
Legal Name							
Prefix	Given Name	Middle Name	Family Name			Suffix	
	Terence	Anthony	Walsh				
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service							

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number		DAS-P0129-03-US-E	
		Application Number			
Title of Invention		NOVEL HERBICIDE RESISTANCE GENES			
City	Zionsville	State/Province	IN	Country of Residence	US
Mailing Address of Inventor:					
Address 1		11638 Promontory Trail			
Address 2					
City	Zionsville	State/Province	IN		
Postal Code	46077	Country i	US		
Inventor 4					Remove
Legal Name					
Prefix	Given Name	Middle Name	Family Name	Suffix	
	Donald		Merlo		
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service					
City	Carmel	State/Province	IN	Country of Residence	US
Mailing Address of Inventor:					
Address 1		11845 Durbin Drive			
Address 2					
City	Carmel	State/Province	IN		
Postal Code	46032	Country i	US		
Inventor 5					Remove
Legal Name					
Prefix	Given Name	Middle Name	Family Name	Suffix	
	Pon Samuel Jayakumar	P.	Jayakumar Samuel		
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service					
City	Carmel	State/Province	IN	Country of Residence	US
Mailing Address of Inventor:					
Address 1		3336 Kilkenny Circle			
Address 2					
City	Carmel	State/Province	IN		
Postal Code	46032	Country i	US		
Inventor 6					Remove
Legal Name					
Prefix	Given Name	Middle Name	Family Name	Suffix	
	Gaofeng		Lin		
Residence Information (Select One) ☒ US Residency ☐ Non US Residency ☐ Active US Military Service					
City	Zionsville	State/Province	IN	Country of Residence	US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	DAS-P0129-03-US-E	
		Application Number		
Title of Invention	NOVEL HERBICIDE RESISTANCE GENES			
Mailing Address of Inventor:				
Address 1	981 Franklin Trace			
Address 2				
City	Zionsville	State/Province	IN	
Postal Code	46077	Country	US	
All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the Add button.				

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below. For further information see 37 CFR 1.33(a).			
☐ An Address is being provided for the correspondence information of this application.			
Customer Number	83067		
Email Address	intear@faegrebd.com	Add Email	Remove Email
Email Address	cynthia.payson@faegrebd.com	Add Email	Remove Email

Application Information:

Title of the Invention	NOVEL HERBICIDE RESISTANCE GENES		
Attorney Docket Number	DAS-P0129-03-US-E	Small Entity Status Claimed	☐
Application Type	Nonprovisional		
Subject Matter	Utility		
Suggested Class (if any)		Sub Class (if any)	
Suggested Technology Center (if any)			
Total Number of Drawing Sheets (if any)	3	Suggested Figure for Publication (if any)	

Publication Information:

☐ Request Early Publication (Fee required at time of Request 37 CFR 1.219)
☐ Request Not to Publish. I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

<p>Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number will be used for the Representative Information during processing.</p>
--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	DAS-P0129-03-US-E
		Application Number	
Title of Invention	NOVEL HERBICIDE RESISTANCE GENES		
Please Select One:	☒ Customer Number	☐ US Patent Practitioner	☐ Limited Recognition (37 CFR 11.9)
Customer Number	83067		

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c) or indicate National Stage entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.

Prior Application Status	Pending	Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)
	Continuation of	12091896	2008-11-03
Prior Application Status	Pending	Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)
12091896	a 371 of international	PCTUS2006042133	2006-10-27
Prior Application Status	Expired	Remove	
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)
PCTUS2006042133	non provisional of	60731044	2005-10-28

Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the **Add** button.

Foreign Priority Information:

This section allows for the applicant to claim benefit of foreign priority and to identify any prior foreign application for which priority is not claimed. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(a).

Remove		
Application Number	Country ¹	Filing Date (YYYY-MM-DD)
		Priority Claimed ☐ Yes ☒ No

Additional Foreign Priority Data may be generated within this form by selecting the **Add** button.

Authorization to Permit Access:

☐ Authorization to Permit Access to the Instant Application by the Participating Offices

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	DAS-P0129-03-US-E
		Application Number	
Title of Invention	NOVEL HERBICIDE RESISTANCE GENES		

If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO), and any other intellectual property offices in which a foreign application claiming priority to the instant patent application is filed access to the instant patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority to the instant patent application is filed to have access to the instant patent application.

In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the instant patent application with respect to: 1) the instant patent application-as-filed; 2) any foreign application to which the instant patent application claims priority under 35 U.S.C. 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of 37 CFR 1.55 has been filed in the instant patent application; and 3) any U.S. application-as-filed from which benefit is sought in the instant patent application.

In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing this Authorization.

Applicant Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.			
Applicant 1			
If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed. The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be identified in this section.			
☒ Assignee		☐ Legal Representative under 35 U.S.C. 117	
☐ Person to whom the inventor is obligated to assign.		☐ Person who shows sufficient proprietary interest	
If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:			
Name of the Deceased or Legally Incapacitated Inventor : <input type="text"/>			
If the Assignee is an Organization check here. ☒			
Organization Name		Dow AgroSciences LLC	
Mailing Address Information:			
Address 1		9330 Zionsville Road	
Address 2			
City		Indianapolis	State/Province
Country		US	Postal Code
Phone Number			Fax Number


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	DAS-P0129-03-US-E
		Application Number	
Title of Invention	NOVEL HERBICIDE RESISTANCE GENES		

Email Address	
---------------	--

Additional Applicant Data may be generated within this form by selecting the Add button.

Signature:

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications					
Signature				Date (YYYY-MM-DD)	2012-10-08
First Name	Jay M.	Last Name	Sanders	Registration Number	39355
Additional Signature may be generated within this form by selecting the Add button.					

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Electronic Acknowledgement Receipt	
EFS ID:	20393716
Application Number:	13647081
International Application Number:	
Confirmation Number:	1022
Title of Invention:	NOVEL HERBICIDE RESISTANCE GENES
First Named Inventor/Applicant Name:	Terry R. Wright
Customer Number:	83067
Filer:	Yonghao Hou
Filer Authorized By:	
Attorney Docket Number:	DAS-P0129-03-US-E
Receipt Date:	12-OCT-2014
Filing Date:	08-OCT-2012
Time Stamp:	23:29:23
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	DAS_P0129_03_REQUEST_CORRECTED_FR_REVISIED_ADS.pdf	221709 da4efda01e4615f9a1d7e4f5ba564d4377230120	no	1

Warnings:

Information:

2	Request for Corrected Filing Receipt	DAS_P0129_03_FRRED.pdf	166709 56b66fe977d5c4626ae868e9705b881474b4253	no	3
Warnings:					
Information:					
3	Oath or Declaration filed	DAS-P0129_03_US_DEC.pdf	230991 e4d0a8bf542dc805444b76e2ef4637b6df3ce13ce	no	5
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
4	Application Data Sheet	DAS_P0129_03_ADSREV.pdf	379465 d9267488e9f20e96aee5168bae4592605fafbd88	no	6
Warnings:					
Information:					
This is not an USPTO supplied ADS fillable form					
Total Files Size (in bytes):			998874		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					

PART B - FEE(S) TRANSMITTAL

**Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885**

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

83067 7590 12/20/2013
Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

Gretchen Haley	(Depositor's name)
/Gretchen Haley/	(Signature)
10/10/2014	(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/647,081	10/08/2012	Terry R. Wright	DAS-P0129-03-US-E	1022

TITLE OF INVENTION: NOVEL HERBICIDE RESISTANCE GENES

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$1780	\$300	\$0	\$2080	03/20/2014

EXAMINER	ART UNIT	CLASS-SUBCLASS
KRUSE, DAVID H	1638	800-300000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

☒ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,

(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 James Daly

2 Kenneth B. Ludwig

3 Faegre Baker Daniels LLP

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Dow AgroSciences, LLC

INDIANAPOLIS, IN USA

Please check the appropriate assignee category or categories (will not be printed on the patent) : ☐ Individual ☒ Corporation or other private group entity ☐ Government

4a. The following fee(s) are submitted:

☒ Issue Fee

☒ Publication Fee (No small entity discount permitted)

☐ Advance Order - # of Copies _____

4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)

☐ A check is enclosed.

☐ Payment by credit card. Form PTO-2038 is attached.

☒ The Director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number 04-1529 (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

☐ Applicant certifying micro entity status. See 37 CFR 1.29

☐ Applicant asserting small entity status. See 37 CFR 1.27

☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature /James Daly/

Date 10/10/2014

Typed or printed name James Daly

Registration No. 51,209

Page 2 of 3

Electronic Patent Application Fee Transmittal				
Application Number:		13647081		
Filing Date:		08-Oct-2012		
Title of Invention:		NOVEL HERBICIDE RESISTANCE GENES		
First Named Inventor/Applicant Name:		Terry R. Wright		
Filer:		James Daly/Gretchen Haley		
Attorney Docket Number:		DAS-P0129-03-US-E		
Filed as Large Entity				
Utility under 35 USC 111(a) Filing Fees				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Plant Issue Fee	1503	1	760	760
Publ. Fee- Early, Voluntary, or Normal	1504	1	0	0

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Extension-of-Time:				
Miscellaneous:				
Total in USD (\$)				760

Electronic Acknowledgement Receipt	
EFS ID:	20410542
Application Number:	13647081
International Application Number:	
Confirmation Number:	1022
Title of Invention:	NOVEL HERBICIDE RESISTANCE GENES
First Named Inventor/Applicant Name:	Terry R. Wright
Customer Number:	83067
Filer:	James Daly/Gretchen Haley
Filer Authorized By:	James Daly
Attorney Docket Number:	DAS-P0129-03-US-E
Receipt Date:	14-OCT-2014
Filing Date:	08-OCT-2012
Time Stamp:	15:39:05
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$760
RAM confirmation Number	2200
Deposit Account	041529
Authorized User	
<p>The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)</p>	

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Issue Fee Payment (PTO-85B)	63979A-US- PCD_ISSUE_FEE_PAYMEN.pdf	181089 <small>e2f67a372f4ee05e4fb82d234607d1e1948f95ea</small>	no	1
Warnings:					
Information:					
2	Fee Worksheet (SB06)	fee-info.pdf	31919 <small>0c16f0b71aabf7970f337ebaf81274c02bdd8f26</small>	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			213008		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					

Document code: WFEE

United States Patent and Trademark Office
Sales Receipt for Accounting Date: 10/14/2014

MTEKLEMI	SALE	#00000032	Mailroom Dt:	10/12/2014	020390	13647081
		01	FC : 1830		140.00	DA



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	TOT CLAIMS	IND CLAIMS
13/647,081	10/08/2012	1663	1710	DAS-P0129-03-US-E	20	3

CONFIRMATION NO. 1022

CORRECTED FILING RECEIPT

83067

Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204



Date Mailed: 10/20/2014

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections**

Inventor(s)

Terry R. Wright, Camel, IN;
Justin M. Lira, Zionsville, IN;
Terence Anthony Walsh, Zionsville, IN;
Donald Merlo, Camel, IN;
Jayakumar P. Samuel, Carmel, IN;
Gaofeng Lin, Zionsville, IN;

Applicant(s)

DOW AGROSCIENCES LLC, Indianapolis, IN

Assignment For Published Patent Application

Dow AgroSciences LLC, Indianapolis, IN

Power of Attorney: The patent practitioners associated with Customer Number 83067

Domestic Priority data as claimed by applicant

This application is a CON of 12/091,896 11/03/2008 PAT 8283522
which is a 371 of PCT/US06/42133 10/27/2006
which claims benefit of 60/731,044 10/28/2005

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see <http://www.uspto.gov> for more information.) - None.

Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

If Required, Foreign Filing License Granted: 10/23/2012

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 13/647,081**

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

Title

NOVEL HERBICIDE RESISTANCE GENES

Preliminary Class

800

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications:

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop technology, manufacture products, deliver services, and grow your business, visit <http://www.SelectUSA.gov> or call +1-202-482-6800.

To: inteias@faegrebd.com,cynthia.payson@faegrebd.com,
From: PAIR_eOfficeAction@uspto.gov
Cc: PAIR_eOfficeAction@uspto.gov
Subject: Private PAIR Correspondence Notification for Customer Number 83067

Oct 20, 2014 05:40:33 AM

Dear PAIR Customer:

Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204
UNITED STATES

The following USPTO patent application(s) associated with your Customer Number, 83067 , have new outgoing correspondence. This correspondence is now available for viewing in Private PAIR.

The official date of notification of the outgoing correspondence will be indicated on the form PTOL-90 accompanying the correspondence.

Disclaimer:

The list of documents shown below is provided as a courtesy and is not part of the official file wrapper. The content of the images shown in PAIR is the official record.

Application	Document	Mailroom Date	Attorney Docket No.
13647081	APP.FILE.REC	10/20/2014	DAS-P0129-03-US-E

To view your correspondence online or update your email addresses, please visit us anytime at <https://sportal.uspto.gov/secure/myportal/privatepair>.

If you have any questions, please email the Electronic Business Center (EBC) at EBC@uspto.gov with 'e-Office Action' on the subject line or call 1-866-217-9197 during the following hours:

Monday - Friday 6:00 a.m. to 12:00 a.m.

Thank you for prompt attention to this notice,

UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT APPLICATION INFORMATION RETRIEVAL SYSTEM

Document code: WFEE

United States Patent and Trademark Office
Sales Receipt for Accounting Date: 11/21/2014

SHASLEY	ADJ #00000001	Mailroom Dt: 03/19/2014		
	Seq No: 42	Sales Acctg Dt: 03/19/2014	041529	13647081
	01 FC : 1501	960.00	CR	

Document code: WFEE

United States Patent and Trademark Office
Sales Receipt for Accounting Date: 11/21/2014

SHASLEY	SALE	#00000004	Mailroom Dt:	10/14/2014	041529	13647081
		01	FC : 1501		960.00	DA

Document code: WFEE

United States Patent and Trademark Office
Sales Receipt for Accounting Date: 11/21/2014

SHASLEY ADJ #00000002 Mailroom Dt: 10/14/2014
Seq No: 2200 Sales Acctg Dt: 10/15/2014 041529 13647081
01 FC : 1503 760.00 CR

PRINTER RUSH

(PTO ASSISTANCE)

Application: 13/647081

Examiner: Kruse, D.

GAU: 1663

From: Marty Willis

Location: RTFM / FMF

Date: 11-20-2014

Tracking #: _____

Week Date: _____

<u>DOC CODE</u>	<u>DOC DATE</u>	<u>MISCELLANEOUS</u>
☐ 1449		☐ Continuing Data
☐ IDS		☐ Foreign Priority
☐ CLM		☐ Document Legibility
☐ IIFW/FWCLM		☒ Fees
☐ SRFW		☐ Petition (TC)
☐ DRW		☐ Other
☐ OATH		
☐ 312		
☐ SPEC		

[RUSH] Message:

Please reapply the previously paid issue fee (\$960 on 3-19-14) to the latest Allowance.

Please note: an additional Plant issue fee was paid in error on 10-14-14 for this Utility.

Thank you,
AMW

[XRUSH] Response:

Done

Plant Issue Fee Removed

Reapply Done

Initials: *BH*

Examiner: PUBS contacts - for DESIGNS: Don Fairchild, 703-756-1566; for ALL OTHER files: Bernadette Queen, 703-756-1565.

NOTE: This form will be included as part of the official USPTO record with the response document coded as XRUSH.

REV: Oct 11



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P. O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/647,081	12/23/2014	8916752	DAS-P0129-03-US-E	1022

83067 7590 12/03/2014
Faege Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (application filed on or after May 29, 2000)

The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site <http://pair.uspto.gov> for additional applicants):

Terry R. Wright, Camel, IN;
Justin M. Lira, Zionsville, IN;
Terence Anthony Walsh, Zionsville, IN;
Donald Merlo, Camel, IN;
Jayakumar P. Samuel, Carmel, IN;
Gaofeng Lin, Zionsville, IN;
DOW AGROSCIENCES LLC, Indianapolis, IN

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.

IR103 (Rev. 10/09)

To: inteas@faegrebd.com,cynthia.payson@faegrebd.com,
From: PAIR_eOfficeAction@uspto.gov
Cc: PAIR_eOfficeAction@uspto.gov
Subject: Private PAIR Correspondence Notification for Customer Number 83067

Dec 04, 2014 05:36:36 AM

Dear PAIR Customer:

Faegre Baker Daniels LLP- Dow AgroSciences
300 North Meridian Street, Suite 2700
Indianapolis, IN 46204
UNITED STATES

The following USPTO patent application(s) associated with your Customer Number, 83067 , have new outgoing correspondence. This correspondence is now available for viewing in Private PAIR.

The official date of notification of the outgoing correspondence will be indicated on the form PTOL-90 accompanying the correspondence.

Disclaimer:

The list of documents shown below is provided as a courtesy and is not part of the official file wrapper. The content of the images shown in PAIR is the official record.

Application	Document	Mailroom Date	Attorney Docket No.
13647081	ISSUE.NTF	12/03/2014	DAS-P0129-03-US-E

To view your correspondence online or update your email addresses, please visit us anytime at <https://sportal.uspto.gov/secure/myportal/privatepair>.

If you have any questions, please email the Electronic Business Center (EBC) at EBC@uspto.gov with 'e-Office Action' on the subject line or call 1-866-217-9197 during the following hours:

Monday - Friday 6:00 a.m. to 12:00 a.m.

Thank you for prompt attention to this notice,

UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT APPLICATION INFORMATION RETRIEVAL SYSTEM